WO2014036016A1 - Benzimidazole derivatives as itk inhibitors - Google Patents
Benzimidazole derivatives as itk inhibitors Download PDFInfo
- Publication number
- WO2014036016A1 WO2014036016A1 PCT/US2013/056877 US2013056877W WO2014036016A1 WO 2014036016 A1 WO2014036016 A1 WO 2014036016A1 US 2013056877 W US2013056877 W US 2013056877W WO 2014036016 A1 WO2014036016 A1 WO 2014036016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyano
- methyl
- benzo
- imidazol
- carboxamide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 49
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 372
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- -1 chloro, fluoro, methyl Chemical group 0.000 claims description 173
- 125000000217 alkyl group Chemical group 0.000 claims description 131
- 239000001257 hydrogen Substances 0.000 claims description 100
- 229910052739 hydrogen Inorganic materials 0.000 claims description 100
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 80
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 78
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 62
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 47
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 42
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 150000003857 carboxamides Chemical class 0.000 claims description 28
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 125000004476 heterocycloamino group Chemical group 0.000 claims description 19
- 125000004414 alkyl thio group Chemical group 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 15
- 208000027866 inflammatory disease Diseases 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 125000005605 benzo group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 10
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 5
- MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 claims description 4
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 claims 2
- 125000005518 carboxamido group Chemical group 0.000 claims 2
- 125000004050 enoyl group Chemical group 0.000 claims 2
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims 1
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 claims 1
- RBGDLYUEXLWQBZ-UHFFFAOYSA-N 2-chlorobenzamide Chemical compound NC(=O)C1=CC=CC=C1Cl RBGDLYUEXLWQBZ-UHFFFAOYSA-N 0.000 claims 1
- OLUXQBMNYZJLPK-UHFFFAOYSA-N 3-(difluoromethyl)thiophene-2-carboxamide Chemical compound NC(=O)C=1SC=CC=1C(F)F OLUXQBMNYZJLPK-UHFFFAOYSA-N 0.000 claims 1
- 101150097504 LHX1 gene Proteins 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 claims 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 23
- 102000020233 phosphotransferase Human genes 0.000 abstract description 23
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract description 20
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract description 20
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract description 15
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract description 15
- 230000001404 mediated effect Effects 0.000 abstract description 10
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract description 6
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 abstract description 5
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract description 4
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 description 186
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 184
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- 238000006243 chemical reaction Methods 0.000 description 101
- 235000019439 ethyl acetate Nutrition 0.000 description 73
- 239000000243 solution Substances 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 239000012044 organic layer Substances 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 64
- 229910001868 water Inorganic materials 0.000 description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 58
- 238000000746 purification Methods 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000012043 crude product Substances 0.000 description 50
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 49
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 description 47
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 44
- 229920006395 saturated elastomer Polymers 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000006196 drop Substances 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 32
- 229910052938 sodium sulfate Inorganic materials 0.000 description 32
- 235000011152 sodium sulphate Nutrition 0.000 description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 30
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 27
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 27
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 27
- 239000011734 sodium Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 239000012299 nitrogen atmosphere Substances 0.000 description 26
- 230000002441 reversible effect Effects 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 229960000583 acetic acid Drugs 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 230000007935 neutral effect Effects 0.000 description 19
- 125000006413 ring segment Chemical group 0.000 description 19
- 239000000377 silicon dioxide Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 235000011054 acetic acid Nutrition 0.000 description 18
- 239000012298 atmosphere Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 101150069380 JAK3 gene Proteins 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 16
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 16
- 101100272634 Mus musculus Bmx gene Proteins 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 108010019421 Janus Kinase 3 Proteins 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 230000004064 dysfunction Effects 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 12
- 239000004215 Carbon black (E152) Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229930195733 hydrocarbon Natural products 0.000 description 12
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 description 10
- 101001010823 Homo sapiens Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 10
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000002427 irreversible effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 8
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 201000009961 allergic asthma Diseases 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 6
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 229940125808 covalent inhibitor Drugs 0.000 description 6
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 201000005962 mycosis fungoides Diseases 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- UQNRTPFLTRZEIM-MRWUDIQNSA-N (2s)-2-amino-3-hydroxy-n-[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride Chemical compound Cl.C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 UQNRTPFLTRZEIM-MRWUDIQNSA-N 0.000 description 5
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 5
- 101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 description 5
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229960001507 ibrutinib Drugs 0.000 description 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- RAIYODFGMLZUDF-UHFFFAOYSA-N piperidin-1-ium;acetate Chemical compound CC([O-])=O.C1CC[NH2+]CC1 RAIYODFGMLZUDF-UHFFFAOYSA-N 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 5
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- HQVOWZWVYHHPHA-UHFFFAOYSA-N 2-(dimethylamino)-2-methylpropanal Chemical compound CN(C)C(C)(C)C=O HQVOWZWVYHHPHA-UHFFFAOYSA-N 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- GLHCKRWFOUAORG-UHFFFAOYSA-N 4-chloro-n-(1-piperidin-4-ylbenzimidazol-2-yl)benzamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CCNCC1 GLHCKRWFOUAORG-UHFFFAOYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000009137 Behcet syndrome Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 108010000817 Leuprolide Proteins 0.000 description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 description 4
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- 208000008963 Transient myeloproliferative syndrome Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 4
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000010085 airway hyperresponsiveness Effects 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 108010075324 emt protein-tyrosine kinase Proteins 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 4
- 229960004338 leuprorelin Drugs 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229940127084 other anti-cancer agent Drugs 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- DQIBOUOHHYMZIZ-UHFFFAOYSA-N tert-butyl 4-(2-aminobenzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=CC=C2N=C1N DQIBOUOHHYMZIZ-UHFFFAOYSA-N 0.000 description 4
- 150000003557 thiazoles Chemical class 0.000 description 4
- 150000003573 thiols Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 3
- ZCGZOPIPEZCKKQ-UHFFFAOYSA-N 2-ethoxy-2-methylpropanoic acid Chemical compound CCOC(C)(C)C(O)=O ZCGZOPIPEZCKKQ-UHFFFAOYSA-N 0.000 description 3
- VTSFNCCQCOEPKF-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one Chemical class NC1=CC=CN=C1O VTSFNCCQCOEPKF-UHFFFAOYSA-N 0.000 description 3
- YMPXKUVQIXMIJU-YMQLSTQVSA-N 4-chloro-N-[1-[1-[2-cyano-4-methyl-4-(methylamino)pent-2-enoyl]piperidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound CNC(C)(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 YMPXKUVQIXMIJU-YMQLSTQVSA-N 0.000 description 3
- OTHWOKGSBYRBNU-YMQLSTQVSA-N 4-chloro-N-[1-[[1-[2-cyano-4-methyl-4-(methylamino)pent-2-enoyl]pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound CNC(C)(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 OTHWOKGSBYRBNU-YMQLSTQVSA-N 0.000 description 3
- JARBNANTFJOVTO-UHFFFAOYSA-N 4-chloro-n-(1-piperidin-3-ylbenzimidazol-2-yl)benzamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CNCCC1 JARBNANTFJOVTO-UHFFFAOYSA-N 0.000 description 3
- IFJYJMVTZFMWGL-UHFFFAOYSA-N 4-chloro-n-[1-(pyrrolidin-2-ylmethyl)benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1CC1NCCC1 IFJYJMVTZFMWGL-UHFFFAOYSA-N 0.000 description 3
- PSGOWZTYEDDSDW-UHFFFAOYSA-N 4-chloro-n-[1-[(1-prop-2-enoylpyrrolidin-2-yl)methyl]benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1CC1N(C(=O)C=C)CCC1 PSGOWZTYEDDSDW-UHFFFAOYSA-N 0.000 description 3
- BOOKLDBOSYOJID-YMQLSTQVSA-N 4-chloro-n-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C1N(C(=O)C(C#N)=CC(C)C)CCCC1N1C2=CC=C(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)C=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 BOOKLDBOSYOJID-YMQLSTQVSA-N 0.000 description 3
- NWOAGVNLHSYBCS-HSTJUUNISA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCCN(C(=O)C=C)C1 NWOAGVNLHSYBCS-HSTJUUNISA-N 0.000 description 3
- BEDWKJCGDZYRIO-HSTJUUNISA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-[(1-prop-2-enoylpyrrolidin-2-yl)methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1CC1CCCN1C(=O)C=C BEDWKJCGDZYRIO-HSTJUUNISA-N 0.000 description 3
- ILKWFRCNNILIJW-UHFFFAOYSA-N 4-fluoro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1F ILKWFRCNNILIJW-UHFFFAOYSA-N 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- KYZFGTKQGDENOJ-YMQLSTQVSA-N CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 KYZFGTKQGDENOJ-YMQLSTQVSA-N 0.000 description 3
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 3
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- JNLNHWLSSBRFRS-UHFFFAOYSA-N N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2cccnc2)nc2ccccc12 JNLNHWLSSBRFRS-UHFFFAOYSA-N 0.000 description 3
- CMAXASPMIZXIER-UHFFFAOYSA-N N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC(CC1)n1c(NC(=O)c2cccnc2)nc2ccccc12 CMAXASPMIZXIER-UHFFFAOYSA-N 0.000 description 3
- JVAMYKUWBGHFLB-GVNKFJBHSA-N N-[1-[1-(4-amino-2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-4-chlorobenzamide Chemical compound C[C@H](NCc1ccc2n(C3CCCN(C3)C(=O)C(=CC(C)(C)N)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(C)(C)C JVAMYKUWBGHFLB-GVNKFJBHSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- KLEPCGBEXOCIGS-XUZZJYLKSA-N ethyl N-[4-[[(2S,4S)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@H]1O[C@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-XUZZJYLKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- XRMXKQUVKODRCE-UHFFFAOYSA-N n-(1-piperidin-3-ylbenzimidazol-2-yl)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=CC=1C(=O)NC1=NC2=CC=CC=C2N1C1CCCNC1 XRMXKQUVKODRCE-UHFFFAOYSA-N 0.000 description 3
- RITORHGNHKPSTL-UHFFFAOYSA-N n-(1-piperidin-4-ylbenzimidazol-2-yl)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=CC=1C(=O)NC1=NC2=CC=CC=C2N1C1CCNCC1 RITORHGNHKPSTL-UHFFFAOYSA-N 0.000 description 3
- NNFTVKCIMDQALS-UHFFFAOYSA-N n-[1-(pyrrolidin-2-ylmethyl)benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1=NC2=CC=CC=C2N1CC1CCCN1 NNFTVKCIMDQALS-UHFFFAOYSA-N 0.000 description 3
- IOKPEECFXVXOTE-UHFFFAOYSA-N n-[1-[1-(2-cyanoacetyl)piperidin-4-yl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C1CN(C(CC#N)=O)CCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 IOKPEECFXVXOTE-UHFFFAOYSA-N 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 229950003600 ombrabulin Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960002340 pentostatin Drugs 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 229960004197 prasugrel Drugs 0.000 description 3
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 108010047846 soblidotin Proteins 0.000 description 3
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 3
- 229950006050 spiromustine Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 108010029464 tasidotin Proteins 0.000 description 3
- VNPMGBUQLYHEKC-UHFFFAOYSA-N tert-butyl 2-[(2-aminobenzimidazol-1-yl)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CN1C2=CC=CC=C2N=C1N VNPMGBUQLYHEKC-UHFFFAOYSA-N 0.000 description 3
- YKUZSULTZPITDY-UHFFFAOYSA-N tert-butyl 2-[(4-formyl-2-nitroanilino)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CNC1=CC=C(C=O)C=C1[N+]([O-])=O YKUZSULTZPITDY-UHFFFAOYSA-N 0.000 description 3
- RFUSWQMYTIJJNM-UHFFFAOYSA-N tert-butyl 3-(2-aminobenzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1N1C2=CC=CC=C2N=C1N RFUSWQMYTIJJNM-UHFFFAOYSA-N 0.000 description 3
- HTRPUELMHVKDEJ-XADRRFQNSA-N tert-butyl 3-[2-amino-5-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1N=C2N)=CC=C1N2C1CCCN(C(=O)OC(C)(C)C)C1 HTRPUELMHVKDEJ-XADRRFQNSA-N 0.000 description 3
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- DXSUORGKJZADET-YFKPBYRVSA-N (2s)-3,3-dimethylbutan-2-amine Chemical compound C[C@H](N)C(C)(C)C DXSUORGKJZADET-YFKPBYRVSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- JYFREZOLRUHBAQ-ZZXKWVIFSA-N (e)-2-cyano-4-methylpent-2-enoic acid Chemical compound CC(C)\C=C(/C#N)C(O)=O JYFREZOLRUHBAQ-ZZXKWVIFSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 2
- WOSZILCYMCIWFB-UHFFFAOYSA-N 2-ethoxy-2-methylpropan-1-ol Chemical compound CCOC(C)(C)CO WOSZILCYMCIWFB-UHFFFAOYSA-N 0.000 description 2
- HHIYJPQUMUPZIZ-UHFFFAOYSA-N 2-ethoxy-2-methylpropanal Chemical compound CCOC(C)(C)C=O HHIYJPQUMUPZIZ-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- IYOHBVDBNAPJGL-UHFFFAOYSA-N 3-nitro-4-(pyrrolidin-2-ylmethylamino)benzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1NCC1NCCC1 IYOHBVDBNAPJGL-UHFFFAOYSA-N 0.000 description 2
- JRXPBLKGFXAZRM-UHFFFAOYSA-N 3-nitro-4-[[1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl]methylamino]benzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1NCC1N(C(=O)C(F)(F)F)CCC1 JRXPBLKGFXAZRM-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
- RBMAULGIKXYACF-YMQLSTQVSA-N 4-chloro-N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 RBMAULGIKXYACF-YMQLSTQVSA-N 0.000 description 2
- NMTOADLKBAVSJS-UHFFFAOYSA-N 4-chloro-N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC(CC1)n1c(NC(=O)c2ccc(Cl)cc2)nc2ccccc12 NMTOADLKBAVSJS-UHFFFAOYSA-N 0.000 description 2
- CJIVEUWTGLLIFU-UHFKCPIBSA-N 4-chloro-N-[1-[1-[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]piperidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C[C@H](NCc1ccc2n(C3CCCN(C3)C(=O)C(=CC(C)(C)N(C)C)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(C)(C)C CJIVEUWTGLLIFU-UHFKCPIBSA-N 0.000 description 2
- VXZBUDYJKDRUQG-YMQLSTQVSA-N 4-chloro-N-[1-[[1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C[C@H](NCc1ccc2n(CC3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(C)(C)C VXZBUDYJKDRUQG-YMQLSTQVSA-N 0.000 description 2
- ZZQOQKYCDUHKGY-UHFFFAOYSA-N 4-chloro-N-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2ccccc12 ZZQOQKYCDUHKGY-UHFFFAOYSA-N 0.000 description 2
- ISKFNLBMHPFKSI-UHFFFAOYSA-N 4-chloro-n-[1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CN(C(=O)C=C)CCC1 ISKFNLBMHPFKSI-UHFFFAOYSA-N 0.000 description 2
- ZLCNMBYBMRKGJA-UHFFFAOYSA-N 4-chloro-n-[1-(1-prop-2-enoylpiperidin-4-yl)benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CCN(C(=O)C=C)CC1 ZLCNMBYBMRKGJA-UHFFFAOYSA-N 0.000 description 2
- IOXLJCZHUISQLE-UHFFFAOYSA-N 4-chloro-n-[1-[1-(2-cyanoacetyl)piperidin-3-yl]benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CN(C(=O)CC#N)CCC1 IOXLJCZHUISQLE-UHFFFAOYSA-N 0.000 description 2
- OSYDFPNBLZKBJE-UHFFFAOYSA-N 4-chloro-n-[1-[1-(2-cyanoacetyl)piperidin-4-yl]benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1C1CCN(C(=O)CC#N)CC1 OSYDFPNBLZKBJE-UHFFFAOYSA-N 0.000 description 2
- JSCQCFUVLYRVPO-UHFFFAOYSA-N 4-chloro-n-[1-[[1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=CC=CC=C2N1CC1N(C(=O)CC#N)CCC1 JSCQCFUVLYRVPO-UHFFFAOYSA-N 0.000 description 2
- YEYYZXOKXFEYBZ-IBGZPJMESA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-1-(1-prop-2-enoylpiperidin-4-yl)benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCN(C(=O)C=C)CC1 YEYYZXOKXFEYBZ-IBGZPJMESA-N 0.000 description 2
- JFQFQQBYOIEJBW-PBVYKCSPSA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-1-piperidin-3-ylbenzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCCNC1 JFQFQQBYOIEJBW-PBVYKCSPSA-N 0.000 description 2
- UUVKWCWCTSLAJZ-HSTJUUNISA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C1CCCN(C(=O)C=C)C1 UUVKWCWCTSLAJZ-HSTJUUNISA-N 0.000 description 2
- DWKZKXRZFPIRSR-IBGZPJMESA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-(1-prop-2-enoylpiperidin-4-yl)benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C1CCN(C(=O)C=C)CC1 DWKZKXRZFPIRSR-IBGZPJMESA-N 0.000 description 2
- RTHKPHCVZVYDFN-UHFFFAOYSA-N 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol Chemical compound NC1=NC=CC(C=2C3=C(O)C=CN=C3N3C(N)=NC=CC3=2)=N1 RTHKPHCVZVYDFN-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- LDZJNMJIPNOYGA-UHFFFAOYSA-N C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O Chemical compound C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O LDZJNMJIPNOYGA-UHFFFAOYSA-N 0.000 description 2
- VQIGCSYDTCTBCH-QGZVFWFLSA-N CC(C)(CN)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CC(C)(CN)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 VQIGCSYDTCTBCH-QGZVFWFLSA-N 0.000 description 2
- CQFUHGVGRCZEJT-JOCHJYFZSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccc(CNCC(C)(C)C)cc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccc(CNCC(C)(C)C)cc12 CQFUHGVGRCZEJT-JOCHJYFZSA-N 0.000 description 2
- YATADSZZTJMECJ-KRWDZBQOSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 YATADSZZTJMECJ-KRWDZBQOSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- YATADSZZTJMECJ-QGZVFWFLSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 YATADSZZTJMECJ-QGZVFWFLSA-N 0.000 description 2
- VIBYUJSXJRKUAT-GVNKFJBHSA-N N-[1-[[1-(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-4-chlorobenzamide Chemical compound C[C@H](NCc1ccc2n(CC3CCCN3C(=O)C(=CC(C)(C)N)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(C)(C)C VIBYUJSXJRKUAT-GVNKFJBHSA-N 0.000 description 2
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102100032983 Phospholipase D2 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 2
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- QPWBZVAOCWJTFK-UHFFFAOYSA-L [2-(azanidylmethyl)-3-hydroxy-2-(hydroxymethyl)propyl]azanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC(C[NH-])(CO)CO.[O-]C(=O)C1(C([O-])=O)CCC1 QPWBZVAOCWJTFK-UHFFFAOYSA-L 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229950004955 adozelesin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RACDEUIVLFZDED-SUHMBNCMSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(C3CCCN(C3)C(=O)C=C)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C RACDEUIVLFZDED-SUHMBNCMSA-N 0.000 description 2
- QMONFXXZDNUHLR-SUHMBNCMSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[1-(2-cyanoacetyl)piperidin-3-yl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(C3CCCN(C3)C(=O)CC#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C QMONFXXZDNUHLR-SUHMBNCMSA-N 0.000 description 2
- KKMCTQSHJXWQCX-GZMKETDRSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[[1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C KKMCTQSHJXWQCX-GZMKETDRSA-N 0.000 description 2
- YHNQHSFDVLDKKP-GZMKETDRSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN([C@@H](C)C(C)(C)C)C(=O)OCc3ccccc3)ccc12 YHNQHSFDVLDKKP-GZMKETDRSA-N 0.000 description 2
- MCNGYWDNGBOVQG-SUHMBNCMSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[[1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3C(=O)CC#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C MCNGYWDNGBOVQG-SUHMBNCMSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- XGMIIDZPVSFQDY-UHFKCPIBSA-N benzyl n-[[2-[(4-chlorobenzoyl)amino]-1-piperidin-3-ylbenzimidazol-5-yl]methyl]-n-[(2s)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1N=C2NC(=O)C=3C=CC(Cl)=CC=3)=CC=C1N2C1CCCNC1 XGMIIDZPVSFQDY-UHFKCPIBSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229950006844 bizelesin Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 229950009494 bropirimine Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 229950007509 carzelesin Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- BZXULYMZYPRZOG-UHFFFAOYSA-N centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 2
- NQGMIPUYCWIEAW-OVCLIPMQSA-N chembl1834105 Chemical compound O/N=C/C1=C(SC)C(OC)=CC(C=2N=CC=CC=2)=N1 NQGMIPUYCWIEAW-OVCLIPMQSA-N 0.000 description 2
- 201000005793 childhood medulloblastoma Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 108010083340 cryptophycin 52 Proteins 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 229960000288 dabigatran etexilate Drugs 0.000 description 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 2
- 229950001426 erbulozole Drugs 0.000 description 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 etanidazole Drugs 0.000 description 2
- WNIHNYUROPJCLW-UHFFFAOYSA-N ethyl 2-ethoxy-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)OCC WNIHNYUROPJCLW-UHFFFAOYSA-N 0.000 description 2
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- 229950005096 fazarabine Drugs 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229950006905 ilmofosine Drugs 0.000 description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003951 masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- 229950002676 menogaril Drugs 0.000 description 2
- IHLFUCCUUDPABC-LURJTMIESA-N methyl n-[(2s)-3,3-dimethylbutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C)C(C)(C)C IHLFUCCUUDPABC-LURJTMIESA-N 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 230000002071 myeloproliferative effect Effects 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- FJVXCDVNWKUTNI-UHFFFAOYSA-N n-[1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C1N(C(=O)C=C)CCCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 FJVXCDVNWKUTNI-UHFFFAOYSA-N 0.000 description 2
- BIHSHFCKGAZEGF-UHFFFAOYSA-N n-[1-(1-prop-2-enoylpiperidin-4-yl)benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C1CN(C(=O)C=C)CCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 BIHSHFCKGAZEGF-UHFFFAOYSA-N 0.000 description 2
- ZCIUIMWOOOPQJN-UHFFFAOYSA-N n-[1-[(1-prop-2-enoylpyrrolidin-2-yl)methyl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C=CC(=O)N1CCCC1CN1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 ZCIUIMWOOOPQJN-UHFFFAOYSA-N 0.000 description 2
- KXDPOXVJEDRXKJ-UHFFFAOYSA-N n-[1-[1-(2-cyanoacetyl)piperidin-3-yl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound C1N(C(CC#N)=O)CCCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 KXDPOXVJEDRXKJ-UHFFFAOYSA-N 0.000 description 2
- XQNUDANVAWGAAG-JOCHJYFZSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-5-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C([C@@H]1CN2C3=CC=C(C=C3N=C2NC(=O)C=2SC(=CC=2)C(F)F)CNCC(C)(C)C)CCN1C(=O)C(C#N)=CC1(C)COC1 XQNUDANVAWGAAG-JOCHJYFZSA-N 0.000 description 2
- SFYOUVPNZCUYFJ-UHFFFAOYSA-N n-[1-[[1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound N#CCC(=O)N1CCCC1CN1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 SFYOUVPNZCUYFJ-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229950008017 ormaplatin Drugs 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- 229950009351 perfosfamide Drugs 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 108010002267 phospholipase D2 Proteins 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229960004293 porfimer sodium Drugs 0.000 description 2
- 229950004406 porfiromycin Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 rogletimide Drugs 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N rohitukine Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- 229950008902 safingol Drugs 0.000 description 2
- CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UWPXRVDIKGZQQW-UHFFFAOYSA-N sodium;(3-fluoro-4-methoxyphenyl)-(2,3,4,5,6-pentafluorophenyl)sulfonylazanide Chemical compound [Na+].C1=C(F)C(OC)=CC=C1[N-]S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F UWPXRVDIKGZQQW-UHFFFAOYSA-N 0.000 description 2
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 2
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 2
- HAOCRCFHEPRQOY-JKTUOYIXSA-N spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- SOGXYCNKQQJEED-MRVPVSSYSA-N tert-butyl (2r)-2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1CN SOGXYCNKQQJEED-MRVPVSSYSA-N 0.000 description 2
- SOGXYCNKQQJEED-QMMMGPOBSA-N tert-butyl (2s)-2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CN SOGXYCNKQQJEED-QMMMGPOBSA-N 0.000 description 2
- SOGXYCNKQQJEED-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CN SOGXYCNKQQJEED-UHFFFAOYSA-N 0.000 description 2
- LVAKRLBWFJEZHM-UHFFFAOYSA-N tert-butyl 2-[(2-aminoanilino)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CNC1=CC=CC=C1N LVAKRLBWFJEZHM-UHFFFAOYSA-N 0.000 description 2
- VPNIORGTYKHCGB-UHFFFAOYSA-N tert-butyl 2-[(2-nitroanilino)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CNC1=CC=CC=C1[N+]([O-])=O VPNIORGTYKHCGB-UHFFFAOYSA-N 0.000 description 2
- ABMCLHGMCSPVSP-UHFFFAOYSA-N tert-butyl 2-[[2-(pyridine-3-carbonylamino)benzimidazol-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CN1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 ABMCLHGMCSPVSP-UHFFFAOYSA-N 0.000 description 2
- ZRAAHHZFCTXZIR-PAMMARIWSA-N tert-butyl 2-[[2-[(4-chlorobenzoyl)amino]-5-[[[(2S)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]benzimidazol-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3C(=O)OC(C)(C)C)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C ZRAAHHZFCTXZIR-PAMMARIWSA-N 0.000 description 2
- YJGNITYSSBERTF-UHFFFAOYSA-N tert-butyl 2-[[2-[(4-chlorobenzoyl)amino]benzimidazol-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2ccccc12 YJGNITYSSBERTF-UHFFFAOYSA-N 0.000 description 2
- QVTQBRFEIAHZAQ-ATNAJCNCSA-N tert-butyl 2-[[4-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-2-nitroanilino]methyl]pyrrolidine-1-carboxylate Chemical compound [O-][N+](=O)C1=CC(CN[C@@H](C)C(C)(C)C)=CC=C1NCC1N(C(=O)OC(C)(C)C)CCC1 QVTQBRFEIAHZAQ-ATNAJCNCSA-N 0.000 description 2
- HWFZPPRPWREWJO-UHFFFAOYSA-N tert-butyl 3-(2-nitroanilino)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1NC1=CC=CC=C1[N+]([O-])=O HWFZPPRPWREWJO-UHFFFAOYSA-N 0.000 description 2
- XCAPFIGFWRUIRR-UHFFFAOYSA-N tert-butyl 3-(4-formyl-2-nitroanilino)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1NC1=CC=C(C=O)C=C1[N+]([O-])=O XCAPFIGFWRUIRR-UHFFFAOYSA-N 0.000 description 2
- XSJPKMUFBHSIRA-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CN)C1 XSJPKMUFBHSIRA-UHFFFAOYSA-N 0.000 description 2
- NWNKGNBJCKIUHP-UHFFFAOYSA-N tert-butyl 3-[2-(pyridine-3-carbonylamino)benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C1)n1c(NC(=O)c2cccnc2)nc2ccccc12 NWNKGNBJCKIUHP-UHFFFAOYSA-N 0.000 description 2
- LVQWKHXWFFFOSI-UHFFFAOYSA-N tert-butyl 3-[2-[(4-chlorobenzoyl)amino]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 LVQWKHXWFFFOSI-UHFFFAOYSA-N 0.000 description 2
- RRSXVPTWVSMCJO-XADRRFQNSA-N tert-butyl 3-[2-amino-4-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]anilino]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1N)=CC=C1NC1CCCN(C(=O)OC(C)(C)C)C1 RRSXVPTWVSMCJO-XADRRFQNSA-N 0.000 description 2
- FYOLXFNGVOVABE-XADRRFQNSA-N tert-butyl 3-[4-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]-2-nitroanilino]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1[N+]([O-])=O)=CC=C1NC1CCCN(C(=O)OC(C)(C)C)C1 FYOLXFNGVOVABE-XADRRFQNSA-N 0.000 description 2
- QAMKZPZMTWAMLU-UHFFFAOYSA-N tert-butyl 4-(2-aminoanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC=C1N QAMKZPZMTWAMLU-UHFFFAOYSA-N 0.000 description 2
- GSTRFYOGNAYPHU-UHFFFAOYSA-N tert-butyl 4-(4-formyl-2-nitroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=C(C=O)C=C1[N+]([O-])=O GSTRFYOGNAYPHU-UHFFFAOYSA-N 0.000 description 2
- NRMIRYCIZFPTIQ-UHFFFAOYSA-N tert-butyl 4-[2-(pyridine-3-carbonylamino)benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=CN=C1 NRMIRYCIZFPTIQ-UHFFFAOYSA-N 0.000 description 2
- IWXCEKZJRRPPNC-FQEVSTJZSA-N tert-butyl 4-[2-[(4-chlorobenzoyl)amino]-5-[[[(2S)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C[C@H](N(Cc1ccc2n(C3CCN(CC3)C(=O)OC(C)(C)C)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)C(F)(F)F)C(C)(C)C IWXCEKZJRRPPNC-FQEVSTJZSA-N 0.000 description 2
- MYAPZQIVFNBYOV-INIZCTEOSA-N tert-butyl 4-[2-amino-4-[[[(2S)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]anilino]piperidine-1-carboxylate Chemical compound C[C@H](N(Cc1ccc(NC2CCN(CC2)C(=O)OC(C)(C)C)c(N)c1)C(=O)C(F)(F)F)C(C)(C)C MYAPZQIVFNBYOV-INIZCTEOSA-N 0.000 description 2
- RMYVXHKTZPBBCN-INIZCTEOSA-N tert-butyl 4-[2-amino-5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCN(C(=O)OC(C)(C)C)CC1 RMYVXHKTZPBBCN-INIZCTEOSA-N 0.000 description 2
- KYBGWERHPVGWLK-INIZCTEOSA-N tert-butyl 4-[4-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-2-nitroanilino]piperidine-1-carboxylate Chemical compound [O-][N+](=O)C1=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 KYBGWERHPVGWLK-INIZCTEOSA-N 0.000 description 2
- SNGJAPFOLOONFM-INIZCTEOSA-N tert-butyl 4-[4-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-2-nitroanilino]piperidine-1-carboxylate Chemical compound [O-][N+](=O)C1=CC(CN[C@@H](C)C(C)(C)C)=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 SNGJAPFOLOONFM-INIZCTEOSA-N 0.000 description 2
- JUJWZUXFWXFHJZ-UHFFFAOYSA-N tert-butyl n-methyl-n-(2-methyl-1-oxopropan-2-yl)carbamate Chemical compound O=CC(C)(C)N(C)C(=O)OC(C)(C)C JUJWZUXFWXFHJZ-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 229950002376 tirapazamine Drugs 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- TVPNFKRGOFJQOO-UHFFFAOYSA-N topsentin b1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000004654 triazenes Chemical class 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- 229950003017 zeniplatin Drugs 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OTWVIYXCRFLDJW-QMVMUTFZSA-N (1-hydroxy-1-phosphonooxyethyl) dihydrogen phosphate;rhenium-186 Chemical compound [186Re].OP(=O)(O)OC(O)(C)OP(O)(O)=O OTWVIYXCRFLDJW-QMVMUTFZSA-N 0.000 description 1
- QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- FNEOHTTZLPHOSX-KZNAEPCWSA-N (1r)-1-[(2r,5r)-5-(hydroxymethyl)oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H](CO)O1 FNEOHTTZLPHOSX-KZNAEPCWSA-N 0.000 description 1
- XJYQGNNBDGDYCE-DXBBTUNJSA-N (1r)-1-[(2r,5r)-5-[(1s)-1-hydroxypent-4-enyl]oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H]([C@@H](O)CCC=C)O1 XJYQGNNBDGDYCE-DXBBTUNJSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 1
- MRJQTLJSMQOFTP-JGTKTWDESA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 MRJQTLJSMQOFTP-JGTKTWDESA-N 0.000 description 1
- KJTPWUVVLPCPJD-VGOFMYFVSA-N (2e)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C/C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-VGOFMYFVSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2e,4e,6e)-7-[(1r,5r,6s)-3-[[(2e,4e)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2s)-2-[(3s,6s)-6-[2-[(1r,2r,4as,8as)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2s)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-MQHIEMKOSA-N (3s,10r,13e)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)OC([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-MQHIEMKOSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3s,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- FRCJDPPXHQGEKS-BCHFMIIMSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-BCHFMIIMSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4as,12br)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- VTTMWBPZTZHGLU-IVSQCGTASA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(e)-1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-5,5,7,9,13-pentamethyl-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(CO)=N1 VTTMWBPZTZHGLU-IVSQCGTASA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8r,9s,10r,13s,14s,16r)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- CNTMOLDWXSVYKD-PSRNMDMQSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CNQCTSLNJJVSAU-UHFFFAOYSA-N 132937-89-4 Chemical compound O.Cl.Cl.Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO CNQCTSLNJJVSAU-UHFFFAOYSA-N 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- NUXKIZBEPYVRKP-RWBWKAGLSA-N 1xa5 Chemical compound O([C@]12[C@@H]3N(C)C4=C([C@]53CCN3CC=C[C@@]([C@@H]53)(CC)C2)C=C(C(=C4)OC)[C@]2(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C2)C[C@@](C3)(O)CC)C(=O)N(CCCl)C1=O NUXKIZBEPYVRKP-RWBWKAGLSA-N 0.000 description 1
- LNELBQZKXVASLW-AWEZNQCLSA-N 2,2,2-trifluoro-n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(=O)C(F)(F)F)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC LNELBQZKXVASLW-AWEZNQCLSA-N 0.000 description 1
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- XRIBIDPMFSLGFS-UHFFFAOYSA-N 2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(C)CO XRIBIDPMFSLGFS-UHFFFAOYSA-N 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 description 1
- WEOZZCRYSSUDTA-QGZVFWFLSA-N 2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-n-(2,2-dimethylpropyl)-1-[[(2r)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazole-5-carboxamide Chemical compound C=1C=C(C(F)F)SC=1C(=O)NC1=NC2=CC(C(=O)NCC(C)(C)C)=CC=C2N1C[C@H]1CCCN1C(=O)C=C WEOZZCRYSSUDTA-QGZVFWFLSA-N 0.000 description 1
- JYNQMUKMAJGBOH-FUHWJXTLSA-N 2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-n-[(2s)-3,3-dimethylbutan-2-yl]-1-[[(2r)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazole-5-carboxamide Chemical compound C=1C=C(C(F)F)SC=1C(=O)NC1=NC2=CC(C(=O)N[C@@H](C)C(C)(C)C)=CC=C2N1C[C@H]1CCCN1C(=O)C=C JYNQMUKMAJGBOH-FUHWJXTLSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- XXSPGBOGLXKMDU-UHFFFAOYSA-N 2-bromo-2-methylpropanoic acid Chemical compound CC(C)(Br)C(O)=O XXSPGBOGLXKMDU-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- WWILHZQYNPQALT-UHFFFAOYSA-N 2-methyl-2-morpholin-4-ylpropanal Chemical compound O=CC(C)(C)N1CCOCC1 WWILHZQYNPQALT-UHFFFAOYSA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- XCRIZPAVJCSAJD-UHFFFAOYSA-N 3-(2-aminoanilino)piperidine-1-carboxylic acid Chemical compound NC1=CC=CC=C1NC1CN(C(O)=O)CCC1 XCRIZPAVJCSAJD-UHFFFAOYSA-N 0.000 description 1
- GTGSTGARZGJSST-UHFFFAOYSA-N 3-(2-aminobenzimidazol-1-yl)piperidine-1-carboxylic acid Chemical compound NC1=NC2=CC=CC=C2N1C1CCCN(C(O)=O)C1 GTGSTGARZGJSST-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- SYVKLBUHZVETHY-CFMCSPIPSA-N 3-[4-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]-2-nitroanilino]piperidine-1-carboxylic acid Chemical compound [O-][N+](=O)C1=CC(CN[C@@H](C)C(C)(C)C)=CC=C1NC1CN(C(O)=O)CCC1 SYVKLBUHZVETHY-CFMCSPIPSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2h-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- JARCFMKMOFFIGZ-UHFFFAOYSA-N 4,6-dioxo-n-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide Chemical compound O=C1NC(=S)NC(=O)C1C(=O)NC1=CC=CC=C1 JARCFMKMOFFIGZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- CTSNHMQGVWXIEG-UHFFFAOYSA-N 4-amino-n-(5-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C(Cl)=CC=C2)C2=N1 CTSNHMQGVWXIEG-UHFFFAOYSA-N 0.000 description 1
- NGGIQWZGTDAAJH-UHFKCPIBSA-N 4-chloro-N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]-methylamino]methyl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN(C)[C@@H](C)C(C)(C)C)ccc12 NGGIQWZGTDAAJH-UHFKCPIBSA-N 0.000 description 1
- UEQXAADALLLSMT-UHFFFAOYSA-N 4-chloro-N-[1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(Cl)cc2)nc2ccccc12 UEQXAADALLLSMT-UHFFFAOYSA-N 0.000 description 1
- XEBOJRDCSPSTGD-UHFKCPIBSA-N 4-chloro-N-[1-[[1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 XEBOJRDCSPSTGD-UHFKCPIBSA-N 0.000 description 1
- IDCBJNSYNBCBLI-UHFKCPIBSA-N 4-chloro-N-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]-methylamino]methyl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN(C)[C@@H](C)C(C)(C)C)ccc12 IDCBJNSYNBCBLI-UHFKCPIBSA-N 0.000 description 1
- ORXBNTKJJCAZQQ-UHFKCPIBSA-N 4-chloro-N-[1-[[1-[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C[C@H](NCc1ccc2n(CC3CCCN3C(=O)C(=CC(C)(C)N(C)C)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(C)(C)C ORXBNTKJJCAZQQ-UHFKCPIBSA-N 0.000 description 1
- JBIGYUSAODIDJA-HSTJUUNISA-N 4-chloro-n-[1-[1-(2-cyanoacetyl)piperidin-3-yl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCCN(C(=O)CC#N)C1 JBIGYUSAODIDJA-HSTJUUNISA-N 0.000 description 1
- BNWOUNYZIXNVOZ-IHOKFDBFSA-N 4-chloro-n-[1-[1-[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]piperidin-2-yl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C1CCCCN1C(=O)C(=CC(C)(C)N(C)C)C#N BNWOUNYZIXNVOZ-IHOKFDBFSA-N 0.000 description 1
- YECFERDISNIONL-YMQLSTQVSA-N 4-chloro-n-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]benzimidazol-2-yl]benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1CN1C2=CC=C(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)C=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 YECFERDISNIONL-YMQLSTQVSA-N 0.000 description 1
- WQCKAILXGNJHNW-HSTJUUNISA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-1-[(1-prop-2-enoylpyrrolidin-2-yl)methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1CC1CCCN1C(=O)C=C WQCKAILXGNJHNW-HSTJUUNISA-N 0.000 description 1
- RITULHCXJOFEKR-KRWDZBQOSA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]-(2,2,2-trifluoroacetyl)amino]methyl]-1-piperidin-4-ylbenzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN([C@@H](C)C(C)(C)C)C(=O)C(F)(F)F)=CC=C2N1C1CCNCC1 RITULHCXJOFEKR-KRWDZBQOSA-N 0.000 description 1
- BEDWKJCGDZYRIO-WMZHIEFXSA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-[[(2r)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C[C@H]1CCCN1C(=O)C=C BEDWKJCGDZYRIO-WMZHIEFXSA-N 0.000 description 1
- BEDWKJCGDZYRIO-CVDCTZTESA-N 4-chloro-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-[[(2s)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazol-2-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C[C@@H]1CCCN1C(=O)C=C BEDWKJCGDZYRIO-CVDCTZTESA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- NGOHKPKJZRSBJH-CYBMUJFWSA-N 5-(difluoromethyl)-N-[1-[[(2R)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazol-2-yl]thiophene-2-carboxamide Chemical compound FC(F)c1ccc(s1)C(=O)Nc1nc2ccccc2n1C[C@H]1CCCN1C(=O)C=C NGOHKPKJZRSBJH-CYBMUJFWSA-N 0.000 description 1
- NXTKFBGDLDPFLB-PKOBYXMFSA-N 5-(difluoromethyl)-n-[5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-1-[[(2r)-1-prop-2-enoylpyrrolidin-2-yl]methyl]benzimidazol-2-yl]thiophene-2-carboxamide Chemical compound C=1C=C(C(F)F)SC=1C(=O)NC1=NC2=CC(CN[C@@H](C)C(C)(C)C)=CC=C2N1C[C@H]1CCCN1C(=O)C=C NXTKFBGDLDPFLB-PKOBYXMFSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(e)-5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- VGULLEUAAMBZTQ-UHFFFAOYSA-N 5-desacetylaltohyrtin A Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C VGULLEUAAMBZTQ-UHFFFAOYSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DODZYUBVSA-N 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DODZYUBVSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N 8,10-dihydroimidazo[4,5-a]acridin-9-one Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-n,6-n-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 101100366892 Anopheles gambiae Stat gene Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N Arg-Lys-Glu-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N Azatyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 102400001242 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 101150082122 Blk gene Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- OQOGKPJFTBYENU-SIKLNZKXSA-N C(#N)C(C(=O)N1[C@H](CCC1)CN1C(=NC2=C1C=CC(=C2)C(=O)N[C@@H](C)C(C)(C)C)NC(=O)C=2SC(=CC2)C(F)F)=CC(C)(C)C Chemical compound C(#N)C(C(=O)N1[C@H](CCC1)CN1C(=NC2=C1C=CC(=C2)C(=O)N[C@@H](C)C(C)(C)C)NC(=O)C=2SC(=CC2)C(F)F)=CC(C)(C)C OQOGKPJFTBYENU-SIKLNZKXSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- GPQKQUDFVKPEOM-KRWDZBQOSA-N CC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 GPQKQUDFVKPEOM-KRWDZBQOSA-N 0.000 description 1
- DWHFOQZDNLHWKO-JOCHJYFZSA-N CC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC3(C)COC3)ccc12 Chemical compound CC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC3(C)COC3)ccc12 DWHFOQZDNLHWKO-JOCHJYFZSA-N 0.000 description 1
- YLPUCKZERGPMRO-GOSISDBHSA-N CC(C)(C)C=C(C#N)C(=O)N1CCC[C@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CO)ccc12 Chemical compound CC(C)(C)C=C(C#N)C(=O)N1CCC[C@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CO)ccc12 YLPUCKZERGPMRO-GOSISDBHSA-N 0.000 description 1
- DMEATURBPVSRRO-JOCHJYFZSA-N CC(C)(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 Chemical compound CC(C)(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 DMEATURBPVSRRO-JOCHJYFZSA-N 0.000 description 1
- KERGKWUCPUYFDY-LJQANCHMSA-N CC(C)(N)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 KERGKWUCPUYFDY-LJQANCHMSA-N 0.000 description 1
- UQWPYWYTSFJMMF-MRXNPFEDSA-N CC(C)(N)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 UQWPYWYTSFJMMF-MRXNPFEDSA-N 0.000 description 1
- KERGKWUCPUYFDY-IBGZPJMESA-N CC(C)(N)C=C(C#N)C(=O)N1CCC[C@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CCC[C@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 KERGKWUCPUYFDY-IBGZPJMESA-N 0.000 description 1
- CXHUGPXIBRZISP-HNNXBMFYSA-N CC(C)(N)C=C(C#N)C(=O)N1CC[C@@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CC[C@@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 CXHUGPXIBRZISP-HNNXBMFYSA-N 0.000 description 1
- SQOPKWDFBJBACR-LJQANCHMSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(F)c(F)c2)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(F)c(F)c2)nc2ccccc12 SQOPKWDFBJBACR-LJQANCHMSA-N 0.000 description 1
- LQCXBVMAZBLOOP-HXUWFJFHSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 LQCXBVMAZBLOOP-HXUWFJFHSA-N 0.000 description 1
- QCRYZUCDZVRVCI-RUZDIDTESA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CCC(CC3)C(C)(C)O)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CCC(CC3)C(C)(C)O)ccc12 QCRYZUCDZVRVCI-RUZDIDTESA-N 0.000 description 1
- JSVFGRVLUTVNGV-OAQYLSRUSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC(C)(C)O)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC(C)(C)O)ccc12 JSVFGRVLUTVNGV-OAQYLSRUSA-N 0.000 description 1
- HZAKXZQYXUIONR-NZQKXSOJSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 HZAKXZQYXUIONR-NZQKXSOJSA-N 0.000 description 1
- JSWURCKNZNBTFH-JOCHJYFZSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(C)c2)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(C)c2)nc2ccccc12 JSWURCKNZNBTFH-JOCHJYFZSA-N 0.000 description 1
- IYPWHKKLZAGNRL-OAQYLSRUSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)(F)F)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)(F)F)nc2ccccc12 IYPWHKKLZAGNRL-OAQYLSRUSA-N 0.000 description 1
- QKHAFOXBAADVOW-AREMUKBSSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)F)nc2cc(CNCC(C)(C)C)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)F)nc2cc(CNCC(C)(C)C)ccc12 QKHAFOXBAADVOW-AREMUKBSSA-N 0.000 description 1
- ZPMXHBLIXDCJKL-JOCHJYFZSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccno2)nc2cc(CNCC(C)(C)C)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccno2)nc2cc(CNCC(C)(C)C)ccc12 ZPMXHBLIXDCJKL-JOCHJYFZSA-N 0.000 description 1
- UIKLDSUEMDXSAO-QGZVFWFLSA-N CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccno2)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccno2)nc2ccccc12 UIKLDSUEMDXSAO-QGZVFWFLSA-N 0.000 description 1
- LFLXTSCSZDXQFA-SIKLNZKXSA-N CC(C)C=C(C#N)C(=O)N1CC[C@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 Chemical compound CC(C)C=C(C#N)C(=O)N1CC[C@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 LFLXTSCSZDXQFA-SIKLNZKXSA-N 0.000 description 1
- SUGHCDXVQDYDJM-UHFFFAOYSA-N CC(C)C=C(C#N)C(=O)NCCn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 Chemical compound CC(C)C=C(C#N)C(=O)NCCn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 SUGHCDXVQDYDJM-UHFFFAOYSA-N 0.000 description 1
- UWIMDJVORIAWPF-JOCHJYFZSA-N CC(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 Chemical compound CC(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 UWIMDJVORIAWPF-JOCHJYFZSA-N 0.000 description 1
- DENLNXZRANWHRM-JOCHJYFZSA-N CC(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 Chemical compound CC(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1 DENLNXZRANWHRM-JOCHJYFZSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- BLNJUTLVGGXVRE-GOSISDBHSA-N CN(C)C(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 Chemical compound CN(C)C(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 BLNJUTLVGGXVRE-GOSISDBHSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- XQCSUFGTKNCUON-IBGZPJMESA-N C[C@H](NCc1ccc2n(CC3CN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C Chemical compound C[C@H](NCc1ccc2n(CC3CN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C XQCSUFGTKNCUON-IBGZPJMESA-N 0.000 description 1
- UCLNSZFXRXOOOC-SIKLNZKXSA-N C[C@H](NCc1ccc2n([C@@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C Chemical compound C[C@H](NCc1ccc2n([C@@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C UCLNSZFXRXOOOC-SIKLNZKXSA-N 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 101100319886 Caenorhabditis elegans yap-1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- DFDTZECTHJFPHE-UHFFFAOYSA-N Crambescidin 816 Natural products C1CC=CC(CC)OC11NC(N23)=NC4(OC(C)CCC4)C(C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)CC(O)CCN)C3(O)CCC2C1 DFDTZECTHJFPHE-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- PQNNIEWMPIULRS-UHFFFAOYSA-N Cytostatin Natural products CC=CC=CC=CC(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-UHFFFAOYSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OALVLUFFPXEHFO-UHFFFAOYSA-N Diazonamide A Natural products O1C=2C34C(O)OC5=C3C=CC=C5C(C3=5)=CC=CC=5NC(Cl)=C3C(=C(N=3)Cl)OC=3C=2N=C1C(C(C)C)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=C(O)C4=C1 OALVLUFFPXEHFO-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- HWMMBHOXHRVLCU-UHFFFAOYSA-N Dioxamycin Natural products CC1OC(C)(C(O)=O)OC1C=CC=CC=CC(=O)OC1C(C)OC(C=2C(=C3C(=O)C4=C(C5(C(=O)C(O)C(C)(O)CC5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-UHFFFAOYSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 101100366894 Drosophila melanogaster Stat92E gene Proteins 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- 102400000220 ERBB4 intracellular domain Human genes 0.000 description 1
- 101800001263 ERBB4 intracellular domain Proteins 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 108010072471 HTI-286 Proteins 0.000 description 1
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 1
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000854607 Homo sapiens Protein FAM167A Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000909637 Homo sapiens Transcription factor COE1 Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108700022013 Insecta cecropin B Proteins 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N Leinamycin Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- ZHTRILQJTPJGNK-UHFFFAOYSA-N Leinamycin Natural products C1CC(C)=CC(O)C(=O)C=CC=CC(N=2)=CSC=2C(C)NC(=O)CC21S(=O)SC(=O)C2(C)O ZHTRILQJTPJGNK-UHFFFAOYSA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- LMVRPBWWHMVLPC-KBPJCXPTSA-N Leptolstatin Natural products CC(CC=CC(=CC(C)C(=O)C(C)C(O)C(C)CC(=CCO)C)C)C=C(C)/C=C/C1CC=CC(=O)O1 LMVRPBWWHMVLPC-KBPJCXPTSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930184337 Mannostatin Natural products 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100533558 Mus musculus Sipa1 gene Proteins 0.000 description 1
- HFPXYDFQVINJBV-UHFFFAOYSA-N Mycaperoxide B Natural products O1OC(C(C)C(O)=O)CCC1(C)CCC1(O)C2(C)CCCC(C)(C)C2CCC1C HFPXYDFQVINJBV-UHFFFAOYSA-N 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- QTNCDFCFEYGFKK-NZQKXSOJSA-N N-[1-[(3R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CC[C@H](C1)n1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 QTNCDFCFEYGFKK-NZQKXSOJSA-N 0.000 description 1
- SLXWPQJEDQZPMP-UHFFFAOYSA-N N-[1-[1-[4-(dimethylamino)but-2-enoyl]piperidin-3-yl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CN(C)CC=CC(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 SLXWPQJEDQZPMP-UHFFFAOYSA-N 0.000 description 1
- RRJNQPXEDXKYDP-UHFFFAOYSA-N N-[1-[2-[(2-cyano-4,4-dimethylpent-2-enoyl)-methylamino]ethyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CN(CCn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12)C(=O)C(=CC(C)(C)C)C#N RRJNQPXEDXKYDP-UHFFFAOYSA-N 0.000 description 1
- LXLHOTHUDCPGSM-UHFFFAOYSA-N N-[1-[2-[(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)-methylamino]ethyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CN(CCn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12)C(=O)C(=CC(C)(C)N1CCOCC1)C#N LXLHOTHUDCPGSM-UHFFFAOYSA-N 0.000 description 1
- LVWIBXVFQWLNMP-UHFFFAOYSA-N N-[1-[2-[(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)-methylamino]ethyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CN(CCn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12)C(=O)C(=CC(C)(C)N1CCOCC1)C#N LVWIBXVFQWLNMP-UHFFFAOYSA-N 0.000 description 1
- JLFPQIUXTNSGGW-UHFFFAOYSA-N N-[1-[2-[(2-cyano-4-methylpent-2-enoyl)-methylamino]ethyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N(C)CCn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 JLFPQIUXTNSGGW-UHFFFAOYSA-N 0.000 description 1
- KITXKLPNBSNKMV-UHFFFAOYSA-N N-[1-[2-[(4-amino-2-cyano-4-methylpent-2-enoyl)amino]ethyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CC(C)(N)C=C(C#N)C(=O)NCCn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 KITXKLPNBSNKMV-UHFFFAOYSA-N 0.000 description 1
- CQGBYYOQYXXHRS-UHFFFAOYSA-N N-[1-[2-[[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]-methylamino]ethyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CN(C)C(C)(C)C=C(C#N)C(=O)N(C)CCn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 CQGBYYOQYXXHRS-UHFFFAOYSA-N 0.000 description 1
- QACOWUHCAADHOL-JOCHJYFZSA-N N-[1-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound CC(C)(C)CNCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccno3)nc2c1 QACOWUHCAADHOL-JOCHJYFZSA-N 0.000 description 1
- RLDPNOKUAJJKAE-NZQKXSOJSA-N N-[1-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccno3)nc2c1)C(C)(C)C RLDPNOKUAJJKAE-NZQKXSOJSA-N 0.000 description 1
- PZXIJOGNZBFDDY-WXVAWEFUSA-N N-[1-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-3-(difluoromethyl)benzamide Chemical compound C[C@H](NCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3cccc(c3)C(F)F)nc2c1)C(C)(C)C PZXIJOGNZBFDDY-WXVAWEFUSA-N 0.000 description 1
- VNEXWKVPCVGXBO-NZQKXSOJSA-N N-[1-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C VNEXWKVPCVGXBO-NZQKXSOJSA-N 0.000 description 1
- LKGICEWFDFZZHU-QGZVFWFLSA-N N-[1-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 LKGICEWFDFZZHU-QGZVFWFLSA-N 0.000 description 1
- GAHMVHLZCTVHRA-XUZZJYLKSA-N N-[1-[[(2R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccno2)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 GAHMVHLZCTVHRA-XUZZJYLKSA-N 0.000 description 1
- QASGUMRFEPXCHH-NEKDWFFYSA-N N-[1-[[(2R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-3-(difluoromethyl)benzamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 QASGUMRFEPXCHH-NEKDWFFYSA-N 0.000 description 1
- MHMWEMPKZFEAKU-XUZZJYLKSA-N N-[1-[[(2R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 MHMWEMPKZFEAKU-XUZZJYLKSA-N 0.000 description 1
- NBENDIJSHOFOAA-JOCHJYFZSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CC4(COC4)C3)ccc12 NBENDIJSHOFOAA-JOCHJYFZSA-N 0.000 description 1
- MRPHBIFIKUPPGR-GOSISDBHSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-(hydroxymethyl)benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CO)ccc12 MRPHBIFIKUPPGR-GOSISDBHSA-N 0.000 description 1
- UHBMPFVURDNWGG-LJQANCHMSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(2,2,2-trifluoroethylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC(F)(F)F)ccc12 UHBMPFVURDNWGG-LJQANCHMSA-N 0.000 description 1
- OYMIVDSFMCRSCY-JOCHJYFZSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC(C)(C)C)ccc12 OYMIVDSFMCRSCY-JOCHJYFZSA-N 0.000 description 1
- QFCOXWTXMYXVCT-RUZDIDTESA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccnc2)nc2cc(CNCC(C)(C)C)ccc12 QFCOXWTXMYXVCT-RUZDIDTESA-N 0.000 description 1
- MCUIASHTUALYOO-HXUWFJFHSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(3-hydroxyazetidin-1-yl)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CC(O)C3)ccc12 MCUIASHTUALYOO-HXUWFJFHSA-N 0.000 description 1
- MIFOJSQZKKCGSR-HSZRJFAPSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[(4-methylpiperazin-1-yl)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CCN(C)CC3)ccc12 MIFOJSQZKKCGSR-HSZRJFAPSA-N 0.000 description 1
- SYGRWQGHGJIPLA-JOCHJYFZSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[(3-methyloxetan-3-yl)methylamino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CNCC3(C)COC3)ccc12 SYGRWQGHGJIPLA-JOCHJYFZSA-N 0.000 description 1
- WBCVELMHKYENBI-HSZRJFAPSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[3-(2-hydroxypropan-2-yl)azetidin-1-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN3CC(C3)C(C)(C)O)ccc12 WBCVELMHKYENBI-HSZRJFAPSA-N 0.000 description 1
- JCVXBWLQGVBORU-WXVAWEFUSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-3-(difluoromethyl)benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 JCVXBWLQGVBORU-WXVAWEFUSA-N 0.000 description 1
- RRKBUDNNABXBGO-NFBKMPQASA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[[[(2R)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccc(CN[C@H](C)C(C)(C)C)cc12 RRKBUDNNABXBGO-NFBKMPQASA-N 0.000 description 1
- RRKBUDNNABXBGO-NZQKXSOJSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccc(CN[C@@H](C)C(C)(C)C)cc12 RRKBUDNNABXBGO-NZQKXSOJSA-N 0.000 description 1
- AMRJPRQJNVHIKR-OAQYLSRUSA-N N-[1-[[(2R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-3-(difluoromethyl)benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2cccc(c2)C(F)F)nc2ccccc12 AMRJPRQJNVHIKR-OAQYLSRUSA-N 0.000 description 1
- MQEUGLCVJJZQIL-QGZVFWFLSA-N N-[1-[[(2R)-1-(2-cyano-5-hydroxy-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)(CO)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2ccccc12 MQEUGLCVJJZQIL-QGZVFWFLSA-N 0.000 description 1
- LQCXBVMAZBLOOP-FQEVSTJZSA-N N-[1-[[(2S)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCC[C@H]1Cn1c(NC(=O)c2ccc(s2)-c2cn[nH]c2)nc2ccccc12 LQCXBVMAZBLOOP-FQEVSTJZSA-N 0.000 description 1
- YHBKVUXNMFCOFE-UNMCSNQZSA-N N-[1-[[(3R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccno3)nc2c1)C(C)(C)C YHBKVUXNMFCOFE-UNMCSNQZSA-N 0.000 description 1
- CPZCGAKTFQMHHE-UNMCSNQZSA-N N-[1-[[(3R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C CPZCGAKTFQMHHE-UNMCSNQZSA-N 0.000 description 1
- XSLYJPFZBPVGAV-GMAHTHKFSA-N N-[1-[[(3R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CC[C@H](Cn2c(NC(=O)c3ccno3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc23)C1 XSLYJPFZBPVGAV-GMAHTHKFSA-N 0.000 description 1
- RCXZMTOUBBQRHR-GMAHTHKFSA-N N-[1-[[(3R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C(#N)C(C(=O)N1C[C@H](CC1)CN1C(=NC2=C1C=CC(=C2)CN[C@@H](C)C(C)(C)C)NC(=O)C=2SC(=CC2)C(F)F)=CC(C)(C)OCC RCXZMTOUBBQRHR-GMAHTHKFSA-N 0.000 description 1
- YHBKVUXNMFCOFE-RBBKRZOGSA-N N-[1-[[(3S)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccno3)nc2c1)C(C)(C)C YHBKVUXNMFCOFE-RBBKRZOGSA-N 0.000 description 1
- CPZCGAKTFQMHHE-RBBKRZOGSA-N N-[1-[[(3S)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C[C@H](NCc1ccc2n(C[C@@H]3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C CPZCGAKTFQMHHE-RBBKRZOGSA-N 0.000 description 1
- XSLYJPFZBPVGAV-JTHBVZDNSA-N N-[1-[[(3S)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CC[C@@H](Cn2c(NC(=O)c3ccno3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc23)C1 XSLYJPFZBPVGAV-JTHBVZDNSA-N 0.000 description 1
- RCXZMTOUBBQRHR-JTHBVZDNSA-N N-[1-[[(3S)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C(#N)C(C(=O)N1C[C@@H](CC1)CN1C(=NC2=C1C=CC(=C2)CN[C@@H](C)C(C)(C)C)NC(=O)C=2SC(=CC2)C(F)F)=CC(C)(C)OCC RCXZMTOUBBQRHR-JTHBVZDNSA-N 0.000 description 1
- CPZCGAKTFQMHHE-AIBWNMTMSA-N N-[1-[[1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C[C@H](NCc1ccc2n(CC3CCN(C3)C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C CPZCGAKTFQMHHE-AIBWNMTMSA-N 0.000 description 1
- MJNVKCZHOZNRBI-UHFFFAOYSA-N N-[1-[[1-(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)azetidin-3-yl]methyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CC(C)(C=C(C#N)C(=O)N1CC(Cn2c(NC(=O)c3ccc(s3)-c3cn[nH]c3)nc3ccccc23)C1)N1CCOCC1 MJNVKCZHOZNRBI-UHFFFAOYSA-N 0.000 description 1
- SMLIDYYRRMBCGF-UHFFFAOYSA-N N-[1-[[1-(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)azetidin-3-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)(C=C(C#N)C(=O)N1CC(Cn2c(NC(=O)c3ccc(s3)C(F)F)nc3ccccc23)C1)N1CCOCC1 SMLIDYYRRMBCGF-UHFFFAOYSA-N 0.000 description 1
- LJPHXQJJIDNMST-YMQLSTQVSA-N N-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-4-(difluoromethyl)benzamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(cc2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 LJPHXQJJIDNMST-YMQLSTQVSA-N 0.000 description 1
- HZAKXZQYXUIONR-AJZOCDQUSA-N N-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)ccc12 HZAKXZQYXUIONR-AJZOCDQUSA-N 0.000 description 1
- NJSLJTDNJJIBGW-UHFFFAOYSA-N N-[1-[[1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]pyridine-3-carboxamide Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2cccnc2)nc2ccccc12 NJSLJTDNJJIBGW-UHFFFAOYSA-N 0.000 description 1
- JOIZELWBJHBORQ-UHFFFAOYSA-N N-[1-[[1-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl]methyl]benzimidazol-2-yl]-5-(1H-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CC(Cn2c(NC(=O)c3ccc(s3)-c3cn[nH]c3)nc3ccccc23)C1 JOIZELWBJHBORQ-UHFFFAOYSA-N 0.000 description 1
- HAMCJNFSHMCJDO-UHFFFAOYSA-N N-[1-[[1-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC(C)(N)C=C(C#N)C(=O)N1CC(Cn2c(NC(=O)c3ccc(s3)C(F)F)nc3ccccc23)C1 HAMCJNFSHMCJDO-UHFFFAOYSA-N 0.000 description 1
- FDOHJLBVPMPGGN-UHFFFAOYSA-N N-[1-[[1-[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]azetidin-3-yl]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CN(C)C(C)(C)C=C(C#N)C(=O)N1CC(Cn2c(NC(=O)c3ccc(s3)C(F)F)nc3ccccc23)C1 FDOHJLBVPMPGGN-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- WMNNTKWYKDYTSO-SIKLNZKXSA-N N-[3-[[(2R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]imidazo[4,5-b]pyridin-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C[C@H](NCc1cnc2n(C[C@H]3CCCN3C(=O)C(=CC(C)(C)C)C#N)c(NC(=O)c3ccc(s3)C(F)F)nc2c1)C(C)(C)C WMNNTKWYKDYTSO-SIKLNZKXSA-N 0.000 description 1
- YFEWHPVXERCYIQ-NZQKXSOJSA-N N-[3-[[(2R)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[[[(2S)-3,3-dimethylbutan-2-yl]amino]methyl]imidazo[4,5-b]pyridin-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1Cn1c(NC(=O)c2ccc(s2)C(F)F)nc2cc(CN[C@@H](C)C(C)(C)C)cnc12 YFEWHPVXERCYIQ-NZQKXSOJSA-N 0.000 description 1
- ZHXNIYGJAOPMSO-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)(C)C)C=C1 ZHXNIYGJAOPMSO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GTEXXGIEZVKSLH-UHFFFAOYSA-N Naphterpin Natural products O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C1C=C(C)CCC1C(C)(C)O2 GTEXXGIEZVKSLH-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 101100438748 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyt-2 gene Proteins 0.000 description 1
- BUSGWUFLNHIBPT-UHFFFAOYSA-N Nisamycin Natural products O=C1C2OC2C(C=CC=CC=CC(=O)O)(O)C=C1NC(=O)C=CC=CC1CCCCC1 BUSGWUFLNHIBPT-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- WQLDJUQUFZDTSD-XXODBJNXSA-N O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQLDJUQUFZDTSD-XXODBJNXSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- LKBBOPGQDRPCDS-UHFFFAOYSA-N Oxaunomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N)C(O)C(C)O1 LKBBOPGQDRPCDS-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- VYOQBYCIIJYKJA-UHFFFAOYSA-N Palauamine Natural products C1N2C(=O)C3=CC=CN3C3N=C(N)NC32C2C1C(CN)C(Cl)C12NC(N)=NC1O VYOQBYCIIJYKJA-UHFFFAOYSA-N 0.000 description 1
- FRCJDPPXHQGEKS-UHFFFAOYSA-N Parabactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- APNRZHLOPQFNMR-UHFFFAOYSA-N Phenazinomycin Natural products C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1CC=C(C)CCC1C(=C)CCCC1(C)C APNRZHLOPQFNMR-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100020937 Protein FAM167A Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- PICZCWCKOLHDOJ-UHFFFAOYSA-N Pseudoaxinellin Natural products N1C(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C1CC1=CC=CC=C1 PICZCWCKOLHDOJ-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N Sarcophytol A Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- GCEUCUGYUPYUEC-UHFFFAOYSA-N Spongistatin 3 Natural products COC1CC2CC(=O)C(C)C(OC(=O)C)C(C)C(=C)CC3CC(C)(O)CC4(CCCC(CC(=O)OC5C(C)C(OC(CC(=C)CC(O)C=CC(=C)Cl)C5O)C(O)C6(O)CC(O)C(C)C(CCCC=C/C7CC(O)CC(C1)(O2)O7)O6)O4)O3 GCEUCUGYUPYUEC-UHFFFAOYSA-N 0.000 description 1
- JOEPUFOWFXWEDN-UHFFFAOYSA-N Spongistatin 5 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-UHFFFAOYSA-N 0.000 description 1
- BTCJGYMVVGSTDN-UHFFFAOYSA-N Spongistatin 7 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 BTCJGYMVVGSTDN-UHFFFAOYSA-N 0.000 description 1
- GLMCWICCTJHQKE-UHFFFAOYSA-N Spongistatin 9 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-UHFFFAOYSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- WXZSUBHBYQYTNM-UHFFFAOYSA-N Tetrazomine Natural products C1=CC=2CC(N34)C(N5C)C(CO)CC5C4OCC3C=2C(OC)=C1NC(=O)C1NCCCC1O WXZSUBHBYQYTNM-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 101150085042 Tnfsf4 gene Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102100024207 Transcription factor COE1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 101710083476 Tyrosine-protein kinase Blk Proteins 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-VRSYWUPDSA-N [(1s,2e,7s,10e,12r,13r,15s)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-VRSYWUPDSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- VQSGYKUTGGRSPK-SIOACEIBSA-N [(3s,4s,7s)-2-[3-[(2s,5s,8s,11s,14r,17r,20s,23r,26r)-11,14-bis(2-amino-2-oxoethyl)-5,20-bis[(1r)-1-hydroxyethyl]-8-methyl-17,23-bis(2-methylpropyl)-26-octyl-3,6,9,12,15,18,21,24,27-nonaoxo-1,4,7,10,13,16,19,22,25-nonazacycloheptacos-2-yl]propyl]-5-chloro- Chemical compound N1C(=O)[C@@H](CCCCCCCC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1[C@@]2(OCCC2)[C@@H](O)C2=C(Cl)C(=O)[C@@](C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-SIOACEIBSA-N 0.000 description 1
- FYQZGCBXYVWXSP-LCHZDSEPSA-N [(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate Chemical compound CN[C@H]1[C@@H](O[C@H]2[C@H](OC(=O)c3c(C)ccc4c(C)cc(OC)cc34)C=C3C#C[C@@]4(O[C@@H]4C#C\C=C2/3)[C@@H]2COC(=O)O2)O[C@H](C)[C@H](O)[C@@H]1O FYQZGCBXYVWXSP-LCHZDSEPSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8e,10e,12e)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- HLAKJNQXUARACO-UHFFFAOYSA-N acylfulvene Natural products CC1(O)C(=O)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-UHFFFAOYSA-N 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- WJSAFKJWCOMTLH-UHFFFAOYSA-N adecypenol Natural products OC1C(O)C(CO)=CC1N1C(NC=NCC2O)=C2N=C1 WJSAFKJWCOMTLH-UHFFFAOYSA-N 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229950010949 ambamustine Drugs 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 230000002244 anti-lymphoproliferative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010055530 arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide Proteins 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229950006933 atrimustine Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- UZCPCRPHNVHKKP-UHFFFAOYSA-N axinastatin 2 Natural products CC(C)CC1NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC(=O)C(NC1=O)C(C)C)C(C)C UZCPCRPHNVHKKP-UHFFFAOYSA-N 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- RTGMQVUKARGBNM-UHFFFAOYSA-N axinastatin 3 Natural products CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC1=O)C(C)C RTGMQVUKARGBNM-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 150000004200 baccatin III derivatives Chemical class 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- FMVYNJMSOLNCJN-GFDSEFBSSA-N benzyl N-[[1-[1-(4-amino-2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]-2-[(4-chlorobenzoyl)amino]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(C3CCCN(C3)C(=O)C(=CC(C)(C)N)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C FMVYNJMSOLNCJN-GFDSEFBSSA-N 0.000 description 1
- DLMNKHNZFKHOPB-GFDSEFBSSA-N benzyl N-[[1-[[1-(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-2-[(4-chlorobenzoyl)amino]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3C(=O)C(=CC(C)(C)N)C#N)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C DLMNKHNZFKHOPB-GFDSEFBSSA-N 0.000 description 1
- GWQQNXBRKWWIBP-UHFKCPIBSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-(pyrrolidin-2-ylmethyl)benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C GWQQNXBRKWWIBP-UHFKCPIBSA-N 0.000 description 1
- ZBJIFWPVYWADHD-SUHMBNCMSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[(1-prop-2-enoylpyrrolidin-2-yl)methyl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound C[C@H](N(Cc1ccc2n(CC3CCCN3C(=O)C=C)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C ZBJIFWPVYWADHD-SUHMBNCMSA-N 0.000 description 1
- WZWLZNJJIGIEPY-GZMKETDRSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound CC(C)C=C(C#N)C(=O)N1CCCC(C1)n1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN([C@@H](C)C(C)(C)C)C(=O)OCc3ccccc3)ccc12 WZWLZNJJIGIEPY-GZMKETDRSA-N 0.000 description 1
- AHBFZFUWEDALGU-GZMKETDRSA-N benzyl N-[[2-[(4-chlorobenzoyl)amino]-1-[[1-[2-cyano-4-methyl-4-(methylamino)pent-2-enoyl]pyrrolidin-2-yl]methyl]benzimidazol-5-yl]methyl]-N-[(2S)-3,3-dimethylbutan-2-yl]carbamate Chemical compound CNC(C)(C)C=C(C#N)C(=O)N1CCCC1Cn1c(NC(=O)c2ccc(Cl)cc2)nc2cc(CN([C@@H](C)C(C)(C)C)C(=O)OCc3ccccc3)ccc12 AHBFZFUWEDALGU-GZMKETDRSA-N 0.000 description 1
- SVXPPSFKJQWISH-UHFFFAOYSA-N benzyl carbamoperoxoate Chemical compound NC(=O)OOCC1=CC=CC=C1 SVXPPSFKJQWISH-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229950002370 bisnafide Drugs 0.000 description 1
- NPSOIFAWYAHWOH-UHFFFAOYSA-N bistratene A Natural products O1C(CC(=O)C=CC)CCC(O2)(O)CC(C)C2CCCNC(=O)C(C)C2OC(CCC(C)C=C(C)C(C)O)CCCCC(C)C1CC(=O)NC2 NPSOIFAWYAHWOH-UHFFFAOYSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229950002361 budotitane Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N chembl118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- JOAASNKBYBFGDN-UHFFFAOYSA-N chembl1214554 Chemical compound ON=C(N)C1=CC=C(O)C(O)=C1 JOAASNKBYBFGDN-UHFFFAOYSA-N 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- DCKFXSZUWVWFEU-JECTWPLRSA-N chembl499423 Chemical compound O1[C@@H](CC)CCCC[C@]11NC(N23)=N[C@]4(O[C@H](C)CCC4)[C@@H](C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)C[C@@H](O)CCN)[C@@]3(O)CC[C@H]2C1 DCKFXSZUWVWFEU-JECTWPLRSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 108010076060 chlorofusin Proteins 0.000 description 1
- VQSGYKUTGGRSPK-UHFFFAOYSA-N chlorofusin Natural products N1C(=O)C(CCCCCCCC)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C1CCCN1C2(OCCC2)C(O)C2=C(Cl)C(=O)C(C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229930193484 collismycin Natural products 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- YFGZFQNBPSCWPN-UHFFFAOYSA-N cryptophycin 52 Natural products C1=CC(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 YFGZFQNBPSCWPN-UHFFFAOYSA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- PESYEWKSBIWTAK-UHFFFAOYSA-N cyclopenta-1,3-diene;titanium(2+) Chemical compound [Ti+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 PESYEWKSBIWTAK-UHFFFAOYSA-N 0.000 description 1
- YXQWGVLNDXNSJJ-UHFFFAOYSA-N cyclopenta-1,3-diene;vanadium(2+) Chemical compound [V+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YXQWGVLNDXNSJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- IJNIQYINMSGIPS-UHFFFAOYSA-N darexaban Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC(O)=C1NC(=O)C1=CC=C(N2CCN(C)CCC2)C=C1 IJNIQYINMSGIPS-UHFFFAOYSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- WRPLJTYNAMMOEE-UHFFFAOYSA-N desmethyleleutherobin Natural products C1=CC2(C)OC1(O)C(COC1C(C(O)C(O)CO1)OC(C)=O)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 WRPLJTYNAMMOEE-UHFFFAOYSA-N 0.000 description 1
- WRPLJTYNAMMOEE-TXILBGFKSA-N desmethyleleutherobin Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(CO[C@H]2[C@H]([C@H](O)[C@H](O)CO2)OC(C)=O)/[C@]2(O)O[C@@]1(C)C=C2)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 WRPLJTYNAMMOEE-TXILBGFKSA-N 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 229950005878 dexverapamil Drugs 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N diazonamide a Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950005678 ecomustine Drugs 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003315 endocardial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HYSIJEPDMLSIQJ-UHFFFAOYSA-N ethanolate;1-phenylbutane-1,3-dione;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C1=CC=CC=C1 HYSIJEPDMLSIQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- WFUNYBAJYAWHLX-UHFFFAOYSA-N ethyl 2-(trifluoromethyl)-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(C(F)(F)F)=N1 WFUNYBAJYAWHLX-UHFFFAOYSA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl n-[4-[[(2r,4r)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229950005682 flurocitabine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 229950004217 forfenimex Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000006650 fundamental cellular process Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229950009926 idramantone Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028862 interferon gamma-1b Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229960003795 iobenguane (123i) Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229950000855 iroplact Drugs 0.000 description 1
- 229950010984 irsogladine Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- DWOIXRLFJBZDSB-MLLHTCFKSA-N isoeleutherobin a Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1O DWOIXRLFJBZDSB-MLLHTCFKSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 229950007654 itasetron Drugs 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- RBBBWKUBQVARPL-UHFFFAOYSA-N lissoclinamide 7 Natural products N1C(=O)C(N=2)CSC=2C(CC=2C=CC=CC=2)NC(=O)C(N=2)CSC=2C(C(C)C)NC(=O)C(C(O2)C)N=C2C2CCCN2C(=O)C1CC1=CC=CC=C1 RBBBWKUBQVARPL-UHFFFAOYSA-N 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N mannostatin A Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108700025096 meterelin Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 1
- CNJJSTPBUHAEFH-UHFFFAOYSA-N methyl 4-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 CNJJSTPBUHAEFH-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229950008541 mirimostim Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950008012 mofarotene Drugs 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N n',n'-diethyl-n-(9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- VYNKVNDKAOGAAQ-RUZDIDTESA-N n-[(1r)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1h-indole-6-carboxamide Chemical compound C1CN(C)CCC1N1CCN(C(=O)[C@H](NC(=O)C=2C=C3NC=CC3=CC=2)C=2C=CC=CC=2)CC1 VYNKVNDKAOGAAQ-RUZDIDTESA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- YBXPDICYKDCZLE-QHELBMECSA-N n-[1-(1-but-2-ynoylpiperidin-3-yl)-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-4-chlorobenzamide Chemical compound C1N(C(=O)C#CC)CCCC1N1C2=CC=C(CN[C@@H](C)C(C)(C)C)C=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 YBXPDICYKDCZLE-QHELBMECSA-N 0.000 description 1
- FRXBAXYQAPOWAR-LROBGIAVSA-N n-[1-(1-but-2-ynoylpiperidin-3-yl)-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C1N(C(=O)C#CC)CCCC1N1C2=CC=C(CN[C@@H](C)C(C)(C)C)C=C2N=C1NC(=O)C1=CC=C(C(F)F)S1 FRXBAXYQAPOWAR-LROBGIAVSA-N 0.000 description 1
- XLTISLKTFVQRJM-UHFFFAOYSA-N n-[1-(1-prop-2-enoylpiperidin-3-yl)benzimidazol-2-yl]-5-(1h-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound C1N(C(=O)C=C)CCCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=C(C2=CNN=C2)S1 XLTISLKTFVQRJM-UHFFFAOYSA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- KCTHPFHTRDQXRF-UHFFFAOYSA-N n-[1-[1-[2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl]piperidin-3-yl]benzimidazol-2-yl]-5-(1h-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound C1N(C(=O)C(C#N)=CC(C)(C)N(C)C)CCCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=C(C2=CNN=C2)S1 KCTHPFHTRDQXRF-UHFFFAOYSA-N 0.000 description 1
- RCMXQIUZBVVIHZ-WMZHIEFXSA-N n-[1-[[(2r)-1-(2-cyano-3-cyclopropylprop-2-enoyl)pyrrolidin-2-yl]methyl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C([C@@H]1CN2C3=CC=C(C=C3N=C2NC(=O)C=2SC(=CC=2)C(F)F)CN[C@@H](C)C(C)(C)C)CCN1C(=O)C(C#N)=CC1CC1 RCMXQIUZBVVIHZ-WMZHIEFXSA-N 0.000 description 1
- YODTUJOVIRISGE-HSZRJFAPSA-N n-[1-[[(2r)-1-(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(1h-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound C([C@H]1CCCN1C(=O)C(C#N)=CC(C)(C)N1CCOCC1)N(C1=CC=CC=C1N=1)C=1NC(=O)C(S1)=CC=C1C=1C=NNC=1 YODTUJOVIRISGE-HSZRJFAPSA-N 0.000 description 1
- RSQYZWWVOQXXCT-JOCHJYFZSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-5-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C([C@@H]1CN2C3=CC=C(C=C3N=C2NC(=O)C=2ON=CC=2)CNCC(C)(C)C)CCN1C(=O)C(C#N)=CC1(C)COC1 RSQYZWWVOQXXCT-JOCHJYFZSA-N 0.000 description 1
- RMJIFMJYPYOYGR-JOCHJYFZSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-5-[(2-methylpropylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C([C@@H]1CN2C3=CC=C(C=C3N=C2NC(=O)C=2SC(=CC=2)C(F)F)CNCC(C)C)CCN1C(=O)C(C#N)=CC1(C)COC1 RMJIFMJYPYOYGR-JOCHJYFZSA-N 0.000 description 1
- NXRYYYPWMLNEQW-JOCHJYFZSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-5-[[(3-methyloxetan-3-yl)methylamino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C=1C=C2N(C[C@@H]3N(CCC3)C(=O)C(=CC3(C)COC3)C#N)C(NC(=O)C=3SC(=CC=3)C(F)F)=NC2=CC=1CNCC1(C)COC1 NXRYYYPWMLNEQW-JOCHJYFZSA-N 0.000 description 1
- RGZZKKVSRWZCTM-NZQKXSOJSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C([C@@H]1CN2C3=CC=C(C=C3N=C2NC(=O)C=2SC(=CC=2)C(F)F)CN[C@@H](C)C(C)(C)C)CCN1C(=O)C(C#N)=CC1(C)COC1 RGZZKKVSRWZCTM-NZQKXSOJSA-N 0.000 description 1
- YPALOWSXANXYME-JOCHJYFZSA-N n-[1-[[(2r)-1-[2-cyano-3-(3-methyloxetan-3-yl)prop-2-enoyl]pyrrolidin-2-yl]methyl]-6-[(2,2-dimethylpropylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C([C@@H]1N(CCC1)C(=O)C(=CC1(C)COC1)C#N)N1C2=CC(CNCC(C)(C)C)=CC=C2N=C1NC(=O)C1=CC=C(C(F)F)S1 YPALOWSXANXYME-JOCHJYFZSA-N 0.000 description 1
- FBQOHNMAOIIGEG-GBXCKJPGSA-N n-[1-[[(2r)-1-but-2-ynoylpyrrolidin-2-yl]methyl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-4-chlorobenzamide Chemical compound CC#CC(=O)N1CCC[C@@H]1CN1C2=CC=C(CN[C@@H](C)C(C)(C)C)C=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 FBQOHNMAOIIGEG-GBXCKJPGSA-N 0.000 description 1
- SCLNOYIYGYTSQW-AZUAARDMSA-N n-[1-[[(2r)-1-but-2-ynoylpyrrolidin-2-yl]methyl]-5-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CC#CC(=O)N1CCC[C@@H]1CN1C2=CC=C(CN[C@@H](C)C(C)(C)C)C=C2N=C1NC(=O)C1=CC=C(C(F)F)S1 SCLNOYIYGYTSQW-AZUAARDMSA-N 0.000 description 1
- YODTUJOVIRISGE-QHCPKHFHSA-N n-[1-[[(2s)-1-(2-cyano-4-methyl-4-morpholin-4-ylpent-2-enoyl)pyrrolidin-2-yl]methyl]benzimidazol-2-yl]-5-(1h-pyrazol-4-yl)thiophene-2-carboxamide Chemical compound C([C@@H]1CCCN1C(=O)C(C#N)=CC(C)(C)N1CCOCC1)N(C1=CC=CC=C1N=1)C=1NC(=O)C(S1)=CC=C1C=1C=NNC=1 YODTUJOVIRISGE-QHCPKHFHSA-N 0.000 description 1
- DZTVDBKFLHTZCP-OAQYLSRUSA-N n-[3-[[(2r)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[(2,2-dimethylpropylamino)methyl]imidazo[4,5-b]pyridin-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound C=1C=C(C(F)F)SC=1C(=O)NC1=NC2=CC(CNCC(C)(C)C)=CN=C2N1C[C@H]1CCCN1C(=O)C(=CC(C)(C)C)C#N DZTVDBKFLHTZCP-OAQYLSRUSA-N 0.000 description 1
- YYFGDDYHQKBPGJ-JOCHJYFZSA-N n-[3-[[(2r)-1-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl]methyl]-6-[(2,2-dimethylpropylamino)methyl]imidazo[4,5-b]pyridin-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide Chemical compound CCOC(C)(C)C=C(C#N)C(=O)N1CCC[C@@H]1CN1C2=NC=C(CNCC(C)(C)C)C=C2N=C1NC(=O)C1=CC=C(C(F)F)S1 YYFGDDYHQKBPGJ-JOCHJYFZSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- DQPJVNQWPBLBAB-UHFFFAOYSA-N n-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=CC(CNC(C)C(C)(C)C)=CC=C1C(=O)NC(S1)=NC=C1SCC1=CC(C)=C(C)C(C(=O)N2CCN(CC2)C(C)=O)=C1 DQPJVNQWPBLBAB-UHFFFAOYSA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- JNGQUJZDVFZPEN-UHFFFAOYSA-N n-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide Chemical compound CN(C)C1=CC=CC=C1C(=O)NC(=O)NC(C=C1C)=CC=C1OC1=NC=C(Br)C=N1 JNGQUJZDVFZPEN-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 osaterone Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 229950009478 otamixaban Drugs 0.000 description 1
- ODHHTIYRUDURPW-UHFFFAOYSA-N ottelione A Natural products C1=C(O)C(OC)=CC=C1CC1C(C(=O)C=CC2=C)C2C(C=C)C1 ODHHTIYRUDURPW-UHFFFAOYSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 229950006361 pazelliptine Drugs 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950000039 peldesine Drugs 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LCADVYTXPLBAGB-GNCBHIOISA-N phenalamide A1 Natural products CC(CO)NC(=O)C(=CC=CC=C/C=C/C(=C/C(C)C(O)C(=CC(C)CCc1ccccc1)C)/C)C LCADVYTXPLBAGB-GNCBHIOISA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000589 photocarcinogenesis Toxicity 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- OBLVPWTUALCMGD-UHFFFAOYSA-N pyridin-1-ium-3-carboxamide;chloride Chemical compound Cl.NC(=O)C1=CC=CN=C1 OBLVPWTUALCMGD-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229950002225 retelliptine Drugs 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- DWZAJFZEYZIHPO-UHFFFAOYSA-N santin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 DWZAJFZEYZIHPO-UHFFFAOYSA-N 0.000 description 1
- YADVRLOQIWILGX-UHFFFAOYSA-N sarcophytol N Natural products CC(C)C1=CC=C(C)CCC=C(C)CCC=C(C)CC1O YADVRLOQIWILGX-UHFFFAOYSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950004296 soblidotin Drugs 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229950004225 sonermin Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229950004796 sparfosic acid Drugs 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- YBZRLMLGUBIIDN-NZSGCTDASA-N spicamycin Chemical compound O1[C@@H](C(O)CO)[C@H](NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1N=CN2 YBZRLMLGUBIIDN-NZSGCTDASA-N 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N spicamycin Natural products O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- DTFYGLNONOLGOT-UHFFFAOYSA-N spongistatin 2 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC=C)OC1C2C DTFYGLNONOLGOT-UHFFFAOYSA-N 0.000 description 1
- VGULLEUAAMBZTQ-YGHPZBLNSA-N spongistatin 3 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](OC(C)=O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C VGULLEUAAMBZTQ-YGHPZBLNSA-N 0.000 description 1
- KRUKGDRIKMPUNX-UHFFFAOYSA-N spongistatin 4 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C KRUKGDRIKMPUNX-UHFFFAOYSA-N 0.000 description 1
- KRUKGDRIKMPUNX-JWFNSJLHSA-N spongistatin 4 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C KRUKGDRIKMPUNX-JWFNSJLHSA-N 0.000 description 1
- GQOOASKKXHUNEJ-PYATXCCJSA-N spongistatin 6 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C=C)OC1[C@@H]2C GQOOASKKXHUNEJ-PYATXCCJSA-N 0.000 description 1
- WYJXOZQMHBISBD-UHFFFAOYSA-N spongistatin 8 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 WYJXOZQMHBISBD-UHFFFAOYSA-N 0.000 description 1
- RSHMLTSGIURLKH-SJMMKZBFSA-N spongistatin-2 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C=C)O[C@@H]2[C@@H]1C RSHMLTSGIURLKH-SJMMKZBFSA-N 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229950005667 tallimustine Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950010168 tauromustine Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DYEBJMGPTVFMHA-XADRRFQNSA-N tert-butyl 2-[[2-amino-4-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]anilino]methyl]pyrrolidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1N)=CC=C1NCC1CCCN1C(=O)OC(C)(C)C DYEBJMGPTVFMHA-XADRRFQNSA-N 0.000 description 1
- RQZVNXZFRLIUCR-XADRRFQNSA-N tert-butyl 2-[[2-amino-5-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]benzimidazol-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1N=C2N)=CC=C1N2CC1CCCN1C(=O)OC(C)(C)C RQZVNXZFRLIUCR-XADRRFQNSA-N 0.000 description 1
- CGCLTUKDSNYXIJ-XADRRFQNSA-N tert-butyl 2-[[4-[[[(2s)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]-2-nitroanilino]methyl]pyrrolidine-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)N([C@@H](C)C(C)(C)C)CC(C=C1[N+]([O-])=O)=CC=C1NCC1CCCN1C(=O)OC(C)(C)C CGCLTUKDSNYXIJ-XADRRFQNSA-N 0.000 description 1
- SMFPDVZJTKXZMI-UHFFFAOYSA-N tert-butyl 3-(2-aminoanilino)piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1NC1=CC=CC=C1N SMFPDVZJTKXZMI-UHFFFAOYSA-N 0.000 description 1
- XNFBQKFPLPLQST-PAMMARIWSA-N tert-butyl 3-[2-[(4-chlorobenzoyl)amino]-5-[[[(2S)-3,3-dimethylbutan-2-yl]-phenylmethoxycarbonylamino]methyl]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C[C@H](N(Cc1ccc2n(C3CCCN(C3)C(=O)OC(C)(C)C)c(NC(=O)c3ccc(Cl)cc3)nc2c1)C(=O)OCc1ccccc1)C(C)(C)C XNFBQKFPLPLQST-PAMMARIWSA-N 0.000 description 1
- FJQOXADFLVHVHD-ATNAJCNCSA-N tert-butyl 3-[4-[[[(2s)-3,3-dimethylbutan-2-yl]amino]methyl]-2-nitroanilino]piperidine-1-carboxylate Chemical compound [O-][N+](=O)C1=CC(CN[C@@H](C)C(C)(C)C)=CC=C1NC1CN(C(=O)OC(C)(C)C)CCC1 FJQOXADFLVHVHD-ATNAJCNCSA-N 0.000 description 1
- FOMQBPGBFQWLBY-UHFFFAOYSA-N tert-butyl 4-(2-nitroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC=CC=C1[N+]([O-])=O FOMQBPGBFQWLBY-UHFFFAOYSA-N 0.000 description 1
- DLHJQQYFBUNBLA-UHFFFAOYSA-N tert-butyl 4-[2-[(4-chlorobenzoyl)amino]benzimidazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=CC=CC=C2N=C1NC(=O)C1=CC=C(Cl)C=C1 DLHJQQYFBUNBLA-UHFFFAOYSA-N 0.000 description 1
- QYJVBVKFXDHFPQ-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)-n-methylcarbamate Chemical compound NCCN(C)C(=O)OC(C)(C)C QYJVBVKFXDHFPQ-UHFFFAOYSA-N 0.000 description 1
- JXLSDCIHYQAXOA-UHFFFAOYSA-N tert-butyl n-(2-methyl-1-oxopropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)C=O JXLSDCIHYQAXOA-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-UHFFFAOYSA-N thaliblastine Natural products CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 125000005000 thioaryl group Chemical group 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- UPGGKUQISSWRJJ-UHFFFAOYSA-N thiocoraline Natural products CN1C(=O)CNC(=O)C(NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)CSC(=O)C(CSC)N(C)C(=O)C(N(C(=O)CNC2=O)C)CSSCC1C(=O)N(C)C(CSC)C(=O)SCC2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 229950010183 thymotrinan Drugs 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- ONYVJPZNVCOAFF-UHFFFAOYSA-N topsentin Natural products Oc1ccc2cc([nH]c2c1)C(=O)c3ncc([nH]3)c4c[nH]c5ccccc45 ONYVJPZNVCOAFF-UHFFFAOYSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 turosteride Drugs 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950008261 velaresol Drugs 0.000 description 1
- XLQGICHHYYWYIU-UHFFFAOYSA-N veramine Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CC=C3C2(C)C(C)C21CCC(C)CN2 XLQGICHHYYWYIU-UHFFFAOYSA-N 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- 229950005561 zanoterone Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present disclosure is directed to certain inhibitors IL2-inducible T-cell kinase (ITK), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.
- ITK IL2-inducible T-cell kinase
- IL2-inducible T-cell kinase is a member of the Tec family of kinases.
- ITK dysfunction e.g., overexpression
- lung inflammation e.g., recruitment of eosinophils, production of mucus
- eosinophils e.g., adenosine kinase ITK
- mucus e.g., mucus
- Ferrara, et al Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase, Journal of Allergy and Clinical Immunology, 117:780-786).
- ITK IL-2-inducible tyrosine kinase activity: a new concept for the therapy of inflammatory skin diseases, Exp Dermatol,2Q: ⁇ - l , 2010). Itk was found to be expressed in lymphoid tissue and upregulated in lesional skin from patients with allergic dermatitis, atopic dermatitis and psoriasis. Itk also plays a role in the pathophysiology of T cell malignancies (see Guo W. et. al, Molecular characteristics of CTA056, a novel Itk inhibitor which selectively targets malignant T cell and modulates oncomirs, Molecular
- the present disclosure provides a compound of Formula (IA):
- Z 1 , Z 2 , and Z 3 are CH (or C if substituted with R 1 or R 2 ) or Z 1 , Z 2 , and Z 3 are
- Z and Z are CH (or C if substituted with R or R ) or Z and Z are independently N or CH (or C if substituted with R 1 or R 2 ) provided that only one of Z 2 and Z 3 is N;
- R 1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NR 3 COR 4 , -CONR 3 R 5 , -(alkylene)-NR 3 R 5 (where each R 3 is hydrogen, or alkyl, R 4 is alkyl, haloalkyl, cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R 5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, cycloalkylalkyl, or heterocyclylalkyl optionally substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxy, alkoxy, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloamino wherein the heterocycloamino ring is optionally substituted with one, two
- R 2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy;
- Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
- X is alkylene, cycloalkylene, (where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NR a -, or -(alkylene)-NR 3 - (where each R a is hydrogen, alkyl or cycloalkyl);
- Y is -CO- or -S0 2 -;
- R b is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl;
- R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNR d R e or cycloalkylene(alkylene)NR d R e (where R d and R e are independently hydrogen, alkyl, or cycloalkyl), alkoxyalkyloxyalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
- R d is hydrogen or alkyl, or R b and R d together form a bond; provided that when R b is other than hydrogen, then R° is not hydrogen and R d is hydrogen;
- Z 1 , Z 2 , and Z 3 are CH (or C if substituted with R 1 or R 2 ) or Z 1 , Z 2 , and Z 3 are independently N or CH (or C if substituted with R 1 or R 2 ) provided that only one of Z 1 , Z 2 , and Z 3 is ; and
- Z and Z are CH (or C if substituted with R or R )or Z and Z are independently N or CH (or C if substituted with R 1 or R 2 ) provided that only one of Z 2 and Z 3 is N;
- R 1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NR J C0R 4 , -CONR J R 3 , -(alkylene)-NR 3 R 5 (where each R 3 is hydrogen or alkyl, R 4 is cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R 5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, or heterocyclylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloammo wherein the heterocycloamino ring is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, -NR
- R 2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy;
- Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
- X is alkylene, cycloalkylene, (where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NR a -, or -(alkylene)-NR 3 - (where each R a is hydrogen, alkyl or cycloalkyl);
- Y is -CO- or -S0 2 -;
- R b is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl;
- R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNR d R e or cycloalkylene(alkylene)NR d R e (where R d and R e are independently hydrogen, alkyl, or cycloalkyl), or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
- R d is hydrogen, alkyl, or R b and R d together form a bond; provided that when R b is other than hydrogen, then R° is not hydrogen and R d is hydrogen; and/or a pharmaceutically acceptable salt thereof.
- Formula (IA) and (I) can be reversible covalent inhibitors where the reversibility of the covalent bond is determined by Mass spec method described in Biological Example 7 below.
- compositions comprising a compound disclosed herein, and/or a pharmaceutically acceptable salt thereof; and a
- a third aspect provided herein are methods of treating a disease treatable by inhibition of ITK in a patient which method comprises administering to the patient in need thereof, a pharmaceutical composition comprising a compound disclosed herein and/or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and a pharmaceutically acceptable excipient.
- the patient is in recognized need of such treatment.
- the compound disclosed herein and/or a pharmaceutically acceptable salt thereof can also inhibit one or more of ITK, BLK, BMX, BTK, JAK3, TEC, TXK (also known as RLK), HER2 (ERBB2), or HER4 (ERBB4) kinase.
- the disease is selected from inflammatory disorders, autoimmune disorders, and lymphoproliferative disorders.
- the inflammatory disorder is asthma, allergic dermatitis, atopic dermatitis and psoriasis.
- any compound of Formula (IA) or (I) is administered in combination with at least one anti- inflammatory, anti-autoimmune, or anti-lymphoproliferative agent described herein.
- Alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
- Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
- Alkylthio means a -SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.
- Alkylsulfonyl means a -SO 2 R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
- Alkoxy means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
- Alkylamino means a -NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, and the like.
- Acyl means a -COR radical where R is alkyl, haloalkyl, optionally substituted aryl, or optionally substituted heteroaryl as defined herein, e.g., acetyl, trifluoroacetyl, benzoyl, and the like.
- Alkoxyalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, preferably one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.
- Alkoxyalkyloxyalkyl means a -(alkylene)-0-(alkylene)-OR where R is alkyl as defined above, e.g., 2-methoxyethyloxyethyl, -C(CH3) 2 0-(CH 2 ) 2 -OCH3, and the like.
- Alkoxycarbonyl means a -C(0)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
- Aminoalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one -NR a R b group, preferably one or two NR a R b groups, where R a and R b are independently hydrogen or alkyl, e.g., aminomethyl, methylaminomethyl, dimethylaminomethyl, 2-aminoethyl, 1-, 2-, or 3-methylaminopropyl, and the like.
- Aryl means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.
- Cycloalkyl means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
- Cycloalkylalkyl means an -(alkylene)-R where R is cycloalkyl as defined above, e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, or cyclohexylethyl, and the like.
- Cycloalkylene means a divalent cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, and the like.
- CycloalkyleneNR d R e " and "Cycloalkylene(alkylene)NR d R e” means a radical of
- cycloalkylene and R d and R e are independently hydrogen, alkyl, or cycloalkyl each term as defined herein.
- Dialkylamino means a - R2 radical where each R is independently alkyl as defined above, e.g., dimethylamino, methylethylamino, and the like.
- Halo means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
- Haloalkyl means alkyl radical as defined above, which is substituted with one or more halogen atoms, preferably one to five halogen atoms, preferably fluorine or chlorine, including those substituted with different halogens, e.g., -CH C1, -CF 3 , -CHF , -CH CF 3 , -CF CF 3 , - CF(CH 3 ) 2 , and the like.
- fluoroalkyl When the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkyl.
- Haloalkoxy means a -OR radical where R is haloalkyl as defined above e.g., -OCF3, - OCHF 2 , and the like.
- R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.
- Hydroalkyl means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom.
- Representative examples include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, l-(hydroxymethyl)-2-methylpropyl, 2- hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, l-(hydroxymethyl)-2- hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and l-(hydroxymethyl)-2-hydroxyethyl.
- Heterocyclyl means a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C.
- the heterocyclyl ring is optionally fused to a (one) aryl or heteroaryl ring as defined herein provided the aryl and heteroaryl rings are monocyclic.
- the heterocyclyl ring fused to monocyclic aryl or heteroaryl ring is also referred to in this Application as "bicyclic heterocyclyl" ring.
- heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2- oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydropyranyl, thiomorpholino, and the like.
- heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic.
- the heterocyclyl group is a saturated ring and is not fused to aryl or heteroaryl ring as stated above, it is also referred to herein as saturated monocyclic heterocyclyl.
- Heterocyclylalkyl means -(alkylene)-R where R is heterocyclyl which is a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group. More specifically the term heterocyclylalkyl includes, but is not limited to, pyrrolidin- 1 -ylmethyl, pyrrolidinylethyl, piperidinylmethyl,
- Heterocycloamino means a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C provided that at least one of the ring atoms is N. Additionally, one or two ring carbon atoms in the heterocycloamino ring can optionally be replaced by a -CO- group. Unless otherwise stated, the heterocycloamino ring can optionally be substituted with one, two, or three substituents independently selected from alkyl, hydroxyl, halo, alkoxy, amino, alkylamino, or dialkylamino.
- Heteroaryl means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon.
- Representative examples include, but are not limited to, pyrrolyl, pyrazolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like.
- the present disclosure also includes the prodrugs of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof.
- the term prodrug is intended to represent covalently bonded carriers, which are capable of releasing the active ingredient of Formula (IA) and (I) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo.
- Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups in vivo or by routine manipulation.
- Prodrugs of compounds of Formula (IA) and (I) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified.
- prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., ⁇ , ⁇ -dimethylamino-carbonyl) of hydroxy or amino functional groups in compounds of Formula (IA) and (I)), amides (e.g., trifluoroacetylamino, acetylamino, and the like), and the like.
- esters e.g., acetate, formate, and benzoate derivatives
- carbamates e.g., ⁇ , ⁇ -dimethylamino-carbonyl
- amides e.g., trifluoroacetylamino, acetylamino, and the like
- Prodrugs of compounds of Formula (IA) and (I) are also within the scope of this disclosure.
- the present disclosure also includes protected derivatives of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof.
- compounds of Formula (IA) and (I) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups.
- the present disclosure also includes amorphous or polymorphic forms (crystalline) and deuterated forms of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof.
- a "pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- Such salts include: acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2- hydroxyethanesulfonic acid, benzenes
- the compounds of the present disclosure may have asymmetric centers.
- Compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, racemic forms are within the scope of this disclosure, unless the specific stereochemistry is specifically indicated.
- Certain compounds of Formula (IA) and (I) can exist as tautomers and/or geometric isomers.
- the compound of Formula (IA) and (I) can exist in following tautomeric form:
- the - CR b CR c R d group in the compound of Formula (IA) and (I) can exist as cis and trans isomers.
- the individual cis or trans forms and mixtures thereof are within the scope of the present disclosure unless a specific isomeric form is specifically indicated.
- alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth.
- the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all the positional isomers albeit only a few examples are set forth.
- all polymorphic forms and hydrates of a compound of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof are within the scope of this disclosure.
- heterocyclyl group optionally substituted with an alkyl group means that the alkyl may but need not be present, and the description includes situations where the heterocyclyl group is substituted with an alkyl group and situations where the heterocyclyl group is not substituted with alkyl.
- Optionally substituted aryl means aryl as defined above which is substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, alkylsulfonyl, amino, alkylamino, dialkylamino, aminoalkyl or cycloalkyl.
- Optionally substituted heteroaryl means heteroaryl as defined above which is substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, alkylsulfonyl, amino, alkylamino, dialkylamino, aminoalkyl or cycloalkyl.
- a "pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
- a pharmaceutically acceptable carrier/excipient includes both one and more than one such excipient.
- “Spiroheterocycloamino” means a bicyclic ring of 7 to 12 ring atoms and joined through one ring atom in which one or two ring atoms are heteroatom selected from N, O, or S(0) n , where n is an integer from 0 to 2, the remaining ring atoms being C provided that at least one of the ring atoms is N. Additionally, one or two ring carbon atoms in the heterocycloamino ring can optionally be replaced by a -CO- group.
- Substituted alkyl means alkyl group as defined herein which is substituted with one, two, or three substituents independently selected from hydroxyl, alkoxy, carboxy, cyano, alkoxycarbonyl, alkylthio, alkylsulfonyl, halo, haloalkoxy, -CONRR' or -NRR' (where each R is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or heterocyclyl and each R' is hydrogen, alkyl, or cycloalkyl), spiroheterocycloamino, or heterocyclyl (preferably heterocycloamino) optionally substituted with one or two groups independently selected from alkyl, hydroxyl, alkoxy, alkylthio, alkylsulfonyl, halo, or -CONRR' where (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and R' is hydrogen, alkyl
- substituted alkyl is alkyl group as defined herein which is substituted with one, two, or three substituents independently selected from hydroxyl, alkoxy, carboxy, cyano, alkoxycarbonyl, alkylthio, alkylsulfonyl, halo, haloalkoxy, -CONRR' or -NRR' (where each R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and each R' is hydrogen, alkyl, or cycloalkyl), or heterocyclyl (preferably heterocycloamino) optionally substituted with one or two groups independently selected from alkyl, hydroxyl, alkoxy, alkylthio, alkylsulfonyl, halo, or -CONRR' where (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and R' is hydrogen, alkyl, or cycloalkyl).
- Treating” or “treatment” of a disease includes:
- a “therapeutically effective amount” means the amount of a compound of Formula (IA) and (I) that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the patient to be treated.
- the compound of Formula (IA) and (I) or a salt thereof has the structure (la):
- the compound of Formula (IA) and (I) or a salt thereof has the structure (lb):
- the compound of Formula (IA) and (I) or a salt thereof has the structure (Ic):
- R b is cyano and R° is alkyl, substituted alkyl, cycloalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro.
- R° is alkyl. Within this group of compounds, in one group of compounds R° is isopropyl or tert-butyl.
- R° is cycloalkyl.
- R° is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- R° is cyclopropyl.
- R° is substituted alkyl.
- R° is alkyl substituted with hydroxy, alkoxy, -NRR' (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl and R' is hydrogen or alkyl) or heterocyclyl which is optionally substituted with one or two groups independently selected from alkyl or hydroxyl.
- R° is-C(CH 3 ) 2 NH 2 , -C(CH 3 ) 2 NHCH 3 , -
- R° is -C(CH 3 ) 2 CH 2 NH 2 or -C(CH 3 ) 2 CH 2 OH.
- R c is -C(CH 3 ) 2 OCH 2 CH 3.
- R° is 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro.
- R° is 2- pyrrolidinyl, 3- or 4-piperidinyl, l-methylpiperidin-4-yl, l-methylpiperidin-3-yl, azetidin-3-yl, oxetan-3-yl, 3-methyloxetan-3-yl, or 4-tetrahydropyranyl.
- Embodiment 6 (a) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the in -X-Y- is
- X-Y- is . . Within the groups in (b), in one group of compounds -X-Y- is
- R 1 is hydrogen, - NR 3 COR 4 , or -(alkylene)-NR 3 R 5 where R 3 is hydrogen or alkyl, R 4 is optionally substituted aryl or heteroaryl, and R 5 is hydrogen, alkyl, haloalkyl, or acyl or R 3 and R 5 together with the nitrogen atom to which they are attached from heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl.
- R 1 is -(alkylene)- NR 3 R 5 where R 3 is hydrogen or alkyl and R 5 is hydrogen, alkyl, haloalkyl, or acyl.
- R 1 is (S)-CH N(COCF 3 )CH(CH 3 )C(CH 3 )3,
- R 1 is - (alkylene)-NR 3 R 5 where R 3 and R 5 together with the nitrogen atom to which they are attached from heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl.
- R 1 is -CH 2 -2,6-dimethylmorpholin-4-yl, -CH 2 -morpholin-4-yl, -CH 2 -4- methylpiperazin-yl,
- Ar is phenyl, 4- Clphenyl, 4-CHF 2 phenyl, 3-CHF 2 phenyl, 3-CF 3 phenyl, 3-CH 3 phenyl, or 3,4-diFphenyl.
- Ar is phenyl, 4-Clphenyl, 4- CHF 2 phenyl, 3-CHF 2 phenyl, 3-CF 3 phenyl, 3-CH 3 phenyl, 3-CN -phenyl 4-CN-pbeoyi, or 3,4- diFphenyl.
- Ar is a five membered heteroaryl ring (such as thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrrolyl, triazolyl, pyrazolyl, or thiazolyl) optionally substituted with one, two, or three substituents selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl (in one group methyl, ethyl, fluoro, trifluoromethyl, or difluoromethyl).
- heteroaryl in one group methyl, ethyl, fluoro, trifluoromethyl, or difluoromethyl.
- Ar is thien-2-yl, 5-chlorothien-2-yl, 5-cyanothien-2-yl, 2-oxazol-4-ylthien-5-yl, 5-CF 3 - thien-2-yl, l-methyl-pyrazol-3-yl, oxazol-5-yl , 2-methyl-oxazol-5-yl, 2-m ethyl, l,2,3-triazol-4-yl, oxazol-5-yl, 2-methyl-oxazol-4-yl, 2-methyl-thiazol-5-yl, 5-CHF 2 thien-2-yl, or isoxazol-5-yl.
- the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- the reactions described herein take place at atmospheric pressure over a temperature range from about -78° C to about 150° C, more preferably from about 0° C to about 125° C and most preferably at about room (or ambient) temperature, e.g., about 20° C.
- aminobenzimidazole compound of formula 4 by treatment with cyanogen bromide in a solvent such as ethanol.
- Coupling of 4 with a carboxylic acid of formula ArCOOH where Ar is as defined in the Summary occurs under standard amide coupling conditions or with an acid derivative such as a carboxylic acid chloride to provide compound of formula 5.
- Removal of the amino protecting group PG, followed by coupling of the resulting compound 6 with cyanoacetic acid provides a compound of formula 7.
- Compound 7 can be then converted to a compound of Formula (LA) or (I) by methods well known in the art.
- compounds of Formula (LA) or (I) where X is -CO- can be prepared by condensing compound 7 with an aldehyde of formula R°CHO, where R° is as defined in the Summary, under standard condensation conditions such as using a base such as piperidine and the like, in the presence or absence of acetic acid and the like in solvents such as ethanol at temperatures ranging from room temperature to reflux to afford compounds of Formula (IA) or (I).
- R°CHO aldehyde of formula R°CHO
- R°CHO is as defined in the Summary
- Ethoxy-2-methylpropanal was prepared from isobutyraldehyde as described in PCT Int. Appl, 2007142576.
- the condensation can be performed by adding the desired aldehyde, base such as pyrrolidine or piperidine with or without chlorotrimethylsilane in dichloromethane or other suitable solvent (e.g. dioxane and ethanol).
- compounds of Formula (IA) or (I) where X is -CO- can be prepared by reacting compound 6 with an acid of formula 10 where R° is as defined in the Summary under amide coupling conditions.
- Compounds of Formula (IA) or (I) where X is -S0 2 - can be prepared by reacting amine 6 with a sulfonyl chloride of formula 9, followed by condensation of resulting compound 11 with an aldehyde of formula R°CHO as described.
- R eaction of a balopyridmes, halopyrazines, or balopyrir dmes 12 which are readily available from commercial suppliers with a compound of formula 14 where R a is as defined in the Summary, PG is a suitable amino protecting group and X' is alkylene or cycloalkylene in the presence of a base such as NaHMDS provides a compound of formula 15 (see J. Org.
- Compounds 14 are either available commercially or can be prepared from a compound such as 13 where LG is a leaving group such as halogen or mesylate and sodium cyanide, PG is a suitable amino protecting group such as benzyloxy carbamate or benzyl, and R a is as defined, previously or alternately a suitable amino protecting group, and X' is alky! or cycloalkylene.
- LG is a leaving group such as halogen or mesylate and sodium cyanide
- PG is a suitable amino protecting group such as benzyloxy carbamate or benzyl
- R a is as defined, previously or alternately a suitable amino protecting group
- X' is alky! or cycloalkylene.
- Reduction of the nitro group in 22 can be accomplished by various reduction methods such as hydrogenation with Pd catalysis or by the action of elemental Zn.
- the resulting diamino compound 23 can be cyclized to the aminobenzimidazole compound of formula 24 by treatment with cyanogen bromide in a solvent such as ethanol.
- Coupling of 24 with a carboxylic acid of formula ArCOOH where Ar is as defined in the Summary under standard amide coupling conditions or with an acid derivative such as a carboxylic acid chloride provides a compound of formula 25.
- X is a ring of formula v — '
- R is cyano
- other groups are as defined in the Summary can also be prepared as illustrated and described in Scheme 4 below.
- X is a ring of formula
- R is cyano
- other groups are as defined in the Summary can also be prepared as illustrated and described in Scheme 5 below.
- a compound of formula 36 (prepared by reacting compound 1 where R 1 is aldehyde with compound la as described in Scheme 1) with an amine of formula R 3 H2 where R 3 is as defined in the Summary, provides a compound of formula 37. Protection of the resultant amine 37 with a suitable orthogonal protecting group PG 2 such as Alloc or Cbz, can be accomplished under standard conditions as described in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. (1999) to afford a compound of formula 38 which can be converted to a compound of formula 42, 43, or 44 as described in Scheme 1 above.
- PG 2 orthogonal protecting group
- ITK dysfunction e.g., overexpression
- lung inflammation e.g., lung inflammation
- eosinophils e.g., pulmonary fibroblasts
- mucus e.g., mucus
- Several drug therapies target Itk in order to treat inflammatory disorders, autoimmune disorders, and lymphoproliferative disorders.
- These drugs include, but are not limited to, BMS-488516 and BMS-509744 (see Lin, et al, Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry, 43(34): 11056-62), 2-amino-5-(thioaryl)thiazoles (Das, Discovery and SAR of 2-amino-5- (thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters, 16(14):3706-12); 3-Aminopyrid-2-ones (see Charrier, et al, Discovery and Structure- Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T- Cell Kinase (Itk) Inhibitors, Journal of Medicinal Chemistry, 54(7):2341-50).
- ITK dysfunction plays a role in multiple inflammatory disorders that are affected by cytokine production, e.g., lung inflammation and pneumonia (see Lin, et al, Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry, 43(34): 11056-62; Das, Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters , 16(14): 3706- 12); allergic asthma (see Mueller, et al, Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK, Journal of Immunology, 170:5056-5063; Das, Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters , 16(14):3706-12); psoriasis (see Eur.
- Itk IL-2-inducible tyrosine kinase
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder characterized by excessive or undesired cytokine production or activity.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat lung inflammation, pneumonia, allergic asthma, psoriasis, atopic dermatitis, or a combination thereof.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat dry eye disease or uveitis.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an autoimmune disorder.
- T cell malignancies e.g., T cell lymphomas and T cell leukemia
- T cell malignancies e.g., T cell lymphomas and T cell leukemia
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat T cell malignancies, such as T cell lymphomas and T cell leukemia.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat PTCL, acute lymphoblastic leukemia (T-ALL), adult T cell leukemia/lymphoma (ATL), and Seazry syndrome/cutaneous T cell lymphoma (CTCL).
- T-ALL acute lymphoblastic leukemia
- ATL adult T cell leukemia/lymphoma
- CCL Seazry syndrome/cutaneous T cell lymphoma
- T helper cell skewing has been suggested to play a role in the responses of chronic lymphocytic leukemia (CLL) patients to ibrutinib therapy through effects of ibrutinib on ITK ⁇ see Dubovsky et al, Ibrutinib is an irreversible molecular inhibitor ITK driving a Thl selective pressure in T- lymphocytes, Blood, 2013, pre- published on line).). It was also suggested that the ITK activity of Ibrutinib was responsible for the suppression of Leishmaniasis in susceptible mice again through the Thl skewing activity.
- CLL chronic lymphocytic leukemia
- Thl skewing may add to the therapeutic benefit of EGFR targeting in cancer patients by boosting local inflammatory response to the tumor ⁇ see Zaiss et al, Amphiregulin enhances regulatory T cell-suppressive function via epidermal growth factor receptor, Immunity, 38: 1-10).
- a compound disclosed herein is administered to a patients in need or recognized need thereof to treat CLL or other cancers or infections such as Leismaniasis that are associated with immune function suppression through skewing of T helper cell populations.
- the compounds of Formula (LA) and (I) and/or pharmaceutically acceptable salts thereof are useful in the treatment of ITK-mediated disorders described above, including disorders such as those associated with T cell and cytokine - mediated disorders.
- the compounds described herein can also inhibit other kinases such as BTK, JAK3, BLK, BMX, HER2 (also known as ERBB2), HER4 (also known as ERBB4), TEC and TXK and hence can also be used for treating diseases or conditions associated with the activity of BTK, JAK3, BLK, BMX, HER2 (also known as ERBB2), HER4 (also known as ERBB4), TEC and TXK.
- BTK BTK
- JAK3, BLK BMX
- HER2 also known as ERBB2
- HER4 also known as ERBB4
- TEC and TXK TEC and TXK
- B lymphocyte kinase is a tyrosine protein kinase. Specifically, it is a member of the src family of proto-oncogenes that are typically involved in cell proliferation and differentiation.
- a compound disclosed herein inhibits or decreases the activity of Blk. In some embodiments, the inhibition or decrease of activity of Blk occurs in a human.
- Blk has been implicated in B-cell receptor signaling and B-cell development.
- a compound disclosed herein is administered to an individual in need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) B-cell receptor signaling and B-cell development.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) insulin synthesis and secretion in response to glucose. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat diabetes.
- SNPs single-nucleotide polymorphisms
- C8orfl3 region of BLK are associated with the development of SLE in Caucasians (Ito, et al, Replication of the association between the C8orfl3-BLK region and systemic lupus erythematosus in a Japanese population, Arthritis and Rheumatism,
- Blk dysfunction has also been implicated in Sjogren's Syndrome (see Nordmark, et al, Association of EBF1, FAM167A(C8orfl3)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome, Genes and Immunity, 12(2): 100-9); ulcerative colitis (see Seidelin, et al., Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis, APMIS, 1 14(7-8):508-17); rheumatoid arthritis and systemic sclerosis (see Tsuchiya, et al, Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases, Nihon Rinsho Meneki Gakkai Kaishi, 33(2):57-65).
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat SLE, Sjogren's Syndrome, ulcerative colitis, rheumatoid arthritis, systemic sclerosis, or a combination thereof.
- Blk dysfunction has also been identified in patients with lymphomas, such as cutaneous T-cell lymphoma (see Krejsgaard, et al, Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma, Blood, 113(23):5896-904).
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a lymphoma.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat cutaneous T-cell lymphoma.
- the compounds described herein can be used to treat Blk-related conditions, included those described herein.
- Bone Marrow X kinase (also, Bmx, Epithelial and endothelial tyrosine kinase and ETK) is a member of Tec family non-receptor tyrosine kinase.
- Bmx can be activated by several extracellular stimuli, including growth factors, cytokines, extracellular matrix and hormones. Activation of Bmx kinase can be achieved by interaction of its pleckstrin homology domain either with the phosphatidylinositol 3-kinase product phosphatidylinositol 3,4,5-triphosphate or the FERM domain of FAK, which leads to plasma membrane translocation of Bmx.
- a compound disclosed herein inhibits or decreases the activity of Bmx. In some embodiments, the inhibition or reduction of activity of Bmx occurs in a human.
- Bmx has been shown to play a role in various cellular processes including cell proliferation, transformation, differentiation, migration and metastasis. Bmx is known to interact with FAK and pl30Cas to regulate actin cytoskeleton and cell motility. It has also been shown that Bmx directly interacts with tumor suppress p53 and inhibit its nuclear translocation, thereby promoting chemoresistance in cancer cells.
- Bmx has been implicated in several signal transduction pathways, including the Stat pathway. There is evidence that it may play a role in signal transduction (and the growth and differentiation of) hematopoietic cells, endocardial endothelial cells, and arterial endothelial cells.
- Bmx dysfunction has been implicated in several types of cancer cells, such as prostate cancer (see Dai, et al, Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse, Cancer Research,
- breast cancer see Bagheri-Yarmand, et al, Etk/Bmx tyrosine kinase activates Pakl and regulates tumorigenicity of breast cancer cells, Journal of Biological Chemistry, 276(31):29403-9); hepatocellular carcinoma (see Guo, et al, Expression of tyrosine kinase
- ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy, PMID: 21408190, 2011); nasopharygeal cancer (see Zhang, et al, Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation, Cancer Biology & Therapy, 1 1(7):690-8); and small cell lung cancer (see Guo, et al, Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells, Experimental and Molecular Pathology, 88(3):401-6).
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a cancer. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat prostate cancer, breast cancer, hepatocellular carcinoma, bladder cancer, nasopharygeal cancer, small cell lung cancer, or a combination thereof.
- Bmx dysfunction has also been associated with multiple autoimmune disorders, such as, but not limited to, rheumatoid arthritis (see Gottar-Guillier,et al, The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner, Journal of Immunology, PMID: 21471444, 2011); and chronic inflammation and angiogenesis in the skin see (Paavonen, et al, Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing, Molecular Biology of the Cell, 15(9):4226-33). Accordingly, the compounds described herein can be used to treat Bmx-related conditions, included those described herein.
- HER2 Human epidermal growth factor receptor 2
- EGF epidermal growth factor receptor
- HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it; however, HER2 is the preferential dimerization partner of other members of the EGF family (see Olayioye, Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members, Breast Cancer Res 3(6): 385-389, 2001).
- Heterodimerization of the EGF family of receptors to HER2 results in stabilization of the ligand-EGF receptor interaction and enhancement of kinase-mediated activation of downstream signaling pathways.
- Downstream signaling pathways initiate signal transduction cascades that drive many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.
- HER2 function Due to its role in cell proliferation, inhibition of HER2 function should reduce or inhibit the development and/or progression of cancers. Amplification and/or overexpression of the HER2 gene has been implicated in numerous cancers, including, but not limited to, breast cancer (see Konecny, et al, Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer, Clin Cancer Res, 7(8):2448-57, 2001), ovarian cancer (see Lafky, et al.
- EGF ErbB/epidermal growth factor
- gastric cancer see Moelans, et al, Low frequency of HER2 amplification and overexpression in early onset gastric cancer, Cell Oncol (Dordr), 34(2):89-95, 201 1
- lung cancer see Hirsch, et al, The role of HER2/neu expression and trastuzumab in non-small cell lung cancer, Semin Oncol, 31(1 Suppll):75-82, 2004
- glioblastoma see Mineo, et al, Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma, J eurooncol, 85(3):281-7, 2007
- biologically aggressive forms of uterine cancer such as uterine serous endometrial carcinoma (see Santin, et al, Tras
- the compounds are used to treat breast cancer, ovarian cancer, gastric cancer, lung cancers, glioblastoma, and biologically aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
- the compounds described herein can be used to treat HER2 -related conditions, included those described herein.
- Human epidermal growth factor receptor 4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor (ErbB) family.
- HER4 is a single-pass type I transmembrane protein with multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif.
- the protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin.
- Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment.
- CTF C-terminal fragment of isoform JMA-A CYT-2 (containing E4ICD2) can stimulate transcription in the presence of YAP 1.
- ERBB4 intracellular domain is involved in the regulation of cell growth.
- Overexpression studies in epithelium show growth inhibition using E4ICD1 and increased proliferation using E4ICD2.
- E4ICD2 has greater in vitro kinase activity than E4ICD1. This kinase activity is required for the nuclear translocation of E4ICD2.
- a compound disclosed herein is administered to an individual in need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) cell proliferation and differentiation.
- this disorder comprises cancers.
- Mutations in and overexpression of the HER4 gene have been associated with numerous cancers, including, but not limited to, breast cancer (see Junttila, et al, Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells, Cancer Res, 65(4): 1384-93, 2005), childhood medulloblastoma (see Gilbertson, et al, Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma., Cancer Res, 57(15):3272-80, 1997), non-small-cell lung cancer (see Starr, et al, ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy, Int.
- breast cancer see Junttila, et al, Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells, Cancer Res, 65(4): 1384-93, 2005
- childhood medulloblastoma
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a disorder characterized by uncontrolled or undesired cell proliferation or differentiation.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat breast cancer, lung cancer, medulloblastoma (including the childhood form), melanoma, or a combination thereof.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat schizophrenia.
- the compounds described herein can be used to treat HER4-related conditions, included those described herein.
- Jak3 is a tyrosine kinase that belongs to the Janus family of tyrosine kinases. It is involved in cytokine receptor-mediated intracellular signal transduction. Jak3 is activated by binding to the yC chain of the type I cytokine receptor family (e.g. IL-2R, IL-4R, IL-7R, IL-9R, IL-15R, and IL-21R). Following binding, Jak3 undergoes tyrosine phosphorylation (either via autophosphorylation and/or transphosphorylation by other JAKs or other families of tyrosine kinases).
- the yC chain of the type I cytokine receptor family e.g. IL-2R, IL-4R, IL-7R, IL-9R, IL-15R, and IL-21R.
- JAKs then phosphorylate receptors on target tyrosine residues that serve as docking sites that allow the binding of other SH2-domain containing signaling molecules such as STATs, Src -kinases, protein phosphatases and other adaptor signaling proteins such as She, Grb2 and PI-3 kinase (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and
- Jak3 is predominantly expressed in immune cells and hematopoietic cells, for example, in T cells, NK cells and monocytes. It appears that Jak3 is involved in T and B cell development and function (see Cox, et al, JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough, Chemistry & Biology, 18(3):277-8). In some embodiments, a compound disclosed herein inhibits the activity of Jak3.
- Jak3 contains a tyrosine kinase (JH1) domain adjacent to a catalytically inactive pseudokinase domain (JH2).
- JH2 domain which lacks any observable tyrosine kinase activity due to the absence of residues that are required for catalytic activity and nucleotide binding, negatively regulates the activity of Jak3 (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies, Genes & Cancer, l(10):979-993).
- JH2 is required for two distinct functions in cytokine signaling: (i) inhibition of the basal activity of Jak3, and (ii) cytokine-inducible activation of signaling.
- Jak3- JH2 deletion mutants are catalytically active, activate STAT5, and interact with other Jak kinases, but the JH2 domain is required to connect these signaling events to receptor activation.
- the pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction, Journal of Biological Chemistry, 277(49):47954-63).
- a compound disclosed herein inhibits the activity of the JH2 domain of Jak3.
- a compound disclosed herein reduces or inhibits the development and/or progression of an immune disorder.
- Jak3 dysfunctions has also been implicated in inflammation and autoimmune disorders, such as arthritis (see Kim, et al, Inhibition of JAK3 alleviates inflammation in monoarthritic rats, British Journal of Pharmacology, PMID: 21434883, 2011), especially rheumatoid arthritis;
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat inflammation, or an autoimmune disorder, or a combination thereof. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat arthritis, transplant rejection, psoriasis, arthritis, type-1 diabetes, or a combination thereof.
- Jak3 dysfunction has been found in myeloproliferative and myelodisplastic syndromes (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and
- TMD transient myeloproliferative disorder
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a myeloproliferative syndrome and/or a myelodisplastic syndrome.
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat transient myeloproliferative disorder.
- T Cell Lymphoma see Krejsgaard, t al, Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway, Journal of Investigative Dermatology, PMID: 21346774, 2011); acute megakaryoblastic leukaemia of Down syndrome (see Sato, et al, Functional analysis of JAK3 mutations in transient
- B-lineage acute lymphoblastic leukemia see Uckun, JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia, Expert Review of Anticancer Therapy, 1 l(l):37-48
- colorectal cancer see Uckun, Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor, Nutrition and Cancer, 62(7):968-72
- chronic lymphocytic leukemia see Steele, et al, The JAK3 -selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment, Blood, 1 16(22):4569-77); and
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a cancer. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat breast adenocarcinoma; T Cell Lymphoma; acute megakaryoblastic leukaemia of Down syndrome; B-lineage acute lymphoblastic leukemia;
- colorectal cancer chronic lymphocytic leukemia
- non-melanoma skin cancer or a combination thereof.
- the compounds described herein can be used to treat Jak3 -related conditions, included those described herein.
- Tec protein tyrosine kinase is a member of the Tec family of non-receptor type protein tyrosine kinases. Tec family kinases are involved in the intracellular signaling mechanisms of cytokine receptors, lymphocyte surface antigens, heterotrimeric G-protein coupled receptors, and integrin molecules and are important components of antigen receptor signaling pathways in B cells, T cells, and mast cells (see Schmidt, et al, The protein tyrosine kinase Tec regulates mast cell function, Eur J Immunol, 39(1 1):3228-38, 2009).
- the domain architecture of the Tec kinases comprises a single Src homology 3 (SH3) domain, a Src homology 2 (SH2) domain, a catalytic kinase domain, a pleckstrin homology (PH) domain, and a Tec homology (TH) domain at the amino-terminus.
- the TH domain consists of a region unique to the Tec kinases followed by one or more proline -rich regions (see Joseph, et al, Conformational snapshots of Tec kinases during signaling, Immunol Rev, 228(l):74-92, 2009).
- a compound disclosed herein modulates the activity of Tec.
- Tec kinase is an integral component of T cell signaling and has a distinct role in T cell activation.
- a compound disclosed herein modulates the activity of Tec in T cell signaling and activation.
- Tec Aberrant expression of Tec has been implicated in various diseases, including, but not limited to, heart disease (Zhang, et al, Stress signaling by Tec tyrosine kinase in the ischemic myocardium, Am J Physiol Heart Circ Physiol, 2993(3 )H713-22, 2010), myelodysplastic syndrome (see Sato, et al, Molecular cloning and analysis of the human Tec protein-tyrosine kinase, Leukemia, 8(10): 1663-72, 1994), and osteoporosis (see Shinohara, et al, Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals, Cell, 132(5):794-806, 2008).
- heart disease Zhang, et al, Stress signaling by Tec tyrosine kinase in the ischemic myocardium, Am J Physiol Heart Circ Physiol, 2993(3
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an immune disorder. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat cardiovascular disease, osteoporosis, or a combination thereof. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat myelodysplastic syndrome thereof. The compounds described herein can be used to treat Tec-related conditions, included those described herein.
- Txk contains several protein domains, including, a COOH-terminal kinase catalytic domain, a Src homology 2 (SH2) protein interaction domain, an SH3 domain, a palmitoylated cysteine-string motif that is required for membrane localization and a proline-rich region (see Readinger, et al, Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk, Immunol Rev, 228(1):93-1 14, 2009).
- Txk is expressed in Thl/ThO cells and is an important modulator of lymphocyte development and function.
- a compound disclosed herein inhibits or decreases or enhances the activity of Txk.
- Txk is a signal-transducing molecule, which consists of the tyrosine kinase cascade downstream from the T cell receptor when an antigen is presented to the T cell through the T cell receptor.
- Txk is phosphorylated and activated by Fyn, one of the Srk family kinases, and it phosphorylates downstream signal molecules (see Suzuki, et al, Skewed Thl responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease, Clin Med Res, 4(2): 147-51, 2006).
- Txk Upon activation, Txk translocates from cytoplasm into nucleus and regulates specifically interferon-gamma gene transcription.
- Txk poly(ADP-ribose) polymerase 1
- elongation factor 1 alpha make a complex to bind to interferon-gamma gene promoter region-53/-39 (Txk responsive element) to exert positive effects on transcription as a Thl cell-associated transcription factor (see Mihara, et al, Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases, Int Rev Immunol, 26(5-6):333-48, 2007).
- a compound disclosed herein modulates the activity of Txk.
- Txk Aberrant overexpression of Txk has been implicated in several immunopathologies, including, but not limited to, rheumatoid arthritis (see Mihara, et al, Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases, Int Rev Immunol, 26(5- 6):333-48, 2007) and Behcet's disease (see Suzuki, et al, Skewed Thl responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease, Clin Med Res, 4(2): 147-51, 2006).
- rheumatoid arthritis see Mihara, et al, Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases, Int Rev Immunol, 26(5- 6):333-48, 2007
- Behcet's disease see Suzuki
- a compound disclosed herein is administered to an individual in need thereof to treat an inflammatory disorder characterized by dysfunction of lymphocyte development and function. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to rheumatoid arthritis, Behcet's disease, or a combination thereof.
- Txk expression has been implicated in bronchial asthma (see Sahu, et al, Selective expression rather than specific function of Txk and Itk regulate Thl and Th2 responses, J. Immunol, 181(9):6125-31, 2008) and atopic dermatitis (see Arakawa, et al, Differential expression of mR A for Thl and Th2 cytokine-associated transcription factors and suppressors of cytokine signaling in peripheral blood mononuclear cells of patients with atopic dermatitis, Clin Exp Immunol, 135(3):505-10, 2004).
- a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder characterized by dysfunction of lymphocyte development and function. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to asthma, atopic dermatitis, or a combination thereof.
- Txk-mediated disorders such as those associated with inflammatory immune disorders.
- the compounds described herein can be used to treat Txk-related conditions, included those described herein.
- the present disclosure is directed to use of compound of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for use as a medicament.
- the use of compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof is for treating proliferative disease (e.g., cancers).
- the present disclosure is directed to the use of a compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for treatment of diseases associated with axonal regeneration, or spinal cord injury.
- the disease is an inflammatory disorder chosen from asthma, allergic dermatitis, atopic dermatitis and psoriasis.
- the present disclosure is directed to the use of a compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for treatment of psoriasis, alleviation of inflammation during organ transplant, treatment of asthma, rheumatoid arthritis, osteoporosis, cardiovascular disease, or any other disease described above.
- any of the aforementioned aspects involving the treatment of proliferative disorders, including cancer are further embodiments comprising administering the compound of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof in combination with at least one additional agent selected from an anti-cancer agent or an agent that modulates growth or regeneration of axons.
- the agents are administered simultaneously or sequentially.
- the ITK inhibitory activity, residence time of the inhibitor ITK bound complex, and the ability of the of the compounds of the present disclosure to form irreversible covalent bond or reversible covalent bond with Cys 442 can be tested using the in vitro, in vivo assays described in working Examples below.
- the kinase inhibitory activity of the compounds of the present disclosure can be tested by methods well known the art.
- kinase inhibitory activity can be tested using the in vitro and in vivo assays described in Biological Examples 1, 3, 4, and 5 below.
- a determination of kinase inhibitory activity by any of those assays is considered to be kinase inhibitory activity within the scope of this disclosure even if any or all of the other assays do not result in a determination of kinase inhibitory activity.
- the compound of the present disclosure is a reversible covalent inhibitor
- the electron deficient carbon atom of the olefin is distal to the carbon attached to the R b group (where R b is not hydrogen) and to the electron withdrawing -X- Y- or -Y- moiety (see Formula (IA) and (I) in the compounds of the present disclosure.
- the combination of the R b group (where R b is not hydrogen) and the "-X-Y-" or “Y” moieties and the olefinic moiety to which they are bonded in the compounds of the present disclosure can increase the reactivity of the olefin to form a thiol adduct with the active site cysteine residue in ITK.
- the compounds of the present disclosure which are reversible covalent inhibitors bind with ITK in two different manners.
- they also form non-covalent binding (e.g., via van der Waals binding, hydrogen binding, hydrophobic binding, hydrophilic binding, and/or electrostatic charge binding) with ITK, the non-covalent binding being sufficient to at least partially inhibit the kinase activity of the ITK.
- the labile covalent binding between the reversible covalent inhibition of the disclosure and ITK occurs between the olefin in the inhibitor and the cysteine 442 residue thiol side chain at or near the site where the inhibitor has the aforementioned non-covalent binding with the ITK.
- the compounds of the present disclosure which are reversible covalent inhibitors have both a cysteine-mediated covalent binding and a non-covalent binding with the ITK. This is in contrast with non-covalent reversible inhibitors which inhibit the ITK only via non-covalent binding and lack the cysteine-mediated covalent binding.
- the binding of the compounds of the present disclosure with ITK in the two different manners mentioned above provides a reversible covalent inhibitor having a slow off-rate and a protracted duration of action, in some instances comparable to an irreversible covalent inhibitor without forming permanent irreversible protein adducts.
- the difference between irreversible and reversible covalent inhibitors, particularly the compounds disclosed herein, can be ascertained utilizing assays disclosed herein.
- the binding involved in an inhibitor that forms a reversible covalent bond with ITK is stable when the ITK is in certain configurations and susceptible to being broken when the ITK is in different configurations (in both cases under physiologic conditions), whereas the interaction between an inhibitor that forms an irreversible covalent bond is stable under physiologic conditions even when the ITK is in different configurations.
- a reversible covalent bond often imparts unique properties related to the residence time of the compound within the cysteine-containing binding site.
- residence time refers to the temporal duration of the compound-target complex under different conditions (see Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5(9), 730-739 (2006).
- a reversible covalent bond in a reversible covalent inhibitor as disclosed herein can lead to an extended residence time when compared to a compound that does not form a covalent bond with ITK.
- the compounds of the present disclosure that are reversible covalent inhibitors have a residence time of at least about 1 h. Residence time may be measured using an occupancy assay in a biochemical or cellular environment (see Biological Example 2 below). Additionally, residence time may be measured using a functional assay following a defined wash-out period.
- a determination of the binding reversibility of the covalent bond between the cysteine residue and the olefinic bond of the compound of the disclosure by any of Biological Examples 2, 6-8 below is considered to be binding reversibility within the scope of this disclosure even if one or both of the other methods does not result in a determination of binding reversibility.
- the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
- Therapeutically effective amounts of compounds disclosed herein may range from about 0.01 to about 200 mg per kg patient body weight per day, which can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 100 mg/kg per day; more preferably about 0.5 to about 50 mg/kg per day.
- the compositions can be provided in the form of tablets containing about 1 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient.
- the actual amount of the compounds disclosed herein, i.e., the active ingredient will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.
- compositions will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
- routes e.g., oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
- parenteral e.g., intramuscular, intravenous or subcutaneous
- compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
- formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance.
- pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size.
- U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules.
- 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
- compositions are comprised of in general, a compounds disclosed herein in nontoxic, aid administration, and do not adversely affect the therapeutic benefit of the compounds disclosed herein.
- excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
- Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
- the compounds of the present disclosure can also be administered intranasally.
- Intranasal formulations are known in the art e.g., see U.S. Patent Nos. 4,476,116, 5,116,817 and 6,391,452, each of which is incorporated herein by reference.
- the choice of excipients will depend upon the nature of the nasal dosage form e.g., solutions, suspensions, or powder.
- the compounds of the present disclosure may be in the form of solutions, suspensions, and powders.
- These formulations are administered as an aerosol, a mist or a powder and can be delivered from pressurized packs or a nebulizer with a suitable propellant such as
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges for use in an inhaler may be formulated containing a powder mix of the compound disclosed herein and a suitable powder base such as lactose or starch.
- Topical formulation can be liquids, suspension, emulsions, and the like, and can be prepared by methods well known in the art.
- the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients and can be administered in single or multiple doses.
- suitable excipients include polymers, surfactants, buffering or pH adjusting agents, tonicity or osmotic adjusting agent(s), preservatives, and/or dispersing agents.
- Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
- the level of the compound in a formulation can vary within the full range employed by those skilled in the art.
- the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (IA) or (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 1-80 wt %.
- the compounds of the present disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present disclosure or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present disclosure.
- a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present disclosure is preferred.
- the combination therapy may also include therapies in which the compound of the present disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present disclosure and the other active ingredients may be used in lower doses than when each is used singly.
- compositions of the present disclosure also include those that contain one or more other active ingredients, in addition to a compound disclosed herein.
- the above combinations include combinations of a compounds disclosed herein not only with one other active compound, but also with two or more other active compounds.
- compounds disclosed herein may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds disclosed herein are useful.
- Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound disclosed herein.
- a pharmaceutical composition containing such other drugs in addition to the compound disclosed herein is preferred.
- the pharmaceutical compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound disclosed herein.
- the weight ratio of the compound disclosed herein to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
- a compound disclosed herein can be used in with one or more of the following therapeutic agents in any combination: immunosuppressants (e.g., tacrolimus, cyclosporin, rapamicin, methotrexate, cyclophosphamide, azathioprine,
- immunosuppressants e.g., tacrolimus, cyclosporin, rapamicin, methotrexate, cyclophosphamide, azathioprine
- glucocorticoids e.g., prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone
- non-steroidal anti-inflammatory drugs e.g., salicylates, arylalkanoic acids, 2-arylpropionic acids, N- arylanthranilic acids, oxicams, coxibs, or sulphonanilides
- Cox-2-specific inhibitors e.g., valdecoxib, celecoxib, or rofecoxib
- leflunomide gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxy chloroqui
- the subject can be treated with a compound disclosed herein in any combination with one or more other anti-cancer agents.
- one or more of the anti-cancer agents are proapoptotic agents.
- anti-cancer agents include, but are not limited to, any of the following: gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'- deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (GleevecTM), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1 -7082, PKC412, PD 184352, or
- TaxolTM also referred to as "paclitaxel", which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule formation, and analogs of TaxolTM, such as TaxotereTM.
- TaxolTM also referred to as "paclitaxel”
- TaxotereTM analogs of TaxolTM, such as TaxotereTM.
- Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
- anti-cancer agents for use in combination with a compound disclosed herein include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
- mitogen-activated protein kinase signaling e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002
- Syk inhibitors e.g., mTOR inhibitors
- mTOR inhibitors e.g., rituxan
- anti-cancer agents that can be employed in combination with a compound disclosed herein include adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin;
- ametantrone acetate aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium;
- bropirimine busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
- carmustine carubicin hydrochloride
- carzelesin cedefingol
- chlorambucil cirolemycin
- cladribine crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin;
- estramustine estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; cambine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine
- hydrochloride hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-la; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride;
- pegaspargase peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman;
- piposulfan piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; pumprazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; torem
- vapreotide verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
- anti-cancer agents that can be employed in combination with a compound disclosed herein include: 20-epi-l, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine;
- ambamustine amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide;
- anastrozole andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1 ; antiandrogen, prostatic carcinoma; antiestrogen;
- antineoplaston antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
- azatyrosine baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A;
- bizelesin breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole;
- carboxyamidotriazole CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin
- collismycin B combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab;
- decitabine dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane;
- dexverapamil diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9- dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
- dronabinol duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine;
- elemene emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; trasrabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors;
- hepsulfam hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin;
- idoxifene idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons;
- loxoribine lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin
- A marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded R A; mitoguazone; mitolactol;
- mitomycin analogues mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin;
- nafarelin nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;
- nemorubicin neridronic acid
- neutral endopeptidase nilutamide
- nisamycin nitric oxide modulators
- nitroxide antioxidant nitrullyn
- 06-benzylguanine octreotide
- okicenone okicenone
- oligonucleotides onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer;
- pyrazoloacridine pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists;
- raltitrexed ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; R.sub.
- phenylacetate solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin;
- anticancer agents that can be employed in combination with a compound disclosed herein include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes
- nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.
- alkyl sulfonates e.g., busulfan
- nitrosoureas e.g., carmustine, lomusitne, etc.
- triazenes e.g., triazenes
- antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g.,
- mercaptopurine thioguanine, pentostatin
- natural products useful in combination with a compound disclosed herein include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L- asparaginase), or biological response modifiers (e.g., interferon alpha).
- vinca alkaloids e.g., vinblastin, vincristine
- epipodophyllotoxins e.g., etoposide
- antibiotics e.g., daunorubicin, doxorubicin, bleomycin
- enzymes e.g., L- asparaginase
- biological response modifiers e.g., interferon alpha
- alkylating agents examples include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.).
- nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.
- ethylenimine and methylmelamines e.g., hexamethlymelamine, thiotepa
- alkyl sulfonates e.g
- antimetabolites include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
- folic acid analog e.g., methotrexate
- pyrimidine analogs e.g., fluorouracil, floxuridine, Cytarabine
- purine analogs e.g., mercaptopurine, thioguanine, pentostatin.
- hormones and antagonists useful in combination a compound disclosed herein include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide).
- adrenocorticosteroids e.g., prednisone
- progestins e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate
- estrogens e.
- platinum coordination complexes e.g., cisplatin, carboblatin
- anthracenedione e.g., mitoxantrone
- substituted urea e.g., hydroxyurea
- methyl hydrazine derivative e.g., procarbazine
- adrenocortical suppressant e.g., mitotane, aminoglutethimide
- anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with a compound disclosed herein include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and SC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochlor
- Phenylahistin also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA- 110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
- PD-1 inhibitors e.g, Nivolumab and MPDL3280A (Genentech).
- the patient can be treated with a compound disclosed herein in any combination with one or more other anti-thromboembolic agents.
- anti- thromboembolic agents include, but are not limited any of the following: thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX-9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelaga
- thrombolytic agents e.g., alteplase anistreplase, streptokin
- Step 2 To a 25 mL round bottomed flaskl, tert-butyl 4-(2-(4-chlorobenzamido)-lH-benzo[d] imidazol-l-yl) piperidine- 1 -carboxylate (0.45 g, 0.00099 mole) was added in 1, 4 dioxane (5 mL) and the solution was cooled to 10° C under 2 atmosphere. To this, 20% HC1 in 1,4 dioxane (5ml) was added drop wise at 10° C and the reaction mixture was stirred for 16 h at room temperature. The completion of the reaction was monitored by TLC.
- nicotinic acid (0.37 g, 0.003 mole) was added in CH 2 C1 2 (10 mL) under N 2 atmosphere.
- EDC-HC1 (0.72 g, 0.0037 mole)
- HOBT-H 2 0 (0.57 g, 0.0037 mole)
- TEA TEA
- N-(l-(piperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide hydrochloride 0.3 g, 0.00084 mole
- DIPEA 0.36 g, 0.0027 mole
- N-(l-(l-(2-cyanoacetyl)piperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide (0.14 g, 0. 36 mmole) was added in dry methanol (15 mL) under 2 atmosphere.
- Piperidine (1 drop) and isobutyraldehyde (0.026 g, 0.00036 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h. After completion of the reaction, methanol was evaporated to get the crude product which was subjected for the column purification.
- N-(l -(piperidin-4-yl)- lH-benzo[d]imidazol-2-yl)nicotinamide hydrochloride (0.1 g, 0.00028 mole) was taken in THF (5 mL) and cooled to -30° C under 2 atmosphere.
- Acryloyl chloride (50% solution in toluene) (0.025 g, 0.00028 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. After completion of the reaction, raise temperature to RT & solvent was evaporated under reduced pressure. To this, saturated NaHC(3 ⁇ 4 solution was added dropwise to make pH basic, extracted with EtOAc.
- the combined organic layer was dried over Na 2 S0 4 and evaporated to get the crude product which was subjected for the column purification.
- the crude compound was purified by column purification using 60- 120 mesh size neutral silica by eluting the compound with 1.2% MeOH in CH2CI2 to yield 0.026 g of N-(l -(l -acryloylpiperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide.
- the combined organic layer was dried over Na 2 S0 4 and evaporated to get the crude product which was subjected for the column purification.
- the crude compound was purified by column chromatography using 60- 120 mesh size neutral silica by eluting the crude product with 3-5% EtOAc in hexanes to yield 1.7g of tert- butyl 3-(2-nitrophenylamino)-piperidine- 1 -carboxylate.
- Step 2 To a 25 niL RBF, tert-butyl 3-(2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l- yl)piperidine-l-carboxylate (0.3 g, 0.00065 mole) was taken in 1,4 -dioxane (5 mL) and cooled to 10° C under 2 atmosphere. HC1 in 1,4 dioxane (20% solution) (6 mL) was added dropwise at 10° C and the reaction mixture was stirred for 16 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with CH2CI2 to yield 0.27g of 4-chloro-N-(l-(piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)benzamide hydrochloride.
- the crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 0.6% methanol in CH2CI2 to yield 0.135 g of 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)benzamide.
- Piperidine acetate (3.3M solution in water) (0.02 mL) and isobutyraldehyde (0.02 mL, 0.00023 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h.
- nicotinic acid (0.280 g, 0.00227 mole) was taken in CH2CI2 (15 mL) under N 2 atmosphere.
- EDC-HC1 0.545 g, 0.00284 mole
- HOBt 0.436 g, 0.00154 mole
- TEA 0.179 mL, 0.0030 mole
- N-(l -(Piperidin-3-yl)-lH-benzo[d]imidazol- 2-yl)nicotinamide hydrochloride (0.14 g, 0.000391 mole) and DIPEA (0.21 mL, 0.001 17 mole) were added to the reaction mixture and the reaction mixture stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and the reaction mixture was extracted with CH2CI2. The combined organic layer was dried over a2S0 4 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified using column purification using 60-120 mesh size neutral silica by eluting the compound with 2-3% methanol in CH2CI2 to yield O. lg of N-(l -(l -(2- cyanoacetyl)piperidin-3-yl)- lH-benzo[d]imidazol-2-yl)nicotinamide.
- N-(l -(l -(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol-2-yl) nicotinamide (0.09 g, 0.00023 mole) was taken in ethanol (5 mL) under 2 atmosphere.
- N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)nicotinamide hydrochloride (0.07g, 0.00019mole) was taken in THF (3 mL) and cooled to -30° C under N 2 atmosphere.
- Acryloyl chloride (50% solution in toluene) (0.015 g, 0.00017 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. After 30 min, saturated NaHC(3 ⁇ 4 solution was added drop wise to make pH basic and extracted the reaction mixture was with EtOAc .
- the combined organic layer was dried over a 2 S0 4 and evaporated to get the crude product.
- the crude product was thus obtained was taken in THF (3 mL) followed by addition of DBU (0.1ml) and the reaction mixture was stirred at room temperature for 9 h.
- the reaction mixture was diluted with water and extracted with EtOAc, the combined organic layer was dried, concentrated and subjected for the column purification.
- the crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 2-3% MeOH in CH 2 C1 2 to yield 0.020 g of N-(l-(l-acryloylpiperidin-3-yl)-lH- benzo[d]imidazol-2-yl)nicotinamide.
- Step 2 To a 10 niL vial, 4-chloro-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)benzamide (0.14 g, 0.00033 mole) was taken in ethanol (5 mL).
- nicotinic acid (0.4 g, 0.0032 mole) was taken in CH 2 CI 2 (5 mL),
- EDC-HC1 (0.72 g, 0.0038 mole), HOBt.H 2 0 (0.58 g, 0.0038 mole), tert-butyl 2-((2-imino-2,3- dihydro-1 H-benzo [d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate (1.012g, 0.0032mole) and TEA (1.3ml, 0.0096 mole) were added to the reaction mixture at room temperature stirred at room temperature for 5h. The completion of the reaction was monitored on TLC using EtOAc: hexanes (7:3) as a mobile phase. After completion of the reaction, water was added to the reaction mixture and extracted with CH 2 CI 2 .
- reaction mixture was diluted with CH 2 CI 2 , neutralized with saturated aHC03 solution and the combined organic layer washed with water and dried over Na 2 S0 4 and evaporated under reduced pressure to yield 0.22 g of N- ( 1 -(pyrrolidin-2-ylmethyl)- 1 H-benzo[d]imidazol-2-yl)nicotinamide.
- N-(l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)nicotinamide (0.1 g, 0.00031 mole) was taken in THF (3 mL) and cooled to -50° C under 2 atmosphere.
- Acryloyl chloride (50% solution in toluene) (0.06 mL, 0.00034 mole) was added drop wise at - 50° C and the reaction mixture was stirred for 15 minutes at -50° C, followed by RT for 1 h. After completion of the reaction, 40% NaOH solution was added drop wise to make pH basic and extracted with EtOAc.
- N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2- yl)nicotinamide (0.075 g, 0.00019 mole) was taken in ethanol (2 mL).
- Piperidine acetate (3.3M solution in water) (0. 2 niL) and isobutyraldehyde (0.043 niL, 0.00048 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h. After completion of the reaction, water was added to the reaction mixture and extracted with EtOAc.
- Step 6 To a 50 niL single neck RBF, 4-chlorobenzoic acid (1.25 g, 0.00799 mole) was taken in CH 2 C1 2 (50 mL) under N 2 atmosphere. EDC.HC1 (1.91 g, 0.00998 mole), HOBt (1.52 g, 0.010 mole) and TEA (2.8 mL, 0.01997 mole) were added to the reaction mixture at room temperature and stirred for 20 min.
- Step 3 To a 250 niL three necked round bottom flask were added tert-butyl 3-(4-(((S)-3,3- dimethylbutan-2-ylamino)methyl)-2-nitrophenylamino)piperidine-l-carboxylate (3.8 g, 0.0087 mole), NaOH (0.77 g, 0.0192 mole) in water (38 mL) and cooled to 0° C-5° C. Benzyl chloroformate (1.88 mL, 0.0131 mole) was added dropwise to reaction mixture at same temperature and then allowedt to warm up to room temperature. Dioxane (15 mL) was added to reaction mixture and stirred it at room temperature for 4 h.
- Step 1 In a 500 mL 3 neck round bottomed flask was dissolved 2-bromo-2-methylpropanoic acid (40 g, 239.5 mmole) in ethanol (320 mL) and cooled to 0 to 5°C followed by dropwise addition of DIPEA (87.4 mL, 502.9 mmole) at 0 to 5° C and the reaction mixture was stirred at 0°C for 30 min. The reaction mixture was warmed to 40°C for 16 h. After 16 h, the reaction mixture was cooled to room temperature, ethanol was removed in vacuo, leaving a thick white slurry. Diethyl ether and water was added to the slurry and cooled to 0° C.
- 2-bromo-2-methylpropanoic acid 40 g, 239.5 mmole
- DIPEA 87.4 mL, 502.9 mmole
- the mixture was acidified with 10 % HC1 (50 mL) and the organic layer was separated and washed with brine.
- To the organic phase was added 10 % aq NaHS(3 ⁇ 4 and the mixture was stirred at room temperature for 6 h.
- the biphasic mixture was acidified with 10 % HC1 (50 mL) to the pH 1.0 ⁇ 0.5.
- the organic phase was washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated to give 30 g of 2-ethoxy-2-methylpropanoic acid.
- the product, 2-ethoxy-2-methylpropanoic acid was carried forwarded to the next step without further purification.
- reaction mixture was purified using column purification by eluting compound with 20% ethyl acetate in hexanes to yield 0.19 g of benzyl (2-(4- chlorobenzamido)-l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-5 yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
- Step 2 To a 20 niL sealed tube were added benzyl (2-(4-chlorobenzamido)-l-(l-(2- cyanoacetyl)piperidin-3-yl)-lH4oenzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate (0.33 g, 0.4931 mmole), tert-butyl 2-methyl- 1 -oxopropan-2-ylcarbamate (0.28g , 1.4739 mmole) and piperidine (0.1 mL) in 1,4 dioxane (8 mL). The reaction mixture was heated at 100° C for 4 h.
- reaction mixture was concentrated under vacuum and purified using column purification eluting compound with 25% ethyl acetate in hexanes to yield 0.2 g tert-butyl N-[4-[3-[5-[[benzyloxycarbonyl-[(lS)-l,2,2-trimethylpropyl]amino]methyl]-2- [(4-chlorobenzoyl)amino]benzimidazol-l-yl]-l-piperidyl]-3-cyano-l,l-dimethyl-4-oxo-but-2- enyl] -N-methyl-carbamate.
- benzyl (1-(1 -acryloylpiperidin-3 - yl)-2- (4-chlorobenzamido)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate (0.3 g, 0.4571 mmole) and acetic acid (3 mL) and the mixture was cooled to 0° C.
- a solution of 30% HBr in acetic acid (12 mL) was added dropwise and the mixture allowed to warm up to room temperature and stirred for 1 h.
- tert-butyl 2- ((4-formyl-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (14g, 0.0400mole) and (S)-3,3- dimethylbutn-2-amine (4.04 g, 0.0400 mole) were added in 1,2 dichloroethane (300 mL) and the mixture stirred at room temperature for 10 min.
- Acetic acid (1.24 mL, catalytic amount) and NaBH(OAc)3 (12.7 g, 0.0601 mole) were added respectively to the reaction mixture and the reaction mixture was stirred at room temperature for 6 h.
- reaction mixture was purified using column purification by eluting compound with 25% ethyl acetate in hexanes to yield 0.2g of benzyl (2-(4-chloro-benzamido)-l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
- benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3- dimethylbutan-2-yl)carbamate (0.17 g, 0.000013 mole) was added in acetic acid (3.4 mL) and cooled to 0° C. 30% HBr in acetic acid (8.5ml) was added dropwise and after the completion of addition, the reaction mixture was allowed to warm up to room temperature and stirred for 30 min.
- reaction mixture was concentrated under vacuum and purified using column purification eluting with 25% ethyl acetate in hexanes to yield 0.24 g tert-butyl N-[4-[2-[[5-[[benzyloxycarbonyl-[(l S)-l,2,2- trimethylpropyl]amino]methyl]-2-[(4-chlorobenzoyl)-amino]benzimidazo-l- yl]methyl]pyrrolidin-l-yl]-3-cyano-l, l-dimethyl-4-oxo-but-2-enyl]-N-methyl-carbamate.
- Step 2 To a 25 mL one necked round bottom flask were added tert-butyl N-[4-[2-[[5- [[benzyloxy-carbonyl-[(lS)-l,2,2-trimethylpropyl]amino]methyl]-2-[(4- chlorobenzoyl)amino]benzimidazo- 1 -yl]methyl]pyrrolidin- 1 -yl]-3-cyano- 1 , 1 -dimethyl-4-oxo- but-2-enyl]-N-methyl-carbamate (0.24 g, 0.00028 mole) in 1,4-dioxane (2.4 mL) and cooled to 0° C followed by drop wise addition of HC1 in dioxane (5 N) (2.4 mL) and then allowed it to warm up to room temperature and stirred for 2 h.
- 1,4-dioxane 2.4 mL
- 5 N dioxane
- Step 1 To a 10 mL seal tube were added pyrrolidine (0.223 g, 0.003138 mole) and TMS-C1 (0.227 g, 0.002092 mole) in acetonitrile (10 mL) followed by pivaldehyde (0.135 g, 0.001569 mole) and the reaction mixture was stirred at RT for 10 min.
- the crude compound was purified using column chromatography by eluting with 25% ethyl acetate in hexanes to yield 0.2 g benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4,4-dimethylpent-2- enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate.
- reaction mixture was allowed to warm up to room temperature and stirred for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHC(3 ⁇ 4 solution at 5° C (pH ⁇ 7-8) and compound was extracted with ethyl acetate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present disclosure is directed to certain inhibitors of kinases such as ITK, BLK, BMX, BTK, JAK3, TEC, TXK, HER2 (ERBB2), or HER4 (ERBB4), in particular ITK, pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.
Description
BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS
FIELD OF THE DISCLOSURE
The present disclosure is directed to certain inhibitors IL2-inducible T-cell kinase (ITK), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases. BACKGROUND
Kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). The IL2-inducible T-cell kinase (ITK) is a member of the Tec family of kinases. ITK dysfunction (e.g., overexpression) has been implicated in lung inflammation, recruitment of eosinophils, production of mucus (see Mueller, et al, Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK, Journal of Immunology, 170:5056-5063) as well as reduced airway hyperresponsiveness (see Ferrara, et al, Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase, Journal of Allergy and Clinical Immunology, 117:780-786). In addition, using knock-out mice, RNAi and chemical inhibitors, ITK has been implicated in T cell-driven inflammatory diseases of the skin (see von Bonin et al. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases, Exp Dermatol,2Q: \- l , 2010). Itk was found to be expressed in lymphoid tissue and upregulated in lesional skin from patients with allergic dermatitis, atopic dermatitis and psoriasis. Itk also plays a role in the pathophysiology of T cell malignancies (see Guo W. et. al, Molecular characteristics of CTA056, a novel Itk inhibitor which selectively targets malignant T cell and modulates oncomirs, Molecular
Pharmacology, doi: 10.1124/mol.112.079889).
Thus, there is a need for compounds that inhibit the activity of Itk. The present disclosure can fulfill this and related needs.
SUMMARY
Formula (IA)
wherein:
(i) when Z is N, then ring B is:
(a)
wherein:
Z1, Z2, and Z3 are CH (or C if substituted with R1 or R2) or Z1, Z2, and Z3 are
independently N or CH (or C if substituted with R1 or R2) provided that only one of Z1, Z2, and Z3 is N: and
(ii) when Z is C , then ring B is:
wherein:
2 3 1 2 2 3
Z and Z are CH (or C if substituted with R or R ) or Z and Z are independently N or CH (or C if substituted with R1 or R2) provided that only one of Z2 and Z3 is N;
R1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NR3COR4, -CONR3R5, -(alkylene)-NR3R5 (where each R3 is hydrogen, or alkyl, R4 is alkyl, haloalkyl, cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, cycloalkylalkyl, or heterocyclylalkyl optionally substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxy, alkoxy, hydroxyalkyl, or alkoxyalkyl; or R3 and R5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloamino wherein the heterocycloamino ring is optionally
substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxyl, alkoxy, hydroxyalkyl, or alkoxyalkyl, -NR6R7 (where R6 is hydrogen or alkyl and R7 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or acyl, or R6 and R7 together with the nitrogen atom to which they are attached form heterocyclyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyl, hydroxyalkyl, or alkoxyalkyl), or -OR8 (where R8 is hydroxyalkyl, alkoxyalkyl, or heterocyclylalkyl optionally substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl);
R2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy;
Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
X is alkylene, cycloalkylene, (where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NRa-, or -(alkylene)-NR3- (where each Ra is hydrogen, alkyl or cycloalkyl);
Y is -CO- or -S02-;
Rb is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl; R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNRdRe or cycloalkylene(alkylene)NRdRe (where Rd and Re are independently hydrogen, alkyl, or cycloalkyl), alkoxyalkyloxyalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
Rd is hydrogen or alkyl, or Rb and Rd together form a bond; provided that when Rb is other than hydrogen, then R° is not hydrogen and Rd is hydrogen;
and/or a pharmaceutically acceptable salt thereof.
Formula (I)
wherein:
(i) when Z is N, then ring B is:
(a)
wherein:
Z1, Z2, and Z3 are CH (or C if substituted with R1 or R2) or Z1, Z2, and Z3 are independently N or CH (or C if substituted with R1 or R2) provided that only one of Z1, Z2, and Z3 is ; and
(ii) when Z is C , then ring B is:
wherein:
2 3 1 2 2 3
Z and Z are CH (or C if substituted with R or R )or Z and Z are independently N or CH (or C if substituted with R1 or R2) provided that only one of Z2 and Z3 is N;
R1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NRJC0R4, -CONRJR3, -(alkylene)-NR3R5 (where each R3 is hydrogen or alkyl, R4 is cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, or heterocyclylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl; or R3 and R5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloammo wherein the heterocycloamino ring is optionally substituted with one or two substituents independently
selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, -NR6R7 (where R6 is hydrogen or alkyl and R7 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or acyl, or R6 and R7 together with the nitrogen atom to which they are attached form heterocyclyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyl, hydroxyalkyl, or alkoxyalkyl), or -OR8 (where R8 is hydroxyalkyl, alkoxyalkyl, or heterocyclylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl);
R2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy; Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
X is alkylene, cycloalkylene,
(where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NRa-, or -(alkylene)-NR3- (where each Ra is hydrogen, alkyl or cycloalkyl);
Y is -CO- or -S02-;
Rb is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl; R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNRdRe or cycloalkylene(alkylene)NRdRe (where Rd and Re are independently hydrogen, alkyl, or cycloalkyl), or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
Rd is hydrogen, alkyl, or Rb and Rd together form a bond; provided that when Rb is other than hydrogen, then R° is not hydrogen and Rd is hydrogen; and/or a pharmaceutically acceptable salt thereof.
In one embodiment, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y- C(Rb)=CRcRd is -X-Y-C(Rb)=CHRc where Rb and Rc are not hydrogen, the compounds of Formula (IA) and (I) can be reversible covalent inhibitors.
In one embodiment, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y-
C(Rb)=CRcRd is -X-Y-C(Rb)=CHRc where Rb is cyano and Rc is not hydrogen, the compounds of Formula (IA) and (I) can be reversible covalent inhibitors.
In one embodiment, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y- C(Rb)=CRcRd is -X-Y-C(Rb)=CHRc where Rb and Rc are not hydrogen the compounds of
Formula (IA) and (I) can be reversible covalent inhibitors where the reversibility of the covalent bond is determined by Mass spec method described in Biological Example 7 below.
In one embodiment, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y- C(Rb)=CRcRd is -X-Y-C(Rb)=CHRc where Rb is cyano and Rc is not hydrogen, the compounds of Formula (IA) and (I) can be reversible covalent inhibitors where the reversibility of the covalent bond is determined by Mass spec method described in Biological Example 7 below. In another embodiment, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y-C(Rb)=CR°Rd is -X-Y- C(Rb)=CHRc where Rb and Rc are not hydro gen, in particular where Rb is cyano, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof can form reversible covalent bond with Cys442 of ITK.
In yet another embodiment, the compounds of Formula (IA) and (I) and/or
pharmaceutically acceptable salts thereof (and any embodiments thereof disclosed herein) where -X-Y-C(Rb)=CRcRd is -X-Y-C(H)=CRcRd where Rc and Rd are as defined above, the compounds of Formula (IA) and (I) and/or pharmaceutically acceptable salts thereof can form irreversible covalent bond with Cys442 of ITK.
In a second aspect, provided herein are pharmaceutical compositions comprising a compound disclosed herein, and/or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable excipient.
In a third aspect, provided herein are methods of treating a disease treatable by inhibition of ITK in a patient which method comprises administering to the patient in need thereof, a pharmaceutical composition comprising a compound disclosed herein and/or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and a pharmaceutically acceptable excipient. In one embodiment of the third aspect, the patient is in recognized need of such treatment. The compound disclosed herein and/or a pharmaceutically acceptable salt thereof can also inhibit one or more of ITK, BLK, BMX, BTK, JAK3, TEC, TXK (also known as RLK), HER2 (ERBB2), or HER4 (ERBB4) kinase. In one embodiment, the disease is selected from inflammatory disorders, autoimmune disorders, and lymphoproliferative disorders. In one embodiment, the inflammatory disorder, is asthma, allergic dermatitis, atopic dermatitis and
psoriasis. In one embodiment, any compound of Formula (IA) or (I) is administered in combination with at least one anti- inflammatory, anti-autoimmune, or anti-lymphoproliferative agent described herein.
DESCRIPTION
Definitions:
Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:
"Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl (including all isomeric forms), pentyl (including all isomeric forms), and the like.
"Alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms unless otherwise stated e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
"Alkylthio" means a -SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.
"Alkylsulfonyl" means a -SO2R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
"Alkoxy" means a -OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
"Alkylamino" means a -NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, and the like.
"Acyl" means a -COR radical where R is alkyl, haloalkyl, optionally substituted aryl, or optionally substituted heteroaryl as defined herein, e.g., acetyl, trifluoroacetyl, benzoyl, and the like.
"Alkoxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one alkoxy group, preferably one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.
"Alkoxyalkyloxyalkyl" means a -(alkylene)-0-(alkylene)-OR where R is alkyl as defined above, e.g., 2-methoxyethyloxyethyl, -C(CH3)20-(CH2)2-OCH3, and the like.
"Alkoxycarbonyl" means a -C(0)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
"Aminoalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with at least one -NRaRb group, preferably one or two NRaRb groups, where Ra and Rb are independently hydrogen or alkyl, e.g., aminomethyl, methylaminomethyl, dimethylaminomethyl, 2-aminoethyl, 1-, 2-, or 3-methylaminopropyl, and the like.
"Aryl" means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.
"Cycloalkyl" means a cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and the like.
"Cycloalkylalkyl" means an -(alkylene)-R where R is cycloalkyl as defined above, e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, or cyclohexylethyl, and the like.
"Cycloalkylene" means a divalent cyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms, e.g., cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, and the like.
cycloalkylene and Rd and Re are independently hydrogen, alkyl, or cycloalkyl each term as defined herein.
"Dialkylamino" means a - R2 radical where each R is independently alkyl as defined above, e.g., dimethylamino, methylethylamino, and the like.
"Halo" means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.
"Haloalkyl" means alkyl radical as defined above, which is substituted with one or more halogen atoms, preferably one to five halogen atoms, preferably fluorine or chlorine, including those substituted with different halogens, e.g., -CH C1, -CF3, -CHF , -CH CF3, -CF CF3, - CF(CH3)2, and the like. When the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkyl.
"Haloalkoxy" means a -OR radical where R is haloalkyl as defined above e.g., -OCF3, - OCHF2, and the like. When R is haloalkyl where the alkyl is substituted with only fluoro, it is referred to in this Application as fluoroalkoxy.
"Hydroxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-
hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, l-(hydroxymethyl)-2-methylpropyl, 2- hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, l-(hydroxymethyl)-2- hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and l-(hydroxymethyl)-2-hydroxyethyl.
"Heterocyclyl" means a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C. The heterocyclyl ring is optionally fused to a (one) aryl or heteroaryl ring as defined herein provided the aryl and heteroaryl rings are monocyclic. The heterocyclyl ring fused to monocyclic aryl or heteroaryl ring is also referred to in this Application as "bicyclic heterocyclyl" ring. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group. More specifically the term heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2- oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydropyranyl, thiomorpholino, and the like. When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds provided that the ring is not aromatic. When the heterocyclyl group is a saturated ring and is not fused to aryl or heteroaryl ring as stated above, it is also referred to herein as saturated monocyclic heterocyclyl.
"Heterocyclylalkyl" means -(alkylene)-R where R is heterocyclyl which is a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group. More specifically the term heterocyclylalkyl includes, but is not limited to, pyrrolidin- 1 -ylmethyl, pyrrolidinylethyl, piperidinylmethyl,
piperidinylethyl, morpholinylethyl, piperazinylethyl, tetrahydropyranylethyl,
thiomorpholinoethyl, and the like.
"Heterocycloamino" means a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C provided that at least one of the ring atoms is N. Additionally, one or two ring carbon atoms in the heterocycloamino ring can optionally be replaced by a -CO- group. Unless otherwise stated, the heterocycloamino ring can optionally be substituted with one, two, or three substituents independently selected from alkyl, hydroxyl, halo, alkoxy, amino, alkylamino, or dialkylamino.
"Heteroaryl" means a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon. Representative examples include, but are not
limited to, pyrrolyl, pyrazolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like.
The present disclosure also includes the prodrugs of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof. The term prodrug is intended to represent covalently bonded carriers, which are capable of releasing the active ingredient of Formula (IA) and (I) when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups in vivo or by routine manipulation. Prodrugs of compounds of Formula (IA) and (I) include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., Ν,Ν-dimethylamino-carbonyl) of hydroxy or amino functional groups in compounds of Formula (IA) and (I)), amides (e.g., trifluoroacetylamino, acetylamino, and the like), and the like. Prodrugs of compounds of Formula (IA) and (I) are also within the scope of this disclosure.
The present disclosure also includes protected derivatives of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof. For example, when compounds of Formula (IA) and (I) contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups. A
comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. (1999), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of Formula (IA) and (I) can be prepared by methods well known in the art.
The present disclosure also includes amorphous or polymorphic forms (crystalline) and deuterated forms of compounds of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof.
A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-
hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'- methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference.
The compounds of the present disclosure may have asymmetric centers. Compounds of the present disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of materials. All chiral, diastereomeric, racemic forms are within the scope of this disclosure, unless the specific stereochemistry is specifically indicated.
Certain compounds of Formula (IA) and (I) can exist as tautomers and/or geometric isomers. For example, the compound of Formula (IA) and (I) can exist in following tautomeric form:
All possible tautomers are within the scope of the present disclosure. Additional, the - CRb=CRcRd group in the compound of Formula (IA) and (I) can exist as cis and trans isomers. The individual cis or trans forms and mixtures thereof are within the scope of the present disclosure unless a specific isomeric form is specifically indicated. Additionally, as used herein
the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all the positional isomers albeit only a few examples are set forth. Furthermore, all polymorphic forms and hydrates of a compound of Formula (IA) and (I) and/or a pharmaceutically acceptable salt thereof, are within the scope of this disclosure.
"Oxo" and "carbonyl" mean =(0) and C=0, group respectively.
"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "heterocyclyl group optionally substituted with an alkyl group" means that the alkyl may but need not be present, and the description includes situations where the heterocyclyl group is substituted with an alkyl group and situations where the heterocyclyl group is not substituted with alkyl.
"Optionally substituted aryl" means aryl as defined above which is substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, alkylsulfonyl, amino, alkylamino, dialkylamino, aminoalkyl or cycloalkyl.
"Optionally substituted heteroaryl" means heteroaryl as defined above which is substituted with one, two, or three substituents independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, carboxy, alkoxycarbonyl, cyano, alkylsulfonyl, amino, alkylamino, dialkylamino, aminoalkyl or cycloalkyl.
A "pharmaceutically acceptable carrier or excipient" means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
"A pharmaceutically acceptable carrier/excipient" as used in the specification and claims includes both one and more than one such excipient.
"Spiroheterocycloamino" means a bicyclic ring of 7 to 12 ring atoms and joined through one ring atom in which one or two ring atoms are heteroatom selected from N, O, or S(0)n, where n is an integer from 0 to 2, the remaining ring atoms being C provided that at least one of the ring atoms is N. Additionally, one or two ring carbon atoms in the heterocycloamino ring can optionally be replaced by a -CO- group.
"Substituted alkyl" means alkyl group as defined herein which is substituted with one, two, or three substituents independently selected from hydroxyl, alkoxy, carboxy, cyano, alkoxycarbonyl, alkylthio, alkylsulfonyl, halo, haloalkoxy, -CONRR' or -NRR' (where each R is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or heterocyclyl and each R' is hydrogen, alkyl, or
cycloalkyl), spiroheterocycloamino, or heterocyclyl (preferably heterocycloamino) optionally substituted with one or two groups independently selected from alkyl, hydroxyl, alkoxy, alkylthio, alkylsulfonyl, halo, or -CONRR' where (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and R' is hydrogen, alkyl, or cycloalkyl). In one embodiment, substituted alkyl is alkyl group as defined herein which is substituted with one, two, or three substituents independently selected from hydroxyl, alkoxy, carboxy, cyano, alkoxycarbonyl, alkylthio, alkylsulfonyl, halo, haloalkoxy, -CONRR' or -NRR' (where each R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and each R' is hydrogen, alkyl, or cycloalkyl), or heterocyclyl (preferably heterocycloamino) optionally substituted with one or two groups independently selected from alkyl, hydroxyl, alkoxy, alkylthio, alkylsulfonyl, halo, or -CONRR' where (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl, and R' is hydrogen, alkyl, or cycloalkyl).
"Treating" or "treatment" of a disease includes:
(1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;
(2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or
(3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms. A "therapeutically effective amount" means the amount of a compound of Formula (IA) and (I) that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the patient to be treated.
Representative compounds of the disclosure are provided in Table I below.
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
10 H H pyridin-3-yl CN H isopropyl
11 H H pyridin-3-yl H H H
12 5-(S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl H H H o
13 5-(S)- H 4-Clphenyl CN H isopropyl
CH2N(COCF3)CH(CH3)C(CH3)3 o
14 5-(S)- H 4-Clphenyl H H H
CH2N(COCF3)CH(CH3)C(CH3)3 o
15 5-(S)- H 4-Clphenyl CN H isopropyl
CH2N(COCF3)CH(CH3)C(CH3)3
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
22 H H 5-(pyrazol-4-yl)- H H -CH2N(CH3)2 thien-2-yl
O
23 5- (S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl CN H isopropyl
o
24 5- (S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl CN H -C(CH3)2NH2
o
25 5- (S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl CN H -C(CH3)2NHCH3
o
26 5- (S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl CN H -C(CH3)2N(CH3)2
o
27 5- (S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl H H H
o
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
40 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
41 H H 5-(pyrazol-4-yl)- CN H isopropyl thien-2-yl
42 H H 5-(pyrazol-4-yl)- CN H isopropyl thien-2-yl
O
43 H H 5-(pyrazol-4-yl)- CN H -C(CH3)2NH2 thien-2-yl
44 H H 5-(pyrazol-4-yl)- CN H -C(CH3)2- thien-2-yl morpholin-4-yl
45 H H 5-(pyrazol-4-yl)- CN H isopropyl thien-2-yl
hil2 teny--
53 H H 5-CHF2thien-2-yl CN H isopropyl
54 H H 5-CHF2thien-2-yl CN H isopropyl
55 H H 5-(pyrazol-4-yl)- CN H isopropyl thien-2-yl (CH2)2N(CH3)C
0-
56 H H 5-(pyrazol-4-yl)- CN H -C(CH3)2- thien-2-yl (CH2)2N(CH3)C morpholin-4-yl
0-
57 5-(S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl H H H
58 5-(S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl H H H
59 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl H H H
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
60 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
61 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H tert-butyl
62 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H cyclopropyl
63 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
64 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H -C(CH3)2OC2H5
65 H H 5-CHF2thien-2-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
66 H H 5-CHF2thien-2-yl CN H -C(CH3)2N(CH3)2
67 H H 5-CHF2thien-2-yl H H H
68 H H 5-CHF2thien-2-yl -(CH2)2- CN H tert-butyl
N(CH3)CO-
69 H H isoxazol-5-yl CN H isopropyl
70 H H 3-CHF2phenyl CN H isopropyl
71 H H 3-CF3phenyl CN H isopropyl
72 H H 3-CH3phenyl CN H isopropyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
92 6-CH2-2,6-dimethyl-morpholin-4- H 5-CHF2thien-2-yl CN H isopropyl
yi
93 6-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
94 6-(R)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
95 H H 5-CHF2thien-2-yl CN H -C(CH3)2CH2NH2
96 5-CH2NHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H tert-butyl
97 5-CH2-morpholin-4-yl H 5-CHF2thien-2-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
98 5-CH2-2,6-dimehtylmorpholin-4-yl H 5-CHF2thien-2-yl CN H tert-butyl
99 5-CH2NHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
100 5-CH2-morpholin-4-yl H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
101 5-CH2-2,6-dimethylmorpholin-4-yl H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
102 5-CH2NHCH2CH(CH3)2 H 5-CHF2thien-2-yl CN H isopropyl
103 5-CH2NHCH2CH(CH3)2 H 5-CHF2thien-2-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
104 5-CH2NHCH2CH(CH3)2 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
105 H 5-CHF2thien-2-yl CN H isopropyl
106 H 5-CHF2thien-2-yl CN H tert-butyl
107 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
108 H 5-CHF2thien-2-yl CN H isopropyl
109 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl bond methyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
110 5-(S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl bond methyl
111 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl bond methyl
O
112 5-(S)-CH2NHCH(CH3)C(CH3)3 H 4-Clphenyl bond methyl
O
113 5-CH2NHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 817 3-yl
114 H H 5-CHF2thien-2-yl CN H -C(CH3)2CH2NH2
115 6-CH2NHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
116 6-CH2NHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
117 5-CH2NHCH2C(CH3)2OH H 5-CHF2thien-2-yl CN H isopropyl
118 5-CH2NHCH2cyclopropyl H 5-CHF2thien-2-yl CN H isopropyl
119 5-CONHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
120 5-CONHCH2C(CH3)3 H 5-CHF2thien-2-yl CN H 3-methyloxetan- 3-yl
121 5-CH2-(3-(2-hydroxypropan-2- H 5-CHF2thien-2-yl CN H isopropyl
yl)azetidin-l-yl)
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
135 5-CH2NHCH2C(CH3)3 H isoxazol-5-yl CN H isopropyl
136 5-CH2NHCH2C(CH3)3 H isoxazol-5-yl CN H tert-butyl
137 5-CH2NHCH2C(CH3)3 H isoxazol-5-yl CN H 3-methyloxetan- 3-yl
138 5-CH2NHCH2C(CH3)3 H pyridin-3-yl CN H isopropyl
139 5-CH2NHCH2C(CH3)3 H 3-CHF2phenyl CN H isopropyl
140 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
141 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H
C(CH3)2OCH2C H3
142 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H tert-butyl
143 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H
C(CH3)2OCH2CH
3
144 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H tert-butyl
145 5-(S)-CH2NHCH(CH3)C(CH3)3 H isoxazol-5-yl CN H
C(CH3)2OCH2CH
3
146 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
147 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H
C(CH3)2OCH2CH
3
148 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H tert-butyl
149 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H
C(CH3)2OCH2CH
3
150 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H tert-butyl
Cpd # R1 R2 Ar -X-Y- Rb Rd Rb+Rd Rc
151 5-(S)-CH2NHCH(CH3)C(CH3)3 H 3-CHF2phenyl CN H tert-butyl
152 5-(S)-CH2NHCH(CH3)C(CH3)3 H 3-CHF2phenyl CN H isopropyl
153 5-(S)-CH2NHCH(CH3)C(CH3)3 H 3-CHF2phenyl CN H
C(CH3)2OCH2C H3
154 5-CH2OH H 5-CHF2thien-2-yl CN H tert-butyl
155 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H
C(CH3)2OCH2C H3
156 5-(S)-CH2NHCH(CH3)C(CH3)3 H 5-CHF2thien-2-yl CN H isopropyl
or an individual E or Z isomers thereof.and are named as:
N-( 1 -( 1 -acryloylpiperidin-4-yl)- 1 H-benzo [d] imidazol-2(3H)-ylidene)-4- chlorobenzamide;
N-(l-(l-acryloylpiperidin-4-yl)-lH-benzo[d]imidazol-2(3H)-ylidene)nicotinamide; N-( 1 -( 1 -acryloylpiperidin-3 -yl)- 1 H-benzo [d] imidazol-2(3H)-ylidene)-4- chlorobenzamide;
4-chloro-N-( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)- 1 H-benzo [d] imidazol- 2(3H)-ylidene)benzamide;
N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-2(3H)- ylidene)nicotinamide;
N-( 1 -( 1 -acryloylpiperidin-3 -yl)- 1 H-benzo[d] imidazol-2(3H)-ylidene)nicotinamide;
4-chloro-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2(3H)-ylidene)benzamide;
N-( 1 -(( 1 -acryloylpyrrolidin-2-yl)methyl)- 1 H-benzo[d] imidazol-2(3H)-ylidene)-4- chlorobenzamide;
N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-lH-benzo[d]imidazol-2(3H)- ylidene)nicotinamide;
N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol- 2 (3 H)-y lidene)nicotinamide;
N-(l -((1 -acryloylpyrrolidin-2-yl)methyl)- lH-benzo[d]imidazol-2(3H)- ylidene)nicotinamide;
(S)-N-(l-(l-acryloylpiperidin-4-yl)-5-(((3,3-dimethylbutan-2-yl)amino)methyl)-lH- benzo[d]imidazol-2(3H)-ylidene)-4-chlorobenzamide;
4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((N-((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2(3H)- ylidene)benzamide;
N-(l-(l-acryloylpiperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)-4-chlorobenzamide;
4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(( -((S)- 3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2(3H)- ylidene)benzamide;
N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)-4-chlorobenzamide;
4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)(methyl)amino)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)benzamide;
4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)(methyl)amino)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)benzamide;
N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH4oenzo[d]imidazol-2(3H)- ylidene)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
N-( 1 -( 1 -acryloylpiperidin-3 -yl)- 1 H-benzo [d] imidazol-2(3H)-ylidene)-5-( 1 H-pyrazol-4- yl)thiophene-2-carboxamide;
N-(l -(1 -(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)piperidin-3-yl)- 1H- benzo[d]imidazol-2(3H)-ylidene)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-( 1 -( 1 -(4-(dimethylamino)but-2-enoyl)piperidin-3 -yl)- 1 H-benzo [d] imidazol-2(3H)- ylidene)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)benzamide;
N-(l-(l-(4-amino-2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2(3H)-ylidene)-4-chlorobenzamide;
4-chloro-N-(l-(l-(2-cyano-4-methyl-4-(methylamino)pent-2-enoyl)piperidin-3-yl)-5- ((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide;
4-chloro-N-(l-(l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)piperidin-3-yl)-5- ((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide;
N-(l -(1 -acryloylpiperidin-3-yl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)- 1H- benzo[d]imidazol-2-yl)-4-chlorobenzamide;
4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide;
N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide;
4-chloro-N-(l-((l-(2-cyano-4-methyl-4-(methylamino)pent-2-enoyl)pyrrolidin-2- yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2- yl)benzamide;
4-chloro-N-(l-((l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2- yl)benzamide;
4-chloro-N-(l-((l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide;
N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d]imidazol-2-yl)-4-chlorobenzamide;
N-(l-(((R)-l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH4Denzo[d]imidazol-2-yl)-4-chlorobenzamide;
4-chloro-N-(l-(l-(2-cyano-4,4-dimethylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH4Denzo[d]imidazol-2-yl)benzamide;
4-chloro-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)benzamide;
N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl) lH4Denzo[d]imidazol-2-yl)-4-(difluoromethyl)benzamide;
N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-(difluoromethyl)benzamide;
N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl) lH4Denzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-((l-(2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH4Denzo[d]imidazol-2- yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(R)-N-( 1 -(( 1 -(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(R)-N-( 1 -((1 -(2-cyano-4-methyl-4-morpholinopent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(S)-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(S)-N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(S)-N-( 1 -(( 1 -(2-cyano-4-methyl-4-morpholinopent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-4-methylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5-(lH- pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-((l-(2-cyano-4-methyl-4-morpholinopent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-(2-(4-amino-2-cyano-4-methylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5 (lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-4-methyl-4-morpholinopent-2-enamido)ethyl)-lH-benzo[d]imidazol-2 yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(S)-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-N,4-dimethylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5-(lH- pyrazol-4-yl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-N,4-dimethyl-4-morpholinopent-2-enamido)ethyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
N-(l -(((S)- 1 -acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide;
N-(l-(((R)-l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide;
N-(l-(((R)-l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-3-cyclopropylacryloyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene- carboxamide;
N-(l-(((R)-l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 -(difluoromethyl)thiophene- 2-carboxamide;
N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 -(difluoromethyl)thiophene- 2-carboxamide;
(R)-N-( 1 -((1 -(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-( 1 -(( 1 -acryloylpyrrolidin-2-yl)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 - (difluoromethyl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-N,4,4-trimethylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-3-(difluoromethyl)benzamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-3-(trifluoromethyl)benzamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-3-methylbenzamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-3,4-difluorobenzamide;
(R)-N-(l-((l-(2-cyano-5-hydroxy-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide.
(R)-N-( 1 -(( 1 -(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(S)-N-( 1 -( 1 -(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(S)-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-N,4-dimethyl-4-morpholinopent-2-enamido)ethyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-(2-(2-cyano-4-(dimethylamino)-N,4-dimethylpent-2-enamido)ethyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-( 1 -(( 1 -(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)azetidin-3-yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-((l-(2-cyano-4-methyl-4-morpholinopent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- (moφholinomethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxami
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((2,6- dimethylmo holino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((2,2,2- trifluoroethyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((4- methylpiperazin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- (moφholinomethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxami
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((2,6- dimethylmo holino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((((R)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(5-amino-2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)py
(moφholinomethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxami 97
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((2,6- dimethylmo holino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- (moφholinomethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide; 100
N-(l-(((R)-l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5-((2,6- dimethylmo holino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide,
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((isobutylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide; 102
(R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((isobutylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((isobutylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((3- methyloxetan-3-yl)methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide; 105
(R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((3- methyloxetan-3-yl)methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5-((((3- methyloxetan-3-yl)methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide; 107
(R)-N-(5-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-l-((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide; 108
N-(l-(((R)-l-(but-2-ynoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-(((R)-l-(but-2-ynoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide;
N-(l -(1 -(but-2-ynoyl)piperidin-3-yl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)- 1H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide; N-(l-(l-(but-2- ynoyl)piperidin-3-yl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2- yl)-4-chlorobenzamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide.
(R)-N-(l-((l-(5-amino-2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((2 -hydroxy -2- methylpropyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoy
(((cyclopropylmethyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thio^ carboxamide;
(R)-l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxami
(R)-l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxami
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((3-(2- hydroxypropan-2-yl)azetidin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((3- hydroxyazetidin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((4-(2- hydroxypropan-2-yl)piperidin- 1 -yl)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 - (difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-(l-(2-cyano-4,4-dimethylpent-2-enoyl)piperidin-3-yl)-lH4Denzo[d]imidazol-2- yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(S)-N-(l-(l-(2-cyano-4,4-dimethylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)- -(l-((l-(2-cyano-4,4-dimethyl-5-mo holinopent-2-enoyl)pyrrolidin-2-yl)methyl)- 5-(hydroxymethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
(R)- 1 -(( 1 -acryloylpyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2- carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxamide;
N-(3-(((R)-l-(2-cyano-4-(2-methoxyethoxy)-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-6-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide;
1 -(((R)- 1 -acryloylpyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2- carboxamido)-N-((S)-3,3-dimethylbutan-2-yl)-lH-benzo[d]imidazole-5-carboxamide;
(S)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)azetidin-3-yl)methyl)-5-(((3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
1 -(((R)- 1 -(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-N-((S)-3,3-dimethylbutan-2-yl)-lH- benzo[d]imidazole-5-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(3- hydroxypentan-3-yl)-lH4Denzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH4Denzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)-methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
(R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)nicotinamide;
(R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-3-(difluoromethyl)benzamide;
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((S)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((S)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
N-(l-(((S)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((S)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 -(difluoromethyl)thiophene 2-carboxamide;
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 -(difluoromethyl)thiophene 2-carboxamide; N-(l-((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-3-(difluoromethyl)benzamide;
N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-3-(difluoromethyl)benzamide;
N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3 ,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d]imidazol-2-yl)-3 - (difluoromethyl)benzamide;
(R)-N-( 1 -( 1 -(2-cyano-4,4-dimethylpent-2-enoyl)piperidin-3 -yl)-5 -(hydroxymethyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide;
N-(l-((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
N-(l-((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)-5-((((S)-3,3-dimethylbutan- 2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide; or an individual E or Z isomers thereof
Other representative compounds of the disclosure are:
N-(3-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide; or
N-(3-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide;
(R)-N-(3-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide; or
(R)-N-(3-((l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide;
or an individual E or Z isomers thereof
Embodiments:
Embodiment 1
In one embodiment, the compound of Formula (IA) and (I) or a salt thereof has the structure (la):
wherein the groups are as defined in Formula (IA) and (I) respectively, in the Summary. Within embodiment 1, in one group of compounds Z1, Z2, and ZJ are CH (or C if substituted with R2).
Embodiment 2
In another embodiment, the compound of Formula (IA) and (I) or a salt thereof has the structure (lb):
wherein the groups are as defined in Formula (IA) and (I) respectively, in the Summary. Within embodiment 2, in one group of compounds Z1 and Z3 are CH (or C if substituted with R2). Embodiment 3
In yet another embodiment, the compound of Formula (IA) and (I) or a salt thereof has the structure (Ic):
wherein the groups are as defined in Formula (IA) and (I) respectively, in the Summary. Within embodiment 3, in one group of compounds Z2 and Z3 are CH (or C if substituted with R2). Embodiment 4
(i)The compounds or salt thereof as defined in Formula (IA) and (I) in the Summary and embodiments 1, 2, and 3, and groups contained therein, wherein Rb and R° are hydrogen.
Embodiment 5
The compounds or a salt thereof as defined in Formula (IA) and (I) in the Summary and embodiments 1, 2, and 3, and groups contained therein, wherein Rb is cyano and R° is alkyl, substituted alkyl, cycloalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro.
(a) Within the groups in embodiment 5, in one group of compounds R° is alkyl. Within this group of compounds, in one group of compounds R° is isopropyl or tert-butyl.
(b) Within the groups in embodiment 5, in another group of compounds R° is cycloalkyl. Within this group of compounds, in one group of compounds R° is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Within this group of compounds, in another group of compounds R° is cyclopropyl.
(c) Within the groups in embodiment 5, in yet another group of compounds R° is substituted alkyl. Within this group of compounds, in one group of compounds R° is alkyl substituted with hydroxy, alkoxy, -NRR' (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl and R' is hydrogen or alkyl) or heterocyclyl which is optionally substituted with one or two groups independently selected from alkyl or hydroxyl. (i) Within this group of compounds, in another group of compounds R° is-C(CH3)2NH2, -C(CH3)2NHCH3, -
C(CH3)2N(CH3)2, -C(CH3)2NHCH2CH3, -C(CH3)2NHCH(CH3)2, -C(CH3)2NH(CH2)2OCH3, -C(CH3)2- NH-(3-methyloxetan-3-yl), -C(CH3)2-N(CH3)(3-methyloxetan-3-yl), -C(CH3)2OCH2CH3, -C(CH3)2OH, -C(CH3)2morpholin-4-yl, -C(CH3)2-(3-methyloxetan-3-yl), -C(CH3)2azetidin-3-yl, -C(CH3)2-(1- methylazetidin-3-yl), -C(CH3)2piperazin-l-yl, -C(CH3)2pyrrolidin-l-yl, or -C(CH3)2-(3- methylpiperazin-l-yl). (ii) Within this group of compounds, in another group of compounds R° is -C(CH3)2CH2NH2 or -C(CH3)2CH2OH. (iii) Within this group of compounds, in another group of compounds Rc is -C(CH3)2OCH2CH3.
(d) Within the groups in embodiment 5, in one group of compounds R° is 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro. Within this group of compounds, in one group of compounds R° is 2- pyrrolidinyl, 3- or 4-piperidinyl, l-methylpiperidin-4-yl, l-methylpiperidin-3-yl, azetidin-3-yl, oxetan-3-yl, 3-methyloxetan-3-yl, or 4-tetrahydropyranyl.
Embodiment 6
(a) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the in -X-Y- is
(b) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the Summary and embodiments 1, 2, 3, 4 and 5 and groups contained therein wherein -X-Y- is
(c) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the Summary and embodiments 1, 2, 3, 4 and 5 and groups contained therein wherein -X-Y- is - alkylene-NHCO- or -alkylene-NHS02-. Within the groups in (c), in one group of compounds -X Y- is -alkylene-NHCO-. Within the groups in (c), in one group of compounds -X-Y- is - (CH2)2NHCO- or -(CH2)2N(CH3)CO-.
(d) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the
(e) The compounds or a salt thereof as defined in the in Formula (IA) and (I) in the Summary and embodiments 1, 2, 3, 4 and 5 and groups contained therein wherein
ithin the groups in (b), in one group of compounds -X-Y-
(f) The compounds or a salt thereof as defined in the in Formula (IA) and (I)
Summary and embodiments 1, 2, 3, 4 and 5 and groups contained therein wherein
Embodiment 7
The compounds or a salt thereof as defined in Formula (IA) and (I) in the Summary and embodiments 1, 2, 3, 4, 5, and 6 and groups contained therein, wherein R1 is hydrogen, - NR3COR4, or -(alkylene)-NR3R5 where R3 is hydrogen or alkyl, R4 is optionally substituted aryl or heteroaryl, and R5 is hydrogen, alkyl, haloalkyl, or acyl or R3 and R5 together with the nitrogen atom to which they are attached from heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl.
(a) Within the groups in embodiment 7, in one group of compounds R1 is hydrogen. (b) Within the groups in embodiment 7, in one group of compounds R1 is -NR3COR4.
(c) Within the groups in embodiment 7, in one group of compounds R1 is -(alkylene)- NR3R5 where R3 is hydrogen or alkyl and R5 is hydrogen, alkyl, haloalkyl, or acyl. Within this group of compounds, in one group of compounds, R1 is (S)-CH N(COCF3)CH(CH3)C(CH3)3,
(S)-CH2NHCH(CH3)C(CH3)3, or (S)-CH2N(CH3)CH(CH3)C(CH3)3, preferably (S)- CH2 HCH(CH3)C(CH3)3. Within this group of compounds, in another group of c<
is CH2NHCH2C(CH3)3, -(R)-CH2NHCH(CH3)C(CH3)3, -(S)-CH2NHCH(CH3)C(CH3)3
(d) Within the groups in embodiment 7, in another one group of compounds R1 is - (alkylene)-NR3R5 where R3 and R5 together with the nitrogen atom to which they are attached from heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl. Within this group of compounds in one group of compounds R1 is -CH2-2,6-dimethylmorpholin-4-yl, -CH2-morpholin-4-yl, -CH2-4- methylpiperazin-yl,
Within the groups in embodiment 7 and groups contained therein, in one group of compounds R2 is hydrogen.
Embodiment 8
The compounds or a salt thereof of Formula (IA) or (I) as defined in the Summary and embodiments 1, 2, 3, 4, 5, 6, and 7 and groups contained therein wherein Ar is phenyl optionally substituted with one, two, or three substituents selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl. Within the groups in embodiment 8, in one group of compounds, Ar is phenyl substituted with one, two, or three substituents independently selected from chloro, fluoro, methyl, trifluoromethyl, trifluoromethoxy, difluoromethoxy, or
difluromethyl. Within the groups in embodiment 8, in one group of compounds, Ar is phenyl, 4- Clphenyl, 4-CHF2phenyl, 3-CHF2phenyl, 3-CF3phenyl, 3-CH3phenyl, or 3,4-diFphenyl. Within the groups in embodiment 8, in one group of compounds, Ar is phenyl, 4-Clphenyl, 4- CHF2phenyl, 3-CHF2phenyl, 3-CF3phenyl, 3-CH3phenyl, 3-CN -phenyl 4-CN-pbeoyi, or 3,4- diFphenyl.
Embodiment 9
The compounds or a salt thereof of Formula (IA) or (I) as defined in the Summary and embodiments 1, 2, 3, 4, 5, 6, and 7 and groups contained therein wherein Ar is heteroaryl optionally substituted with one, two, or three substituents selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl. Within the groups in embodiment 8, in one group of compounds, Ar is pyridin-3-yl, 5-(pyrazol-4-yl)-thien-2-yl, 5-CHF2thien-2-yl, or isoxazol-5-yl. Within the groups in embodiment 8, in one group of compounds, Ar is a five membered heteroaryl ring ( such as thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrrolyl, triazolyl, pyrazolyl, or thiazolyl) optionally substituted with one, two, or three substituents selected from hydrogen, alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl (in one group methyl, ethyl, fluoro, trifluoromethyl, or difluoromethyl). Within the groups in embodiment 8, in another group of compounds, Ar is thien-2-yl, 5-chlorothien-2-yl, 5-cyanothien-2-yl, 2-oxazol-4-ylthien-5-yl, 5-CF3- thien-2-yl, l-methyl-pyrazol-3-yl, oxazol-5-yl , 2-methyl-oxazol-5-yl, 2-m ethyl, l,2,3-triazol-4-yl, oxazol-5-yl, 2-methyl-oxazol-4-yl, 2-methyl-thiazol-5-yl, 5-CHF2thien-2-yl, or isoxazol-5-yl.
General Synthetic Schemes
Compounds of this disclosure can be made by the methods depicted in the reaction schemes shown below.
The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem
(Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this disclosure can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78° C to about 150° C, more preferably from about 0° C to about 125° C and most preferably at about room (or ambient) temperature, e.g., about 20° C.
Compounds of Formula (IA) and (I) can be prepared as illustrated and described in Schemes 1 and 5 below.
Compounds of Formula (IA) or (I) where ring B is (a) where Z1 is CH, X is a ring of formul
, R is cyano, and other groups are as defined in the Summary can be prepared as illustrated and described in Scheme 1 below.
Scheme 1
Displacement of the fluorine or other halogen group in a compound of formula 1 where Z2, Z3, R1, and R2 are as defined in the Summary, by a monoprotected diamine la where ring A and Z are as defined in the Summary and PG is a suitable nitrogen protecting group, in a solvent such as acetonitrile provides a compound of formula 2. Compounds of formula 1 and la e.g., (R)- tert-butyl 2-(aminomethyl)pyrrolidine-l-carboxylate, (S)-tert-butyl 2-(aminomethyl)pyrrolidine- 1 -carboxylate, tert-butyl 3-aminopiperidine-l-carboxylate, tert-butyl 4-aminopiperidine-l- carboxylate, tert-butyl 3-(aminomethyl)azetidine-l -carboxylate are commercially available or they can be prepared by methods well known in the art. Reduction of the nitro group in 2 can be accomplished by various reduction methods such as hydrogenation with Pd catalysis or by the action of elemental Zn. The resulting diamino compound 3 can be cyclized to the
aminobenzimidazole compound of formula 4 by treatment with cyanogen bromide in a solvent such as ethanol. Coupling of 4 with a carboxylic acid of formula ArCOOH where Ar is as defined in the Summary occurs under standard amide coupling conditions or with an acid derivative such as a carboxylic acid chloride to provide compound of formula 5. Removal of the amino protecting group PG, followed by coupling of the resulting compound 6 with cyanoacetic acid provides a compound of formula 7. Compound 7 can be then converted to a compound of Formula (LA) or (I) by methods well known in the art. For example, compounds of Formula (LA) or (I) where X is -CO- can be prepared by condensing compound 7 with an aldehyde of
formula R°CHO, where R° is as defined in the Summary, under standard condensation conditions such as using a base such as piperidine and the like, in the presence or absence of acetic acid and the like in solvents such as ethanol at temperatures ranging from room temperature to reflux to afford compounds of Formula (IA) or (I). Compounds of formula R°CHO are commercially available or they can be prepared by methods well known in the art e.g. such as , e.g., acetaldehyde, cyclopropylaldehyde, isobutyraldehyde, 2-(dimethyl amino)-2-methylpropanal, and 2-methyl-2-(morpholin-4-yl)propanal are commercially available. Ethoxy-2-methylpropanal was prepared from isobutyraldehyde as described in PCT Int. Appl, 2007142576. Likewise the condensation can be performed by adding the desired aldehyde, base such as pyrrolidine or piperidine with or without chlorotrimethylsilane in dichloromethane or other suitable solvent (e.g. dioxane and ethanol).
Alternatively, compounds of Formula (IA) or (I) where X is -CO- can be prepared by reacting compound 6 with an acid of formula 10 where R° is as defined in the Summary under amide coupling conditions. Compounds of Formula (IA) or (I) where X is -S02- can be prepared by reacting amine 6 with a sulfonyl chloride of formula 9, followed by condensation of resulting compound 11 with an aldehyde of formula R°CHO as described.
be apparent to a person of ordinary skilled in the art, that substituting
amines of formula NH2-X-NHPG where PG is a suitable amino protecting group and X is cycloalkylene or alkylene e.g., tert-butyl N-(2-aminoethyl)carbamate or NH2-X- OPG1 where PG1 is a suitable hydroxy protecting group and X is alkylene, followed by steps described above would give compounds of Formula (IA) or (I) where X is -alkyleneNH-, - cycloalkyleneNH-, and -alkylene-O- and Y is CO or SO2. Compounds of Formula (IA) or (I) where Rb and R° are hydrogen, can be prepared by the addition of acryloyl chloride to amines such as 6 in a solvent such as toluene or THF.
Compounds of Formula (IA) or (I) where ring B is (b), Rb is cyano and other groups are as defined in the Summary can be prepared as illustrated and described in Scheme 2 below.
Scheme 2
R eaction of a balopyridmes, halopyrazines, or balopyrir dmes 12 which are readily available from commercial suppliers with a compound of formula 14 where Ra is as defined in the Summary, PG is a suitable amino protecting group and X' is alkylene or cycloalkylene in the presence of a base such as NaHMDS provides a compound of formula 15 (see J. Org. Chem, 2005, 101 86-10189), Compounds 14 are either available commercially or can be prepared from a compound such as 13 where LG is a leaving group such as halogen or mesylate and sodium cyanide, PG is a suitable amino protecting group such as benzyloxy carbamate or benzyl, and Ra is as defined, previously or alternately a suitable amino protecting group, and X' is alky! or cycloalkylene. Using procedures described in Chemical & Pharmaceutical Bulletin (1973), 21( 10), 2146-60, addition of hydroxylamine to compound 15 affords the hydroxyamicline compound 16 which is then cyclized by the action of acetic anhydride to form compound 17. Acidic hydrolysis affords compound 18 which can be acvlated. as described in scheme 1 to form compound 19. Deprotection, via hydrogenation with Pd catalyst of a CBZ or benzyl protecting group for example, affords compound 20. Compound 20 can be carried forward to afford compounds of Formula (LA) or (I) as described in Scheme 1 above.
Compounds of Formula (IA) or (I) where ring B is (a) where Z1 is CH (or C if substituted with R1 or R2), R1 is -(CH2)-NR3R5 where R3 and R5 are as defined in the Summary, X is a ring
of formula
, R is cyano, and other groups are as defined in the Summary can also be prepared as illustrated and described in Scheme 3 below.
Displacement of a halogen X in a compound of formula 21 where Z2 and Z3 are as defined in the Summary by a monoprotected diamine la where Ring A and Z are as defined in the Summary, and PG is a suitable nitrogen protecting group, in a solvent such as acetonitrile provides a compound of formula 22. Compounds of formula 21 and la e.g., methyl 4-fluoro-3- nitrobenzoate, methyl 3-fluoro-4-nitrobenzenecarboxylate, tert-butyl (2-aminoethyl)carbamate, tert-butyl (2-aminoethyl)(methyl)-carbamate, (R)-tert-butyl 2-(aminomethyl)pyrrolidine- 1 -
carboxylate, (S)-tert-butyl 2-(aminomethyl)pyrrolidine-l-carboxylate, tert-butyl 3- aminopiperidine- 1 -carboxylate, tert-butyl 4-aminopiperidine-l -carboxylate, tert-butyl 3- (aminomethyl)azetidine-l -carboxylate are commercially available or they can be prepared by methods well known in the art.
Reduction of the nitro group in 22 can be accomplished by various reduction methods such as hydrogenation with Pd catalysis or by the action of elemental Zn. The resulting diamino compound 23 can be cyclized to the aminobenzimidazole compound of formula 24 by treatment with cyanogen bromide in a solvent such as ethanol. Coupling of 24 with a carboxylic acid of formula ArCOOH where Ar is as defined in the Summary under standard amide coupling conditions or with an acid derivative such as a carboxylic acid chloride provides a compound of formula 25.
Reduction of the ester group in compound 25 with a suitable reducing agent such as lithium aluminum hydride affords alcohol 26 which can be oxidized with an oxidizing agent such as Dess-Martin Periodinane or PCC other standard oxidizing protocols such as the Swern oxidation and the like to afford aldehyde 27. Compound 27 can undergo reductive amination with amines of formula 31 where R3 and R5 are as described in the Summary to afford compound 28. Removal of the amino protecting group PG provides compound 29 which can be converted to a compound of Formula (LA) or (I) as described in Scheme I above.
Alternatively, compounds of Formula (LA) or (I) where ring B is (a) where Z1 is CH (or C if substituted with R1 or R2), R1 is -(CH2)-NR3R5 where R3 and R5 are as defined in the
Summary, X is a ring of formula v— ' , R is cyano, and other groups are as defined in the Summary can also be prepared as illustrated and described in Scheme 4 below.
Scheme 4
Removal of the amino protecting group PG in compound 26, followed by coupling of the resulting compound 32 with cyanoacetic acid provides a compound of formula 33. Compound 33 can be oxidized with reagents such as Dess-Martin Periodinane or PCC other standard oxidizing protocols such as the Swern oxidation and the like to afford aldehyde 34. Compound 34 can undergo reductive amination with amines 31 , where R3 and R5 are as described in the Summary to afford compound 35. Compound 35 can be then converted to a compound of Formula (IA) and (I) as described in Scheme 1 above.
Alternatively compounds of Formula (IA) or (I) where ring B is (a) where Z1 is CH (or C if substituted with R1 or R2), R1 is -(CH2)-NR3R5 where R3 and R5 are as defined in the
Summary, X is a ring of formula
, R is cyano, and other groups are as defined in the Summary can also be prepared as illustrated and described in Scheme 5 below.
Scheme 5
Treatment of a compound of formula 36 (prepared by reacting compound 1 where R1 is aldehyde with compound la as described in Scheme 1) with an amine of formula R3 H2 where R3 is as defined in the Summary, provides a compound of formula 37. Protection of the resultant amine 37 with a suitable orthogonal protecting group PG2 such as Alloc or Cbz, can be
accomplished under standard conditions as described in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. (1999) to afford a compound of formula 38 which can be converted to a compound of formula 42, 43, or 44 as described in Scheme 1 above.
Removal of the amino protecting group then provides a compound of Formula (IA) or (I).
arent to a person of ordinary skilled in the art, that substituting
amines of formula NH2-X-NHPG where PG is a suitable amino protecting group and X is cycloalkylene or alkylene e.g., tert-butyl N-(2-aminoethyl)carbamate or NH2-X- OPG1 where PG1 is a suitable hydroxy protecting group and X is alkylene, followed by steps described above would give compounds of Formula (I) where X is -alkyleneNH-, - cycloalkyleneNH-, and -alkylene-O- and Y is CO or SO2. Compounds of Formula (IA) or (I) where Rb and R° are hydrogen, can be prepared by the addition of acryloyl chloride to amines such as 41 in a solvent such as toluene or THF.
Utility
ITK dysfunction (e.g., overexpression) has been implicated in lung inflammation, recruitment of eosinophils, production of mucus (see Mueller, et al, Attenuation of
immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK, Journal of Immunology, 170:5056-5063) as well as reduced airway hyperresponsiveness (see Ferrara, et al, Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase, Journal of Allergy and Clinical Immunology, 1 17:780-786). Due to its role in the production of cytokines and T cells, inhibiting Itk function can reduce or inhibit the development and/or progression of multiple inflammatory disorders, autoimmune disorders, and lymphoproliferative disorders. Several drug therapies target Itk in order to treat inflammatory disorders, autoimmune disorders, and lymphoproliferative disorders. These drugs include, but are not limited to, BMS-488516 and BMS-509744 (see Lin, et al, Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry, 43(34): 11056-62), 2-amino-5-(thioaryl)thiazoles (Das, Discovery and SAR of 2-amino-5- (thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters, 16(14):3706-12); 3-Aminopyrid-2-ones (see Charrier, et al, Discovery and Structure- Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T- Cell Kinase (Itk) Inhibitors, Journal of Medicinal Chemistry, 54(7):2341-50).
There is evidence that ITK dysfunction plays a role in multiple inflammatory disorders that are affected by cytokine production, e.g., lung inflammation and pneumonia (see Lin, et al, Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry,
43(34): 11056-62; Das, Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters , 16(14): 3706- 12); allergic asthma (see Mueller, et al, Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK, Journal of Immunology, 170:5056-5063; Das, Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors, Bioorganic and Medicinal Chemistry Letters , 16(14):3706-12); psoriasis (see Eur. J. Pharm. Sci. 2012 Oct 9;47(3):574-88. doi: 10.1016/j.ejps.2012.07.013. Epub 2012 Jul 20. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. Kaur M, Bahia MS, Silakari O. and Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a002287. Epub 2010 Jun 2 T-cell signaling regulated by the Tec family kinase, Itk. Andreotti A. H, Schwartzberg P. L, Joseph R. E, Berg L.J.) and atopic dermatitis (see Exp Dermatol. 2011 Jan; 20 (l):41-7. doi: 10.1111/j.1600-0625.2010.01198.x. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases, von Bonin A, Rausch A, Mengel A, Hitchcock M, Kriiger M, von Ahsen O, Merz C, Rose L, Stock C, Martin SF, Leder G, Docke WD, Asadullah K, Zugel U.
In one embodiment, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder. In another embodiment, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder characterized by excessive or undesired cytokine production or activity. In yet another embodiment, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat lung inflammation, pneumonia, allergic asthma, psoriasis, atopic dermatitis, or a combination thereof. In yet another embodiment, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat dry eye disease or uveitis.
Additionally, it is thought that Itk dysfunction affects the development and progression of autoimmune disorders (see Charrier, et al, Discovery and Structure-Activity Relationship of 3- Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk)
Inhibitors, Journal of Medicinal Chemistry, 54(7):2341-50). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an autoimmune disorder.
There is also evidence that ITK overexpression results in the development and progression of T cell malignancies (e.g., T cell lymphomas and T cell leukemia) (see Guo W. et. al, Molecular characteristics of CTA056, a novel Itk inhibitor which selectively targets malignant T cell and modulates oncomirs, Molecular Pharmacology,
doi: 10.1124/mol.112.079889). CTA056 was found to modulate the growth of cell lines with high ITK levels, but not those with low levels or not expressing ITK at all. In addition, normal T
cell growth was not affected. The effect of ITK inhibitor was via induction of apoptosis indicating a potential therapeutic mechanism for elimination of tumor cells. In addition, inhibition of ITK modulates genes that are associated with survival pathways and oncogenesis, which also supports a mechanism to inhibit tumor cell growth. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat T cell malignancies, such as T cell lymphomas and T cell leukemia. In one embodiment, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat PTCL, acute lymphoblastic leukemia (T-ALL), adult T cell leukemia/lymphoma (ATL), and Seazry syndrome/cutaneous T cell lymphoma (CTCL).
The effects of ITK inhibition on Th2 responses (Andreotti et al, T-cell signaling regulated by the TEC family kinase, ITK, Cold Spring Harb Perspect Biol, 2(7): 1-21) suggest that blockade of ITK function in T cells could lead to a shift in the relative proportions (or skewing) of the Thl and Th2 populations in patients treated with an ITK inhibitor. In animal models, this Thl/2 skewing affects the susceptibility to infectious agents such as Listeria monocytogenes and allergic asthma in animal models {see Mizuki et al, Interference between host resistance to Listeria monocytogenes infection and ovalbumin-induced allergic responses in mice, Infection and Immunity, 69(3): 1883-1888). Such T helper cell skewing has been suggested to play a role in the responses of chronic lymphocytic leukemia (CLL) patients to ibrutinib therapy through effects of ibrutinib on ITK {see Dubovsky et al, Ibrutinib is an irreversible molecular inhibitor ITK driving a Thl selective pressure in T- lymphocytes, Blood, 2013, pre- published on line).). It was also suggested that the ITK activity of Ibrutinib was responsible for the suppression of Leishmaniasis in susceptible mice again through the Thl skewing activity. In addition, it has been suggested that Thl skewing may add to the therapeutic benefit of EGFR targeting in cancer patients by boosting local inflammatory response to the tumor {see Zaiss et al, Amphiregulin enhances regulatory T cell-suppressive function via epidermal growth factor receptor, Immunity, 38: 1-10). Taken together, these data supports that inhibition of ITK in patients with CLL or other cancers , with the resultant skewing of the T helper cell population towards Thl cells, could play a role in therapy both through anti-tumor activity as well as an adjuvant therapy to boost immune responses to pathogens that contribute to infections in these settings. In one embodiment, a compound disclosed herein is administered to a patients in need or recognized need thereof to treat CLL or other cancers or infections such as Leismaniasis that are associated with immune function suppression through skewing of T helper cell populations.
The compounds of Formula (LA) and (I) and/or pharmaceutically acceptable salts thereof (and embodiments thereof described herein) are useful in the treatment of ITK-mediated
disorders described above, including disorders such as those associated with T cell and cytokine - mediated disorders.
The compounds described herein can also inhibit other kinases such as BTK, JAK3, BLK, BMX, HER2 (also known as ERBB2), HER4 (also known as ERBB4), TEC and TXK and hence can also be used for treating diseases or conditions associated with the activity of BTK, JAK3, BLK, BMX, HER2 (also known as ERBB2), HER4 (also known as ERBB4), TEC and TXK.
B lymphocyte kinase (Blk) is a tyrosine protein kinase. Specifically, it is a member of the src family of proto-oncogenes that are typically involved in cell proliferation and differentiation. In some embodiments, a compound disclosed herein inhibits or decreases the activity of Blk. In some embodiments, the inhibition or decrease of activity of Blk occurs in a human.
Blk has been implicated in B-cell receptor signaling and B-cell development. In some embodiments, a compound disclosed herein is administered to an individual in need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) B-cell receptor signaling and B-cell development.
There is also evidence that Blk stimulates insulin synthesis and secretion in response to glucose and enhances the expression of several pancreatic beta-cell transcription factors by up- regulating the expression of PDX1 and KX6-l. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) insulin synthesis and secretion in response to glucose. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat diabetes.
Blk dysfunction has been implicated in multiple diseases, for example, single-nucleotide polymorphisms (SNPs) in the C8orfl3 region of BLK are associated with the development of SLE in Caucasians (Ito, et al, Replication of the association between the C8orfl3-BLK region and systemic lupus erythematosus in a Japanese population, Arthritis and Rheumatism,
60(2):553-8). Blk dysfunction has also been implicated in Sjogren's Syndrome (see Nordmark, et al, Association of EBF1, FAM167A(C8orfl3)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome, Genes and Immunity, 12(2): 100-9); ulcerative colitis (see Seidelin, et al., Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis, APMIS, 1 14(7-8):508-17); rheumatoid arthritis and systemic sclerosis (see Tsuchiya, et al, Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases, Nihon Rinsho Meneki Gakkai Kaishi, 33(2):57-65). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat SLE, Sjogren's Syndrome, ulcerative colitis, rheumatoid arthritis, systemic sclerosis, or a combination thereof.
Blk dysfunction has also been identified in patients with lymphomas, such as cutaneous T-cell lymphoma (see Krejsgaard, et al, Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma, Blood, 113(23):5896-904). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a lymphoma. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat cutaneous T-cell lymphoma. The compounds described herein can be used to treat Blk-related conditions, included those described herein.
Bone Marrow X kinase (also, Bmx, Epithelial and endothelial tyrosine kinase and ETK) is a member of Tec family non-receptor tyrosine kinase. Bmx can be activated by several extracellular stimuli, including growth factors, cytokines, extracellular matrix and hormones. Activation of Bmx kinase can be achieved by interaction of its pleckstrin homology domain either with the phosphatidylinositol 3-kinase product phosphatidylinositol 3,4,5-triphosphate or the FERM domain of FAK, which leads to plasma membrane translocation of Bmx. In some embodiments, a compound disclosed herein inhibits or decreases the activity of Bmx. In some embodiments, the inhibition or reduction of activity of Bmx occurs in a human.
Bmx has been shown to play a role in various cellular processes including cell proliferation, transformation, differentiation, migration and metastasis. Bmx is known to interact with FAK and pl30Cas to regulate actin cytoskeleton and cell motility. It has also been shown that Bmx directly interacts with tumor suppress p53 and inhibit its nuclear translocation, thereby promoting chemoresistance in cancer cells.
Bmx has been implicated in several signal transduction pathways, including the Stat pathway. There is evidence that it may play a role in signal transduction (and the growth and differentiation of) hematopoietic cells, endocardial endothelial cells, and arterial endothelial cells.
Bmx dysfunction has been implicated in several types of cancer cells, such as prostate cancer (see Dai, et al, Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse, Cancer Research,
66(16):8058-64); breast cancer (see Bagheri-Yarmand, et al, Etk/Bmx tyrosine kinase activates Pakl and regulates tumorigenicity of breast cancer cells, Journal of Biological Chemistry, 276(31):29403-9); hepatocellular carcinoma (see Guo, et al, Expression of tyrosine kinase
Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma, Oncology, 72(5-6):410-6); bladder cancer (see Guo, et al, Tyrosine Kinase
ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy, PMID: 21408190, 2011); nasopharygeal cancer (see Zhang, et al, Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation, Cancer
Biology & Therapy, 1 1(7):690-8); and small cell lung cancer (see Guo, et al, Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells, Experimental and Molecular Pathology, 88(3):401-6). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a cancer. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat prostate cancer, breast cancer, hepatocellular carcinoma, bladder cancer, nasopharygeal cancer, small cell lung cancer, or a combination thereof.
Bmx dysfunction has also been associated with multiple autoimmune disorders, such as, but not limited to, rheumatoid arthritis (see Gottar-Guillier,et al, The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner, Journal of Immunology, PMID: 21471444, 2011); and chronic inflammation and angiogenesis in the skin see (Paavonen, et al, Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing, Molecular Biology of the Cell, 15(9):4226-33). Accordingly, the compounds described herein can be used to treat Bmx-related conditions, included those described herein.
Human epidermal growth factor receptor 2 (HER2) is a cell-surface receptor tyrosine kinase for the epidermal growth factor receptor (EGF) family. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it; however, HER2 is the preferential dimerization partner of other members of the EGF family (see Olayioye, Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members, Breast Cancer Res 3(6): 385-389, 2001).
Heterodimerization of the EGF family of receptors to HER2 results in stabilization of the ligand-EGF receptor interaction and enhancement of kinase-mediated activation of downstream signaling pathways. Downstream signaling pathways initiate signal transduction cascades that drive many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.
Due to its role in cell proliferation, inhibition of HER2 function should reduce or inhibit the development and/or progression of cancers. Amplification and/or overexpression of the HER2 gene has been implicated in numerous cancers, including, but not limited to, breast cancer (see Konecny, et al, Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer, Clin Cancer Res, 7(8):2448-57, 2001), ovarian cancer (see Lafky, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer, Biochim Biophys Acta, 178(2):232-65, 2008), gastric cancer (see Moelans, et al, Low frequency of HER2 amplification and overexpression in early onset gastric cancer, Cell Oncol (Dordr), 34(2):89-95, 201 1), lung cancer (see Hirsch, et al, The role of HER2/neu
expression and trastuzumab in non-small cell lung cancer, Semin Oncol, 31(1 Suppll):75-82, 2004), glioblastoma (see Mineo, et al, Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma, J eurooncol, 85(3):281-7, 2007) and biologically aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma (see Santin, et al, Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu, Int J Gynaecol Obstet, 102(2): 128-31, 2008). In some embodiments, the compounds are used to treat breast cancer, ovarian cancer, gastric cancer, lung cancers, glioblastoma, and biologically aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma. The compounds described herein can be used to treat HER2 -related conditions, included those described herein.
Human epidermal growth factor receptor 4 (HER4) is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor (ErbB) family. HER4 is a single-pass type I transmembrane protein with multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment.
The C-terminal fragment (CTF) of isoform JMA-A CYT-2 (containing E4ICD2) can stimulate transcription in the presence of YAP 1. ERBB4 intracellular domain is involved in the regulation of cell growth. Overexpression studies in epithelium show growth inhibition using E4ICD1 and increased proliferation using E4ICD2. E4ICD2 has greater in vitro kinase activity than E4ICD1. This kinase activity is required for the nuclear translocation of E4ICD2. In some embodiments, a compound disclosed herein is administered to an individual in need thereof to treat a disorder characterized by undesired or excessive (or, uncontrolled) cell proliferation and differentiation.
Due to its role in cell proliferation and differentiation, inhibition of HER4 function should reduce or inhibit the development and/or progression of disorders characterized by undesired or uncontrolled cell proliferation or differentiation. In some embodiments, this disorder comprises cancers.
Mutations in and overexpression of the HER4 gene have been associated with numerous cancers, including, but not limited to, breast cancer (see Junttila, et al, Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells, Cancer Res, 65(4): 1384-93, 2005), childhood medulloblastoma (see Gilbertson, et al, Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma., Cancer Res, 57(15):3272-80, 1997), non-small-cell
lung cancer (see Starr, et al, ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy, Int. J. Cancer, 119(2):269- 274, 2006), and melanoma (see Prickett, et al, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4, Nat Genet, 41(10): 1127-32, 2009). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a disorder characterized by uncontrolled or undesired cell proliferation or differentiation. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat breast cancer, lung cancer, medulloblastoma (including the childhood form), melanoma, or a combination thereof.
In addition, single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia (see Silberberg, et al. The involvement of ErbB4 with schizophrenia: association and expression studies, Am J Med Genet B Neuropsychiatr Genet 141(B2): 142-8, 2006). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat schizophrenia. The compounds described herein can be used to treat HER4-related conditions, included those described herein.
Jak3 is a tyrosine kinase that belongs to the Janus family of tyrosine kinases. It is involved in cytokine receptor-mediated intracellular signal transduction. Jak3 is activated by binding to the yC chain of the type I cytokine receptor family (e.g. IL-2R, IL-4R, IL-7R, IL-9R, IL-15R, and IL-21R). Following binding, Jak3 undergoes tyrosine phosphorylation (either via autophosphorylation and/or transphosphorylation by other JAKs or other families of tyrosine kinases). Activated JAKs then phosphorylate receptors on target tyrosine residues that serve as docking sites that allow the binding of other SH2-domain containing signaling molecules such as STATs, Src -kinases, protein phosphatases and other adaptor signaling proteins such as She, Grb2 and PI-3 kinase (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and
Myeloproliferative Disorders: Approaches for Targeted Therapies, Genes & Cancer, 1(10):979- 993). Jak3 is predominantly expressed in immune cells and hematopoietic cells, for example, in T cells, NK cells and monocytes. It appears that Jak3 is involved in T and B cell development and function (see Cox, et al, JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough, Chemistry & Biology, 18(3):277-8). In some embodiments, a compound disclosed herein inhibits the activity of Jak3.
Jak3 contains a tyrosine kinase (JH1) domain adjacent to a catalytically inactive pseudokinase domain (JH2). The JH2 domain, which lacks any observable tyrosine kinase activity due to the absence of residues that are required for catalytic activity and nucleotide binding, negatively regulates the activity of Jak3 (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies, Genes
& Cancer, l(10):979-993). JH2 is required for two distinct functions in cytokine signaling: (i) inhibition of the basal activity of Jak3, and (ii) cytokine-inducible activation of signaling. Jak3- JH2 deletion mutants are catalytically active, activate STAT5, and interact with other Jak kinases, but the JH2 domain is required to connect these signaling events to receptor activation. (see Saharinen, et al, The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction, Journal of Biological Chemistry, 277(49):47954-63). In some embodiments, a compound disclosed herein inhibits the activity of the JH2 domain of Jak3.
Due to its role in the growth, survival, development, and differentiation of immune cells, inhibiting Jak3 function would likely reduce or inhibit the development and/or progression of immune disorders. In some embodiments, a compound disclosed herein reduces or inhibits the development and/or progression of an immune disorder.
Jak3 dysfunctions has also been implicated in inflammation and autoimmune disorders, such as arthritis (see Kim, et al, Inhibition of JAK3 alleviates inflammation in monoarthritic rats, British Journal of Pharmacology, PMID: 21434883, 2011), especially rheumatoid arthritis;
transplant rejection (Flanagan, et al, Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection, Journal of Medicinal Chemistry, 53(24):8468-84), especially, kidney transplant rejection;
psoriasis and arthritis (see West, CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders, Current Opinion in Investigational Drugs, 10(5):491-504); and Type-1 diabetes (Cetkovic-Cvrlje, et al, Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice, Clinical Immunology, 106(3):213-25). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat inflammation, or an autoimmune disorder, or a combination thereof. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat arthritis, transplant rejection, psoriasis, arthritis, type-1 diabetes, or a combination thereof.
Additionally, Jak3 dysfunction has been found in myeloproliferative and myelodisplastic syndromes (see Jatiani, et al, JAK/STAT Pathways in Cytokine Signaling and
Myeloproliferative Disorders: Approaches for Targeted Therapies, Genes & Cancer, 1(10):979- 993), for example, transient myeloproliferative disorder (TMD) (see Sato, et al, Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome, British Journal of Haemotology, 141(5):681-8). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a myeloproliferative syndrome and/or a myelodisplastic
syndrome. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat transient myeloproliferative disorder.
Roles for Jak3 dysfunction have also been found in multiple cancers, including breast adenocarcinoma (see Henkels, Cell Invasion of Highly Metastatic MTLn3 Cancer Cells Is Dependent on Phospholipase D2 (PLD2) and Janus Kinase 3 (JAK3), Journal of Molecular
Biology, PMID: 21414324, 201 1); T Cell Lymphoma (see Krejsgaard, t al, Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway, Journal of Investigative Dermatology, PMID: 21346774, 2011); acute megakaryoblastic leukaemia of Down syndrome (see Sato, et al, Functional analysis of JAK3 mutations in transient
myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome, British Journal of Haemotology, 141(5):681-8); B-lineage acute lymphoblastic leukemia (see Uckun, JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia, Expert Review of Anticancer Therapy, 1 l(l):37-48); colorectal cancer (see Uckun, Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor, Nutrition and Cancer, 62(7):968-72); chronic lymphocytic leukemia (see Steele, et al, The JAK3 -selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment, Blood, 1 16(22):4569-77); and non- melanoma skin cancer (see Uckun, et al, Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase, Arzneimittelforschung, 60(4):218-25). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat a cancer. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat breast adenocarcinoma; T Cell Lymphoma; acute megakaryoblastic leukaemia of Down syndrome; B-lineage acute lymphoblastic leukemia;
colorectal cancer; chronic lymphocytic leukemia; non-melanoma skin cancer; or a combination thereof. The compounds described herein can be used to treat Jak3 -related conditions, included those described herein.
Tec protein tyrosine kinase is a member of the Tec family of non-receptor type protein tyrosine kinases. Tec family kinases are involved in the intracellular signaling mechanisms of cytokine receptors, lymphocyte surface antigens, heterotrimeric G-protein coupled receptors, and integrin molecules and are important components of antigen receptor signaling pathways in B cells, T cells, and mast cells (see Schmidt, et al, The protein tyrosine kinase Tec regulates mast cell function, Eur J Immunol, 39(1 1):3228-38, 2009). The domain architecture of the Tec kinases comprises a single Src homology 3 (SH3) domain, a Src homology 2 (SH2) domain, a catalytic
kinase domain, a pleckstrin homology (PH) domain, and a Tec homology (TH) domain at the amino-terminus. The TH domain consists of a region unique to the Tec kinases followed by one or more proline -rich regions (see Joseph, et al, Conformational snapshots of Tec kinases during signaling, Immunol Rev, 228(l):74-92, 2009). In some embodiments, a compound disclosed herein modulates the activity of Tec.
In T cells, three members of this family, Itk, Rlk, and Tec, are expressed. They are also key players in the regulation of the immune functions. Tec kinase is an integral component of T cell signaling and has a distinct role in T cell activation. In some embodiments, a compound disclosed herein modulates the activity of Tec in T cell signaling and activation.
Aberrant expression of Tec has been implicated in various diseases, including, but not limited to, heart disease (Zhang, et al, Stress signaling by Tec tyrosine kinase in the ischemic myocardium, Am J Physiol Heart Circ Physiol, 2993(3 )H713-22, 2010), myelodysplastic syndrome (see Sato, et al, Molecular cloning and analysis of the human Tec protein-tyrosine kinase, Leukemia, 8(10): 1663-72, 1994), and osteoporosis (see Shinohara, et al, Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals, Cell, 132(5):794-806, 2008). In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an immune disorder. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat cardiovascular disease, osteoporosis, or a combination thereof. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat myelodysplastic syndrome thereof. The compounds described herein can be used to treat Tec-related conditions, included those described herein.
The kinase known as Txk contains several protein domains, including, a COOH-terminal kinase catalytic domain, a Src homology 2 (SH2) protein interaction domain, an SH3 domain, a palmitoylated cysteine-string motif that is required for membrane localization and a proline-rich region (see Readinger, et al, Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk, Immunol Rev, 228(1):93-1 14, 2009). Txk is expressed in Thl/ThO cells and is an important modulator of lymphocyte development and function. In some embodiments, a compound disclosed herein inhibits or decreases or enhances the activity of Txk.
Txk is a signal-transducing molecule, which consists of the tyrosine kinase cascade downstream from the T cell receptor when an antigen is presented to the T cell through the T cell receptor. Txk is phosphorylated and activated by Fyn, one of the Srk family kinases, and it phosphorylates downstream signal molecules (see Suzuki, et al, Skewed Thl responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with
Behcet's disease, Clin Med Res, 4(2): 147-51, 2006). Upon activation, Txk translocates from cytoplasm into nucleus and regulates specifically interferon-gamma gene transcription. Txk, poly(ADP-ribose) polymerase 1, and elongation factor 1 alpha make a complex to bind to interferon-gamma gene promoter region-53/-39 (Txk responsive element) to exert positive effects on transcription as a Thl cell-associated transcription factor (see Mihara, et al, Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases, Int Rev Immunol, 26(5-6):333-48, 2007). In some embodiments, a compound disclosed herein modulates the activity of Txk.
Aberrant overexpression of Txk has been implicated in several immunopathologies, including, but not limited to, rheumatoid arthritis (see Mihara, et al, Role of Txk, a member of the Tec family of tyrosine kinases, in immune-inflammatory diseases, Int Rev Immunol, 26(5- 6):333-48, 2007) and Behcet's disease (see Suzuki, et al, Skewed Thl responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease, Clin Med Res, 4(2): 147-51, 2006). In some embodiments, a compound disclosed herein is administered to an individual in need thereof to treat an inflammatory disorder characterized by dysfunction of lymphocyte development and function. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to rheumatoid arthritis, Behcet's disease, or a combination thereof.
Additionally, a reduction in Txk expression has been implicated in bronchial asthma (see Sahu, et al, Selective expression rather than specific function of Txk and Itk regulate Thl and Th2 responses, J. Immunol, 181(9):6125-31, 2008) and atopic dermatitis (see Arakawa, et al, Differential expression of mR A for Thl and Th2 cytokine-associated transcription factors and suppressors of cytokine signaling in peripheral blood mononuclear cells of patients with atopic dermatitis, Clin Exp Immunol, 135(3):505-10, 2004). In the absence of Itk and Txk, T-cell receptor signaling is impaired, with defects in mitogen-activated protein kinase activation, Ca2+ mobilization, and actin polymerization. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to treat an inflammatory disorder characterized by dysfunction of lymphocyte development and function. In some embodiments, a compound disclosed herein is administered to a patient in need or recognized need thereof to asthma, atopic dermatitis, or a combination thereof.
Modulation of Txk expression should lead to the correction of aberrant immunity and, consequently, disease treatment. Accordingly, there is a need for drug therapies that modulate Txk and are therefore useful in the treatment of Txk-mediated disorders, such as those associated with inflammatory immune disorders. The compounds described herein can be used to treat Txk-related conditions, included those described herein.
In one aspect, the present disclosure is directed to use of compound of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for use as a medicament. In one embodiment, the use of compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof is for treating proliferative disease (e.g., cancers). In another aspect, the present disclosure is directed to the use of a compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for treatment of diseases associated with axonal regeneration, or spinal cord injury. In another embodiment, the disease is an inflammatory disorder chosen from asthma, allergic dermatitis, atopic dermatitis and psoriasis.
In further aspects, the present disclosure is directed to the use of a compounds of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof (and any embodiments thereof described herein) for treatment of psoriasis, alleviation of inflammation during organ transplant, treatment of asthma, rheumatoid arthritis, osteoporosis, cardiovascular disease, or any other disease described above.
In any of the aforementioned aspects involving the treatment of proliferative disorders, including cancer, are further embodiments comprising administering the compound of Formula (IA) or I and/or a pharmaceutically acceptable salt thereof in combination with at least one additional agent selected from an anti-cancer agent or an agent that modulates growth or regeneration of axons. When combination therapy is used, the agents are administered simultaneously or sequentially.
Testing
The ITK inhibitory activity, residence time of the inhibitor ITK bound complex, and the ability of the of the compounds of the present disclosure to form irreversible covalent bond or reversible covalent bond with Cys 442 (UniprotKB Sequence ID Q08881) can be tested using the in vitro, in vivo assays described in working Examples below.
The kinase inhibitory activity of the compounds of the present disclosure can be tested by methods well known the art. The ITK inhibitory activity of the compounds and/or a
pharmaceutically acceptable salt thereof of the present disclosure can be tested using the in vitro and in vivo assays described in Biological Examples 1, 3, 4, and 5 below. A determination of kinase inhibitory activity by any of those assays is considered to be kinase inhibitory activity within the scope of this disclosure even if any or all of the other assays do not result in a determination of kinase inhibitory activity.
Without being bound to any specific mechanistic theory, in those embodiments wherein the compound of the present disclosure is a reversible covalent inhibitor, it is believed that the
cysteine sulfhydryl group and a carbon atom forming part of the carbon-carbon double bond in the group -X-Y-C(Rb)=CHR° where Rb is other than hydrogen, in particular cyano, (see Formula IA and I) of the compound of the present disclosure can form a reversible, i.e., labile, covalent bond, defined herein, such as wherein Cys 442 (UniprotKB Sequence ID Q08881) attacks an electron deficient carbon atom of the carbon-carbon double bond in the group -X-Y-
C(Rb)=CHR° in the compound of present disclosure to form a thiol adduct (e.g., Michael reaction with cysteine).
In some embodiments, the electron deficient carbon atom of the olefin is distal to the carbon attached to the Rb group (where Rb is not hydrogen) and to the electron withdrawing -X- Y- or -Y- moiety (see Formula (IA) and (I) in the compounds of the present disclosure.
Therefore, the combination of the Rb group (where Rb is not hydrogen) and the "-X-Y-" or "Y" moieties and the olefinic moiety to which they are bonded in the compounds of the present disclosure can increase the reactivity of the olefin to form a thiol adduct with the active site cysteine residue in ITK.
The compounds of the present disclosure which are reversible covalent inhibitors bind with ITK in two different manners. In addition to the labile covalent binding, discussed above, they also form non-covalent binding (e.g., via van der Waals binding, hydrogen binding, hydrophobic binding, hydrophilic binding, and/or electrostatic charge binding) with ITK, the non-covalent binding being sufficient to at least partially inhibit the kinase activity of the ITK.
As disclosed herein, the labile covalent binding between the reversible covalent inhibition of the disclosure and ITK occurs between the olefin in the inhibitor and the cysteine 442 residue thiol side chain at or near the site where the inhibitor has the aforementioned non-covalent binding with the ITK.
As is evident, the compounds of the present disclosure which are reversible covalent inhibitors have both a cysteine-mediated covalent binding and a non-covalent binding with the ITK. This is in contrast with non-covalent reversible inhibitors which inhibit the ITK only via non-covalent binding and lack the cysteine-mediated covalent binding.
The binding of the compounds of the present disclosure with ITK in the two different manners mentioned above provides a reversible covalent inhibitor having a slow off-rate and a protracted duration of action, in some instances comparable to an irreversible covalent inhibitor without forming permanent irreversible protein adducts. The difference between irreversible and reversible covalent inhibitors, particularly the compounds disclosed herein, can be ascertained utilizing assays disclosed herein.
In general, the binding involved in an inhibitor that forms a reversible covalent bond with ITK is stable when the ITK is in certain configurations and susceptible to being broken when the
ITK is in different configurations (in both cases under physiologic conditions), whereas the interaction between an inhibitor that forms an irreversible covalent bond is stable under physiologic conditions even when the ITK is in different configurations.
A reversible covalent bond often imparts unique properties related to the residence time of the compound within the cysteine-containing binding site. In this context, residence time refers to the temporal duration of the compound-target complex under different conditions (see Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5(9), 730-739 (2006).
The presence of a reversible covalent bond in a reversible covalent inhibitor as disclosed herein can lead to an extended residence time when compared to a compound that does not form a covalent bond with ITK. In one embodiment disclosed herein the compounds of the present disclosure that are reversible covalent inhibitors have a residence time of at least about 1 h. Residence time may be measured using an occupancy assay in a biochemical or cellular environment (see Biological Example 2 below). Additionally, residence time may be measured using a functional assay following a defined wash-out period.
Compounds that form an irreversible covalent bond in an irreversible covalent inhibitor share these extended residence time properties but may nonetheless be differentiated from reversible covalent inhibitor using a reversibility assay. The ability of the compound of the disclosure to form reversible or irreversible covalent bond with Cys442 of ITK (UniprotKB Sequence ID Q06187) and the olefinic bond in the compound of the disclosure, can be determined by the assays described in Biological Examples 2, 6-8 below. A determination of the binding reversibility of the covalent bond between the cysteine residue and the olefinic bond of the compound of the disclosure by any of Biological Examples 2, 6-8 below is considered to be binding reversibility within the scope of this disclosure even if one or both of the other methods does not result in a determination of binding reversibility.
Administration and Pharmaceutical Composition
In general, the compounds of this disclosure will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds disclosed herein may range from about 0.01 to about 200 mg per kg patient body weight per day, which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 100 mg/kg per day; more preferably about 0.5 to about 50 mg/kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600,
750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compounds disclosed herein, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.
In general, compounds disclosed herein will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
The compositions are comprised of in general, a compounds disclosed herein in nontoxic, aid administration, and do not adversely affect the therapeutic benefit of the compounds disclosed herein. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
The compounds of the present disclosure can also be administered intranasally. Intranasal formulations are known in the art e.g., see U.S. Patent Nos. 4,476,116, 5,116,817 and 6,391,452,
each of which is incorporated herein by reference. The choice of excipients will depend upon the nature of the nasal dosage form e.g., solutions, suspensions, or powder. For administration by inhalation, the compounds of the present disclosure may be in the form of solutions, suspensions, and powders. These formulations are administered as an aerosol, a mist or a powder and can be delivered from pressurized packs or a nebulizer with a suitable propellant such as
dichlorodifluoromethane, trichlorofluoromethane, nitrogen, carbon dioxide, etc. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges for use in an inhaler may be formulated containing a powder mix of the compound disclosed herein and a suitable powder base such as lactose or starch.
Topical formulation can be liquids, suspension, emulsions, and the like, and can be prepared by methods well known in the art. The formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound disclosed herein based on the total formulation, with the balance being one or more suitable pharmaceutical excipients and can be administered in single or multiple doses. Suitable excipients include polymers, surfactants, buffering or pH adjusting agents, tonicity or osmotic adjusting agent(s), preservatives, and/or dispersing agents. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (IA) or (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.
The compounds of the present disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present disclosure or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present disclosure. When a compound of the present disclosure is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present disclosure is preferred. However, the combination therapy may also include therapies in which the compound of the present disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the
present disclosure and the other active ingredients may be used in lower doses than when each is used singly.
Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other active ingredients, in addition to a compound disclosed herein.
The above combinations include combinations of a compounds disclosed herein not only with one other active compound, but also with two or more other active compounds. Likewise, compounds disclosed herein may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds disclosed herein are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound disclosed herein. When a compound disclosed herein is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound disclosed herein is preferred. Accordingly, the pharmaceutical compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound disclosed herein. The weight ratio of the compound disclosed herein to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
Where the patient is suffering from or at risk of suffering from an autoimmune disease, an inflammatory disease, or an allergy disease, a compound disclosed herein can be used in with one or more of the following therapeutic agents in any combination: immunosuppressants (e.g., tacrolimus, cyclosporin, rapamicin, methotrexate, cyclophosphamide, azathioprine,
mercaptopurine, mycophenolate, or FTY720), glucocorticoids (e.g., prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone), non-steroidal anti-inflammatory drugs (e.g., salicylates, arylalkanoic acids, 2-arylpropionic acids, N- arylanthranilic acids, oxicams, coxibs, or sulphonanilides), Cox-2-specific inhibitors (e.g., valdecoxib, celecoxib, or rofecoxib), leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxy chloroquinine, minocycline, TNF-a binding proteins (e.g., infliximab, etanercept, or adalimumab), abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, allergy vaccines, antihistamines, antileukotrienes, beta-agonists, theophylline, anticholinergics, B cell inhibitors such as anti-CD 19, 20, 22 antibodies, and BTK inhibitors such as Ibrutinib.
Where the patient is suffering from or at risk of suffering from a proliferative disorder, the subject can be treated with a compound disclosed herein in any combination with one or more other anti-cancer agents. In some embodiments, one or more of the anti-cancer agents are proapoptotic agents. Examples of anti-cancer agents include, but are not limited to, any of the
following: gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'- deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (GleevecTM), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1 -7082, PKC412, PD 184352, or
Taxol™, also referred to as "paclitaxel", which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule formation, and analogs of Taxol™, such as Taxotere™. Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
Further examples of anti-cancer agents for use in combination with a compound disclosed herein include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
Other anti-cancer agents that can be employed in combination with a compound disclosed herein include adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin;
ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium;
bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin;
cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin;
enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride;
estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine
hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-la; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride;
lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine;
mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran;
pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman;
piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate;
trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa;
vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.
Other anti-cancer agents that can be employed in combination with a compound disclosed herein include: 20-epi-l, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine;
ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide;
anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1 ; antiandrogen, prostatic carcinoma; antiestrogen;
antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin;
azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A;
bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole;
carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin
A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones;
cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab;
decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane;
dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9- dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine;
elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors;
hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin;
idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons;
interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin;
loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin
A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded R A; mitoguazone; mitolactol;
mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin;
monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides;
nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;
nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone;
oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer;
ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol;
phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins;
pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists;
raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; R.sub. l 1 retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl ; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived 1 ; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium
phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfm; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
Yet other anticancer agents that can be employed in combination with a compound disclosed herein include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes
(decarbazine, etc.). Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g.,
mercaptopurine, thioguanine, pentostatin).
Examples of natural products useful in combination with a compound disclosed herein include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L- asparaginase), or biological response modifiers (e.g., interferon alpha).
Examples of alkylating agents that can be employed in combination a compound disclosed herein include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
Examples of hormones and antagonists useful in combination a compound disclosed herein include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).
Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with a compound disclosed herein include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and SC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also known as LU- 103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA), Epothilone D (also referred to as KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21- aminoepothilone B (also known as BMS-310705), 21 -hydroxyepothilone D (also known as
Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC- 654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS- 4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559
(Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH- 49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM- 132 (Armad), AM- 138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), HI 6 (Kansas State University), Oncocidin Al (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T- 138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt.
Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR- 115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350
(Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-
Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA- 110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi). Yet another class of anticancer that can be used in combination with the compounds of the present disclosure include PD-1 inhibitors e.g, Nivolumab and MPDL3280A (Genentech).
Where the subject is suffering from or at risk of suffering from a thromboembolic disorder (e.g., stroke), the patient can be treated with a compound disclosed herein in any combination with one or more other anti-thromboembolic agents. Examples of anti-
thromboembolic agents include, but are not limited any of the following: thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX-9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.
Examples
The following preparations of compounds of Formula (IA) and (I) and intermediates are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.
Synthetic Examples
Intermediate 1
Synthesis of tert-butyl 4-(2-imino-2,3-dihydro- 1 H-benzo[d]imidazol- 1 -yl)piperidine- 1 - carboxylate
Step 1
In a 100 mL three necked round bottom flask, l-fluoro-2 -nitrobenzene (1.0 g, 0.0071 mole) was taken up in acetonitrile (20 mL) and DIPEA (2.75 g, 0.0213 mole) was added dropwise at room temperature. After completion of addition, the reaction mixture was stirred for 15 min at same temperature followed by slow addition of tert-butyl 4-aminopiperidine-l- carboxylate (1.71 g, 0.0085 mole) over 15 min at the same temperature. After completion of the addition, the reaction mixture was stirred for 16 h at room temperature. The completion of the reaction was monitored on TLC. After completion of the reaction, acetonitrile was distilled out and water was added to the residue. The aqueous phase was extracted with ethyl acetate and the combined organic layer was dried over Na2S04, filtered and concentrated to afford crude product which was subjected for the column purification to yield 0.9 g of tert-butyl 4-(2- nitrophenylamino)piperidine- 1 -carboxylate.
Step 2
To a suspension of 10% dry Pd/C (0.18 g, 10%w/w) in methanol (15 mL), tert-butyl 4- (2-nitrophenylamino)piperidine-l -carboxylate (1.8g, 0.0056mole) in methanol (15 mL) was added under 2 atmosphere. The ¾ gas was added to the reaction mixture for 1.5 h at room
temperature. The completion of the reaction was monitored by TLC using EtOAc: hexanes (7:3). After completion of the reaction, reaction mixture was filtered through celite and washed with methanol and the filtrate was concentrated to yield 1.4 g of tert-butyl 4-(2- aminophenylamino)piperidine- 1 -carboxylate.
Step 3
To a flask charged with tert-butyl 4-(2-aminophenylamino)piperidine-l -carboxylate (1.4 g, 0.0048 mole) was added ethanol (25 mL). To this, cyanogen bromide (0.61 g, 0.0058 mole) was added at room temperature and the reaction mixture was stirred for 3 h. The completion of the reaction was monitored by TLC using CH2CI2: methanol (9: 1). After completion of the reaction, ethanol was distilled out and saturated NaHCC solutionwas added to adjust pH basic. The reaction mixture was stirred for lh then filtered it and washed with water. The organic phase was dried over sodium sulfate, filtered and the solvent removed to afford 1.5 g of tert-butyl 4-(2- imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-l -carboxylate. Intermediate 2
Synthesis of 4-chloro-N-(l-(piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide hydrochloride
Step 1
To a 50 mL single neck RBF, 4-chlorobenzoic acid (0.178 g, 0.00114 mole) was added in
CH2CI2 (15 mL) under N2 atmosphere. EDC-HC1 (0.273 g, 0.00142 mole), HOBT.H20 (0.219 g, 0.00142 mole) and TEA (0.4 mL, 0.00285 mole) were added to the reaction mixture at room temperature and stirred for 20 min. tert-Butyl 4-(2-imino-2,3-dihydro-lH-benzo[d] imidazol-1- yl)piperidine-l -carboxylate (0.3g, 0.00095mole) in CH2CI2 (15 mL) was added dropwise to the reaction mixture and stirred at room temperature for 16 h. The completion of the reaction was monitored on TLC using EtOAc: Hexanes (1 : 1) as a mobile phase. Saturated aHC03 solution was added to the reaction mixture and the aqueous phase was extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the pure product to yield 0.41 g of tert-butyl 4-(2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l-yl)piperidine-l- carboxylate.
Step 2
To a 25 mL round bottomed flaskl, tert-butyl 4-(2-(4-chlorobenzamido)-lH-benzo[d] imidazol-l-yl) piperidine- 1 -carboxylate (0.45 g, 0.00099 mole) was added in 1, 4 dioxane (5 mL) and the solution was cooled to 10° C under 2 atmosphere. To this, 20% HC1 in 1,4 dioxane (5ml) was added drop wise at 10° C and the reaction mixture was stirred for 16 h at room temperature. The completion of the reaction was monitored by TLC. After completion of the reaction, the solvent was evaporated under reduced pressure to get the crude compound which was triturated with acetone to yield 0.33g of 4-chloro-N-(l-(piperidin-4-yl)-lH- benzo[d]imidazol-2-yl)benzamide hydrochloride.
Intermediate 3
Synthesis of 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-4-yl)-lH-benzo[d]imidazol-2- yl)benzamide
2-Cyanoacetic acid (0.086g, O.OOlmole) was taken up in CH2CI2 (25ml) and cooled to 0 C under N2 atmosphere. To this, TBTU (0.285 g, 0.0009 mole) in DMF (1 mL) was added dropwise at 0° C. After addition, the reaction mixture was allowed to attain rise to room temperature. Then, 4-chloro-N-(l-(piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide hydrochloride (0.3 g, 0.00077 mole) and DIPEA (0.4 mL, 0.00255 mole) were added and the reaction mixture stirred at room temperature for 16 h. The completion of the reaction was monitored by TLC using CH2CI2: MeOH (9: 1) as a mobile phase. After completion of the reaction, water was added to the reaction mixture and product was extracted with CH2CI2. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was purified using column chromatography using 100-200 mesh size neutral silica by eluting the compound with 0.5% methanol in CH2C12 to yield 0.140g of 4-chloro-N-(l-(l-(2- cyanoacetyl)piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide.
Example 1
Synthesis of 4-chloro-N-( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)- 1 H-benzo
To a 25 niL round bottomed flask, 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)benzamide (0.14 g, 0.00033 mole) was added and dissolved in methanol (10 mL) under 2 atmosphere. To this, piperidine (1 drop) and isobutyraldehyde (0.024 g, 0.00033 mole) were added at room temperature and the reaction mixture was heated to reflux for 4 h. The completion of the reaction was monitored by TLC using CH2CI2: MeOH (9: 1). After completion of the reaction, methanol was evaporated to get the crude product which was purified using column chromatography using 60-120 mesh size neutral silica by eluting the compound with 25% ethyl acetate in hexanes to yield 0.058g of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2- enoyl)piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 476 [M+H].
Example 2
Synthesis of -(l-(l -acryloylpiperi imidazol-2-yl)-4-chlorobenzamide
To a 10 mL vial, 4-chloro-N-(l-(piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide hydrochloride (0.15 g, 0.0004 mole) was added in THF (5 mL) and the solution was cooled to - 30° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.035 g, 0.00039 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. The completion of the reaction was monitored by TLC using CH2CI2: MeOH (9: 1) as a mobile phase. After completion of the reaction, raise temperature to RT, solvent was evaporated under reduced pressure. To this, saturated aHC03 solution was added drop wise to make pH basic, extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 0.2% MeOH in CH2C12 to yield 0.058g of N-(l-(l-acryloylpiperidin-4-yl)-lH-benzo[d]imidazol-2-yl)- 4-chlorobenzamide. LC-MS (ES, m/z): 409.7 [M+H].
Intermediate 4
Synthesis of N-(l-(piperidin-4-yl)-l -benzo[d]imidazol-2-yl)nicotinamide hydrochloride
Step 1
To a 50 mL single neck round bottomed flask, nicotinic acid (0.37 g, 0.003 mole) was added in CH2C12 (10 mL) under N2 atmosphere. EDC-HC1 (0.72 g, 0.0037 mole), HOBT-H20 (0.57 g, 0.0037 mole) and TEA (0.76g, 0.0075 mole) were added to the reaction mixture at room temperature and stirred for 20 min. tert-Butyl 4-(2-imino-2,3-dihydro-lH-benzo[d] imidazol-1- yl)piperidine-l-carboxylate (0.8 g, 0.0025 mole) in CH C12 (15 mL) was added dropwise to the reaction mixture and stirred at room temperature for 16 h. The completion of the reaction was monitored on TLC using EtOAc: Hexanes (8:2) as a mobile phase. Saturated NaHC(¾ solution (30 mL) was added to the reaction mixture and aq. was extracted with EtOAc. The combined organic layer was dried over Na S04 and evaporated to get the pure product to yield 0.9 g of tert- butyl 4-(2-(nicotinamido)- lH-benzo[d]imidazol- 1 -yl)piperidine- 1 -carboxylate.
Step 2
To a 25 mL round bottomed flask, tert-butyl 4-(2-(nicotinamido)-lH-benzo[d]imidazol-l- yl)piperidine-l -carboxylate (0.5g, 0.0012 mole) was added in 1,4 dioxane (5 mL) and the solution was cooled to 10° C under N2 atmosphere. To this, 20% HCl in 1, 4-dioxane (5 mL) was added dropwise at 10° C and the reaction mixture was stirred for 16 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound which was triturated with acetone (10 mL) to yield 0.32g of N-(l-(piperidin-4-yl)-lH- benzo[d]imidazol-2-yl)nicotinamide hydrochloride. Intermediate 5
Synthesis of N-(l-(l-(2-cyanoacetyl)piperidin-4-yl)-lH-benzo[d]imidazol-2-yl)nicotinamide
To a 25 mL round bottomed flask, 2-cyanoacetic acid (0.095 g, 0.0011 mole) was added in CH C12 (10 mL) and the solution was cooled to 0° C under N2 atmosphere. TBTU (0.313 g,
0.0009 mole) in DMF (1 mL) was added drop wise at 0 C. After addition, the reaction mixture was allowed to attain the room temperature. Then, N-(l-(piperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide hydrochloride (0.3 g, 0.00084 mole) and DIPEA (0.36 g, 0.0027 mole) were added to the reaction mixture and stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and product was extracted with CH2CI2. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification using 100-200 mesh size neutral silica by eluting the compound with 3% methanol in CH2CI2 to yield 0.150 g of N-(l-(l-(2-cyanoacetyl)piperidin-4- yl)-lH-benzo[d]imidazol-2-yl)nicotinamide.
Example 3
Synthesis of N-( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)- 1 H-benzo [d] imidazol-2-yl) nicotinamide
To a 25 mL IN RBF, N-(l-(l-(2-cyanoacetyl)piperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide (0.14 g, 0. 36 mmole) was added in dry methanol (15 mL) under 2 atmosphere. Piperidine (1 drop) and isobutyraldehyde (0.026 g, 0.00036 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h. After completion of the reaction, methanol was evaporated to get the crude product which was subjected for the column purification. The crude compound was purified using column purification using 60-120 mesh size neutral silica by eluting the compound with 2% Methanol in CH2CI2 to yield 0.038 g of N- ( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)- 1 H-benzo[d] imidazol-2-yl) nicotinamide. LC-MS (ES, m/z): 443 [M+H].
Example 4
Synthesis of N-( 1 -( 1 -acryloylpip o [d]imidazol-2-yl)nicotinamide
To a 10 niL vial, N-(l -(piperidin-4-yl)- lH-benzo[d]imidazol-2-yl)nicotinamide hydrochloride (0.1 g, 0.00028 mole) was taken in THF (5 mL) and cooled to -30° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.025 g, 0.00028 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. After completion of the reaction, raise temperature to RT & solvent was evaporated under reduced pressure. To this, saturated NaHC(¾ solution was added dropwise to make pH basic, extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60- 120 mesh size neutral silica by eluting the compound with 1.2% MeOH in CH2CI2 to yield 0.026 g of N-(l -(l -acryloylpiperidin-4-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide. LC-MS (ES, mix): 376.3 [M+H].
Intermediate 6
Synthesis of tert-butyl 3-(2-imino-2,3-dihydro-lH-benzo[d]imidazol- l -yl)piperidine- l- carboxylate
Step 1
To a 250 mL 3 neck RBF, l-fluoro-2 -nitrobenzene (3.52 g, 0.02496 mole) was taken in acetonitrile (50 mL) under 2 atmosphere. DIPEA (13 mL, 0.075 mole) was added followed by slow addition of tert-butyl 3-aminopiperidine- l-carboxylate (5.0 g, 0.02496 mole) at room temperature and the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored on TLC using EtOAc: hexanes (4:6) as a mobile phase. After 32 h, water was added to the reaction mixture and product was extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column chromatography using 60- 120 mesh size neutral silica by eluting the crude product with 3-5% EtOAc in hexanes to yield 1.7g of tert- butyl 3-(2-nitrophenylamino)-piperidine- 1 -carboxylate.
Step 2
In a 100 mL 3 neck RBF, to a suspension of 10% Pd/C (0.180 g, 10%w/w) in methanol (15 mL), tert-butyl 3-(2-nitrophenylamino)piperidine- l -carboxylate (1.7 g, 0.00528 mole) in methanol (15 mL) was added under 2 atmosphere. H2 gas was purged to the reaction mixture for 2 h at room temperature. After completion of the reaction, the reaction mixture was filtered
through celite and washed with methanol and filtrate was concentrated to yield 1.4g of tert-butyl
3-(2-aminophenyl-amino)piperidine-l-carboxylate.
Step 3:
To a 100 mL RBF, tert-butyl 3-(2-aminophenylamino)piperidine-l-carboxylate (1.4 g, 0.00481 mole) was taken in ethanol (30 mL). Cyanogen bromide (0.61 g, 0.00577 mole) was added at room temperature and stirred for 2 h. After completion of the reaction, the pH of the reaction mass was adjusted to basic by drop wise addition of saturated aHC03 solution and product was extracted with CH2CI2. The organic layer was dried over Na2S04 and evaporated to get crude which was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 3-4% methanol in CH2CI2 to yield 1.3g of tert-butyl 3-(2-imino-2,3- dihydro-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate. LC-MS (ES, m/z): 317.3 [M+H].
Example 5
Synthesis of 4-chloro-N-( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin
benzo[ amide
Step 1
To a 50 mL single neck RBF, 4-chlorobenzoic acid (0.192 g, 0.00123 mole) was taken in CH2CI2 (15 mL) under N2 atmosphere. EDC-HC1 (0.295 g, 0.00154 mole), HOBt (0.208 g, 0.00154 mole) and TEA (0.4 mL, 0.003 mole) were added to the reaction mixture at room temperature and stirred for 20 min. 3-(2-Imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)piperidine-l-carboxylate (0.325 g, 0.00102 mole) in CH2CI2 (15 mL) was added dropwise to the reaction mixture and stirred at room temperature for 16 h. The completion of the reaction was monitored on TLC using EtOAc: hexanes (4:6) as a mobile phase. Water was added to the reaction mixture and extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 20-25% EtOAc in hexanes to yield 0.3g of tert-butyl 3-(2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate.
Step 2
To a 25 niL RBF, tert-butyl 3-(2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l- yl)piperidine-l-carboxylate (0.3 g, 0.00065 mole) was taken in 1,4 -dioxane (5 mL) and cooled to 10° C under 2 atmosphere. HC1 in 1,4 dioxane (20% solution) (6 mL) was added dropwise at 10° C and the reaction mixture was stirred for 16 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with CH2CI2 to yield 0.27g of 4-chloro-N-(l-(piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)benzamide hydrochloride.
Step 3
To a 25 mL RBF, 2-cyanoacetic acid (0.039 g, 0.00046 mole) was taken in CH2C12 (10 mL) and DIPEA (0.02 mL) and cooled to 0° C under N2 atmosphere. TBTU (0.129 g, 0.00040 mole) in DMF (0.5 mL) was added dropwise at 0° C. After addition, the reaction mixture was allowed warm to room temperature. 4-Chloro-N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)benzamide hydrochloride (0.15 g, 0.00038 mole) and DIPEA (0.19 mL, 0.001 1 mole) were added and trhe reaction mixture was stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 0.6% methanol in CH2CI2 to yield 0.135 g of 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)benzamide.
Step 4
To a 10 mL vial, 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol- 2-yl) benzamide (0.1 g, 0.00023 mole) was taken in ethanol (5 mL) under 2 atmosphere.
Piperidine acetate (3.3M solution in water) (0.02 mL) and isobutyraldehyde (0.02 mL, 0.00023 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h.
Water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over Na2S04 and evaporated to get the crude which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 75% CH2CI2 in hexanes to yield 0.035g of 4-chloro- N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 476.3 [M+H].
Example 6
To a 10 niL vial, 4-chloro-N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide hydrochloride (0.07 g, 0.00017 mole) was taken in THF (3 mL) and cooled to -30° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.029 g, 0.00016 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. After completion of the reaction, saturated NaHC(¾ solution was added drop wise to make pH basic at -30° C and the reaction mixture was allowed to warm up to room temperature and extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 2-3% MeOH in CH2CI2 to yield 0.037g of N-(l-(l-acryloylpiperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide. LC-MS (ES, m/z): 409.2 [M+H].
Example 7
Synthesis of N-( 1 -( 1 -(2-cyano-4-methylpent-2-enoyl)piperidin-3 -yl)- 1 H-benzo [d] imidazol-2- yl)nicotinamide
Step 1
To a 50 mL single neck RBF, nicotinic acid (0.280 g, 0.00227 mole) was taken in CH2CI2 (15 mL) under N2 atmosphere. EDC-HC1 (0.545 g, 0.00284 mole), HOBt (0.436 g, 0.00154 mole) and TEA (0.79 mL, 0.0030 mole) were added to the reaction mixture at room temperature and stirred for 20 min. tert-Butyl 3-(2-Imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine- 1-carboxylate (0.600 g, 0.00182 mole) in CH2CI2 (15 mL) was added drop wise to the reaction mixture and stirred at room temperature for 16 h. After 16 h, water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was purified by column purification using 60-120
mesh size neutral silica by eluting the compound with 0.9% MeOH in CH2CI2 to yield 0.3g of tert-butyl 3-(2-(nicotinamido)- lH-benzo[d]imidazol- l-yl)piperidine- l-carboxylate.
Step 2
To a 25 mL RBF, tert-butyl 3-(2-(nicotinamido)-lH-benzo[d]imidazol- l -yl)piperidine- l - carboxylate (0.27 g, 0.00064 mole) was taken in 1 ,4- dioxane (20 mL) and cooled to 10° C under 2 atmosphere. HC1 in 1 ,4-dioxane (20% solution) (10 mL) was added drop wise at 10° C and the reaction mixture was stirred for 16 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with CH2CI2 to yield 0.24 g of N-(l -(piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)nicotinamide hydrochloride.
Step 3
To a 25 mL RBF, 2-cyanoacetic acid (0.039 g, 0.000469 mole) was taken in CH2C12 (10 mL) and DIPEA (0.02 mL) and cooled to 0° C under N2 atmosphere. TBTU (0.131 g, 0.00041 mole) in DMF (0.5 mL) was added drop wise at 0° C. After addition was complete, the reaction mixture was allowed to attain the room temperature. N-(l -(Piperidin-3-yl)-lH-benzo[d]imidazol- 2-yl)nicotinamide hydrochloride (0.14 g, 0.000391 mole) and DIPEA (0.21 mL, 0.001 17 mole) were added to the reaction mixture and the reaction mixture stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and the reaction mixture was extracted with CH2CI2. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified using column purification using 60-120 mesh size neutral silica by eluting the compound with 2-3% methanol in CH2CI2 to yield O. lg of N-(l -(l -(2- cyanoacetyl)piperidin-3-yl)- lH-benzo[d]imidazol-2-yl)nicotinamide.
Step 4
To a 10 mL vial, N-(l -(l -(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol-2-yl) nicotinamide (0.09 g, 0.00023 mole) was taken in ethanol (5 mL) under 2 atmosphere.
Piperidine acetate (3.3M solution in water) (0.02 mL) and isobutyraldehyde (0.06 mL, 0.00069 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h. The completion of the reaction was monitored on TLC using CH2CI2: MeOH (9: 1) as a mobile phase. Water was added to the reaction mixture and the reaction mixture was extracted with CH2CI2. The combined organic layer was dried over Na2S04 and evaporated to get the crude which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 2.5-3% MeOH in CH2CI2 to yield 0.035g of N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)- lH-benzo[d]imidazol-2- yl)nicotinamide (LC-MS (ES, mix): 443 [M+H].
Example 8
Synthesis of N-( 1 -( 1 -acryloylpip o [d]imidazol-2-yl)nicotinamide
To a 10 mL vial, N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)nicotinamide hydrochloride (0.07g, 0.00019mole) was taken in THF (3 mL) and cooled to -30° C under N2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.015 g, 0.00017 mole) was added drop wise at -30° C and the reaction mixture was stirred for 20 minutes at -30° C. After 30 min, saturated NaHC(¾ solution was added drop wise to make pH basic and extracted the reaction mixture was with EtOAc . The combined organic layer was dried over a2S04 and evaporated to get the crude product. The crude product was thus obtained was taken in THF (3 mL) followed by addition of DBU (0.1ml) and the reaction mixture was stirred at room temperature for 9 h. The reaction mixture was diluted with water and extracted with EtOAc, the combined organic layer was dried, concentrated and subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 2-3% MeOH in CH2C12 to yield 0.020 g of N-(l-(l-acryloylpiperidin-3-yl)-lH- benzo[d]imidazol-2-yl)nicotinamide. LC-MS (ES, m/z): 376[M+H].
Example 9
Synthesis of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide
Step 1
To a 50 mL single-neck RBF, l-fluoro-2-nitrobenzene (2g, 0.0141mole) was taken in acetonitrile (20 mL) under N2 atmosphere. DIEA (7.39 mL, 0.0425 mole) was added followed by addition of tert-butyl 2-(aminomethyl)pyrrolidine-l-carboxylate (3.4 g, 0.0170 mole) at room temperature and the reaction mixture was stirred at room temperature for 16 h. After 32 h, water was added to the reaction mixture and product was extracted with EtOAc. The combined organic
layer was dried over Na2S04 and evaporated to get the crude product which was purified by column chromatography using 60-120 mesh size neutral silica by eluting the compound with 3- 5% EtOAc in hexanes to yield 2.8 g of tert-butyl 2-((2-nitrophenylamino)methyl)pyrrolidine-l- carboxylate.
Step 2
In a 100 mL 3neck RBF, to a suspension of 10% Pd/C (0.33g, 10%w/w) in methanol (30 mL), tert-butyl 2-((2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (3.3 g, 0.0102 mole) in methanol (30 mL) was added under 2 atmosphere. The ¾ gas was purged to the reaction mixture for 1.5 h at room temperature. After completion of the reaction, the reaction mixture was filtered through celite and washed with methanol and filtrate was concentrated to yield 2.8 g of tert-butyl 2-((2-aminophenylamino)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a 100 mL RBF, tert-butyl 2-((2-aminophenylamino)methyl)pyrrolidine-l -carboxylate (2.2 g, 0.00755 mole) was taken in ethanol (50 mL). Cyanogen bromide (0.959 g, 0.00906 mole) was added at room temperature and stirred for 4 h. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound & water added to this crude, then the pH of the reaction mass was adjusted to basic by addition of 40% NaOH solution and product was extracted with EtOAc. The organic layer was washed with water, dried over a2S04 and evaporated to yield 2.2 g of tert-butyl 2-((2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate.
Step 4
To a 35 mL seal-tube, 4-chlorobenzoic acid (0.5 g, 0.0031 mole) was taken in CH2CI2 (10 mL), EDC-HC1 (0.71 g, 0.00372 mole), HOBt.H20 (0.571 g, 0.00372 mole), tert-butyl 2-((2- imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate (1.11 g, 0.0035 mole) and TEA (1.29 mL, 0.0093 mole) were added to the reaction mixture at room temperature & the reaction mixture was stirred for 3 h. Water was added to the reaction mixture and the reaction mixture was extracted with CH2CI2. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 20-25% EtOAc in hexanes to yield 0.434 g of tert-butyl 2-((2-(4-chlorobenzamido)- 1 H-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 - carboxylate.
Step 5
To a 25 mL RBF, tert-butyl 2-((2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l -carboxylate (0.41 g, 0.00090 mole) was taken in CH2CI2 (20 mL) and cooled to 0-5° C. TFA (8.2 mL) was added drop wise and after addition, the reaction mixture was
stirred for 12 h at room temperature. After completion of the reaction, dilute the reaction mixture with CH2CI2, neutralized with saturated NaHC(¾ solution and the combined organic layer washed with water and finally dried over Na2S04 and evaporated under reduced pressure to yield 0.3 g of 4-chloro-N-(l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)benzamide. Step 6
To a 10 mL vial, 4-chloro-N-(l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2- yl)benzamide (0.3g, 0.00028 mole) was taken in THF (5 mL) and cooled to -50° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.06 mL, 0.00031 mole) was added drop wise at -50° C and the reaction mixture was stirred for 15 minutes at -50° C, followed by RT for 1 h. After completion of the reaction, to this, 40% NaOH solution was added drop wise to make pH basic and the reaction mixture was extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was purified by Prep TLC in 50% EtOAc in hexanes to yield 0.030 g of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-4-chlorobenzamide. LC-MS (ES, m/z): 409 [M+H].
Example 10
Synthesis of 4-chloro-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo amide
Step 1
To a 35 mL seal-tube, 2-cyanoacetic acid (0.052 g, 0.0062 mole) was taken in CH2CI2 (5 mL), EDC-HC1 (0.127 g, 0.00067 mole), HOBt.H20 (0.127 g, 0.00067 mole), 4-chloro-N-(l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)benzamide (0.2 g, 0.0005 6mole) and TEA (0.23 mL, 0.00168 mole) were added to the reaction mixture at room temperature and stirred at room temperature for 3 h. After completion of the reaction, water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was purified by column purification using column- chromatography by eluting with 20-25% EtOAc in hexanes to yield 0.14g of 4-chloro-N-(l-((l- (2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)benzamide.
Step 2
To a 10 niL vial, 4-chloro-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)benzamide (0.14 g, 0.00033 mole) was taken in ethanol (5 mL).
Piperidine acetate (3.3M solution in water) (1 mL) and isobutyraldehyde (0.074 mL, 0.00082 mole) were added at room temperature and the reaction mixture was heated to reflux for 6 h. After completion of the reaction, water was added to the reaction mixture and extracted with EtOAc. The combined organic layer washed with water, brine, dried over a2S04 and evaporated to get the crude product. The crude compound was purified by Prep TLC in 50% EtOAc in hexanes to yield 0.016g of 4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 376 [M+H].
Example 11
Synthesis of N-( 1 -(( 1 -acryloylpyrroli -benzo [d] imidazol-2-yl)nicotinamide
Step 1
To a 35ml seal-tube, nicotinic acid (0.4 g, 0.0032 mole) was taken in CH2CI2 (5 mL),
EDC-HC1 (0.72 g, 0.0038 mole), HOBt.H20 (0.58 g, 0.0038 mole), tert-butyl 2-((2-imino-2,3- dihydro-1 H-benzo [d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate (1.012g, 0.0032mole) and TEA (1.3ml, 0.0096 mole) were added to the reaction mixture at room temperature stirred at room temperature for 5h. The completion of the reaction was monitored on TLC using EtOAc: hexanes (7:3) as a mobile phase. After completion of the reaction, water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer washed with brine, finally dried over Na2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 5-10% EtOAc in hexanes to yield 0.4g of tert-butyl 2-((2-(nicotinamido)- lH-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate. Step 2
To a 25 mL RBF, tert-butyl 2-((2-(nicotinamido)-lH-benzo[d]imidazol-l-yl)methyl)- pyrrolidine- 1 -carboxylate (0.4 g, 0.00094 mole) was taken in CH2CI2 (15 mL) and cooled to 0-51 C. TFA (8 mL) was added drop wise at 0-5° C and the reaction mixture was stirred for 12 h at room temperature. After completion of the reaction, the reaction mixture was diluted with CH2CI2, neutralized with saturated aHC03 solution and the combined organic layer washed
with water and dried over Na2S04 and evaporated under reduced pressure to yield 0.22 g of N- ( 1 -(pyrrolidin-2-ylmethyl)- 1 H-benzo[d]imidazol-2-yl)nicotinamide.
Step 3
To a 10 niL vial, N-(l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)nicotinamide (0.1 g, 0.00031 mole) was taken in THF (3 mL) and cooled to -50° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.06 mL, 0.00034 mole) was added drop wise at - 50° C and the reaction mixture was stirred for 15 minutes at -50° C, followed by RT for 1 h. After completion of the reaction, 40% NaOH solution was added drop wise to make pH basic and extracted with EtOAc. The combined organic layer washed with water, brine, dried over a2S04 and evaporated to get the crude product. The crude compound was purified by Prep TLC in 3% MeOH in CH2C12 to yield 0.023g of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)nicotinamide. LC-MS (ES, m/z): 376.2 [M+H].
Example 12
Synthesis of N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d] tinamide
Step 1
To a 35 mL seal-tube, 2-cyanoacetic acid (0.058 g, 0.0068 mole) was taken in CH2CI2 (5 mL), EDC-HC1 (0.14 g, 0.00074 mole), HOBt.H20 (0.113 g, 0.00074 mole), N-(l-(pyrrolidin-2- ylmethyl)-lH-benzo[d]imidazol-2-yl)nicotinamide (0.2 g, 0.00062 mole) and TEA (0.25 mL, 0.00186 mole) were added to the reaction mixture at room temperature stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and the reaction mixture was extracted with CH2CI2. The combined organic layer washed with saturated aHC03 solution, water and brine. The organic layer was dried over a2S04 and evaporated to get the crude product which was purified by column purification by eluting the compound with 3% MeOH in CH2C12 to yield 0.08g of N-(l-((l-(2-cyanoacetyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-2-yl)nicotinamide.
Step 2
To a 10ml vial, N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2- yl)nicotinamide (0.075 g, 0.00019 mole) was taken in ethanol (2 mL). Piperidine acetate (3.3M
solution in water) (0. 2 niL) and isobutyraldehyde (0.043 niL, 0.00048 mole) were added at room temperature and the reaction mixture was heated to reflux for 2 h. After completion of the reaction, water was added to the reaction mixture and extracted with EtOAc. The combined organic layer washed with water, brine, dried over Na S04 and evaporated to get the crude which was purified by Prep TLC in 3% MeOH in CH2C12 to yield 0.03g of N-(l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)nicotinamide. LC-MS (ES, m/z): 443.3 [M+H].
Example 13
Synthesis of (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-((3,3-dimethylbutan-2-ylamino)methyl)-lH- benzo de
Step 1
To a 100 mL three necked round bottom flask, 4-fluoro-3-nitrobenzaldehyde (2.0 g, 0.0118 mole) was taken in acetonitrile (25 mL) and DIPEA (6.1 mL, 0.0354 mole) was added drop wise at room temperature. After completion of addition, the reaction mass was stirred for 15 min at same temperature followed by slow addition of tert-butyl 4-aminopiperidine-l-carboxylate (3.5 g, 0.0177 mole) over 15 min. After completion of the addition, the reaction mixture was stirred for 16 h. After completion of the reaction, acetonitrile was distilled out and water was added to residue, aq. was extracted by ethyl acetate. The combined organic layer was dried over Na S04, filtered and concentrated to afford crude product was purified using column purification by eluting the compound with 20% ethyl acetate in hexanes to yield 2.62 g of tert-butyl 4-(4- formyl-2-nitrophenylamino)piperidine- 1 -carboxylate.
Step 2
In a 100 mL 3 -neck RBF, tert-butyl 4-(4-formyl-2-nitrophenylamino)piperidine-l- carboxylate (3.25 g, 0.00932 mole), (S)-3,3-dimethylbutan-2-amine (1.27 mL, 0.00932 mole) was added in 1 ,2-dichloroethane (50 mL) under N2 atmosphere followed by addition of 5 drops of glacial acetic acid. The reaction mixture was stirred for 15min at same temperature, followed by slow addition of sodium triacetoxyborohydride (2.96 g, 0.01398 mole). The reaction mixture was stirred for 6 h. After completion of the reaction, the reaction was quenched with 2M Na2C(¾ solution and extracted by ethyl acetate. The combined organic layers were dried over Na2S04,
filtered and concentrated to afford yield 4.0g of (S)-tert-butyl 4-(4-((3,3-dimethylbutan-2- ylamino)methyl)-2-nitrophenylamino)piperidine- 1 -carboxylate.
Step 3
In a 100 mL 3-neck RBF, (S)-tert-butyl 4-(4-((3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenylamino)piperidine- 1 -carboxylate (4.0 g, 0.00932 mole) was added in CH2CI2 (20 mL) followed by pyridine (0.9 mL, 0.011 18 mole) and cooled the reaction mixture to 0° C.
Trifluroacetic anhydride (1.95 mL, 0.01397 mole) was added drop wise to the reaction mixture at 0° C. After completion of the addition, the reaction mixture was stirred for 1 h at room temperature. After completion of the reaction, the reaction mixture was quenched with 2M NaHC(¾ solution and extracted by CH2CI2. The combined organic layer was dried over a2S04, filtered and concentrated to afford yield 4.0 g of (S)-tert-butyl4-(4-(( - (3,3-dimethylbutan-2-yl)- 2,2,2-trifluoroacetamido)methyl)-2-nitrophenylamino)piperidine-l -carboxylate.
Step 4
In a 100 mL hydrogenator autoclave, to a suspension of 10% dry Pd/C (0.4g, 10%w/w) in methanol (50 mL), (S)-tert-butyl4-(4-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl) -2-nitrophenylamino)piperidine-l -carboxylate (3.0 g, 0.00282 mole) was added and the autoclave was screwed air tight. The reaction mixture was flushed twice under nitrogen atmosphere. The ¾ gas was pressurized into the autoclave at 50 psi pressure and the reaction mixture was stirred at room temperature for 4 h. After completion of the reaction, the reaction mixture was filtered through celite and washed with methanol and filtrate was concentrated to afford 3.0g of (S)-tert-butyl 4-(2-amino-4-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)phenylamino)piperidine-l -carboxylate which was used in the next step without further purification.
Step 5
To a 100 mL RBF, (S)-tert-butyl 4-(2-amino-4-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoro-acetamido)-methyl)phenylamino)piperidine-l-carboxylate (3.0 g, 0.00599 mole) was taken in ethanol (25 mL). Cyanogen bromide (0.76 g, 0.00719 mole) was added at room temperature and stirred reaction mass for 3 h. After completion of the reaction, ethanol was distilled out and saturated aHC03 solution was added to adjust pH basic and the reaction mixture was stirred for 1 h ande filtered. The filtrate was washed by water and dried to yield 3.05g of (S)-tert-butyl 4-(5-(( -(3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-2- imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate which was used in next step without further purification.
Step 6
To a 50 niL single neck RBF, 4-chlorobenzoic acid (1.25 g, 0.00799 mole) was taken in CH2C12 (50 mL) under N2 atmosphere. EDC.HC1 (1.91 g, 0.00998 mole), HOBt (1.52 g, 0.010 mole) and TEA (2.8 mL, 0.01997 mole) were added to the reaction mixture at room temperature and stirred for 20 min. (S)-tert-Butyl 4-(5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-l- carboxylate (3.5 g, 0.0066 mole) in CH2CI2 (50 mL) was added drop wise to the reaction mixture and the reaction mixture was stirred at room temperature for 9 h. After completion of the reaction, saturated NaHC(¾ solution was added to the reaction mixture and aq. layer was extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get the crude product was purified using column purification by eluting the compound with 10% ethyl acetate in hexanes to yield 3.0 g of (S)-tert-butyl 4-(2-(4-chlorobenzamido)-5-((N-(3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)- 1 H-benzo[d]imidazol- 1 -yl)piperidine- 1 - carboxylate.
Step 7
To a 25 mL RBF, (S)-tert-butyl4-(2-(4-chlorobenzamido)-5-((N-(3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-l-yl)piperidine-l -carboxylate (2.0 g, 0.00301 mole) was cooled to 10° C under 2 atmosphere. 20% HC1 in 1,4-dioxane (10 mL) was added drop wise and the reaction mixture was stirred for 6 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with acetone to yield 1.5g of (S)-4-chloro-N-(5-((N- (3,3-dimethylbutan-2-yl)-2,2,2 rifluoroacetamido)methyl)-l-( iperidine-4-yl)-lH- benzo[d]imidazol-2-yl)benzamide.
Step 8
In a 50 mL single neck RBF, (S)-4-chloro-N-(5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-l-(piperidine-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.5 g, 0.00088 mole) was added in THF (5 mL), and the reaction mixture was cooled to -30° C.
Acroloyl chloride (50% in toluene) (0.144 g, 0.00079 mole) was added drop wise to the reaction mixture at -30° C. After completion of addition, the reaction mixture was stirred for 30 minutes at room temperature. After completion of the reaction, the reaction mixture was quenched with 2M NaHCC solution and extracted by EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated to afford yield crude product. The crude product was taken in THF (2 mL) and DBU (0.3 mL) was added to it and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction, water was added and the aq. layer was extracted with EtOAc. The combined organic layers were dried over a2S04 and evaporated to
get 0.5g of (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide.
Step 9
To a 25 niL RBF, (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-(( -(3,3-dimethylbutan-2-yl)- 2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide (0.325 g, 0.00052 mole) was added in ethanol (4 mL) and cooled to 0° C under 2 atmosphere. NaBH4 (0.079 g, 0.00210 mole) was added at 0° C and the reaction mixture was stirred for 6 h at room temperature. After completion of the reaction, solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with n-pentane (10ml) to yield 400mg of crude product, which was submitted to prep HPLC for further purification to get 15mg of (S)-N- ( 1 -( 1 -acryloylpiperidin-4-yl)-5 -((3 ,3 -dimethylbutan-2-ylamino)methyl)- 1 H-benzo [d] imidazol-2- yl)-4-chlorobenzamide. LC-MS (ES, m/z): 522 [M+H].
Intermediate 7
Synthesis of 4-chloro-N-(5-(( -((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)- 1 -
(piperidin-3 -yl)- 1 H-benzo [d] imidazol-2-yl)benzamide
Intermediate 7 was prepared by following the steps 1-7 in example 13 but replacing tert- butyl 4-aminopiperidine-l-carboxylate with tert-butyl 3-aminopiperidine-l-carboxylate.
Example 14
Synthesis of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-(( -((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 10 mL seal tube, 4-chloro-N-(5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoro- acetamido)methyl)-l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.05 g, 0.0886 mmol) and 2-cynoaceticacid (0.011 g, 0.132 mmol) were taken in DCM (1.0 mL). EDC.HC1
(0.02 g, 0.106 mmol), HOBt (0.014 g, 0. 106 mmol) and TEA (0.026 g, 0. 265 mmol) were added at room temperature under nitrogen atmosphere. The reaction mixture was stirred for overnight at room temperature. After completion of the reaction, water was poured into reaction mixture and extracted with ethyl acetate. The combined organic layers were dried over sodium sulphate and concentrated to give the crude product which was purified using column purification by eluting with 10-20% ethyl acetate in hexanes to yield 30 mg of 4-chloro-N-(l-(l-(2- cyanoacetyl)piperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)benzamide.
Step 2
To a 10 mL seal tube were added 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-5-((N-
((S)-3,3-dimethyl butan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2- yl)benzamide (180 mg,0. 285 mmole), isobutaraldehyde (61.7 mg, 0. 855 mmole), 3.3M solution of piperidine acetate in water (0.259 mL, 0. 855 mmole) and ethanol (5 mL). The reaction mixture was heated in a seal tube at 80° C for 2 h. After completion of the reaction, the reaction mixture was poured in water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulphate, concentrated, and purified using column purification by eluting the compound with 0.5-1.0% methanol in chloroform to yield 30mg 4- chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)-methyl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 685 [M+H].
Example 15
Synthesis of N-(l-(l-acryloylpiperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
To a 25 mL one necked round bottom flask, 4-chloro-N-(5-((N-((S)-3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)methyl)-l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.250 g, 0.000443 mol) was taken in THF (2 mL) followed by drop wise addition of acryloyl chloride (50% sol. in toluene) (0.060 g, 0.000664 mol) at -30° C and the reaction mixture was allowed to stir at same temperature for 30 min. and 1.5 h at 0° C. After completion of the
reaction, the reaction mass quenched with saturated sodium bicarbonate solution and extracted with CH2CI2 and the combined organic layer was dried over sodium sulphate, concentrated to afford crude product which was purified using column purification by eluting the compound with 25-35% ethyl acetate in hexanes to yield 130 mg of N-(l-(l-acryloylpiperidin-3-yl)-5-((N-((S)- 3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)-methyl)-lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide. LC-MS (ES, m/z): 685 [M+H].
Intermediate 8
Synthesis of tert-butyl 3-(5-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2- imino-2,3-dihydro- 1H- benzo[d]imidazol- 1 -yl)piperidine- 1 -carboxylate
Step 1
To a single necked round bottom flask were added 4-fluoro-3-nitrobenzaldehyde (8.5 g, 0.0502 mole) and DIPEA (25.8 mL, 0.1507 mole) in acetonitrile (85 mL) followed by addition of tert-butyl 3-aminopiperidine-l -carboxylate (15 g, 0.0753 mole) at room temperature and the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified using column purification by eluting the crude product with 25% ethyl acetate in hexanes to yield 13.5 g of tert- butyl 3-(4-formyl-2-nitrophenylamino)piperidine- 1 -carboxylate.
Step 2
To a 500 mL three necked round bottom flask were added tert-butyl 3-(4-formyl-2- nitrophenylamino)piperidine-l -carboxylate (13.5 g, 0.0386 mole) and (S)-3,3-dimethylbutan-2- amine (3.9 g, 0.0386 mole) in ethylene dichloride (208 mL) under nitrogen atmosphere at room temperature. After 10 min., the reaction mixture was stirred at room temperature and glacial acetic acid (0.1ml) and NaBH(OAc)3 (0.0579mole) were added to reaction mixture and stirred at room temperature for 6 h. After completion of the reaction; the reaction mixture was diluted with water and extracted with CH2CI2. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to yield 18 g of 3-(4-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenyl-amino)piperidine- 1 -carboxylate.
Step 3
To a 250 niL three necked round bottom flask were added tert-butyl 3-(4-(((S)-3,3- dimethylbutan-2-ylamino)methyl)-2-nitrophenylamino)piperidine-l-carboxylate (3.8 g, 0.0087 mole), NaOH (0.77 g, 0.0192 mole) in water (38 mL) and cooled to 0° C-5° C. Benzyl chloroformate (1.88 mL, 0.0131 mole) was added dropwise to reaction mixture at same temperature and then allowedt to warm up to room temperature. Dioxane (15 mL) was added to reaction mixture and stirred it at room temperature for 4 h. After completion of reaction, the reaction mixture was acidified with dilute HC1 up to the pH=3-4, then extracted with ethyl acetate. Combined organic layer was dried over sodium sulfate, concentrated to give crude product which was purified using column purification by eluting compound with 5-10% ethyl acetate in hexanes to yield 4.0g of tert-butyl 3-(4-(((benzyloxycarbonyl) ((S)-3,3-dimethylbutan- 2-yl)amino)methyl)-2-nitrophenylamino)-piperidine-l-carboxylate.
Step 4
To a 250 mL single necked round bottom flask were added tert-butyl 3-(4-(((benzyloxy- carbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-nitrophenylamino)piperidine-l- carboxylate (4 g,0.0070 mole) in methanol (80 mL) and saturated NH4C1 solution (80 mL) at room temperature; followed by portionwise addition of Zn powder (4 g). The reaction mixture was heated at 60° C for 2 h. After completion of the reaction, methanol was evaporated under vacuum and the reaction mixture was filtered to remove the Zn. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate and concentrated to yield 2.8 g of tert-butyl 3-(2-amino-4-(((benzyloxycarbonyl) ((S)-3,3- dimethylbutan-2-yl)amino)methyl)-phenylamino)-piperidine-l-carboxylate.
Step 5
To a 250 mL three necked round bottom flask were added tert-butyl 3-(2-amino-4- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)phenylamino)piperidine-l- carboxylate (2.8 g, 0.0052 mole) and ethanol (56 mL) followed by portion wise addition of cyanogen bromide (0.66 g, 0.0062 mole) at room temperature and stirred for 2 h. After completion of the reaction, the reaction mixture was concentrated under vacuum and diluted with saturated aHC03 solution, then extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated to yield 2.5 g of tert-butyl 3-(5- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH- benzo[d]imidazol-l-yl)piperidine-l-carboxylate. LC-MS (ES, m/z): 564.6 [M+H].
Intermediate 9
Synthesis of benzyl (2-(4-chlorobenzamido)-l-(piperidin-3-yl)-lH-benzo[d]imidazol-5- yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate
Step 1
To a 100 niL three necked round bottom flask were added 4-chlorobenzoic acid (0.832 g,
0.0053 mole), EDCI (1.275 g, 0.0066 mole), HOBt-H20 (1.018 g, 0.0066 mole) and TEA (1.34 mL, 0.0133 mole) in CH2CI2 (50 mL) at room temperature and stirred for 10 min. tert-Butyl 3-(5- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro- lH- benzo[d]imidazol-l -yl)piperidine-l -carboxylate (2.5 g, 0.0044 mole) was added and the reaction mixture was stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was diluted with saturated aHC03 solution and the compound was extracted with CH2CI2. The combined organic layer was dried over sodium sulfate, concentrated under vacuum to give crude product which was purified using column purification by eluting compound with 10- 15% ethyl acetate in hexanes to yield 2.0 g of tert-butyl 3-(5-(((benzyloxycarbonyl)-(S)-3,3- dimethylbutan-2-yl)amino)methyl)-2-(4-chlorobenzamido)-lH-benzo[d]imidazol- l- yl)piperidine- 1 -carboxylate.
Step 2
To a 100 mL three necked round bottom flask were added tert-butyl 3-(5-(((benzyloxy- carbonyl)-((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-(4-chlorobenzamido)- lH-benzo[d]- imidazol- l -yl)piperidine- l -carboxylate (2 g, 0.0028 mole) and CH2CI2 (20 mL) followed by dropwise addition of TFA (5 mL) at 0° C. The reaction mixture was allowed to warm up to room temperature and stirred for 2 h. The completion of reaction was monitored by TLC using chloroform: methanol (9: 1) as a mobile phase. After completion, the reaction mixture was concentrated under vacuum, azeotroped with toluene and triturated with pentane to give solid product, which was dried under vacuum to yield 2.0g of benzyl (2-(4-chlorobenzamido)-l - (piperidin-3-yl)- lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate as a
TFA salt. LC-MS (ES, mix): 602.7 [M+H].
Intermediate 10
Step 1
In a 500 mL 3 neck round bottomed flask was dissolved 2-bromo-2-methylpropanoic acid (40 g, 239.5 mmole) in ethanol (320 mL) and cooled to 0 to 5°C followed by dropwise addition of DIPEA (87.4 mL, 502.9 mmole) at 0 to 5° C and the reaction mixture was stirred at 0°C for 30 min. The reaction mixture was warmed to 40°C for 16 h. After 16 h, the reaction mixture was cooled to room temperature, ethanol was removed in vacuo, leaving a thick white slurry. Diethyl ether and water was added to the slurry and cooled to 0° C. The mixture was acidified with 10 % HC1 (50 mL) and the organic layer was separated and washed with brine. To the organic phase was added 10 % aq NaHS(¾ and the mixture was stirred at room temperature for 6 h. The biphasic mixture was acidified with 10 % HC1 (50 mL) to the pH 1.0 ± 0.5. The organic phase was washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated to give 30 g of 2-ethoxy-2-methylpropanoic acid. The product, 2-ethoxy-2-methylpropanoic acid, was carried forwarded to the next step without further purification.
Step 2
In a 500 mL three neck round bottomed flask was dissolved 2-ethoxy-2-methylpropanoic acid (30 g, 227.2 mmole) in ethanol (300 mL) and cooled to 0°C followed by dropwise addition of thionyl chloride (49.7 mL, 681.8 mmole) at 0° C. The reaction mixture was refluxed at 80° C for 3 h. After completion of the reaction, thionyl chloride and ethanol were evaporated in vacuo and the residue was cooled to 0° C and basified with saturated NaHC(¾ solution and extracted with CH2CI2 , dried over sodium sulfate, filtered and concentrated to give 32 g of ethyl 2-ethoxy- 2-methylpropanoate.
Step 3
In a 500 mL three neck round bottomed flask was dissolved ethyl 2-ethoxy-2- methylpropanoate (16 g, 100 mmole) in dry THF (133 mL) and cooled to 0 to -10° C followed by dropwise addition of 1M solution of LiAlH4 in THF (100 mL, 100 mmole) at 0 to -10° C and the reaction mixture was stirred at 0° C for 3 h. After completion of the reaction, the reaction mixture was quenched with sat. NH4C1 solution and filtered through Buchner funnel to remove colloidal precipitates. The filtrate was extracted with ethyl acetate. The combined organics was dried over sodium sulfate and evaporated to afford 9 g of 2-ethoxy-2- methylpropan-l-ol.
Step 4
In a 100 mL single neck round bottomed flask was dissolved 2-ethoxy-2-methylpropan-l- ol (9 g, 76.2 mmole) in dry CH2CI2 (20 mL) and cooled to 10 °C. Pyridinium chlorochromate was added to the reaction mixture portion wise at 10° C and the reaction mixture was stirred at room temperature for 16 h. The completion of the reaction was monitored by TLC using neat CH2CI2 as a mobile phase. After completion of the reaction, the reaction mixture was poured
directly into the column for the purification, eluting the compound in neat CH2CI2. The solvent was distilled at 50 °C to yield 5 g of 2-ethoxy-2-methylpropanal.
Intermediate 11
To a 250 mL three neck round bottomed flask, DMSO (10.27 mL, 143.3 mmole) and CH2CI2 (15 mL) were cooled to -78° C. Oxalyl chloride (8.77 mL, 102.2 mmole) in CH2C12 (35 mL) was added dropwise at -78° C. The reaction mixture was stirred for 30 min at same temperature and 2-(dimethylamino)-2-methylpropan-l-ol (4 g, 34.1 mmole) in CH2CI2 (25 mL) was added dropwise by maintaining the temperature at -78° C and further stirred for 20 min at same temperature. TEA (32.6 mL, 232.6 mmole) was added dropwise at -78° C and stirred for 40 min at same temperature, followed by stirring at room temperature for 10 min. After completion of the reaction, the reaction mixture was diluted with CH2CI2 and neutralized with saturated NaHC(¾ solution. Organic layer was washed with brine solution, dried over Na2S04 and distilled out excess of the solvent using downward distillation at 30° C to yield crude product. The crude compound was purified using column purification by eluting compound with CH2CI2 to yield 1 g of 2-(dimethylamino)- 2-methylpropanal.
Example 16
Synthesis of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5
Step 1
To a 50 mL one necked round bottom flask were added benzyl (2-(4-chlorobenzamido)-l-
(piperidin-3-yl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt (0.5 g,0.7150 mmole), 2-cyano-4-methylpent-2-enoic acid (0.298 g, 2.1450 mmole) and
CH2CI2 (10 mL); followed by addition of PyBrOP (0.366 g, 0.7860 mmole) and TEA (0.3 mL) at
0° C under nitrogen atmosphere and stirred for 15 min at the same temperature. After completion of the reaction, the reaction mixture was purified using column purification by eluting compound with 20% ethyl acetate in hexanes to yield 0.19 g of benzyl (2-(4-
chlorobenzamido)-l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-5 yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 2
To a 50 niL one necked round bottom flask were added benzyl(2-(4-chlorobenzamido)-l- (l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)carbamate (0.19 g, 0.2626 mmole) and acetic acid (1.9 mL) and cooled to 0° C; followed by drop wise addition of 30% HBr in acetic acid (7.6 mL). After completion of addition the reaction mixture was allowed to warm up to room temperature and stirred for lh. After completion of the reaction; the reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5°C (pH ~7-8) and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give the crude product, which was purified by prep HPLC to yield 16 mg of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2- enoyl)piperidin-3-yl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2- yl)benzamide. LC-MS (ES, m/z): 589.4 [M+H].
Example 17
Synthesis of N-(l-(l-(4-amino-2-cyano -4-methylpent-2-enoyl)piperidin-3-yl)-5-(((S)-3,3- dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
Step 1
To a 50 mL three necked round bottom flask were added 2-cyanoacetic acid (0.08 g, 0.9439 mmole) and HATU (0.45 g, 1.1799 mmole) in DMF (5 mL) under nitrogen atmosphere and stirred at room temperature for 10 min. A solution of benzyl (2-(4-chlorobenzamido)-l- (piperidin-3-yl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt (0.55 g, 0.7866 mmole) in DMF (5 mL) was dropwise added, followed by addition of DIPEA (0.54 mL, 3.1464 mmole) at room temperature. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was poured in to water and extracted with ethyl acetate. The combined organic layer was washed with saturated NaHCC>3 solution, brine solution and dried over sodium sulfate and concentrated under vacuum to give 0.33 g of benzyl (2-(4-chlorobenzamido)-l-(l-(2-cyanoacetyl)piperidine-3-yl)-lH- benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 2
To a 20 niL sealed tube were added benzyl (2-(4-chlorobenzamido)-l-(l-(2- cyanoacetyl)piperidin-3-yl)-lH4oenzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate (0.33 g, 0.4931 mmole), tert-butyl 2-methyl- 1 -oxopropan-2-ylcarbamate (0.28g , 1.4739 mmole) and piperidine (0.1 mL) in 1,4 dioxane (8 mL). The reaction mixture was heated at 100° C for 4 h. After completion of the reaction; the reaction mixture was concentrated under vacuum and the crude compound was purified using column purification by eluting the compound with 25% ethyl acetate in hexanes to yield 0.25 g benzyl N-[[l-[l-[4-(tert- butoxycarbonylamino)-2-cyano-4-methyl-pent-2-enoyl]-3-piperidyl]-2-[(4- chlorobenzoyl)amino]benzimidazol-5-yl]methyl]-N-[(lS)-l,2,2-trimethylpropyl]carbamate. Step 3
To a 50 mL one necked round bottom flask was added N-Boc protected benzyl(l-(l-(4- amino-2-cyano-4-methylpent-2-enoyl)piperidine-3-yl)-2-(4-chlorobenzamido)-lH-benzo[d]- imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.25 g, 0.2982 mmole) in acetic acid (2.5 mL) and the mixture cooled to 0° C. A solution of 30% HBr in acetic acid (10 mL) was added dropweise and after completion of addition the reaction mixture was allowed to warm up to room temperature and stirred for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5°C (pH -7-8) and the product was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by prep HPLC to yield 19 mg of N-(l-(l-(4-amino-2-cyano -4-methylpent-2-enoyl)piperidin-3-yl)-5-(((S)-3,3- dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide as the formic acid salt. LC-MS (ES, m/z): 604.6 [M+H].
Example 18
Synthesis of N-( 1 -( 1 -(4-methylamino-2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5 -((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
Step 1
To a 20 mL seal tube were added benzyl (2-(4-chlorobenzamido)-l-(l-(2-cyanoacetyl)- piperidin-3 -yl)- 1 H-benzo [d] imidazol-5 -yl)methyl-((S)-3 ,3-dimethylbutan-2-yl)carbamate (0.6 g, 0.8965 mmole), tert-butyl methyl (2-methyl- 1 -oxopropan-2-yl)carbamate (0.54 g, 2.6895 mmole)
and piperidine (0.17 niL) in 1,4 dioxane (12 niL). The reaction mixture was heated at 100° C for 20 h. After completion of the reaction; the reaction mixture was concentrated under vacuum and purified using column purification eluting compound with 25% ethyl acetate in hexanes to yield 0.2 g tert-butyl N-[4-[3-[5-[[benzyloxycarbonyl-[(lS)-l,2,2-trimethylpropyl]amino]methyl]-2- [(4-chlorobenzoyl)amino]benzimidazol-l-yl]-l-piperidyl]-3-cyano-l,l-dimethyl-4-oxo-but-2- enyl] -N-methyl-carbamate.
Step 2
To a 50 mL one necked round bottom flask were added tert-butyl N-[4-[3-[5-
[[benzyloxycarbonyl-[(lS)-l,2,2-trimethylpropyl]amino]methyl]-2-[(4-chlorobenzoyl)amino]- benzimidazol- 1 -yl]-l -piperidyl]-3-cyano- 1, 1 -dimethyl-4-oxo-but-2-enyl] -N-methyl-carbamate (0.2 g, 0.2347 mmole) in acetic acid (2 mL) and cooled to 0° C followed by drop wise addition of 30% HBr in acetic acid (8 mL). The reaction mixture was allowed to warm up to room temperature and stirred for 1 h. After completion of the reaction; the reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5°C (pH ~7-8) and compound was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by prep HPLC to yield 25 mg of N-(l-(l-(4- methylamino-2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3-dimethylbutan-2- yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide as the formic acid salt. LC-MS (ES, m/z): 619 [M+H].
Example 19
Synthesis of 4-chloro-N-( 1 -( 1 -(2-cyano-4-(dimethylamino)-4-methylpent-2- enoyl)piperidin-yl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2- yl)benzamide
4-Chloro-N-(l-(l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)piperidin-3-yl)-5- (((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide as the formic acid salt was prepared using the same procedure as example 18 but substituting 2- (dimethylamino)-2-methylpropanal for tert-butyl methyl (2-methyl-l-oxopropan-2-yl)carbamate. LC-MS (ES, m/z): 633 [M+H].
Example 20
Synthesis of N-( 1 -( 1 -acryloylpiperidin-3 -yl)-5 -(((S)-3,3 -dimethylbutan-2- ylamino)methyl)- lH-benzo[d] imidazol-2- l -4-chlorobenzamide
Step 1
To a 50 mL one necked round bottom flask, a 50% solution of acrolyl chloride in toluene (0.3 mL, 0.858 mmole) was dropwise added to a solution of benzyl (2-(4-chlorobenzamido)- 1 - (piperidin-3-yl)-lH benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt (0.4 g, 0.5720 mmole) in THF (10 mL) at -30° C under nitrogen atmosphere. The reaction mixture was allowed to warm up to room temperature and stirred for 1 h. After completion, the reaction mixture was poured in saturated NaHCC>3 solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate and concentrated under vacuum to give crude product To a 25 mL one necked round bottom flask were added the crude product (0.5 g) and cesium carbonate (0.56 g, 1.7162 mmole) in THF (5 mL) and heated at 60° C for 15 min. The reaction mixture was cooled to room temperature; then water was added and the product was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to yield 0.3 g of benzyl(l-(l-acryloylpiperidin-3-yl)-2-(4- chlorobenzamido)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate. Step 2
To a 50 mL one necked round bottom flask were added benzyl (1-(1 -acryloylpiperidin-3 - yl)-2- (4-chlorobenzamido)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate (0.3 g, 0.4571 mmole) and acetic acid (3 mL) and the mixture was cooled to 0° C. A solution of 30% HBr in acetic acid (12 mL) was added dropwise and the mixture allowed to warm up to room temperature and stirred for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHCC>3 solution at 5° C (pH ~7-8) and the compound was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by prep HPLC to yield 38 mg of N-( 1 -( 1 -acryloylpiperidin-3-yl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)- 1 H- benzo[d]imidazol-2-yl)-4- chlorobenzamide. LC-MS (ES, m/z): 522.5 [M+H].
Intermediate 12
Synthesis of tert-butyl 2-((5-(((benzyloxycarbonyl)-((S)-3,3-dimethylbutan-2-yl)amino)methyl)- 2-imino-2,3-dihydro- lH-benzo ethyl)pyrrolidine- 1 -carboxylate
Step 1
To a 250 niL three necked round bottom flask, 4-fluoro-3-nitrobenzaldehyde (7.0 g, 0.0416 mole) was added in acetonitrile (100 mL) followed by addition of DIPEA (21.5 mL, 0.1248 mole) and the reaction mixture was stirred at room temperature for 10 min. tert-Butyl 2- (aminomethyl)-pyrrolidine- 1 -carboxylate (12.5 g, 0.0624 mole) in acetonitrile (100 mL) was dropwise added to the reaction mixture and stirred at room temperature for 16 h. After 16 h, the reaction mixture was concentrated, diluted with water and extracted with CH2CI2. The combined organic layers were dried over sodium sulphate and concentrated to give crude product which was purified using column purification eluting with 10% ethyl acetate in hexanes to yield 14 g of tert-butyl 2-((4-formyl-2-nitrophenylamino)methyl)pyrrolidine- 1 -carboxylate.
Step 2
To a 500 mL three necked round bottom flask under nitrogen atmosphere, tert-butyl 2- ((4-formyl-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (14g, 0.0400mole) and (S)-3,3- dimethylbutn-2-amine (4.04 g, 0.0400 mole) were added in 1,2 dichloroethane (300 mL) and the mixture stirred at room temperature for 10 min. Acetic acid (1.24 mL, catalytic amount) and NaBH(OAc)3 (12.7 g, 0.0601 mole) were added respectively to the reaction mixture and the reaction mixture was stirred at room temperature for 6 h. After completion of the reaction, the reaction mixture was poured into saturated Na2C(¾ solution followed by extraction with CH2CI2. The combined organic layers were dried over sodium sulphate and concentrated to yield 17 g of tert-butyl 2-((4-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenylamino)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a 50 mL three necked round bottom flask, tert-butyl 2-((4-(((S)-3,3-dimethylbutan-2- ylamino)methyl)-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (2.0 g, 0.0046 mole), NaOH (0.40 g,0.0101 mole) were added in 1, 4-dioxane (10 mL) and water (20 mL) and the reaction mixture was cooled it to 10° C. Benzyl chloroformate (0.98 mL, 0.0069 mole) was added dropwise to the cooled reaction mixture and the reaction mixture was allowed to warm to room temperature. Reaction mixture was stirred at room temperature for 3 h. After completion of the reaction, the reaction mixture was washed with IN HCl and saturated NaHC03 solution. The
organic layer was dried over sodium sulphate and concentrated to yield 1.7 g of tert-butyl 2-((4- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-nitrophenylamino)- methyl)pyrrolidine- 1 -carboxylate.
Step 4
To a 50 mL three necked round bottom flask, tert-butyl 2-((4-(((benzyloxycarbonyl)((S)-
3,3-dimethylbutan-2-yl)amino)methyl)-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (1.7 g, 0.00298 mole) was added in methanol (17 mL) followed by zinc dust (0.5 g, 0.0149 mole) and saturated NH4C1 solution (8.5 mL). The resultant mixture was heated at 50°C for 2 h with stirring. After completion of the reaction, the reaction mixture was filtered through a celite bed, washed with methanol and the filtrate was concentrated to give the crude product. Water was added and the product was extracted with EtOAc. The combined organic layer was dried over sodium sulphate, concentrated to give the crude compound which was purified using column purification to yield 1.3 g of tert-butyl 2-((2-amino-4-(((benzyloxycarbonyl)((S)-3,3- dimethylbutan-2-yl)amino)methyl)-phenylamino)methyl)pyrrolidine-l -carboxylate.
Step 5
To a 50 mL three necked round bottom flask under nitrogen atmosphere, tert-butyl 2-((2- amino-4-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)phenylamino- methyl)pyrrolidine- 1 -carboxylate (1.3 g, 0.00241 mole) was added in ethanol (13 mL) followed by addition of cyanogen bromide (0.30 g, 0.00289 mole) at room temperature. The mixture was stirred at same temperature for 16 h and completion of the reaction was monitored on TLC using CH2CI2: methanol (9: 1) as a mobile phase. After completion of the reaction, the reaction mixture was concentrated under vacuum, diluted with saturated aHC03 solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate and concentrated to give the crude product which was purified using column purification by eluting the compound with 1.5-2.0% methanol in chloroform to yield 1.2g of tert-butyl 2-((5-
(((benzyloxycarbonyl)((S)-3,3-dimethyl-butan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH- benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate. LC-MS (ES, m/z): 564.7 [M+H].
Example 21
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)- 3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 25 niL three necked round bottom flask under nitrogen atmosphere, 4-chlorobenzoic acid (0.366 g, 0.00234 mole) was added in CH2C12 (12 mL) followed by addition of EDC.HC1 (0.485 g, 0.00254 mole), HOBt.H20 (0.389 g, 0.00254 mole) and TEA (0.88 mL, 0.00636 mole) and the mixture was stirred at room temperature for 10 min. tert-Butyl 2-((5- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH- benzo[d]imidazol-l-yl)methyl)-pyrrolidine-l-carboxylate (1.2 g,0.00212 mole) was added to a reaction mixture and the reaction mixture was stirred it at room temperature for 4 h. After completion of the reaction, the reaction mixture was washed with saturated NaHC(¾ solution. The organic layer was dried over sodium sulphate, concentrated to give the crude product which purified using column purification by eluting the compound with 20% ethyl acetate in hexanes to yield lg of tert-butyl 2-((5-(((benzyloxy-carbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2- (4-chlorobenzamido)- lH-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate.
Step 2
To a 50 mL RBF, tert-butyl 2-((5-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2- yl)amino)methyl)-2-(4-chlorobenzamido)- 1 H-benzo [d] imidazol- 1 -yl)methyl)pyrrolidine- 1 - carboxylate (1 g, 0.00142 mole) was added in CH2C12 and cooled to 0° C. TFA (11.1 mL) was slowly added at 0° C and the reaction mixture was stirred for 16 h at RT. After completion of the reaction, CH C12 was completely distilled out in vacuum followed by stripping with THF to get the crude residue which was triturated with diethyl ether and filtered to yield 1 g of benzyl (2-(4- chlorobenzamido)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)carbamate as TFA salt.
Step 3
To a 25 mL one necked round bottom flask, benzyl (2-(4-chlorobenzamido)-l-
(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt (0.55 g, 0.00091 mole), 2-cyano-4-methylpent-2-enoic acid (0.380 g, 0.00274 mole) were added in CH2C12 (3 mL), followed by addition of PyBrOP (0.466 g, 0.001 mole) and TEA (0.63 mL,0.0045 mole) at 0° C under nitrogen atmosphere and the reaction mixture was stirred for 15 min at same temperature. After the completion of the reaction, the reaction mixture was purified using column purification by eluting compound with 25% ethyl acetate in hexanes to
yield 0.2g of benzyl (2-(4-chloro-benzamido)-l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 4
To a 50 niL round bottom flask, benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3- dimethylbutan-2-yl)carbamate (0.17 g, 0.000013 mole) was added in acetic acid (3.4 mL) and cooled to 0° C. 30% HBr in acetic acid (8.5ml) was added dropwise and after the completion of addition, the reaction mixture was allowed to warm up to room temperature and stirred for 30 min. After completion of the reaction, the reaction mixture was slowly diluted with 6N NaOH solution at 5° C (pH -11-12) and the compound was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by prep HPLC to yield 28 mg of 4-chloro-N-(l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH- benzo[d]imidazol-2-yl)benzamide as the formic acid salt. LC-MS (ES, m/z): 589.7 [M+H].
Example 22
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4-methyl-4-(methylamino)pent-2-enoyl)pyrrolidin-2- yl)-methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 10 mL seal tube were added benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyanoacetyl)- pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.5 g, 0.000747 mole), tert-butyl methyl-(2-methyl-l-oxopropan-2-yl)carbamate (0.6 g, 0.002988 mole) and piperidine (0.36 mL) in 1,4 dioxane (5 mL). The reaction mixture was heated at 100° C for 20 h. After completion of the reaction, the reaction mixture was concentrated under vacuum and purified using column purification eluting with 25% ethyl acetate in hexanes to yield 0.24 g tert-butyl N-[4-[2-[[5-[[benzyloxycarbonyl-[(l S)-l,2,2- trimethylpropyl]amino]methyl]-2-[(4-chlorobenzoyl)-amino]benzimidazo-l- yl]methyl]pyrrolidin-l-yl]-3-cyano-l, l-dimethyl-4-oxo-but-2-enyl]-N-methyl-carbamate.
Step 2
To a 25 mL one necked round bottom flask were added tert-butyl N-[4-[2-[[5- [[benzyloxy-carbonyl-[(lS)-l,2,2-trimethylpropyl]amino]methyl]-2-[(4- chlorobenzoyl)amino]benzimidazo- 1 -yl]methyl]pyrrolidin- 1 -yl]-3-cyano- 1 , 1 -dimethyl-4-oxo- but-2-enyl]-N-methyl-carbamate (0.24 g, 0.00028 mole) in 1,4-dioxane (2.4 mL) and cooled to 0° C followed by drop wise addition of HC1 in dioxane (5 N) (2.4 mL) and then allowed it to warm up to room temperature and stirred for 2 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHCC>3 solution at 5°C (pH ~7-8) and the compound was extracted with EtOAc. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to yield 0.14 g of benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4- methyl-4-(methylamino)pent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 3
To a 25 mL one necked round bottom flask were added benzyl (l-((l-(4-amino-2-cyano- 4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(4-chlorobenzamido)-lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.14 g, 0.00018 mole) in acetic acid (1.4 mL) and cooled to 0° C followed by drop wise addition of 30% HBr in acetic acid (5.6 mL). The reaction mixture was allowed it to warm up to room temperature and stirred for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5° C (pH ~7-8) and the compound was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by column purification using 8% methanol in CH2CI2 followed by trituration with diethyl ether to yield 0.028 g of 4-chloro-N-(l-((l-(2-cyano-4-methyl-4- (methylamino)pent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2- ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z):619 [M+H].
Example 23
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((((S)-3,3-dimethylbutan- -yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 10 mL seal tube were added pyrrolidine (0.223 g, 0.003138 mole) and TMS-C1 (0.227 g, 0.002092 mole) in acetonitrile (10 mL) followed by pivaldehyde (0.135 g, 0.001569 mole) and the reaction mixture was stirred at RT for 10 min. Benzyl (2-(4-chlorobenzamido)-l- ((l-(2-cyano-acetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)-carbamate (0.35 g, 0.000523 mole) was added and stirred the mixture for lhr at RT. After the completion of the reaction, the reaction mixture was diluted with water and extracted with EtOAc and the combined organic layer was concentrated under vacuum. The crude compound was purified using column chromatography by eluting with 25% ethyl acetate in hexanes to yield 0.2 g benzyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4,4-dimethylpent-2- enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate.
Step 2
To a 50 mL one necked round bottom flask were added benzyl (2-(4-chlorobenzamido)-l- ((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5- yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate (0.19 g, 0.000257 mole) in acetic acid (1.9 mL) and cooled to 0° C; followed by drop wise addition of 30% HBr in acetic acid (7.6 mL). After completion of addition, the reaction mixture was allowed to warm up to room temperature and stirred for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5° C (pH ~7-8) and compound was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by column chromatography by using 3-5% methanol in DCM to yield 0.033 g of 4-chloro-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2- yl)benzamide. LC-MS (ES, m/z):603.5 [M+H].
Example 24
Synthesis of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2- ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
Step 1
To a 25 mL three necked round bottom flask under nitrogen atmosphere, benzyl (2-(4- chlorobenzamido)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-
dimethylbutan-2-yl)carbamate TFA salt (0.4 g, 0.000747 mole) as prepared above, was added in THF (8 mL) and the mixture was cooled to -30° C. A 50% solution of acryloyl chloride in toluene (0.13 mL, 0.000822 mole) was added and then the mixture was warmed to room temperature and stirred for 2 h. After completion of the reaction, the reaction mixture was diluted with saturated NaHCC>3 solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate, concentrated to give a solid which was dissolved in DMF (2 mL) followed by addition of Cs2C03 (1.11 g, 0.00343 mole) and stirred at 55° C overnight. Column purification afforded 0.35 g benzyl (l-((l-acryloylpyrrolidin-2-yl)methyl)-2-(4- chlorobenzamido)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate. Step 2
Deprotection as in Step 4, Example 21, with HBr afforded N-(l-((l -acryloylpyrrolidin-2- yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide as the formic acid salt. LC-MS (ES, m/z): 523 [M+H]. Example 25
Synthesis of N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
Step 1
To a 100 mL RBF, tert-butyl 2-((4-formyl-2-nitrophenylamino)methyl)pyrrolidine-l- carboxylate (7.5 g, 0.02146 mole) was added in CH2C12 (30 mL) and cooled to 0° C. TFA (12 mL) was slowly added at 0° C and the reaction mixture was stirred for 1.5 h at RT. After the completion of the reaction, CH2CI2 was completely distilled out in vacuum followed by stripping with THF to get the crude residue which was triturated with diethyl ether and filtered to yield 7.5 g of 3-nitro-4-(pyrrolidin-2-ylmethylamino)benzaldehyde as TFA salt, which was used in the next step.
Step 2
To a 100 mL three necked round bottom flask under nitrogen atmosphere were added 3- nitro-4-(pyrrolidin-2-ylmethylamino)benzaldehyde as TFA salt (7.5 g, 0.02066 mole), pyridine (4.89 g, 0.00309 mole) in CH2C12 (50 mL) and cooled it to 0° C. Trifluoroacetic anhydride (6.5
g, 0.0619 mole) was added drop wise to the cooled reaction mixture and then allowed it to warm up to room temperature and stirred at room temperature for 12 h. After completion of the reaction, the solvent is concentrated to give the crude product in which water was added and the solid obtained was filtered, washed with water and hexanes and dried in vacuum to yield 6 g of 3-nitro-4-((l-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)methylamino)benzaldehyde.
Step 3
To a 50 mL three necked round bottom flask under nitrogen atmosphere, 3-nitro-4-((l- (2,2,2-trifluoroacetyl)pyrrolidin-2-yl)methylamino)benzaldehyde (6 g, 0.0173 mole) and (S)-3,3- dimethyl butyl-2-amine (2.44 mL, 0.0173 mole) were added in 1,2 dichloroethane (30 mL) and stirred at room temperature for 10 min. Acetic acid (0.52 mL, catalytic amount) and
NaBH(OAc)3 (5.53 g, 0.0260 mole) were added respectively to the reaction mixture and stirred at room temperature for 6 h. After completion of the reaction, the reaction mixture was poured in to saturated Na2C(¾ solution, followed by extraction with CH2CI2. The combined organic layers were dried over sodium sulphate, concentrated to yield 4.6 g of l-(2-((4-(((S)-3,3-dimethylbutan- 2-ylamino)methyl)-2-nitrophenylamino)methyl)pyrrolidin- 1 -yl)-2,2,2-trifluoroethanone.
Step 4
To a 100 mL round bottom flask, l-(2-((4-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenylamino)methyl)pyrrolidin-l-yl)-2,2,2-trifluoroethanone (4.6 g, 0.01069 mole) and TEA (4.3 mL) were taken in CH2C12 (40 mL). (Boc)20 (3.49 g, 0.01604 mole) at 0° C was added and the reaction mixture was stirred at room temperature for 16 hr. After completion of the reaction, the reaction mixture was poured in to water followed by extraction with EtOAc. The combined organic layers were dried over sodium sulphate and concentrated to give crude product which was purified using column purification by eluting the compound with 5% EtOAc in hexanes to yield 1.8 g tert-butyl(S)-3,3-dimethylbutan-2-yl (3-nitro-4-((l -(2,2,2- trifluoroacetyl)pyrrolidin-2-yl)methyl-amino)benzyl)-carbamate.
Step 5
To a 50 mL three necked round bottom flask, tert-butyl (S)-3,3-dimethylbutan-2-yl (3- nitro-4-((l-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)methylamino)benzyl)carbamate (1.8 g, 0.0033 mole) were added in methanol (20 mL) followed by moist 10% Pd/C (0.36 g). The reaction mixture was stirred under a balloon of ¾ gas for 4 h with stirring. After completion of the reaction, the reaction mixture was filtered through celite bed; washed with methanol and filtrate was concentrated to yield 1.5 g of tert-butyl 3-amino-4-((l-(2,2,2-trifluoroacetyl)pyrrolidin-2- yl)methylamino)benzyl((S)-3,3-dimethylbutan-2-yl)-carbamate.
Step 6
To a 50 niL three necked round bottom flask under nitrogen atmosphere, tert-butyl 3- amino-4-((l-(2,2,2 rifluoroacetyl)pyrrolidin-2-yl)methylamino)benzyl((S)-3,3-dimethylbutan-2- yl)carbamate (1.5g, 0.0030 mole) was added in ethanol (15 mL) followed by addition of cyanogen bromide (0.38 g, 0.0036 mole) at room temperature and stirred at same temperature for 4 h. After completion of the reaction, the reaction mixture was concentrated under vacuum and diluted with saturated NaHC(¾ solution and extracted with EtOAc. The combined organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting the compound with 1.5-2.0% methanol in chloroform to yield 1.6g (crude) of tert-butyl (S)-3,3-dimethylbutan-2-yl((2-imino-l-((l-(2,2,2-trifluoroacetyl)pyrrolidin- 2-yl)methyl)-2,3-dihydro- lH-benzo[d]imidazol-5-yl)methyl)carbamate.
Step 7
To a 100 mL three necked round bottom flask under nitrogen atmosphere, 4- chlorobenzoic acid (0.571 g, 0.00365 mole) was added in CH2CI2 (30 mL) followed by addition of EDC.HC1 (0.875 g, 0.00456 mole), HOBt (0.616 g, 0.00456 mole) and TEA (1.28 mL, 0.00914 mole) and stirred at room temperature for 10 min. tert-Butyl (S)-3,3-dimethylbutan-2- yl((2-imino- 1 -(( 1 -(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)methyl)-2,3 -dihydro- 1 H- benzo[d]imidazol-5-yl)methyl)carbamate (1.6g, 0.00304mole) was added to the reaction mixture and stirred it at room temperature for 4 h. After completion of the reaction, the reaction mixture was washed with saturated NaHC(¾ solution. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting with 20% EtOAc in hexanes to yield 1.28g of tert-butyl (2-(4-chlorobenzamido)-l-((l-(2,2,2- trifluoroacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan- 2-yl)carbamate.
Step 8
To a 50 mL one necked round bottom flask were added tert-butyl (2-(4- chlorobenzamido)-l-((l-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (1.08 g, 0.00162 mole) in ethanol (10 mL), followed by addition of NaBH4 (0.247 g, 0.00650 mole) and stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was slowly diluted with saturated NH4C1 solution and the product was extracted with EtOAc. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by trituration with diethyl ether to yield 0.7 g of tert-butyl (2-(4-chlorobenzamido)-l-(pyrrolidin-2- ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 9
To a 100 niL three necked round bottom flask were added 2-cyanoacetic acid (0.143 g, 0.00169 mole) and HATU (0.802 g, 0.00211 mole) in DMF (8 mL) under nitrogen atmosphere and stirred at room temperature for 10 min. A solution of tert-butyl (2-(4-chlorobenzamido)-l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.8 g, 0.00140 mole) in DMF (7 mL) was drop wise added, followed by addition of DIPEA (0.71 mL, 0.00422 mole) at rt. The reaction mixture was stirred at room temperature for 2.5 h. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with saturated NaHC(¾ solution, brine solution, and dried over sodium sulfate and concentrated under vacuum to yield crude compound, which was subjected for the column purification using 2% MeOH in CH2CI2 to give 0.85 g of tert-butyl (2-(4- chlorobenzamido)-l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 10
To a 10 mL seal tube were added tert-butyl (2-(4-chlorobenzamido)-l-((l-(2- cyanoacetyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2- yl)carbamate (0.225 g, 0.00035 mole), tert-butyl 2-methyl-l-oxopropan-2-ylcarbamate (0.198 g, 0.00106 mole) and piperidine (0.06 g) in 1,4 dioxane (2 mL). The reaction mixture was heated at 110° C for 1 h. After completion of the reaction; the reaction mixture was concentrated under vacuum and the crude product was purified using column purification by eluting with 2% MeOH in CH2C12 to yield 0.125 g of tert-butyl N-[[l-[[l-[4-(tert-butoxycarbonylamino)-2-cyano-4- methyl-pent-2-enoyl]pyrrolidin-2-yl]methyl]-2-[(4-chlorobenzoyl)amino]benzimidazol-5- yl]methyl]-N-[(lS)-l,2,2-trimethylpropyl]carbamate.
Step 11
To a 50 mL one necked round bottom flask were added tert-butyl N-[[l-[[l-[4-(tert- butoxycarbonylamino)-2-cyano-4-methyl-pent-2-enoyl]pyrrolidin-2-yl]methyl]-2-[(4- chlorobenzoyl)amino]benzimidazol-5-yl]methyl]-N-[(lS)-l,2,2-trimethylpropyl]carbamate (0.125 g,0.00015 mole) in CH2C12 (4.5 mL) and cooled to 0° Cfollowed by drop wise addition of TFA (0.5 mL). After completion of addition, the reaction mixture was allowed to warm up to room temperature and stirred for 2.5 h. After completion of the reaction; the reaction mixture was slowly diluted with saturated NaHC(¾ at 5° C (pH ~7-8) and the product was extracted with EtOAc. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by trituration with diethyl ether followed by again trituration with water and dried in vacuum to yield 0.030g of N-(l-((l-(4-amino-2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH- benzo[d]imidazol-2-yl)-4-chlorobenzamide. LC-MS (ES, m/z): 605 [M+H].
Example 26
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 10 mL seal tube were added pyrrolidine (0.39 mL, 0.0000472 mole) and TMS-C1 (0.4 mL, 0.00314 mole) in acetonitrile (5 mL) followed by 2-ethoxy-2-methylpropanal (0.274 g, 0.000236 mole) and the reaction mixture was stirred at RT for 10 min. tert-Butyl (2-(4- chlorobenzamido)- 1-((1 -(2-cyanoacetyl)pyrrolidin-2-yl)methyl)- lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.5 g, 0.000787 mole) was added and the reaction mixture was stirred for 1 h at RT. After completion of the reaction; the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layer was concentrated under vacuum. The crude product was purified using column purification by eluting with 25% EtOAc in hexanes to yield 0.209 g of tert-butyl (2-(4-chlorobenzamido)-l-((l-(2-cyano-4- ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)carbamate.
Step 2
To a 10 mL one necked round bottom flask were added tert-butyl (2-(4- chlorobenzamido)- l-((l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.209 g, 0.00028 mole) in CH2CI2 (1 mL) and cooled to 0° C followed by drop wise addition of TFA (1 mL). After completion of addition, the reaction mixture was allowed to warm up to room temperature and stirred for 1 h. The reaction mixture was slowly diluted with saturated NaHC(¾ solution at 5°C (pH ~7-8) and the product was extracted with EtOAc. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by column purification by using 3-5% methanol in CH2CI2 to yield 0.070 g of 4-chloro-N-(l-((l-(2- cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2- ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide (39.1% yield). LC-MS (ES, m/z): 633 [M+H].
Example 27
Synthesis of 4-chloro-N-( 1 -(( 1 -(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2- yl)-methyl)-5-(((S)-3,3-dime enzo[d]imidazol-2-yl)benzamide
Step 1
To a 100 mL three necked round bottom flask, tert-butyl 2-((4-(((S)-3,3-dimethylbutan-2- ylamino)methyl)-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (3.0 g, 0.0069 mole) was taken in water (15 mL) and dioxane (25 mL) followed by addition of Na2C(¾ (1.98 g, 0.0186 mole). The reaction mixture was cooled to 0° C and allyl chloroformate was added drop wise at 0° C. The reaction mixture was allowed to warm up to room temperature and stirred at RT for 24 h. Dioxane was evaporated under vacuum and the reaction mixture was diluted with EtOAc and washed with water. The organic was dried and concentrated to give the crude product which was purified using column purification by eluting the compound with 30% EtOAc in hexanes to yield 1.9 g of tert-butyl 2-((4-(((allyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2- nitrophenylamino)methyl)-pyrrolidine- 1 -carboxylate.
Step 2
To a 250 mL three necked round bottom flask, tert-butyl 2-((4-(((allyloxycarbonyl)((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-2-nitrophenylamino)methyl)pyrrolidine-l-carboxylate (1.9 g, 0.00366 mole), Zn powder (1.9 g, w/w) were taken in methanol (40 mL) and sat.
ammonium chloride solution (40 mL) and heated at 50° C for 1 h. After completion of the reaction, the reaction mixture was filtered through cotton; concentrated under vacuum to give the crude product which was diluted with EtOAc and washed with water and dried and concentrated to get 1.7 g (impure, used as such in next step without purification) of tert-butyl 2-((4- (((allyloxycarbonyl) ((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2- aminophenylamino)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a 50 mL three necked round bottom flask, tert-butyl 2-((4-(((allyloxycarbonyl) ((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-2-aminophenylamino)methyl)pyrrolidine-l-carboxylate (1.7 g, 0.00348 mole) was taken in ethanol (17 mL) under nitrogen atmosphere followed by addition of cyanogen bromide (0.445 g, 0.00418 mole) at room temperature and stirred at same
temperature for 3 h. After completion of the reaction, the reaction mixture was concentrated under vacuum and diluted with water and extracted with ethyl acetate . The combined organic layer was washed with saturated NaHCC>3 solution, dried over sodium sulphate and concentrated to get 2 g (impure, used as such in next step without purification) of tert-butyl 2-((5- (((allyloxycarbonyl)-((S)-3,3-dimethyl-butan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH- benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate.
Step 4
To a 100 mL three necked round bottom flask, 4-chlorobenzoic acid (0.732 g, 0.00467 mole) was take in DCM (80 mL) under nitrogen atmosphere followed by addition of EDC.HC1 (1.12 g, 0.00585 mole), HOBt. H20 (0.895 g, 0.00585 mole) and TEA (1.64 mL, 0.0117 mole) and stirred at room temperature for 15 min. tert-Butyl 2-((5-(((allyloxycarbonyl)-((S)-3,3- dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l -carboxylate (2 g, 0.00389 mole) was added to reaction mixture and stirred it at room temperature for 12 h. After completion of the reaction, the reaction mixture was diluted with water and extracted with CH2CI2. The organic layers were combined, dried over sodium sulphate and concentrated to give the crude product which was purified using column purification by eluting the compound with 10% EtOAc in hexanes to give 1.9 g of tert-butyl 2- ((5-(((allyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-(4-chlorobenzamido)-lH- benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate.
Step 5
To a 50 mL single necked round bottom flask, tert-butyl 2-((5-(((allyloxycarbonyl)-((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-2-(4-chlorobenzamido)-lH-benzo[d]imidazol-l- yl)methyl)-pyrrolidine- 1 -carboxylate (1.9g, 0.0052mole) was taken in CH2CI2 (10ml) and cooled to 0° C followed by drop wise addition of TFA (8 mL). After completion of addition, the reaction mixture was allowed to warm up to RT and stirred at rt for 7 h. After completion of the reaction, the reaction mixture was concentrated to dryness with the stripping of THF. The crude thus obtained was dissolved in diethyl ether, hexanes was added to it and the reaction mixture was stirred for 30 min. The white solid thus precipitated out was filtered and dried under vacuum to give 1.4 g of allyl (2-(4-chlorobenzamido)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5- yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt.
Step 6
To a 50 mL single necked round bottom flask, 2-cyanoacetic acid (0.2 g, 0.002359 mole) was taken in DMF (26 mL) under 2 atmosphere, followed by addition of HATU (1.35 g, 0.003538 mole) and stirred at room temperature for 30 min. Allyl (2-(4-chlorobenzamido)-l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-
yl)carbamate as TFA salt (1.3 g, 0.002359 mole) and DIPEA (1.65 mL, 0.004718 mole) were added to reaction mixture and the reaction mixture was stirred at room temperature for 16 h. After completion of reaction, the reaction mixture was diluted with ice cold water at 0-5° C and solid thus obtained was filtered and dried under vacuum to get solid which was further triturated with pentane to give 1.2 g of allyl (2-(4-chlorobenzamido)-l-((l-(2-cyanoacetyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 7
To a 35 mL sealed tube, allyl (2-(4-chlorobenzamido)-l-((l-(2-cyanoacetyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate (0.35 g, 0.00056 mole), 2-(dimethylamino)-2-methylpropanal (0.195 g, 0.001696 mole) and piperidine (0.112 mL, 0.00113 mole) were taken in dioxane (8 mL). The reaction mixture was heated at 90° C for 12 h. Dioxane was evaporated and the crude product was purified using column purification by eluting with 0.7-2% methanol in CH2CI2 to yield 0.19g of allyl (2-(4- chlorobenzamido)-l-((l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 8
To a 25 mL singled necked round bottom flask under, allyl (2-(4-chlorobenzamido)-l-((l- (2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-5-yl)methyl-((S)-3,3-dimethylbutan-2-yl)carbamate (180 mg, 0.00025 mole) in THF (4 mL) followed by addition of dimedone (211 mg, 0.0015 mole) and tetrakis- triphenylphosphine (6 mg, 0.000005 mole) and the reaction mixture was stirred for 6 h at rt. After completion of the reaction, THF was evaporated, reaction mixture was diluted with DCM, washed with excess of water to remove the dimedone. The organic layer was dried and concentrated to get the crude which was subjected to prep HPLC purification to afford 37 mg of 4-chloro-N-( 1 -(( 1 -(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5 - (((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 632.5 [M+H].
Example 28
Synthesis of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)
methyl)- lH-benzo[ omethyl)benzamide
To a 100 niL three necked round bottom flask were added 4-(difluoromethyl)benzoic acid (0.91 g, 0.0053 mole) and HATU (2.53 g, 0.0066 mole) in DMF (10 mL) under nitrogen atmosphere at 0° C and stirred it for 15 min. tert-Butyl 2-((5-(((benzyloxycarbonyl)((S)-3,3- dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l-carboxylate (2.5 g, 0.0044 mole) in DMF (15 mL) and DIPEA (2.3 mL, 0.0133 mole) were drop wise added to it. The reaction mixture was allowed to warm up to room temperature and stirred for 12 h. After completion of the reaction, the reaction mixture was diluted with cold water and product was extracted with ethyl acetate. The combined organic layer was washed with brine solution, dried over sodium sulphate, concentrated under vacuum and resultant crude product was purified using column purification eluting compound with 20- 30% ethyl acetate in hexanes to yield 2.0g of tert-butyl 2-((5-(((benzyloxycarbonyl)((S)-3,3- dimethylbutan-2-yl)amino)methyl)-2-(4-(difluoromethyl)-benzamido)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate.
Step 2
To a 100 mL single necked round bottom flask were added tert-butyl 2-((5-(((benzyloxy- carbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-(4-(difluoromethyl)benzamide)-lH- benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate (2 g, 0.0027 mole) in CH2CI2 (20 mL) under nitrogen atmosphere at 0° C. TFA (8 mL) was drop wise added at same temperature and then the reaction mixture was allowed it to warm up to room temperature and stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was concentrated under vacuum, azeotroped with toluene, triturated with pentane and dried under vacuum to yield 2.0 g of benzyl (2-(4-(difluoromethyl)benzamido)-l-(pyrrolidin -2-ylmethyl)-lH- benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate TFA salt.
Step 3
To a 50 mL one necked round bottom flask 50% solution of acrolyl chloride in toluene (0.4 mL, 1.0249 mmole) was drop wise added to a solution of benzyl (2-(4- (difluoromethyl)benzamido)-l-( yrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)- 3,3-dimethylbutan-2-yl)carbamate TFA salt (0.5 g, 0.6833 mmole) in THF (10 mL) at -30° C under nitrogen atmosphere. The reaction mixture was allowed to warm up to room temperature and stirred it for 1 h. After completion of the reaction; the reaction mixture was poured in saturated NaHCC>3 solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate and concentrated under vacuum to give crude product. To a 25ml one necked round bottom flask were added crude product (0.55 g), cesium carbonate (0.667 g, 2.0499
mmole) in THF (5 niL) and heated at 60° C for 15 min. The reaction mixture was cooled to room temperature; then water was added to it and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to yield 0.4 g of benzyl (1- ((l-acryloylpyrrolidin-2-yl)methyl)-2-(4-(difluoromethyl)-benzamido)-lH-benzo[d]imidazol-5- yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 4
To a 50 mL one necked round bottom flask were added benzyl (l-((l-acryloylpyrrolidin- 2-yl)methyl)-2-(4-(difluoromethyl)benzamido)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)carbamate (0.4 g, 0.5954 mmole) in acetic acid (4 mL) and cooled to 0° C. 30% HBr in acetic acid (16 mL) was added dropwise and the reaction mixture was allowed it to warm up to room temperature and stirred for 1 h. After completion of the reaction; reaction mixture was slowly diluted with saturated NaHCC>3 solution at 5° C (pH -7-8) and the product was extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated under vacuum to give crude product, which was purified by prep HPLC to yield 78 mg of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl- lH-benzo[d] imidazol-2-yl)-4-(difluoromethyl)benzamide formic salt. LC-MS (ES, m/z): 538 [M+H].
Example 29
Synthesis of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)- methyl)-lH-benzo[d]imid l)thiophene-2-carboxamide
N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide was prepared according to the procedure described in example 28 but substituting 5-(difluoromethyl)thiophene-2- carboxylic acid for 4-(difluoromethyl)benzoic acid and repeating steps 2-4. LC-MS (ES, m/z):544.2 [M+H].
Example 30
Synthesis of N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethyl-butan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-4-(difluoromethyl)benzamide
Step 1
To a 25 mL sealed tube under nitrogen atmosphere, benzyl (2-(4-(difluoromethyl)- benzamido)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan- 2-yl)carbamate as TFA salt (0.5 g, 0.000683 mole), 2-cyano-4-methylpent-2-enoic acid (0.284 g, 0.002049 mole) and PyBrOP (0.350 g, 0.000751 mole) were taken in CH2C12 (5 mL) and cooled to 0° C. TEA (0.47 mL, 0.003415 mole) was added drop wise to a reaction mixture and to stir at 0 °C for 30 min. After completion of the reaction, water was added to reaction mixture and product was extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get crude. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting with 20% EtOAc in hexanes to yield 0.27g of benzyl (l-((l-(2- cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(4-(difluoromethyl)benzamido)-lH- benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate.
Step 2
To a 25 mL single neck round bottom flask under nitrogen atmosphere were taken benzyl
(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(4-(difluoromethyl)benzamido)- lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate (0.3 g, 0.000406 mole) was taken in acetic acid (3 mL) and cooled to 0° C. HBr in acetic acid (33% solution) (12 mL) was added drop wise to the reaction mixture to a reaction mixture and allowed it to stir at room temperature for 30 min. The reaction was monitored on TLC using CH2CI2: methanol (9.5: 0.5) as a mobile phase. After completion of reaction, saturated NaHCC>3 solution was added to it and product was extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get crude. The crude compound was purified using Prep HPLC to yield 0.105g N- (l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2- ylamino)-methyl)-lH-benzo[d]imidazol-2-yl)-4-(difluoromethyl)benzamide as formic salt. LC- MS (ES, m/z): 605 [M+H].
Example 31
Synthesis of N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethyl-butan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
N-(l-((l-(2-Cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide was prepared as decribed in Example 30 but substituting 5-(difluoromethyl)- thiophene-2-carboxylic acid for 4-(difluoromethyl)benzoic acid. LC-MS (ES, m/z): 61 1.3
[M+H].
Example 32
Synthesis of (S)-N-(l -(1 -acryloylpiperidin-4-yl)-5-((3,3-dimethylbutan-2-ylamino)methyl)- 1H- benzo[ amide
Step 1
To a 100 mL three necked round bottom flask, 4-fluoro-3-nitrobenzaldehyde (2.0 g, 0.0118 mole) was taken in acetonitrile (25 mL) and DIPEA (6.1 mL, 0.0354 mole) was added drop wise at room temperature. After completion of addition, the reaction mass was stirred for 15 min at same temperature followed by slow addition of tert-butyl 4-aminopiperidine-l- carboxylate (3.5 g, 0.0177 mole) over 15 min. After completion of the addition, the reaction mixture was stirred for 16 h. Acetonitrile was distilled out and water was added to the residue. The product was extracted by ethyl acetate and the combined organic layer was dried over Na2S04, filtered and concentrated to afford crude product which was purified using column purification by eluting the compound with 20% ethyl acetate in hexanes to yield 2.62 g of tert- butyl 4-(4-formyl-2-nitrophenylamino)-piperidine- 1 -carboxylate.
Step 2
In a 100 niL 3neck flask, tert-butyl 4-(4-formyl-2-nitrophenylamino)piperidine-l- carboxylate (3.25 g, 0.00932 mole), (S)-3,3-dimethylbutan-2-amine (1.27 mL, 0.00932 mole) was added in 1 ,2-dichloroethane (50 mL) under 2 atmosphere followed by addition of 5 drops of glacial acetic acid. The reaction mass was stirred for 15 min followed by slow addition of sodium triacetoxyborohydride (2.96g, 0.01398mole). After completion of the addition, the reaction mixture was stirred for 6 h. The reaction mixture was quenched with 2M Na2C(¾ solution and extracted by ethyl acetate and the combined organic layers were dried over a2S04, filtered and concentrated to afford yield 4.0g of (S)-tert-butyl 4-(4-((3,3-dimethylbutan-2- ylamino)methyl)-2-nitrophenylamino)piperidine-l -carboxylate. The product was carried forward to the next step without further purification.
Step 3
In a 100 mL 3neck RBF, (S)-tert-butyl 4-(4-((3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenylamino)piperidine- 1 -carboxylate (4.0 g, 0.00932 mole) was added in CH2CI2 (20 mL) followed by pyridine (0.9 mL, 0.01118 mole) and cooled the reaction mixture to 0° C.
Trifluoroacetic anhydride (1.95 mL, 0.01397 mole) was added drop wise to the reaction mixture at 0° C. After completion of addition, the reaction mixture was stirred for 1 h at room
temperature. The reaction mixture was quenched with 2M NaHC(¾ solution and extracted by CH2CI2 and the combined organic layer was dried over Na2S04, filtered and concentrated to afford yield 4.0 g of (S)-tert-butyl4-(4-((N- (3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-2-nitrophenylamino)-piperidine- 1 -carboxylate. The product was carried forward to the next step without further purification.
Step 4
In a 100 mL hydrogenator autoclave, to a suspension of 10% dry Pd/C (0.4 g, 10% w/w) in methanol (50 mL), (S)-tert-butyl4-(4-((N-(3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)- methyl)-2-nitrophenylamino)piperidine-l -carboxylate (3.0 g, 2.82 mmole) was added and the autoclave was sealed. The reaction mixture was flushed twice under nitrogen atmosphere. The ¾ gas was pressurized into the autoclave at 50 psi pressure and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was filtered through celite and washed with methanol and filtrate was concentrated to afford 3.0 g of (S)-tert-butyl 4-(2-amino-4-((N-(3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)phenylamino)piperidine-l-carboxylate. The product was carried forward to the next step without further purification.
Step 5
To a 100 mL RBF, (S)-tert-butyl 4-(2-amino-4-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)phenylamino)piperidine-l-carboxylate (3.0 g, 0.00599 mole) was taken in ethanol (25 mL). Cyanogen bromide (0.76 g, 0.00719 mole) was added at room
temperature and stirred reaction mass for 3 h. Ethanol was distilled out and saturated NaHC(¾ solution was added to adjust pH basic and stirred it for 1 h then filtered it and washed by water followed by drying the product to yield 3.05 g of (S)-tert-butyl 4-(5-(( -(3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)-methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)piperidine-l-carboxylate (96.82% yield; crude). The product was carried forward to the next step without further purification.
Step 6
To a 50 mL single neck RBF, 4-chlorobenzoic acid (1.25 g, 0.00799 mole) was taken in CH2C12 (50 mL) under N2 atmosphere. EDC.HC1 (1.91 g, 0.00998 mole), HOBt (1.52 g, 0.00998 mole) and TEA (2.8 mL, 0.01997 mole) were added to the reaction mixture at room temperature and stirred for 20 min. (S)-tert-Butyl 4-(5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)-methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-l- carboxylate (3.5 g, 0.00665 mole) in CH2CI2 (50 mL) was added drop wise to the reaction mixture and stirred at room temperature for 9 h. Saturated NaHC(¾ solution was added to the reaction mixture and aq. layer was extracted with EtOAc. The combined organic layer was dried over Na2S04 and evaporated to get the crude product which was purified using column purification by eluting the compound with 10% ethyl acetate in hexanes to yield 3.0 g of (S)-tert- butyl 4-(2-(4-chlorobenzamido)-5-((N-(3,3-dimethylbutan-2-yl)-2,2,2-trifluoro-acetamido)- methyl)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate.
Step 7
To a 25 mL RBF, (S)-tert-butyl 4-(2-(4-chlorobenzamido)-5-((N-(3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate (2.0 g, 0.00301 mole) was cooled to 10° C under 2 atmosphere. 20% HC1 in 1, 4-dioxane (10 mL) was added drop wise at 10° C and the reaction mixture was stirred for 6 h at room temperature. The solvent was evaporated under reduced pressure to get crude compound which was triturated with acetone to yield 1.5 g of (S)-4-chloro-N-(5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-l-(piperidine-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide.
Step 8
In a 50 mL single neck flask, (S)-4-chloro-N-(5-((N-(3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-l-(piperidine-4-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.5 g, 0.00088 mole) was added in THF (5 mL), and the reaction mixture was cooled to -30° C.
Acryloyl chloride (50% in toluene) (0.144 g, 0.00079 mole) was added dropwise to the reaction mixture at -30° C. The reaction mixture was stirred for 30 minutes at room temperature and then quenched with 2M NaHCC>3 solution and extracted by EtOAc and the combined organic layer was dried over Na2S04, filtered and concentrated to afford yield crude product. The crude
product was taken in THF (2 niL) and DBU (0.3 niL) was added to it and the reaction mixture was stirred at room temperature for 16 h. The combined organic layer was dried over a2S04 and evaporated to get 0.5 g of (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-((N-(3,3-dimethylbutan-2-yl)- 2,2,2-trifluoroacetamido)-methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide.
Step 9
To a 25 mL RBF, (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-(( -(3,3-dimethylbutan-2-yl)- 2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide (0.325 g, 0.00052 mole) was added in ethanol (4 mL) and cooled to 0° C under 2 atmosphere. NaBH4 (0.079 g, 0.00210 mole) was added at 0° C and the reaction mixture was stirred for 6 h at room temperature. The solvent was evaporated under reduced pressure to get crude compound. Crude compound was triturated with n-pentane to yield 400 mg of crude product, which was purified by prep HPLC to get 15mg pure (S)-N-(l-(l-acryloylpiperidin-4-yl)-5-((3,3-dimethylbutan-2- ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide. LC-MS (ES, m/z): 522.4
[M+H].
Example 33
Synthesis of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((N-((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
Step 1
To a 10 mL seal tube, 4-chloro-N-(5-(( -((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.05 g, 0.0000886 mol) and 2-cynoacetic acid (0.01 1 g, 0.000132 mol) were taken in DCM (1.0 mL). EDC.HC1 (0.02 g, 0.000106 mol), HOBt (0.014 g, 0.000106 mol) and TEA (0.026 g, 0.000265 mol) were added at room temperature under nitrogen atmosphere. The reaction mass was stirred for overnight at room temperature. After completion of the reaction, water was poured into reaction mixture and extracted with ethyl acetate. The combined organic layers were dried over sodium sulphate and concentrated to give the crude product which was purified using column purification by eluting the compound with 10-20% ethyl acetate in hexanes to yield 30 mg of 4- chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)- 1 H-benzo [d] imidazol-2-yl)benzamide.
Step 2
To a 10 niL seal tube were added 4-chloro-N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-5-(( - ((S)-3,3-dimethyl butan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2- yl)benzamide (180 mg,0.000285 mole), isobutyraldehyde (61.7 mg, 0.000855 mole), 3.3M solution of piperidine acetate in water (0.259 mL, 0.000855 mole) and ethanol (5 mL). The reaction mixture was heated in a seal tube at 80° C for 2 h. After completion of the reaction, the reaction mixture was poured in water and extracted with ethyl acetate. The combined organic layer was washed with brine solution. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by with 0.5- 1.0% methanol in chloroform to yield 30mg 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2- enoyl)piperidin-3-yl)-5-(( -((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH- benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 683.4 [M-H].
Example 34
Synthesis of N-(l-(l-acryloylpiperidin-3-yl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)m ethyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
To a 25 mL one necked round bottom flask, 4-chloro-N-(5-((N-((S)-3,3-dimethylbutan-2- yl)-2,2,2-trifluoroacetamido)methyl)-l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)benzamide (0.250 g, 0.000443 mol) was taken in THF (2 mL) followed by drop wise addition of acryloyl chloride (50% sol. in toluene) (0.060 g, 0.000664 mol) at -30° C and the reaction mixture was allowed to stir at same temperature for 30min. and 1.5 h at 0° C. After completion of the reaction, the reaction mass quenched with saturated sodium bicarbonate solution and extracted with CH2C2 and the combined organic layer was dried over sodium sulphate, concentrated to afford crude product which was purified using column purification by eluting the compound with 25-35% ethyl acetate in hexanes to yield 130 mg of N-(l-(l-acryloylpiperidin-3-yl)-5-((N-((S)- 3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)-methyl)-lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide. LC-MS (ES, m/z): 618.4 [M+H].
Example 35
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((N- ((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2- yl)benzamide
Step 1
To a 100 mL three necked round bottom flask under nitrogen atmosphere were added tert- butyl2-((4-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-2-nitrophenylamino)methyl)pyrrolidine-
1- carboxylate (5.0 g, 0.0023 mole), pyridine (1.11 mL, 0.0027 mole) in DCM (50 mL) and cooled it to 0° C. Trifluoroacetic anhydride (2.41 mL, 0.0034 mmole) was added dropwise to the cooled reaction mixture and then allowed it to warm up to room temperature. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was washed with 10% HC1 solution followed by saturated NaHC(¾ solution). The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting the compound with 5% ethyl acetate in hexanes to yield 4.9g of tert-butyl 2-((4-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-
2- nitrophenylamino)-methyl)pyrrolidine- 1 -carboxylate.
Step 2
To a 100 mL three necked round bottom flask were added tert-butyl 2-((4-((N-((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-2-nitrophenylamino)methyl)pyrrolidine-l- carboxylate (4.9 g, 0.0097 mole), 10% Pd/C (0.5 g, 0.1 times) in methanol (50 mL) followed by ¾ purging at room temperature for 2 h with stirring. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was filtered through celite bed; washed with methanol and filtrate was concentrated to give the crude product which was purified using column purification by eluting the compound with 5% ethyl acetate in hexanes to yield 4.1 g of tert-butyl2-((2-amino-4-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)-methyl)phenylamino)methyl)pyrrolidine-l -carboxylate.
Step 3
To a 250 mL three necked round bottom flask under nitrogen atmosphere were added tert- butyl 2-((2-amino-4-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)phenyl- amino)methyl)-pyrrolidine- 1 -carboxylate (4.1 g, 0.0081 mole) in ethanol (80 mL) followed by addition of cyanogen bromide (1.04 g, 0.0098 mole) at room temperature and stirred at same
temperature for 1 hr. After completion of the reaction, the reaction mixture was concentrated under vacuum and diluted with saturated NaHC(¾ solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting the compound with 1.5-2.0% methanol in chloroform to yield 3.7g of tert-butyl 2-((5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-2-imino-2,3- dihydro-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine- 1 -carboxylate.
Step 4
To a 250 mL three necked round bottom flask under nitrogen atmosphere were added 4- chlorobenzoic acid (1.32 g, 0.0084 mole) in DCM (80 mL) followed by addition of EDC.HC1 (2.02 g, 0.0105 mole), HOBt (1.62 g, 0.0105 mole) and TEA (2.94 mL, 0.0211 mole) and stirred at room temperature for 10 min. tert-Butyl 2-((5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoro-acetamido)methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l-yl)methyl)- pyrrolidine- 1 -carboxylate (3.70 g, 0.0070 mole) was added to a reaction mixture and stirred it at room temperature for 12 h. After completion of the reaction, the reaction mixture was washed with saturated NaHC(¾ solution. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting the compound with 20% ethyl acetate in hexanes to yield 3.6g of tert-butyl 2-((2-(4-chlorobenzamido)-5-((N- ((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)- lH-benzo[d]imidazol- 1 - yl)methyl)pyrrolidine- 1 -carboxylate.
Step 5
To a 250 mL three necked round bottom flask under nitrogen atmosphere were added tert- butyl 2-((2-(4-chlorobenzamido)-5-(( -((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)- methyl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate (3.40 g, 0.0052 mole) and 20% HC1 in dioxane (70 mL) and stirred at room temperature for 2 h. After completion of the reaction, the reaction mixture was concentrated to dryness; ethyl acetate was added the reaction mixture was stirred it at 40° C for 15 min and then filtered the solid under vacuum. The resultant solid was washed with diethyl ether and dried under vacuum to yield 2.8 g of 4-chloro-N-(5-((N- ((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-l-( yrrolidin-2-ylmethyl)-lH- benzo[d]-imidazol-2-yl)benzamide hydrochloride.
Step 6
To a 50 mL three necked round bottom flask under nitrogen atmosphere were added 2- cyanoacetic acid (77 mg, 0.0009158 mole) in DMF (11 mL) followed by addition of HATU (552 mg, 0.0013737 mole) and stirred at room temperature for 30 min. 4-Chloro-N-(5-((N-((S)-3,3- dimethylbutan-2-yl)- 2,2,2-trifluoroacetamido)methyl)-l-(pyrrolidin-2-ylmethyl)-lH-
benzo[d]imidazol-2-yl)benzamide hydrochloride (550 mg, 0.0009158 mole) and DIEA (0.63 mL, 0.0036633 mole) were added to a reaction mixture and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with saturated NaHC(¾ solution and extracted with ethyl acetate. The combined organic layer was washed with cold water and brine. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting with 60-70% ethyl acetate in hexanes to yield 400mg 4-chloro-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(( -((S)-3,3-dimethylbutan- 2-yl)-2,2,2-trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)benzamide.
Step 7
To a 10 mL sealed tube were added 4-chloro-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2- yl)methyl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH- benzo[d]imidazol-2-yl)benzamide (150 mg, 0.000237 mole), isobutaraldehyde (0.07 mL, 0.000713 mole), 3.3M solution of piperidine acetate in water (0.21 mL, 0.000713 mole) and ethanol (5 mL). The reaction mixture was heated in a seal tube at 80° C for 2 h. After completion of the reaction, the reaction mixture was poured in water and extracted with ethyl acetate. The combined organic layer was washed with brine. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting with 0.5-1.0% methanol in chloroform to yield 24mg 4-chloro-N-(l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]- imidazol-2-yl)benzamide. LC-MS (ES, m/z): 685
[M+H].
Example 36
Synthesis of N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-2-yl)-4-chlorobenzamide
To a 25 mL three necked round bottom flask under nitrogen atmosphere were added 4- chloro-N-(5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-l-(pyrrolidin-2- ylmethyl)-lH-benzo[d]imidazol-2-yl)benzamide (200 mg, 0.00033 3mole) in THF (5 mL) and cooled to -30° C. 50% Solution of acrolyl chloride in toluene (0.1 mL, 0.000299 mole) was added and the reaction mixture was allowed it to warm up to room temperature and stirred for 2
h. After completion of the reaction, the reaction mixture was diluted with saturated NaHC(¾ solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulphate, concentrated to give the crude product which was dissolved in THF (2 mL) followed by addition of DBU (151 mg, 0.000999 mole) and the reaction mixture stirred it at room
temperature overnight and then purified using column purification by eluting with 30% ethyl acetate in hexanes to yield 1 lOmg N-(l-((l-acryloylpyrrolidin-2-yl)methyl)-5-((N-((S)-3,3- dimethylbutan-2-yl)-2,2,2-trifluoroacetamido) methyl)- lH-benzo[d]imidazol-2-yl)-4- chlorobenzamide. LC-MS (ES, m/z): 618.3 [M+H].
Example 37
Synthesis of 4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)- 3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH4Denzo[d]imidazol-2-yl)benzamide.
Step 1
To a 50 mL three necked round bottom flask under nitrogen atmosphere were added
NaBH4 (683 mg, 0.0212 mole) in ethanol (10 mL) at room temperature followed by addition of tert-butyl 2-((2-(4-chlorobenzamido)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2- trifluoroacetamido)methyl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate (800 mg, 0.0014 mole) in ethanol (5 mL) at room temperature. The reaction mixture was stirred at room temperature for 4 h. After completion of the reaction, the reaction mixture was
concentrated and diluted with water and extracted with ethyl acetate. The combined organic layer was washed with brine. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting with 1-3% methanol in chloroform to yield 500 mg of tert-butyl 2-((2-(4-chlorobenzamido)-5-(((S)-3,3- dimethylbutan-2-ylamino)methyl)- 1 H-benzo[d]Imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate. Step 2
To a 35 mL seal tube under nitrogen atmosphere were added tert-butyl 2-((2-(4- chlorobenzamido)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l -carboxylate (350 mg, 0.0006 mole), paraformaldehyde (37 mg, 0.0012 mole), acetic acid (0.1 mL) and THF at room temperature. The reaction mixture was heated at
80° C for 2 h in a sealed tube, and then NaBH(OAc)3 (391 mg, 0.0018 mole) was added to reaction mixture and heating continued at 80° C for 30 min. After completion of the reaction, the reaction mixture was poured in water and extracted with ethyl acetate. The combined organic layer was washed with brine. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting the compound with 40% ethyl acetate in hexanes to yield 140 mg of tert-butyl 2-((2-(4-chlorobenzamido)-5- ((((S)-3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a 10 mL one necked round bottom flask under nitrogen atmosphere were added tert- butyl 2-((2-(4-chlorobenzamido)-5-((((S)-3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH- benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate (140 mg, 0.000240 mole) in 20% HC1 in dioxane (3 mL) and stirred at room temperature for 16 h. After completion of the reaction, the reaction mixture was concentrated to dryness, the resultant solid was triturated with ethyl acetate and pentane and then dried under vacuum to yield 95 mg of 4-chloro-N-(5-((((S)-3,3- dimethylbutan-2-yl)(methyl)amino) methyl)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2- yl)benzamide hydrochloride.
Step 4
To a 10 mL one necked round bottom flask under nitrogen atmosphere were added 2- cyanoacetic acid (25 mg, 0.000183 mole) in DMF (2 mL) followed by addition of HATU (112 mg, 0.000274 mole) and stirred at room temperature for 30 min. 4-Chloro-N-(5-((((S)-3,3- dimethylbutan-2-yl)(methyl)amino)methyl)-l-( yrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2- yl)benzamide hydrochloride (95 mg, 0.000183 mole) and DIEA (0.13 mL, 0.000732 mole) were added to a reaction mixture and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated NaHCC>3 solution and extracted with ethyl acetate. The combined organic layer was washed with cold water and brine solution. The organic layer was dried over sodium sulphate, concentrated to give the crude product which was purified using column purification by eluting with 0.5% methanol in chloroform to yield 60 mg 4-chloro- N-(l-((l-(2-cyanoacetyl)pyrrolidin -2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2- yl)(methyl)amino)-methyl)- 1 H-benzo [d] imidazol-2-yl)benzamide.
Step 5
To a 10 mL seal tube were 4-chloro-N- (1-((1- (2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5- ((((S)-3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide (60 mg, 0.109 mmole), isobutaraldehyde (0.03 mL, 0.3278 mmole), 3.3 M solution of piperidine acetate in water (0.1 mL, 0.0003278 mole) and ethanol (2 mL). The reaction mixture was heated
in a sealed tube at 80° C for 2 h. After completion of the reaction, the reaction mixture was poured in to water and extracted with ethyl acetate. The combined organic layer was washed with brine. The organic layer was dried over sodium sulphate, concentrated to give the desired crude product which was purified using column purification by eluting the compound with 0.5-1.0% methanol in chloroform to yield 13mg 4-chloro-N-(l-((l-(2-cyano-4-methylpent-2-enoyl) pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH- benzo[d]imidazol-2-yl)benzamide. LC-MS (ES, m/z): 504.3 [M+H].
Example 38
Synthesis of 4-chloro-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-5-((((S)-3,3- dimethylbutan-2-yl)(methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)benzamide
The title compound was prepared using the procedure in example 27 but substituting tert- butyl 3-(2-(4-chlorobenzamido)-5-((N-((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)- methyl)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate for tert-butyl 2-((2-(4-chloro- benzamido)-5-(( -((S)-3,3-dimethylbutan-2-yl)-2,2,2-trifluoroacetamido)methyl)-lH- benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate. Similarly, 4-chloro-N-( 1 -( 1 -(2- cyanoacetyl)piperidin-3-yl)-5-((((S)-3,3-dimethylbutan-2-yl)(methyl)amino)methyl)-lH- benzo[d]imidazol-2-yl)benzamide was prepared. LC-MS (ES, m/z): 603.2 [M+H].
Example 39
Synthesis of N-(l-(l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)piperidin-3-yl)-lH- benzo [d] imidazol-2-yl -5 -( 1 H-pyrazol-4-yl)thiophene-2-carboxamide
Step 1
To a 35 niL seal-tube, 5-bromothiophene-2-carboxylic acid (1.7 g, 0.0082 mole) was taken in CH2CI2 (20 mL), and tert-butyl 3-(2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)piperidine-l-carboxylate (2.85 g, 0.0090 mole), DIPEA (4.28 mL, 0.0246 mole) and DMAP (0.097 g, 0.0008 mole) were added to it followed by drop-wise addition of T3P (7.8 mL, 0.0123 mole) to reaction mixture at RT and stirred for 1 h. The completion of the reaction was monitored on TLC using EtOAc: hexanes (4:6) as a mobile phase. Water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over a2S04 and evaporated to get the crude product which was subjected for the column purification. The crude compound was purified by column purification using 60-120 mesh size neutral silica by eluting the compound with 20-25% EtOAc in hexanes to yield 1.2 g of tert-butyl 3-(2-(5-bromothiophene-2- carboxamido)- 1 H-benzo [d]imidazol- 1 -yl)piperidine- 1 -carboxylate.
Step 2
In a 150 mL seal tube, to a solution of tert-butyl 3-(2-(5-bromothiophene-2- carboxamido)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate (1 g, 0.00198 mole), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate (0.641 g, 0.00218 mole) in 1,4-dioxane (40 mL) and water (10 mL), CS2CO3 (0.71 g, 0.00218 mole) was added and degassed for 15 min using N2. Bis(tri-t-butylphophine)Pd(0) (0.101 g, 0.000198 mole) was added and the reaction was carried out under 2 atmosphere at 80° C for 2 h. After completion of the reaction, the reaction mixture was diluted with water and extracted with EtOAc. The organic layers were combined washed with brine, dried and concentrated to get the crude product which was purified by column chromatography using 60-120 mesh size neutral silica by eluting with 14-15% EtOAc in hexanes to yield s a mixture of tert-butyl 3-(2-(5-(lH-pyrazol-4- yl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l-yl)piperidine-l-carboxylate and tert-butyl 3-(2-(5-( 1 -(tert-butoxycarbonyl)- 1 H-pyrazol-4-yl)thiophene-2-carboxamido)- 1 H- benzo[d] imidazol- 1 -yl)piperidine- 1 -carboxylate.
Step 3
Tert-butyl 3-(2-(5-(lH-pyrazol-4-yl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l- yl)piperidine-l -carboxylate (1.5 g, 0.00304mole) was taken in CH2CI2 (25 mL) and cooled to 0- 5° C. TFA (14 mL) was added drop wise at 0-5° C and the reaction mixture was stirred for 4 h at room temperature. After completion of the reaction, the reaction mixture was poured in to aHC03 solution and extracted with EtOAc. The combined organics were washed with water. The organic layer was separated and dried over sodium sulphate, concentrated to yield 0.95 g of N-(l-( iperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide. Step 4
To a 25 mL RBF, 2-cyanoacetic acid (0.095 g, 0.00112 mole) was taken in CH2C12 (8 mL) and cooled to 0° C under N2 atmosphere. TBTU (0.359 g, 0.00112 mole) and DMF (0.04 mL) was added at 0° C. After addition was complete the reaction mixture was allowed to warm to room temperature. N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide (0.4 g, 0.00101 mole) and DIPEA (0.52 mL, 0.00243 mole) were added to the reaction mixture and stirred at room temperature for 16 h. After completion of the reaction, water was added to the reaction mixture and extracted with CH2CI2. The combined organic layer was dried over Na S04 and evaporated to get the crude product which was purified using column purification using 60-120 mesh size neutral silica by eluting the compound with 2- 3% methanol in CH2C12 to yield 0.13 g of N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide.
Step 5
To a 10 mL sealed tube, N-(l-(l-(2-cyanoacetyl) piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide (0.105 g, 0.00023 mole) was taken in ethanol (0.6 mL). Piperidine (0.07 mL, 0.00069 mole) and 2-(dimethylamino)-2-methylpropanal (0.065 g, 0.00057 mole) were added at room temperature and the reaction mixture was heated to reflux for 8 h. After completion of the reaction, ethanol was evaporated and water was added to the reaction mixture and extracted with EtOAc. The combined organic layer was washed with water, brine, dried over Na2S04 and evaporated to get the crude which was purified by prep HPLC to yield 0.022 g of N-(l-(l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl) thiophene-2-carboxamide. LC-MS (ES, m/z): 557.6 [M+H].
Example 40
Synthesis of N-(l-(l-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-
5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
To a 10 mL vial, N-(l-(l-(2-cyanoacetyl)piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-5- (lH-pyrazol-4-yl)thiophene-2-carboxamide (0.12 g, 0.00026 lmole) was taken in ethanol (3 m]
Piperidine acetate (3.3M solution in water) (0.236 mL, 0.000783 mole) and isobutyraldehyde (0.026 mL, 0.000287 mole) were added at room temperature and the reaction mixture was heated to reflux for 1 h. After completion of the reaction, ethanol was evaporated and water was added to the reaction mixture and extracted with EtOAc. The combined organic layer was washed with water brine, dried over Na2S04 and evaporated to get the crude which was purified by prep HPLC to yield 0.026 g of N-(l-(l-(2-cyano-4-methylpent-2-enoyl) piperidin-3-yl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl) thiophene-2-carboxamide. LC-MS (ES, m/z): 514.2 [M+H]. Example 41
Synthesis of N-( 1 -( 1 -acryloylpiperidin-3 -yl)- 1 H-benzo [d]imidazol-2-yl)-5 -( 1 H-pyrazol-4- yl)thiophene-2-carboxamide
To a 10 mL vial, N-(l-(piperidin-3-yl)-lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide (0.1 g, 0.00025 mole) was taken in THF (3 mL) and cooled to -50° C under 2 atmosphere. Acryloyl chloride (50% solution in toluene) (0.049 mL, 0.00027 mole) was added dropwise at -50° C and the reaction mixture was stirred for 15 minutes at -50° C, and at RT for 30 min. After completion of the reaction, 40% NaOH solution was added drop wise to make pH basic and extracted with EtOAc. The combined organic layer was dried over a2S04 and evaporated to get the crude which purified by Prep TLC in 50% EtOAc in hexanes to yield 0.030 g of N-( 1 -( 1 -acryloylpiperidin-3 -yl)- 1 H-benzo [d] imidazol-2-yl)-5 -( 1 H-pyrazol-4- yl)thiophene-2-carboxamide. LC-MS (ES, m/z): 447.3 [M+H].
Example 42
Synthesis of N-( 1 -( 1 -(4-(dimethylamino)but-2-enoyl)piperidin-3 -yl)- 1 H-benzo [d] imidazol-2-yl)-
5-(lH- oxamide
To a 10 niL seal tube under nitrogen atmosphere were added 4-(dimethylamino)but-2- enoic acid (0.032 g, 0.00025 mole) in DMF (3 mL) followed by addition of HATU (0.131 g, 0.00034 mole) and the reaction mixture stirred at room temperature for 15 min. N-(l-(Piperidin- 3-yl)-lH4oenzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide (0.09 g, 0.00023 mole) and DIPEA (0.11 mL, 0.00069 mole) were added to the reaction mixture and stirred at room temperature for 2 h. The reaction was monitored on TLC using MeOH: CH2CI2 (0.5:9.5) as a mobile phase. After 2 h, the reaction mixture was diluted with saturated aHC03 solution and extracted with EtOAc. The combined organic layer was washed with cold water and brine solution. The organic layer was dried over sodium sulphate and concentrated to give the crude product which was purified using column purification by eluting with 0.5% methanol in CH2CI2 to yield 0.020 g N-(l-(l-(4-(dimethylamino)but-2-enoyl)piperidin-3-yl)-lH-benzo[d]imidazol-2- yl)-5-(lH-pyrazol-4-yl)-thiophene-2-carboxamide. LC-MS (ES, m/z): 504.3 [M+H].
Example 43
Synthesis of N-(l-((l-(2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
Step 1
Into a 20-mL round-bottom flask, was placed l-fluoro-2-nitrobenzene (197.4 mg, 1.40 mmol, 1.00 equiv), tert-butyl 3-(aminomethyl)azetidine-l-carboxylate (260.4 mg, 1.40 mmol, 1.00 equiv), potassium carbonate (386.4 mg, 2.80 mmol, 2.00 equiv) and MeCN (10 mL). The resulting solution was stirred overnight at 80° C. The resulting mixture was concentrated under vacuum and then diluted with 10 mL of water. The resulting solution was extracted with ethyl acetate and the organic layers combined, washed with brine and then dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (30: 1 to 5: 1). This resulted in 400 mg (93%) of tert-butyl 3- [[(2-nitrophenyl)amino]methyl]-azetidine-l-carboxylate as a yellow solid.
Step 2
Into a 250-mL round-bottom flask, was placed tert-butyl 3-[[(2- nitrophenyl)amino]methyl]-azetidine-l-carboxylate (5.8 g, 18.87 mmol, 1.00 equiv), palladium
on carbon (2.9 g) and ethanol (150 niL). ¾ (gas) was introduced into the reaction vessel and the resulting solution was stirred overnight at 25° C. The solids were then filtered out and the resulting mixture was concentrated under vacuum. The resulting residue was diluted with sodium carbonate (sat.) and extracted with dichloromethane. The organic layers were combined, washed with brine and then dried with anhydrous sodium sulfate. After filtration and concentrated under vacuum, this resulted in 5.18 g (crude) of tert-butyl 3-[[(2-aminophenyl)amino]methyl]azetidine- 1 -carboxylate as a brown oil.
Step 3
Into a 250-mL round-bottom flask, was placed tert-butyl 3-[[(2- aminophenyl)amino]methyl]-azetidine-l -carboxylate (5.18 g, 18.68 mmol, 1.00 equiv), cyanogen bromide (2.08 g, 19.64 mmol, 1.05 equiv) and ethanol (100 mL). The resulting solution was stirred overnight at 25° C and then concentrated under vacuum. The resulting residue was diluted with 100 mL of a sat. a2C03 solution and extracted with ethyl acetate. The organic layers were combined, washed with brine and then dried with anhydrous sodium sulfate, filtrated and concentrated under vacuum, to give 4.5 g of tert-butyl 3-[(2-amino-lH-l,3-benzodiazol-l- yl)methyl]azetidine-l -carboxylate as a light yellow solid.
Step 4
Into a 250-mL round-bottom flask, was placed tert-butyl 3-[(2-amino-lH-l,3- benzodiazol-l-yl)methyl]azetidine-l -carboxylate (3.5 g, 11.58 mmol, 1.00 equiv), 5- bromothiophene-2-carboxylic acid (4.6 g, 22.22 mmol, 1.92 equiv), PyBop (11.6 g, 22.35 mmol, 1.93 equiv), N,N-dimethylformamide (150 mL) and triethylamine (7.524 g, 74.50 mmol, 6.44 equiv). The resulting solution was stirred overnight at 25° C and then quenched with water. This was extracted with dichloromethane and the organic layers were combined, washed with brine and dried over anhydrous sodium sulfate. Filtration and concentration of the organics under vacuum, resulted in 4.7 g of tert-butyl 3-[[2-(5-bromothiophene-2-amido)-lH-l,3-benzodiazol-l- yl]methyl]azetidine-l -carboxylate as a light yellow solid.
Step 5
Into a 50-mL round-bottom flask, was placed tert-butyl 3-[[2-(5-bromothiophene-2- amido)-lH-l,3-benzodiazol-l-yl]methyl]azetidine-l-carboxylate (4.7 g, 9.56 mmol, 1.00 equiv), tert-butyl 4-(tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate (3.67 g, 12.48 mmol, 1.30 equiv), potassium carbonate (3.974 g, 28.80 mmol, 3.01 equiv), 1,4-dioxane (120 mL), water (30 mL) and Pd(dppf)Cl2 (784 mg, 0.96 mmol, 0.10 equiv). The resulting solution was stirred overnight at 100° C and then the solids were filtered out. The resulting solution was diluted with water and extracted with ethyl acetate. The organic layers were combined, washed with brine and then dried over anhydrous sodium sulfate. After filtration and concentrated under
vacuum, the residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :30 to 1 : 1) to give 1.68 g of tert-butyl 3-([2-[5-(lH-pyrazol-4-yl)thiophene-2-amido]-lH- l,3-benzodiazol-l-yl]methyl)-azetidine-l-carboxylate as a light yellow solid.
Step 6
Into a 50-mL round-bottom flask, was placed tert-butyl 3-([2-[5-(lH-pyrazol-4- yl)thiophene-2-amido]-lH-l,3-benzodiazol-l-yl]methyl)azetidine-l-carboxylate (250 mg, 0.52 mmol, 1.00 equiv), dichloromethane (15 mL) and trifluoroacetic acid (3 mL). The resulting solution was stirred for 4 h at 25° C and then concentrated under vacuum to give 250 mg (crude) of N- [ 1 -(azetidin-3-ylmethyl)- 1 H- 1 ,3 -benzodiazol-2-yl] -5 -( 1 H-pyrazol-4-yl)thiophene-2- carboxamide as a brown oil.
Step 7
Into a 250-mL round-bottom flask, was placed N-[l-(azetidin-3-ylmethyl)-lH-l, 3- benzodiazol-2-yl]-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide (89 mg, 0.24 mmol, 1.00 equiv), 2-cyanoacetic acid (26.8 mg, 0.32 mmol, 1.34 equiv), HATU (1 19 mg), N,N-dimethylformamide (5 mL) and TEA (106 mg). The resulting solution was stirred overnight at room temperature and then diluted with ¾0. The resulting solution was extracted with ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give 30 mg of N-(l-[[l-(2-cyanoacetyl)azetidin-3-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(lH- pyrazol-4-yl)thiophene-2-carboxamide as a light green solid.
Step 8
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed -(l-[[l-(2-cyanoacetyl)azetidin-3-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5- (lH-pyrazol-4-yl)thiophene-2-carboxamide (110 mg, 0.25 mmol, 1.00 equiv), dichloromethane (10 mL), methanol (10 mL), piperidine (63 mg) and 2-methylpropanal (89 mg, 1.23 mmol, 5.00 equiv). The resulting solution was stirred overnight at room temperature and then concentrated under vacuum. The crude product (55 mg) was purified by Prep-HPLC with the following conditions (l#-Pre-HPLC-005(Waters)): Column, SunFire Prep C18 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH3CN (10% CH3CN up to 40% in 10 min); Detector, 254 nm. This resulted in 15.1 mg (12%) of N-[l-([l-[(2E)-2-cyano-2-(2- methylpropylidene)acetyl]azetidin-3-yl]methyl)-lH-l,3-benzodiazol-2-yl]-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide as a white solid. LC-MS m/z: 500 (M+l).
Example 44
Synthesis of N-(l-[[(2R)-l-[2-cyano-2-[2-methyl-2-(morpholin-4-yl)propylidene]acetyl]- pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
Step 1
Into a 1-L round-bottom flask, was placed a solution of 1 -fluoro-2-nitrobenzene (8.1 g, 57.41 mmol, 1.10 equiv), CH3CN (500 mL), potassium carbonate (14.4 g, 104.19 mmol, 2.00 equiv) and tert-butyl (2R)-2-(aminomethyl)pyrrolidine-l-carboxylate (10 g, 49.93 mmol, 1.00 equiv). The resulting solution was stirred overnight at 80° C in an oil bath. The reaction mixture was then quenched by the addition of water. The resulting solution was extracted with ethyl acetate and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 : 10) to give 6 g of tert-butyl (2R)-2-[[(2-nitrophenyl)amino]methyl]-pyrrolidine- 1 -carboxylate as a yellow oil.
Step 2
Into a 1-L round-bottom flask, was placed methanol (300 mL), palladium on carbon (1 g) and tert-butyl (2R)-2-[[(2-nitrophenyl)amino]methyl]pyrrolidine-l-carboxylate (6 g, 18.67 mmol, 1.00 equiv). The flask was evacuated and flushed three times with nitrogen, followed by flushing with ¾ (gas) and then stirred at 25° C overnight. The solids were filtered out and the resulting mixture was concentrated under vacuum to give 4.9 g of tert-butyl (2R)-2-[[(2- aminophenyl)-amino]-methyl]-pyrrolidine-l-carboxylate as a red solid.
Step 3
Into a 1-L round-bottom flask, was placed a solution of tert-butyl (2R)-2-[[(2- aminophenyl)amino]-methyl]pyrrolidine-l -carboxylate (4.9 g, 16.82 mmol, 1.00 equiv), ethanol (500 mL) and cyanogen bromide (2 g, 18.88 mmol, 1.12 equiv). The resulting solution was stirred overnight at room temperature and then concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (10: 1). This resulted in 3 g of (R)-tert-butyl 2-((2-amino-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate as a red solid.
Step 4
Into a 1-L round-bottom flask, was placed a solution (R)-tert-butyl 2-((2-amino-lH- benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate (6.3 g, 21.62 mmol, 1.00 equiv), 5- bromothiophene-2-carboxylic acid (2.29 g, 21.62 mmol, 1.00 equiv), PyBop (6.6 g, 1.50 equiv), N,N-dimethylformamide (300 mL) and TEA (4.3 g, 42.49 mmol, 5.00 equiv). The resulting
solution was stirred overnight at room temperature and then concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (10: 1). This resulted in 6.3 g of of (R)-tert-butyl 2-((2-(5-bromothiophene-2-carboxamido)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l-carboxylate as a red solid.
Step 5
Into a 1-L round-bottom flask, was placed a solution of of (R)-tert-butyl 2-((2-(5- bromothiophene-2-carboxamido)- lH-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate (4.3 g, 8.52 mmol, 1.00 equiv), 1,4-dioxane (400 mL), 4-(tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazole (3 g, 15.46 mmol, 1.20 equiv), potassium carbonate (3.5 g, 25.36 mmol, 3.00 equiv) and Pd(dppf)Cl2 (1.4 g, 1.72 mmol). The resulting solution was stirred overnight at 80oC in an oil bath. The reaction mixture was then quenched by the addition of water and extracted with ethyl acetate, The organic layers were combined and dried over anhydrous sodium sulfate. The solids were filtered out and the resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 : 10). This resulted in 1 g of (R)-tert-butyl 2-((2-(5-(lH-pyrazol-4-yl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l -carboxylate as a white solid.
Step 6
Into a 250-mL round-bottom flask, was placed a solution of (R)-tert-butyl 2-((2-(5-(lH- pyrazol-4-yl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l- carboxylate (1 g, 2.03 mmol, 1.00 equiv), dichloromethane (100 mL) and trifluoroacetic acid (25 mL). The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 800 mg (crude) of (R)-5-(lH-pyrazol-4-yl)-N-(l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)thiophene-2-carboxamideas an off-white solid.
Step 7
Into a 250-mL round-bottom flask, was placed 2-cyanoacetic acid (300 mg, 3.53 mmol, 2.00 equiv), HATU (1.36 g, 3.58 mmol, 2.00 equiv), triethylamine (900 mg, 8.91 mmol, 5.00 equiv), and a solution of (R)-5-(lH-pyrazol-4-yl)-N-(l-(pyrrolidin-2-ylmethyl)-lH- benzo[d]imidazol-2-yl)thiophene-2-carboxamide (700 mg, 1.78 mmol, 1.00 equiv) ίη Ν,Ν- dimethylformamide (100 mL). The resulting solution was stirred overnight at room temperature and then quenched by the addition of water. The solid was collected by filtration. This resulted in 0.65 g (crude) of N-(l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2- yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide as an off-white solid.
Step 8
Into a 100-mL round-bottom flask, was placed a solution of N-(l-[[(2R)-l-(2- cyanoacetyl)pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2- carboxamide (200 mg, 0.44 mmol, 1.00 equiv), DCM:MeOH(l : l) (50 mL), piperidine (111 mg, 1.30 mmol, 3.00 equiv) and 2-methyl-2-(morpholin-4-yl)propanal (341 mg, 2.17 mmol, 4.98 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product (90 mg) was purified by Prep-HPLC with the following conditions (l#-Pre-HPLC-005 (Waters)): Column, SunFire Prep CI 8 19* 150mm 5um; mobile phase, WATER WITH 0.05%TFA and CH3CN (10% CH3CN up to 40% in 10 min); Detector, 254 nm. This resulted in 34 mg (13%) of N-(l-[[(2R)-l-[2-cyano-2-[2-methyl-2- (morpholin-4-yl)propylidene] acetyl] -pyrrolidin-2-yl]methyl] - 1 H- 1 ,3-benzodiazol-2-yl)-5 -( 1 H- pyrazol-4-yl)thiophene-2-carboxamide as a white solid. LC-MS: m/z 599 (M+ H+).
Example 45
Synthesis of (S)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]- imidazol-2-yl)-5- -pyrazol-4-yl)thiophene-2-carboxamide
Step 1
Into a 500-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-fluoro-2-nitrobenzene (1.41 g, 9.99 mmol, 1.00 equiv) in N,N-dimethylformamide (120 mL), tert-butyl (2S)-2-(aminomethyl)pyrrolidine-l-carboxylate (2.00 g, 9.99 mmol, 1.00 equiv) and potassium carbonate (2.21 g, 16.01 mmol, 1.60 equiv). The resulting solution was stirred overnight at 75° C and then diluted with ¾0. The resulting solution was extracted with ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. This resulted in 3 g (crude) of tert-butyl (2S)-2-[(2-nitrophenyl)amino]pyrrolidine-l-carboxylate as a yellow solid.
Step 2
Into a 1000-mL round-bottom flask, was placed a solution of tert-butyl (2S)-2-[(2- nitrophenyl)amino]pyrrolidine-l-carboxylate (6.42 g, 20.89 mmol, 1.00 equiv) in ethanol (500 mL) and palladium on carbon (3 g, 0.50 equiv). To the reaction vessel, was introduced ¾(gas). The resulting solution was stirred overnight at room temperature. The solids were filtered out.
The resulting mixture was concentrated under vacuum. This resulted in 5 g (crude) of tert-butyl (2S)-2-[(2-aminophenyl)amino]pyrrolidine-l -carboxylate as a yellow oil.
Step 3
Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl (2S)-2-[(2-aminophenyl)amino]pyrrolidine-l- carboxylate (2.83 g, 9.71 mmol, 1.00 equiv) in ethanol (100 mL) and BrCN (1.08 g, 10.19 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum and then diluted with ¾0. The pH value of the solution was adjusted to 9-10 with K2CO3 (sat., aq.). The resulting solution was extracted with ethyl acetate and the organic layers combined. The resulting mixture was washed with brine, dried and concentrated under vacuum. This resulted in 2 g of (S)-tert-butyl 2-((2-amino-lH- benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate as a yellow solid.
Step 4
Into a 100-mL round-bottom flask, was placed (S)-tert-butyl 2-((2-amino-lH-benzo[d]- imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate (2.5 g, 7.90 mmol, 1.00 equiv), 5- bromothiophene-2-carboxylic acid (2.1 g, 11.11 mmol, 1.20 equiv), PyBop (6.6 g, 1.50 equiv), N,N-dimethylformamide (30 mL) and TEA (4.3 g, 42.49 mmol, 5.00 equiv). The resulting solution was stirred overnight at r.t. The resulting mixture was concentrated under vacuum and then applied onto a silica gel column with ethyl acetate/petroleum ether (1 :3). This resulted in 2.1 g of tert-butyl (2S)-2-[[2-(5-bromothiophene-2-amido)-lH-l,3-benzodiazol-l- yl]methyl]pyrrolidine-l -carboxylate as a red solid.
Step 5
Into a 500-mL round-bottom flask, was placed tert-butyl (2S)-2-[[2-(5-bromothiophene- 2-amido)-lH-l,3-benzodiazol-l-yl]methyl]pyrrolidine-l -carboxylate (2.5 g, 4.96 mmol, 1.00 equiv), 4-(tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (1.2 g, 6.18 mmol, 1.20 equiv), Pd(pddf)Cl2 (0.8 g, 0.20 equiv), water(50 mL), 1,4-dioxane (200 mL) and potassium carbonate (2.1 g, 3.00 equiv) was stirred overnight at 95° C in an oil bath. The resulting mixture was concentrated under vacuum and the residue was applied onto a silica gel column with dichloromethane/ethyl acetate (3: 1). This resulted in 0.7 g of tert-butyl (2S)-2-([2-[5-(lH- pyrazol-4-yl)thiophene-2-amido]-lH-l,3-benzodiazol-l-yl]methyl)pyrrolidine-l -carboxylate as a light yellow solid.
Step 6
Into a 50-mL round-bottom flask, was placed tert-butyl (2S)-2-([2-[5-(lH-pyrazol-4- yl)thiophene-2-amido]- lH-l,3-benzodiazol-l-yl]methyl)pyrrolidine-l -carboxylate (300 mg, 0.61 mmol, 1.00 equiv), trifluoroacetic acid (2 mL) and dichloromethane (10 mL). The resulting
solution was stirred overnight at room temperature and then concentrated under vacuum. This resulted in 200 mg of 5-(lH-pyrazol-4-yl)-N-[3-[(2S)-pyrrolidin-2-ylmethyl]-lH-l,3- benzodiazol-2-yl]thiophene-2-carboxamide as a yellow green solid.
Step 7
Into a 50-mL round-bottom flask, was placed a solution of 5-(lH-pyrazol-4-yl)-N-[l-
[(2S)-pyrrolidin-2-ylmethyl]-lH-l,3-benzodiazol-2-yl]thiophene-2-carboxamide (50 mg, 0.13 mmol, 1.00 equiv), N,N-dimethylformamide (10 mL), 2-cyanoacetic acid (22 mg, 0.26 mmol, 2.00 equiv), TEA (129 mg, 1.28 mmol, 10.00 equiv) and HATU (97 mg, 0.26 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature and then quenched by the addition of water. The solids were collected by filtration. This resulted in 9.4 mg of N-(1-[[(2S)- l-(2-cyanoacetyl)-pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide as a white solid.
Step 8
Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of (S)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide (225 mg, 0.49 mmol, 1.00 equiv), dioxane (12.4 mL), isobutyraldehyde (177 mg, 2.45 mmol, 5.00 equiv) and piperidine (83.6 mg, 0.98 mmol, 2.00 equiv). The resulting solution was stirred overnight at 40° C and then concentrated under vacuum. The crude product (100 mL) was purified by Prep-HPLC with the following conditions: Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, water and CH3CN (10% CH3CN up to 60% in 20 min); Detector, 254 nm. The resulting solution was concentrated under vacuum and lyophilized. This resulted in 50 mg of (S)-N-(l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide as a white solid. LC-MS: m/z 514 (M+ H+).
Example 46
Synthesis of N-( 1 -(( 1 -(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3 -yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide trifluoroacetic acid salt
Step 1
Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed -(l-[[l-(2-cyanoacetyl)azetidin-3-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5- (lH-pyrazol-4-yl)thiophene-2-carboxamide (250 mg, 0.56 mmol, 1.00 equiv), DCM/MeOH(l : l) (40 mL), piperidine (143.1 mg, 1.68 mmol, 2.99 equiv), 4A molecular sieves (250 mg) and tert- butyl N-(2-methyl-l-oxopropan-2-yl)carbamate (524.7 mg, 2.80 mmol, 4.99 equiv). The resulting solution was stirred overnight at 40° C and then the solids were filtered out. The resulting mixture was concentrated under vacuum to provide tert-butyl (5-(3-((2-(5-(lH-pyrazol- 4-yl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l-yl)methyl)azetidin-l-yl)-4-cyano-2- methyl-5-oxopent-3-en-2-yl)carbamate.
Step 2
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl (5-(3-((2-(5-(lH-pyrazol-4-yl)thiophene-2-carboxamido)-lH- benzo[d]imidazol-l-yl)methyl)azetidin-l-yl)-4-cyano-2-methyl-5-oxopent-3-en-2-yl)carbamate (300 mg, 0.49 mmol, 1.00 equiv), dichloromethane (10 mL) and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at room temperature and then concentrated under vacuum. The resulting solution was diluted with 10 mL of DMSO and the solids were filtered out to collect 75 mg of N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide as a trifluoroacetic acid salt.
Example 47
Synthesis of (S)-N-(l-((l-(2-cyano-4-methyl-4-morpholinopent-2-enoyl)pyrrolidin-2-yl)methyl)- lH-benzo[d]imidazol- -yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
Into a 100 mL round-bottom flask, was placed a solution of N-(l-[[(2S)-l-(2- cyanoacetyl)-pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2- carboxamide (230 mg, 0.50 mmol, 1.00 equiv), NMP (10 mL), 2-methyl-2-(morpholin-4- yl)propanal (393 mg, 2.50 mmol, 5.00 equiv), piperidine (85 mg, 1.00 mmol, 2.00 equiv), AcOH (6 mg, 0.10 mmol, 0.20 equiv) and 4A molecular sieves (230 mg). The resulting solution was
stirred overnight at 40° C and then the solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (150 mg) was purified by Prep-HPLC with the following conditions (l#-Pre-HPLC-005 (Waters)): Column, SunFire Prep C18 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH3CN (10% CH3CN up to 33% in 10 min); Detector, 254 nm. This resulted in 100 mg of N-(l-[[(2S)-l-[2-cyano-2-[2-methyl-2-(morpholin-4- yl)propylidene] acetyl]pyrrolidin-2-yl]methyl]- 1 H- 1 ,3 -benzodiazol-2-yl)-5 -( 1 H-pyrazol-4- yl)thiophene-2-carboxamide as a white solid. LC-MS: m/z 599 (M+ H+).
Example 48
Synthesis of N-(l-(2-(2-cyano-4-methylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5-
( 1 H-p oxamide
Step 1
Into a 1L mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-fluoro-2-nitrobenzene (20 g, 141.74 mmol, 1.00 equiv),
N,N-dimethylformamide (400 mL), tert-butyl N-(2-aminoethyl)carbamate (22.7 g, 141.69 mmol, 1.00 equiv) and potassium carbonate (31.4 g, 227.54 mmol, 1.60 equiv). The resulting solution was stirred overnight at 75° C and then diluted with H2O. The resulting solution was extracted with ethyl acetate and the organic layers combined, washed with brine and then dried over anhydrous sodium sulfate. After filtration and concentrated under vacuum, this resulted in 35 g of tert-butyl N-[2-[(2-nitrophenyl)amino]ethyl]carbamate as a solid.
Step 2
Into a 2000-mL round-bottom flask, was placed methanol (1000 mL), palladium on carbon (8 g) and tert-butyl N-[2-[(2-nitrophenyl)amino]ethyl]carbamate (20 g, 71.10 mmol, 1.00 equiv). To the reaction vessel was introduced H2(gas) and the resulting mixture was stirred overnight at 25° C. The solids were then filtered out and the solvent was concentrated under vacuum. This resulted in 17 g (crude) of tert-butyl N-[2-[(2-aminophenyl)amino]ethyl]carbamate as a red solid.
Step 3
Into a 250-mL round-bottom flask, was placed a solution of tert-butyl N-[2-[(2- aminophenyl)amino]ethyl]carbamate (500 mg, 1.99 mmol, 1.00 equiv), ethanol (50 mL), and cyanogen bromide (230 mg, 2.17 mmol, 1.09 equiv). The resulting solution was stirred for 2 h at room temperature and then concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :20 to 1 :5). This resulted in 0.5 g of tert-butyl N-[2- (2-amino-lH-l,3-benzodiazol-l-yl)ethyl]carbamate as a red solid.
Step 4
Into a 250-mL round-bottom flask, was placed a solution of N-[2-(2-amino-lH-l,3- benzodiazol-l-yl)ethyl]carbamate (5 g, 18.09 mmol, 1.00 equiv), 5-bromothiophene-2-carboxylic acid (4.5 g, 21.73 mmol, 1.20 equiv), TEA (4.5 g, 44.55 mmol, 2.46 equiv), N,N-dimethyl- formamide (100 mL) and PyBop (9.3 g, 17.92 mmol, 0.99 equiv). The resulting solution was stirred overnight at 25° C and then quenched by the addition of water. The solids were collected by filtration. The filter cake washed with ethyl acetate: petroleum ether (1 : 1). This resulted in 4.6 g of tert-butyl N-[2-[2-(5-bromothiophene-2-amido)-lH-l,3-benzodiazol-l-yl]ethyl]carbamate as a yellow solid.
Step 5
Into a 1000-mL round-bottom flask, was placed tert-butyl N-[2-[2-(5-bromothiophene-2- amido)-lH-l,3-benzodiazol-l-yl]ethyl]carbamate (1.89 g, 4.06 mmol, 1.00 equiv), tert-butyl 4- (tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate (2.864 g, 9.74 mmol, 2.40 equiv), Pd(dppf)Cl2 (1.334 g, 1.82 mmol, 0.45 equiv), potassium carbonate (2.224 g, 16.12 mmol, 4.00 equiv), 1,4-dioxane (380 mL) and water (95 mL). The resulting solution was stirred for 45 h at 100° C and then cooled to room temperature. The reaction mixture was then quenched by the addition of 100 mL of water and extracted with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered and then concentrated under vacuum. This resulted in 0.7 g of tert-butyl N-(2-[2-[5-(lH-pyrazol-4-yl)thiophene-2-amido]-lH-l,3- benzodiazol-l-yl]ethyl)-carbamate as a light yellow solid.
Step 6
Into a 100-mL round-bottom flask, was placed dichloromethane (60 mL), tert-butyl N-(2- [2-[5-(lH-pyrazol-4-yl)thiophene-2-amido]- 1H- 1 ,3-benzodiazol- l-yl]ethyl)carbamate (1.6 g, 3.54 mmol, 1.00 equiv) and trifluoroacetic acid (15 mL). The resulting solution was stirred overnight at 25° C and then concentrated under vacuum. This resulted in 1.2 g (crude) of N-[l-(2- aminoethyl)-lH-l,3-benzodiazol-2-yl]-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide as a yellow solid.
Step 7
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed N-[l-(2-aminoethyl)-lH-l,3-benzodiazol-2-yl]-5-(lH-pyrazol-4- yl)thiophene- 2-carboxamide (1.2 g, 3.41 mmol, 1.00 equiv), N,N-dimethylformamide (20 mL), TEA (3.44 g, 34.00 mmol, 9.98 equiv), HATU (2.6 g) and 2-cyanoacetic acid (580 mg, 6.82 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature and then quenched by the addition of water/ice. The solids were collected by filtration and then dried in an oven under reduced pressure. This resulted in 1.107 g of N-[l-[2-(2-cyanoacetamido)ethyl]-lH- l,3-benzodiazol-2-yl]-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide as a tan solid.
Step 8
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed -[l-[2-(2-cyanoacetamido)ethyl]-lH-l,3-benzodiazol-2-yl]-5-(lH- pyrazol-4-yl) thiophene-2-carboxamide (200 mg, 0.48 mmol, 1.00 equiv), dichloromethane (10 mL), methanol (10 mL), piperidine (121.7 mg, 1.43 mmol, 3.00 equiv) and 2-methylpropanal (171.8 mg, 2.38 mmol, 5.00 equiv). The resulting solution was stirred overnight at room temperature and then concentrated under vacuum. The crude product was purified by Flash-Prep- HPLC with the following conditions (IntelFlash-1): Column, silica gel; mobile phase ; Detector, UV 254 nm. This resulted in 17.5 mg (8%) of N-(l-(2-(2-cyano-4-methylpent-2-enamido)ethyl)- lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide as a white solid. LC- MS m/z: 473+l(M+l).
Example 49
Synthesis of N-(l-(2-(4-amino-2-cyano-4-methylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2- yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide trifluoroacetic acid salt
Step 1
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed -[l-[2-(2-cyanoacetamido)ethyl]-lH-l,3-benzodiazol-2-yl]-5-(lH- pyrazol-4-yl)thiophene-2-carboxamide (300 mg, 0.72 mmol, 1.00 equiv), DCM/MeOH (1 : 1) (20 mL), piperidine (182.6 mg, 2.14 mmol, 3.00 equiv), 4A molecular sieves (300 mg) and tert-butyl N-(2-methyl-l-oxopropan-2-yl)carbamate (669.5 mg, 3.58 mmol, 5.00 equiv). The resulting
solution was stirred overnight at 40° C and then the solids were filtered out and the resulting mixture was concentrated under vacuum.
Step 2
Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl N-[4-cyano-2-methyl-4-[(2-[2-[5-(lH-pyrazol-4-yl)thiophene-2- amido]-lH-l,3-benzodiazol-l-yl]ethyl)carbamoyl]but-3-en-2-yl]carbamate (400 mg, 0.68 mmol, 1.00 equiv), dichloromethane (10 mL) and trifluoroacetic acid (2 mL). The resulting solution was stirred for 4 h at room temperature and then the solids were collected by filtration. The resulting solution was diluted with DMSO and the solids were filtered out to collect 80 mg of N-(l-(2-(4- amino-2-cyano-4-methylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4- yl)thiophene-2-carboxamide as a trifluoroacetic acid salt. LC-MS m/z: 488+1 (M+l).
Example 50
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide trifluoroacetic acid salt
Step 1
Into a 100 mL round-bottom flask, was placed 5-(difluoromethyl)thiophene-2-carboxylic acid (100 mg, 0.56 mmol, 1.00 equiv), PyBop (490 mg), tert-butyl (2R)-2-[(2-amino-lH-l,3- benzodiazol-l-yl)methyl]pyrrolidine-l-carboxylate (198 mg, 0.63 mmol, 1.1 1 equiv), TEA (0.5 mL) and N,N-dimethylformamide (5 mL). The resulting solution was stirred overnight at 25° C and then diluted with ¾0. The resulting solution was extracted with ethyl acetate and the organic layers were combined and concentrated under vacuum. This resulted in 280 mg (crude) of tert-butyl (2R)-2-([2-[5-(difluoromethyl)thiophene-2-amido]-lH-l,3-benzodiazol-l- yl]methyl)pyrrolidine-l-carboxylate as brown oil.
Step 2
Into a 100-mL round-bottom flask, was placed tert-butyl (2R)-2-([2-[5-(difluoromethyl)- thiophene-2-amido]-lH-l,3-benzodiazol-l-yl]methyl)pyrrolidine-l-carboxylate (280 mg, 0.59 mmol, 1.00 equiv), dichloromethane (10 mL) and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at 25° C and then concentrated under vacuum. This resulted in 200
mg (crude) of 5-(difluoromethyl)-N-[ 1 -[(2R)-pyrrolidin-2-ylmethyl]- 1H- 1 ,3-benzodiazol-2- yl]thiophene-2-carboxamide as a brown oil.
Step 3
Into a 100-mL round-bottom flask, was placed 5-(difluoromethyl)-N-[l-[(2R)-pyrrolidin- 2-ylmethyl]-lH-l,3-benzodiazol-2-yl]thiophene-2-carboxamide (100 mg, 0.27 mmol, 1.00 equiv), HATU (152 mg, 0.40 mmol, 1.50 equiv), 2-cyanoacetic acid (34 mg, 0.40 mmol, 1.50 equiv), TEA (80.5 mg, 0.80 mmol, 3.00 equiv) and N,N-dimethylformamide (50 mL). The resulting solution was stirred for 12 h at room temperature and then quenched by the addition of water. The solids were collected by filtration to isolate N-(l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin- 2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide.
Step 4
Into a 50-mL round-bottom flask, was placed N-(l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin-2- yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (21 1 mg, 0.48 mmol, 1.00 equiv), 2-methylpropanal (0.2 mL, 5.00 equiv), piperidine (1 17.2 mg, 3.00 equiv), 4A molecular sieves (10 mg) and DCM/MeOHl : 1 (20 mL). The resulting solution was stirred overnight at room temperature and then the solids were filtered out. The filtrate was concentrated under vacuum and the crude product was purified by Prep-HPLC with the following conditions: ACN/H2O(0.05%TFA)30%-80%; Detector, 254nm. This resulted in 50 mg of (R)-N-(l-((l-(2- cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide trifluoroacetate as an off-white solid. LC-MS m/z: 498 (M+l).
Example 51
Synthesis (S)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2- -5-(difluoromethyl)thiophene-2-carboxamide
Step 1
Into a 100-mL round-bottom flask, was placed 5-(difluoromethyl)thiophene-2-carboxylic acid (100 mg, 0.56 mmol, 1.00 equiv), tert-butyl (2S)-2-[(2-amino-lH-l,3-benzodiazol-l- yl)methyl]pyrrolidine-l-carboxylate (198 mg, 0.63 mmol, 1.00 equiv), PyBop (490 mg, 0.94 mmol, 1.50 equiv), N,N-dimethylformamide (5 mL) and TEA (0.5 mL). The resulting solution
was stirred overnight at 25° C and then diluted with ¾0. The resulting solution was extracted with ethyl acetate and the organic layers were combined and concentrated under vacuum. This resulted in 280 mg (crude) of tert-butyl (2S)-2-([2-[5-(difluoromethyl)thiophene-2-amido]-lH- l,3-benzodiazol-l-yl]methyl)pyrrolidine-l-carboxylate as a brown oil.
Step 2
Into a 50-mL round-bottom flask, was placed a solution of tert-butyl (2S)-2-([2-[5- (difluoromethyl)thiophene-2-amido]-lH-l,3-benzodiazol-l-yl]methyl)pyrrolidine-l-carboxylate (300 mg, 0.63 mmol, 1.00 equiv) in dichloromethane (50 mL) and trifluoroacetic acid (15 mL). The resulting solution was stirred overnight at room temperature and then concentrated under vacuum. This resulted in 250 mg (crude) of 5-(difluoromethyl)-N-[l-[(2S)-pyrrolidin-2- ylmethyl]-lH-l,3-benzodiazol-2-yl]thiophene-2-carboxamide as a red oil.
Step 3
Into a 100-mL round-bottom flask, was placed 5-(difluoromethyl)-N-[l-[(2S)-pyrrolidin- 2-ylmethyl]-lH-l,3-benzodiazol-2-yl]thiophene-2-carboxamide (200 mg, 0.53 mmol, 1.00 equiv), HATU (404 mg, 1.06 mmol, 2.00 equiv), TEA (268.8 mg, 2.66 mmol, 5.00 equiv), 2- cyanoacetic acid (90.4 mg, 1.06 mmol, 2.00 equiv) and N,N-dimethylformamide (50 mL). The resulting solution was stirred for 12 h at room temperature and then quenched by the addition of water. The solids were collected by filtration which resulted in 120 mg of N-(l-[[(2S)-l-(2- cyanoacetyl)pyrrolidin-2-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide as an off-white solid.
Step 4
Into a 50-mL round-bottom flask, was placed -(l-[[(2S)-l-(2-cyanoacetyl)pyrrolidin-2- yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (140 mg, 0.32 mmol, 1.00 equiv), 2-methylpropanal (0.14 mL, 5.00 equiv), piperidine (77.8 mg, 3.00 equiv), 4A molecular sieves (10 mg) and DCM/MeOHl : 1 (20 mL). The resulting solution was stirred overnight at room temperature and then the solids were filtered out. The filtrate was concentrated under vacuum and the crude product was purified by Prep-HPLC with the following conditions: ACN/H2O(0.05%TFA) 30%-80%; Detector, 254nm. This resulted in 40 mg of (S)-N-(l-((l-(2- cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide trifluoroacetate as an off-white solid.
Intermediate 13
Synthesis of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-5- (hydroxymethyl)benzimidazol- 1 -yl]methyl]pyrrolidine- 1 -carboxylate
Step 1
To the mixture of methyl 4-fluoro-3-nitro-benzoate (20.0 g, 100 mmol), N-ethyl-N- isopropyl-propan-2-amine (35.5 mL, 200 mmol) and MeCN (150 mL) was stirred in a 3-neck flask and flushed with argon for 15 minutes. tert-Butyl (2R)-2-(aminomethyl)pyrrolidine-l- carboxylate (25.0 g, 124.86 mmol) was diluted with CH3CN (130 mL) and was added dropwise over 50 min. The reaction mixture was allowed to stir at room temp for 3.5 h. The orange mixture was concentrated to dryness and partitioned between DCM and HCl (IN). Organic layers were washed with brine, dried over MgS04, and concentrated to obtain 37.5 g of tert-butyl (2R)- 2-[(4-methoxycarbonyl-2-nitro-anilino)methyl]pyrrolidine- 1 -carboxylate as a yellow oil.
Step 2
A mixture of tert-butyl (2R)-2-[(4-methoxycarbonyl-2-nitro-anilino)methyl]pyrrolidine-l- carboxylate (37.5 g, 98.8 mmol) and methanol (1200 mL) was cooled to 0 °C. Saturated ammonium chloride (200 mL) was added to solution. Zinc dust (32.74g, 500.78 mmol) was added to resultant slurry and the resultant mixture was stirred at rt for 35 min. The reaction mixture was filtered through a thin pad of celite and washed with MeOH. The filtrated solution was concentrated and worked up with EtOAc and water). The organic was pushed through a short silica plug and washed with EtOAc. The collected solution was concentrated to obtain 32.1 grams (93%) brown solid of tert-butyl (2R)-2-[(2-amino-4-methoxycarbonyl- anilino)methyl]pyrrolidine- 1 -carboxylate.
Step 3
A mixture of tert-butyl (2R)-2-[(2-amino-4-methoxycarbonyl-anilino)methyl]pyrrolidine- 1 -carboxylate (32.1 g, 91.87 mmol) and ethanol (380 mL) was stirred at room temperature under Argon for 10 minutes cyanogen bromide (10.7 g, 101 mmol) was added. The resultant mixture was stirred at rt for 3 h. The reaction mixture was evaporated to dryness and worked up with
NaHC03 and DCM. The layers were separated. The organic layers were dried (MgS04), filtered and concentrated to obtain 34.5 grams (100%) gray solid of methyl l-[[(2R)-l-tert- butoxycarbonyl-pyrrolidin-2-yl]methyl]-2-imino-3H-benzimidazole-5-carboxylate.
Step 4
To a solution of 5-(difluoromethyl)thiophene-2-carboxylic acid (40.4 mg, 22.7mmol) in
DMF (25 mL) at 0 °C for 15 minutes was added methyl l-[[(2R)-l-tert-
butoxycarbonylpyrrolidin-2-yl]methyl]-2-imino-3H-benzimidazole-5-carboxylate (8.50 mg, 22.7 mmol) in DMF (12 mL) and DIPEA (7.82 mL, 45.4 mmol). After stirring 4 h at rt, the solution was evaporated. The crude mixture was diluted with DCM and was washed with NaHC(¾ (sat). The organic layers were separated and dried with MgS04, filtered and concentrated to black crude oil. The crude oil was purified by column chromatography to obtain 7.35 grams of methyl l-[[(2R)-l-tert-butoxycarbonylpyrrolidin-2-yl]methyl]-2-[[5-(difluoromethyl)thiophene-2- carbonyl]amino]-benzimidazole-5-carboxylate as off white solid.
Step 5
To a solution of methyl l-[[(2R)-l-tert-butoxycarbonylpyrrolidin-2-yl]methyl]-2-[[5- (difluoromethyl)thiophene-2-carbonyl]amino]benzimidazole-5-carboxylate (5.89 g, 1 1.01 mmol) in THF (40mL) at -78° C for 5 minutes was added 2M LiAlH4 in THF (6.6 mL, 13.21 mmol). The reaction mixture was stirred for 10 minutes at -78° C and then was allowed to warm to room temp. After 30-45 minutes, the reaction mixture was quenched with NaHCC>3 (sat) and worked up with DCM. The organic layers were separated, brined and dried (MgS04). The crude was concentrated and purified by column chromatography to obtain 3.05 grams (55%) of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-5-(hydroxymethyl)benzimidazol-l- yl]methyl]pyrrolidine-l-carboxylate as yellow solid. MS (pos. ion) m/z: 507 (M+l).
Example 52
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-
((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Step 1
To a solution of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]- 5-(hydroxymethyl)benzimidazol-l-yl]methyl]pyrrolidine-l-carboxylate (547 mg, 1.08 mmol) in DCM (8 mL) was added 4N HC1 in dioxane (5 mL). The reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated and dried under reduced pressure to obtain 545 mgs of 5-(difluoromethyl)-N-[5-(hydroxymethyl)-l-[[(2R)-pyrrolidin-2-yl]methyl]benzimidazol-2-yl]- thiophene-2-carboxamide.
Step 2
To a solution of 5-(difluoromethyl)-N-[5-(hydroxymethyl)-l-[[(2R)-pyrrolidin-2- yl]methyl]-benzimidazol-2-yl]thiophene-2-carboxamide (600 mg, 1.48 mmol) and 2-cyanoacetic acid (376.7 mg, 4.43 mmol) in DMF (20 mL) was added DIPEA (1.27 mL, 7.38 mmol). The solution was stirred at rt for 7 minutes and then HATU (1.68 g, 4.43 mmol) was added. The resultant mixture was stirred at rt for 4.5 h. The reaction mixture was evaporated to an oil which was purified by chromatography to obtain 650 mg (93%) of N-f l-I^R^l-^- cyanoacety pyiTolidin^-y^methy^-S^hydroxymethy benzm^
(difluoromethyl)thiophene-2-carboxamide as white solid. Step 3
To a solution of N-[l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-5-
(hydroxymethyl)-benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide (680 mg, 1.44 mmol) in DCM (15 mL) was added Dess-Martin Periodinane (1.22 g, 2.87 mmol). The reaction mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated and purified by chromatography to obtain 430 mg (64%) of N-[l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin- 2-yl]methyl]-5-formyl-benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide as brown solid.
Step 4
To a solution of N-[l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-5-formyl- benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide (82 mg, 0.17 mmol), 2,2- dimethylpropan-1 -amine (30.32 mg, 0.35 mmol) in DCM (7 mL) was added NaBH3CN (16.39 mg, 0.26 mmol). The reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated and purified by chromatography to obtain 40 mg (42%) of N-fl-I^R^l-^- cyanoacety pyiTolidin^-y^methy^-S-^^-dimem^
(difluoromethyl)thiophene-2-carboxamide as oil.
Step 5
A solution of N-[l-[[(2R)-l-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-5-[(2,2-dimethyl- propylamino)methyl]benzimidazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide (40 mg, 0.07 mmol), pyrrolidine (0.02 mL, 0.22 mmol), and 2-methylpropanal (26.58 mg, 0.37 mmol in DCM (7 mL) was stirred at room temperature for 10 minutes and then chloro(trimethyl)silane (0.04 mL, 0.29 mmol) was added dropwise. The resultant mixture was stirred at room
temperature for lh. The crude mixture was concentrated and purified by chromatography to obtain 18 mg (41%) of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide as white solid. MS (pos. ion) m/z: 597 (M+l).
Example 53
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((2,2,2- trifluoroethyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Substituting trifluoroethylamine for 2,2-dimethylpropan-l -amine in step 4, Ex 52 above and continuing as in step 5 affords (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 609 (M+l).
Example 54
Synthesis of N-( 1 -(((R)- 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5 -((2,6- dimethylmorpholino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Step 1
To solution of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-5- (hydroxymethyl)benzimidazol-l-yl]methyl]pyrrolidine-l-carboxylate (452 mg, 0.89 mmol) and DCM (15 mL) was added Dess Martin Periodinane. The result was stirred at room temp for 18 h. The reaction mixture was worked up with water and DCM and the organic layer was dried (MgS04) and concentrated to oil. The crude was purified by column chromatography to obtain 445 mg (98%) of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-5- formyl-benzimidazol-l-yl]methyl]pyrrolidine-l-carboxylate as gray solid.
Step 2
To solution of tert-butyl (2R)-2-[[2-[[5-(difluoromethyl)thiophene-2-carbonyl]amino]-5- formyl-benzimidazol-l-yl]methyl]pyrrolidine-l-carboxylate (100 mg, 0.20 mmol), 2,6- dimethylmorpholine (0.06 mL, 0.40 mmol) in DCM (5 mL) was added NaBH3CN (24.9 mg, 0.40 mmol). The reaction mixture was stirred at room temp for 2 h. The reaction mixture was purified by chromatography to obtain 100 mg (84%) of tert-butyl (2R)-2-[[2-[[5-
(difluoromethyl)thiophene-2-carbonyl]amino]-5-[(2,6-dimethylmorpholin-4-yl)methyl]- benzimidazol- 1 -yl]methyl]pyrrolidine- 1 -carboxylate.
Step 3
To solution mixture of (2R)-tert-butyl 2-((2-(5-(difluoromethyl)thiophene-2- carboxamido)-5-((2,6-dimethylmorpholino)methyl)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate (100 mg, 0.17 mmol) and 4M HC1 in dioxane (4 mL, 0.17 mmol) was dissolved in DCM (3 mL) and stirred at room temp. After 2 h, the reaction mixture was worked up with water and DCM. Then the aqueous layer was basified with KOH to pH~l 1 and extracted with DCM and dried (MgS04) to obtain 65 mg (78%) of 5-(difluoromethyl)-N-(5- ((2,6-dimethylmorpholino)methyl)-l-((R)-pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2- yl)thiophene-2-carboxamide.
Step 4
To the solution of 5-(difluoromethyl)-N-(5-((2,6-dimethylmorpholino)methyl)-l-((R)- pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)thiophene-2-carboxamide (65 mg, 0.13 mmol), DIPEA (0.07 mL, 0.39 mmol), 2-cyano-4-methyl-pent-2-enoic acid (53.88 mg, 0.39 mmol) and DMF (4 mL) was stirred for 10 minutes and then added HATU (98.09 mg, 0.26 mmol). The reaction mixture was stirred at room temperature. After 4 h, the crude mixture was concentrated and purified by chromatography to obtain 55 mg (68%) of N-(l-(((R)-l-(2-cyano-4-methylpent- 2-enoyl)pyrrolidin-2-yl)methyl)-5-((2,6-dimethylmorpholino)methyl)-lH-benzo[d]imidazol-2- yl)-5-(difluoromethyl)thiophene-2-carboxamide as off white solid. MS (pos. ion) m/z: 625 (M+l).
Example 55
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- (morpholinomethyl)-lH-benz thyl)thiophene-2-carboxamide
Substituting morpholine for 2,6-dimethylmorpholine in step 2 and followed by steps 3-5 as described in example 54 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-(mo holinomethyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoro-methyl)thiop carboxamide. MS (pos. ion) m/z: 597 (M+l).
Example 56
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((4-methyl- piperazin-l-yl)methyl)-lH-b thyl)thiophene-2-carboxamide
Substituting N-methyl piperazine for 2,6-dimethylmorpholine in step 2 and following steps 3-5 as described in example 54 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-((4-methylpiperazin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 610 (M+l).
Intermediate 14
Synthesis of (R)-tert-butyl 2-((2-amino-5-((((benzyloxy)carbonyl)((S)-3,3-dimethylbutan-2- yl)amino)methyl)- 1 H-benzo [d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate
Step 1
To a 500 niL three neck round bottomed flask, 4-fluoro-3-nitrobenzaldehyde (10.0 g, 59 mmol) was dissolved in acetonitrile (100 mL) followed by addition of DIPEA (22.8 gm, 177 mmol). After stirringlO min. at rt, (S)-tert-butyl 2-(aminomethyl)pyrrolidine-l -carboxylate (14.2 g, 70 mmol) in acetonitrile (100 mL) was added dropwise and the reaction mixture was stirred at rt for 24 h. The reaction mixture was concentrated, diluted with water and extracted with CH2CI2. The combined organic layer were dried over sodium sulfate and concentrated to give crude product which was purified using column purification by eluting the compound with 10% ethyl acetate in hexanes to yield 18.2 g of (S)-tert-butyl 2-((4-formyl-2-nitrophenylamino)- methyl)pyrrolidine- 1 -carboxylate.
Step 2
To a 1L three neck round bottomed flask under nitrogen atmosphere, (S)-tert-butyl 2-((4- formyl-2-nitrophenylamino)methyl)pyrrolidine-l -carboxylate (18 g, 51 mmol) and (S)-3,3- dimethyl butn-2-amine (5.2 g, 51 mmol) were dissolved in 1,2 dichloroethane (400 mL) and stirred at rt for 10 min. Acetic acid (1.6 mL, catalytic amount) and NaBH(OAc)3 (16.37 g, 77 mmol) were added and the reaction mixture tirred at room temperature for 16 h. The reaction mixture was poured in to saturated Na2C(¾ solution (100 mL) followed by extraction with CH2CI2. The combined organic layers were dried over sodium sulfate and concentrated to yield 22.4 g of (S)-tert-butyl 2-((4-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-2- nitrophenylamino)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a 500 mL three neck round bottomed flask, (S)-tert-butyl 2-((4-(((S)-3,3- dimethylbutan-2-ylamino)methyl)-2-nitrophenylamino)methyl)pyrrolidine- 1 -carboxylate (22.3 g, 51 mmol) and aOH (4.5 g, 112 mmol) were suspended in 1, 4-dioxane (200 mL) & water (200 mL) and cooled to 10°C. Benzyl chloroformate (13.1 g, 77 mmol) was added dropwise to the cooled reaction mixture and then the reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with ethyl acetate and washed with IN HC1 solution followed by saturated NaHC(¾ solution. The organic layer was dried over sodium sulfate and concentrated to yield 22
g of (S)-tert-butyl 2-((4-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2- nitrophenyl-amino)-methyl)pyrrolidine- 1 -carboxylate.
Step 4
To a 500 niL three neck round bottomed flask,(S)-tert-butyl 2-((4-(((benzyloxycarbonyl) ((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-nitrophenylamino)methyl)pyrrolidine- 1 - carboxylate (21.9 g, 38 mmol) was dissolved in methanol (250 mL) followed by addition of zinc dust (12.5 g, 193 mmol) and saturated NH4C1 solution (10.3 g,193 mmol). The mixture was heated at 50° C for 2 h with stirring. The reaction mixture was filtered through a celite bed and washed with methanol and the filtrate was concentrated to give the crude product. Water was added & extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated to give the crude compound which was purified using column purification to yield 20.1 g of (S)-tert-butyl 2-((2-amino-4-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2- yl)amino)methyl)phenylamino)-methyl)pyrrolidine- 1 -carboxylate.
Step 5
To a 500 mL three neck round bottomed flask under nitrogen atmosphere, (S)-tert-butyl
2-((2-amino-4-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)phenylamino)- methyl)-pyrrolidine- 1 -carboxylate (20 g, 37 mmol) was dissolved in ethanol (200 mL) followed by addition of cyanogen bromide (4.7 g, 45 mmol) at rt and the mixture was stirred for 4 h. The reaction mixture was concentrated under vacuum and diluted with saturated NaHC(¾ solution and extracted with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated to give the crude product which was purified using diethyl ether trituration to yield 13.2 g of (S)-tert-butyl 2-((5-(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)- 2-imino-2,3-dihydro- 1 H-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate.
Intermediate 15
Step 1
To a 35ml microwave vial, ethyl thiophene-2-carboxylate (1.5 g, 0.01019 mole) and hexamine (2.68 g, 0.02038 mole) were dissolved in TFA (12 mL). The reaction mixture was heated at 90°C in microwave for 3h. The reaction mass was diluted and basified with saturated Na2C(¾ solution and extracted with EtOAc. The combined organic layer was washed with brine ,
dried over Na2S04 and evaporated to get the crude compound which was purified by flash column chromatography to obtain 0.75g of ethyl 5-formylthiophene-2-carboxylate.
Step 2
To a 250 mL 3 neck round bottomed flask, ethyl 5-formylthiophene-2- carboxylate (7g, 37.83 mmole) was dissolved in dry CH2CI2 (60 mL) and stirred at room temperature. To this solution, DAST (5 mL, 37.83 mmole) (in dry CH2CI2 (20 mL)) was added dropwise at room temperature and the reaction mixture was stirred 1 h. DAST (5 mL, 0. 37.83 mmole) was again added dropwise at room temperature and the reaction mixture was further stirred for 3 h. The reaction mixture was slowly diluted with sat. NaHC(¾ solution and kept overnight. Product was extracted with EtOAc. The combined organic layer was washed with brine, dried over a2S04 and evaporated to get crude. The crude compound was purified by flash column purification to yield 5.5g of ethyl 5-(difluoromethyl)-thiophene-2-carboxylate.
Step 3
To a 250 mL 3-neck round bottomed flask, ethyl 5-(difluoromethyl) thiophene -2- carboxylate (5.5g, 28.65mmole) was dissolved in methanol (100ml) at room temperature. To this, IN NaOH solution (60 mL) was added slowly and stirred for 2 h at room temperature. Methanol was evaporated under reduced pressure, cooled to 5-10°C and IN HC1 was added dropwise to make pH 5-6. The precipitate was filtered, washed with hexanes and dried to get pure 4.5g of 5- (difluoromethyl)thiophene -2-carboxylic acid.
Intermediate 16
Synthesis of benzyl ((2-(5-(difluoromethyl)thiophene-2-carboxamido)-l-((R)-pyrrolidin-2- ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl)((S)-3,3-dimethylbutan-2-yl)carbamate
Step 1
To a 100 mL 3-neck round bottomed flask, 5-(difluoromethyl)thiophene-2-carboxylic acid (0.947g, 0.00532 mole) was dissolved in DMF (25 mL) and cooled to 0°C under N2 atmosphere. To this, HATU (2.528 g, 6.653 mmole) was added at 0°C and the reaction mixture was stirred for 30 minutes at same temperature. tert-Butyl-2-((5-(((benzyloxycarbonyl)((S)-3,3- dimethylbutan-2-yl)amino)methyl)-2-imino-2,3-dihydro-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine-l -carboxylate (2.5 g, 4.435 mmole) was added followed by DIPEA (2.25
mL, 3.30 mmole) and the reaction mixture was stirred at room temperature for 4h. Water was added to the reaction mixture and product was extracted with EtOAc. The combined organic layer was washed with water and brine, dried over Na2S04 and evaporated to afford a crude compound which was purified by column chromatography to yield 2.0 g of tert-butyl 2-((5- (((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-(5-
(difluoromethyl)thiophene-2-carboxamido)- lH-benzo[d]imidazol- 1 -yl)-methyl)pyrrolidine- 1 - carboxylate.
Step 2
100 mL single neck round bottomed flask, tert-butyl 2-((5-
(((benzyloxycarbonyl)((S)-3,3-dimethylbutan-2-yl)amino)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l- carboxylate (2g, 2.762 mmole) was dissolved in CH2CI2 (20 mL) and cooled to 0°C under 2 atmosphere. To this solution, TFA (10 mL) was added dropwise and stirred for 6h at room temperature. CH2CI2 and TFA were evaporated under reduced pressure followed by stripping with THF. The crude thus obtained was dissolved in minimum diethyl ether and pure product was precipitated out with hexanes to afford 1.5 g of benzyl (2-(5-(difluoromethyl)thiophene-2- carboxamido)- 1 -(pyrrolidin-2-ylmethyl)- lH-benzo[d]imidazol-5-yl)-methyl((S)-3,3- dimethylbutan-2-yl)carbamate as TFA salt.
Example 57
Synthesis of N-(l-(((R)-l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((((S)-3,3 -dimethylbutan-2-yl)amino)methyl)- 1 H-benzo [d] imidazol-2-yl)-5 - (difluoromethyl)thiophene-2-carboxamide
Step 1
To a 100 mL three neck round bottomed flask, under nitrogen atmosphere, 2-cyanoacetic acid (0.613 g, 7.214 mmole) was dissolved in dry DMF (30 mL) and cooled to 0 °C. To this, HATU (1.37 g, 3.607 mmole) dissolved in dry DMF (10 mL) was added dropwise and stirred at 0 °C for 30 minutes. Benzyl (2-(5-(difluoromethyl)thiophene 2-carboxamido)-l-((R)-pyrrolidin- 2-ylmethyl)-lH-benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethylbutan-2-yl)carbamate as a TFA
salt (1.5 g, 2.404 mmole) dissolved in dry DMF (10 mL) was added dropwise followed by addition of DIPEA (2.06 mL, 12.02 mmole) at same temperature and the reaction mass was stirred at room temperature for 2 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layer was dried over a2S04 and concentrated to give the crude compound which was subjected to column to yield 1.1 g of benzyl (l-(((R)-l-(2- cyanoacetyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-lH- benzo[d]imidazol-5-yl)methyl((S)-3,3-dimethyl-butan-2-yl)carbamate.
Step 2
To a 25 mL vial, benzyl (l-(((R)-l-(2-cyanoacetyl)pyrrolidin-2-yl) methyl)-2-(5- (difluoro-methyl)thiophene-2-carboxamido)- lH-benzo[d]imidazol-5-yl)methyl((S)-3,3- dimethylbutan-2-yl)carbamate (0.75 g, 1.085 mmole) was dissolved in acetonitrile (7.5 mL). TMSI (0.75 mL) diluted in CH2CI2 (0.75 mL) was added dropwise at room temperature and the reaction mixture was heated at 60°C for 30 minutes. The reaction mixture was concentrated to give crude compound which was subjected to column purification to yield 0.5 g of N-(1-(((R)-1- (2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)- 1H- benzo[d]imidazol-2-yl)-5-(difluoro-methyl)thiophene-2-carboxamide.
Step 3
To a 25 mL sealed vial under nitrogen atmosphere N-(l-(((R)-l-(2- cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (0.25 g, 0.449 mmole), 3- methyloxetane-3-carbaldehyde (0.135 g, 1.348 mmole) and piperidine (0.088 mL, 0.899 mmole) was taken in 1,4 dioxane (5 mL). The reaction mixture was heated at 80 °C for 5 h and then was diluted with water (30 mL) and extracted with EtOAc. The combined organic layer was dried over a2S04 and concentrated to give the crude compound which was purified using Prep HPLC to give 15 mg of N-(l-(((R)-l-(2-cyano-3-(3-methyloxetan-3-yl) acryloyl)pyrrolidin-2- yl)methyl)-5-(((S)-3,3-dimethylbutan-2-ylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoro methyl)thiophene-2-carboxamide as a formic acid salt. MS (pos. ion) m/z: 658 (M+l).
Example 58
Synthesis of N-(l-(((R)-l-(2-cyano-4-ethoxy-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide
Using the procedure described for Example 57 but substituting 2-ethoxy-2- methylpropanal for 3-methyloxetane-3-carbaldehyde afforded N-(l-(((R)-l-(2-cyano-4-ethoxy- 4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)- lH4oenzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide as a formic acid salt. MS (pos. ion) m/z: 658 (M+l).
Example 59
Synthesis of N-(l-(((R)-l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3- dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Using the protocol as in Ex. 31, but using benzyl ((2-(5-(difluoromethyl)thiophene-2- carboxamido)-l-((R)-pyrrolidin-2-ylmethyl)-lH4oenzo[d]imidazol-5-yl)methyl)((S)-3,3- dimethylbutan-2-yl)carbamate in place of the racemate, N-(l-(((R)-l-(2-cyano-4-dimethylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH-benzo[d]- imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide was prepared.
Example 60
Synthesis of N-( 1 -(((R)- 1 -(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5 -((((S)- 3,3-dimethylbutan-2-yl)amino)methyl)-lH4oenzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-
Using the same protocol as in Ex. 59, but using 2-cyano-4,4-dimethylpent-2-enoic acid place of 2-cyano-4-methylpent-2-enoic acid, N-(l-(((R)-l-(2-cyano-4,4-dimethylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-((((S)-3,3-dimethylbutan-2-yl)amino)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide was prepared.
Example 61
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((isobutylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Substituting 2-methylpropan-l -amine for 2,2-dimethylpropan-l -amine in Step 4, Example 52 above and continuing as in Step 5 affordd (R)-N-(l-((l-(2-cyano-4-methylpent-2- enoyl)-pyrrolidin-2-yl)methyl)-5-((isobutylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)-thiophene-2-carboxamide. MS (pos. ion) m/z: 583 (M+l).
Example 62
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((((3- methyloxetan-3-yl)methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide
Substituting (3-methyloxetan-3-yl)methanamine for 2,2-dimethylpropan-l -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(l-((l-(2-cyano-4-methylpent- 2-enoyl)pyrrolidin-2-yl)methyl)-5-((((3-methyloxetan-3-yl)methyl)amino)methyl)-lH-benzo[d]- imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 611 (M+l).
Example 63
Synthesis of (R)-N-(5-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-l-((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Substituting 2-oxa-6-azaspiro[3.3]heptane; oxalic acid for 2,2-dimethylpropan-l -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(5-(2-oxa-6-azaspiro- [3.3]heptan-6-ylmethyl)-l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 609 (M+l).
Example 64
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(((2- hydroxy-2-methylpropyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide
Substituting l-amino-2-methyl-propan-2-ol for 2,2-dimethylpropan- 1 -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-(((2-hydroxy-2-methylpropyl)amino)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 599 (M+l).
Example 65
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- (((cyclopropyl-methyl)amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene- -carboxamide
Substituting cyclopropylmethanamine for 2,2-dimethylpropan- 1 -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-2- enoyl)-pyrrolidin-2-yl)methyl)-5-(((cyclopropylmethyl)amino)methyl)-lH-benzo[d]imidazol-2- yl)-5-(difluoromethyl)-thiophene-2-carboxamide. MS (pos. ion) m/z: 581 (M+l).
Example 66
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((3-(2- hydroxy-propan-2-yl)azetidin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide
Substituting 2-(azetidin-3-yl)propan-2-ol hydrochloride for 2,2-dimethylpropan-l -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((3-(2-hydroxypropan-2-yl)azetidin-l-yl)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 625 (M+l).
Example 67
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((3- hydroxy-azetidin-l-yl)methyl)-lH ethyl)thiophene-2-
Substituting azetidin-3-ol hydrochloride for 2,2-dimethylpropan-l -amine in Step 4, Example 52 above and continuing as in Step 5 provided (R)-N-(l-((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-((3-hydroxyazetidin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)-thiophene-2-carboxamide. MS (pos. ion) m/z: 583 (M+l).
Example 68
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((4-(2- hydroxypropan-2-yl)piperidin-l-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide
Substituting 2-(4-piperidyl)propan-2-ol for 2,2-dimethylpropan- l -amine in Step 4, Example 52 above and continuing as in Step 5 afforded (R)-N-(l -((l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-2-yl)methyl)-5-((4-(2-hydroxypropan-2-yl)piperidin- l-yl)methyl)- lH-benzo[d]- imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 653 (M+l).
Example 69
Synthesis of (R)-N-(l-((l -(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Substituting 3-methyloxetane-3-carbaldehyde for 2-methylpropanal in Step 5, Example 52 above afforded (R)-N-(l-((l -(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2- yl)methyl)-5 -((neopentylamino)methyl)- 1 H-benzo[d] imidazol-2-yl)-5 - (difluoromethyl)thiophene-2-carboxamide. MS (pos. ion) m/z: 625 (M+l).
Example 70
Synthesis of (R)-N-(l -((l-(2-cyano-4,4-dimethyl-5-morpholinopent-2-enoyl)pyrrolidin-2-yl)- methyl)-5-(hydroxymethyl)- lH methyl)thiophene-2-
carboxam e
To a mixture of (R)-N-(l-((l -(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (l l l .mg, 0.23 mmol) (from Example 52, Steps 1 and 2) 2,2-dimethyl-3-morpholino-propanal (O. lmL, 0.47 mmol),
pyrrolidine (0.06 niL, 0.70 mmol), and DCM (3 niL) were stirred at rt for 5 minutes and added chloro(trimethyl)silane (0.12mL, 0.940 mmol). The resultant mixture was stirred at rt for 3h, concentrated and purified by chromatography to obtain 12 mg of (R)-N-(l-((l-(2-cyano-4,4- dimethyl-5-morpholinopent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)-thiophene-2-carboxamide. MS (pos. ion) m/z: 627 (M+l).
Example 71
Synthesis of (R)-N-( 1 -(( 1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(hydroxy- methyl)- lH-benzo[d]imi ophene-2-carboxamide
To a solution of (R)-5-(difluoromethyl)-N-(5-(hydroxymethyl)-l-(pyrrolidin-2- ylmethyl)-lH-benzo[d]imidazol-2-yl)thiophene-2-carboxamide (27 mg, 0.07 mmol), 2-cyano-4- methyl-pent-2-enoic acid (13.87 mg, 0.10 mmol), HATU (25.24 mg, 0.07 mmol), DIPEA (0.01 mL, 0.07 mmol) in DMF (10 mL) was stirred at rt for 100 minutes. The reaction mixture was evaporated to afford an oil which was worked up with DCM and water. The organic layers were dried (MgS04) and concentrated and the oil was purified by chromatography to obtain 10 mg of (R)-N-( 1 -((1 -(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)- 1 H- benzo[d]-imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamideas white solid. MS (pos. ion) m/z: 528 (M+l).
Example 72
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-(3-hydroxy- pentan-3-yl)-lH-benzo[d] )thiophene-2-carboxamide
A mixture of (R)-methyl l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-lH-benzo[d]imidazole-5-carboxylate (482 mg, 0.90 mmol), and THF (20 mL) was cooled to 0 °C in an ice-bath and bromo(ethyl)magnesium in 3M diethyl ether (721 mg, 5.41 mmol) was added dropwise over 5 min. The resultant mixture was stirred at 0 °C for 15 min and then allowed to warm to rt and stirred 2 hours. The reaction mixture was quenched with saturated ammonium chloride and washed with DCM and the organic layers was dried with MgS04. The concentrated crude was purified by chromatography to obtain (R)-tert-butyl 2-((2-(5-(difluoromethyl)thiophene-2-carboxamido)-5-(3-hydroxypentan- 3-yl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidine-l-carboxylate, 180 mg as a yellow oil. Continuing as in Steps 1, 2, and 5, Example 52, afforded 48 mg of (R)-N-(l-((l-(2-cyano-4- methylpent-2-enoyl)-pyrrolidin-2-yl)methyl)-5-(3-hydroxypentan-3-yl)-lH-benzo[d]imidazol-2- yl)-5-(difluoromethyl)-thiophene-2-carboxamide as a white solid.
Example 73
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-
((neopentylamino)meth -lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide
Stepl
To a solution of (R)-methyl l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-imino- 2,3-dihydro-lH-benzo[d]imidazole-5-carboxylate (1 120 mg, 2.99 mmol) (Intermediate 13, Step 3), isoxazole-5-carboxylic acid (507.3 mg, 4.49 mmol), and DIPEA (1.03 mL, 5.9 8mmol) in DMF (6 mL)) was added HATU (1705 mg, 4.49 mmol). The resultant mixture was stirred at rt for 2 hours. The reaction mixture was evaporated, then the crude mixture was diluted with DCM and washed with brine. The organic layers were separated and dried with MgS04, filtered and concentrated to crude oil. This crude oil was purified by chromatography to obtain 1380 mg of (R)-methyl l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-(isoxazole-5-carboxamido)-lH- benzo[d]imidazole-5-carboxylate.
Step2
A mixture of (R)-methyl l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-(isoxazole- 5-carboxamido)-lH-benzo[d]imidazole-5-carboxylate (1027 mg, 2.19 mmol) in THF (20mL)
was stirred at 0° C and then was added LAH (2M in THF) (3.3 niL, 6.56 mmol). The resultant mixture was then stirred at rt for 1 hour. The reaction mixture was quenched with NaHCC>3 (sat, 30 mL) and worked up with DCM. The organic layers were washed with brine and dried
(MgS04). The crude was concentrated to an oil and purified by chromatography to obtain 600 mg of (R)-tert-butyl 2-((5-(hydroxymethyl)-2-(isoxazole-5-carboxamido)-lH-benzo[d]imidazol-l- yl)methyl)pyrrolidine- 1 -carboxylate.
Step3
To the mixture of (R)-tert-butyl 2-((5-(hydroxymethyl)-2-(isoxazole-5-carboxamido)-lH- benzo[d]imidazol-l-yl)methyl)pyrrolidine-l -carboxylate (320 mg, 0.72 mmol)in DCM (2mL) was added 4N HC1 in dioxane (3.mL). The resultant mixture was stirred at rt for 4 hours. The reaction mixture was concentrated and dried in hi-vac to obtain309 mg of (R)-N-(5- (hydroxymethyl)-l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide as the HC1 salt.
Step 4
To a solution of (R)-N-(5-(hydroxymethyl)-l-(pyrrolidin-2-ylmethyl)-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, HC1 salt (247 mg, 0.72 mmol), DIPEA
(0.37mL, 2.17mmol), and 2-cyanoacetic acid (123 mg, 1.45 mmol) in DMF (4 mL) was stirred at rt for 10 minutes then added HATU (412.44 mg, 1.09 mmol). The resulting mixture was stirred at rt for 1 hour. The reaction mixture was concentrated and worked up with water and then the organic layers was dried (MgS04) and concentrated to oil. DCM was added and the resulting precipitate was filtered to collect the solid product which was purified by chromatography to obtain 280 mg of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide.
Step 5
To the solution of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-
(hydroxymethyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide (280 mg, 0.69 mmol) was added Dess Martin periodinane (436.18 mg, 1.0 3mmol). The resulting mixture was stirred at rt for 100 min . The reaction mixture was worked up with DCM and water and the organic layer was dried (MgS04) then concentrated to oil. The crude oil was purified by chromatography to afford 230 mg of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-formyl-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide.
Step 6
To a mixture of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-formyl-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide (278 mg, 0.68 mmol), 2,2-dimethylpropan-l- amine (0.19 mL, 1.71 mmol), and DCM (8 mL) was added NaBH3CN (85.97 mg, 1.37 mmol).
The resultant mixture was stirred at rt for 1 hour. The reaction mixture was washed sequentially with water and brine. The organic layer was dried (MgS04) and concentrated to oil then purified by chromatography to obtain 230 mg of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5- ((neopentyl-amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide.
Step7
To a solution of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)-methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide (115 mg, 0.24 mmol), 2-methylpropanal (0.07 mL, 0.72 mmol), pyrrolidine (0.1 mL, 1.2 mmol), and DCM (3 mL) was added chloro(trimethyl)-silane (0.12 mL, 0.96 mmol). The resultant solution was stirred at rt for 1 hour. The reaction mixture was concentrated to dryness and then purified by chromatography to obtain (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 5-((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, 48mg. MS (pos. ion) m/z: 532 (M+l).
Example 74
Synthesis of (R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl -lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide
Substituting 2,2-dimethylpropanal for 2-methylpropanal in Step7, Example 73 above affordd (R)-N-(l-((l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((neopentyl- amino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide. MS (pos. ion) m/z: 546 (M+l).
Example 75
Synthesis of (R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide
Substituting 3-methyloxetane-3-carbaldehyde for 2-methylpropanal in Step7, Example 73 above afforded (R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)- 5-((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide. MS (pos. ion) m/z: 560 (M+l).
Example 76
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)nicotinamide
Substituting nicotinic acid for isoxazole-5-carboxylic acid in Stepl, Ex 73 above and continuing as in Steps 2-7 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-5-((neopentylamino)methyl)-lH4oenzo[d]imidazol-2-yl)nicotinamide. MS (pos. ion) m/z: 542 (M+l).
Example 77
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-5-((neopentyl- amino)methyl)-lH- methyl)benzamide
Substituting 3-(difluoromethyl)benzoic acid for isoxazole-5-carboxylic acid in Stepl, Example 73 above and continuing as in Steps 2- 7 afforded (R)-N-(l-((l-(2-cyano-4-methylpent-
2-enoyl)pyiTolidin-2-yl)methyl)-5-((neopentylamino)^
(difluoromethyl)benzamide. MS (pos. ion) m/z: 591 (M+l).
Example 78
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Step 1
To a solution (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-6-(hydroxymethyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (245mg, 0.52 mmol), (prepared as (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-5-(hydroxymethyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide but using methyl 3-fluoro-4- nitrobenzoate) in 10 mL of DCM was added Dess-Martin periodinane. The reaction mixture was stirred lh, filtered and the solvent removed to afford 240 mg of (R)-N-(l-((l-(2- cyanoacetyl)pyrrolidin-2-yl)methyl)-6-formyl-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide.
Step 2
To a mixture of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-6-formyl-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (240 mg) in 10 mL of DCM was added ,2-dimethylpropan-l -amine (0.06 mL) followed by NaB]¾CN (29 mg). The mixture was stirred for 2h and then partitioned between DCM and saturated sodium chloride. The organic phase was dried over sodium sulfate, filtered, and concentrated to afford 184 mg of (R)-N-(l-((l- (2-cyanoacetyl)pyrrolidin-2-yl)methyl)-6-((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)- 5-(difluoromethyl)thiophene-2-carboxamide.
Step 3
To a solution of (R)-N-(l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-6-((neopentyl- amino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (85 mg) in 10 mL of DCM was added 2-methylpropanal (0.3 mL). The reaction mixture was cooled to 0° C and pyrrolidine (0.08 mL, 0.93 mmol) was added followed by TMS-C1 (0.08 mL, 0.62 mmol).
The ice bath was removed and the reaction mixture was stirred at rt for 1 hour. After removal of solvent under vacuum, the residue was purified by chromatography to afford (R)-N-(l-((l-(2- cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-6-((neopentylamino)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide (30mg) as a white powder. LC-MS (ES, m/z): 597 [M+H].
Example 79
Synthesis of (R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-6- ((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide
Following the procedure in Step 3, Example 78, but replacing 2-methylpropanal with 3- methyloxetane-3-carbaldehyde afforded (R)-N-(l-((l-(2-cyano-3-(3-methyloxetan-3- yl)acryloyl)pyrrolidin-2-yl)methyl)-6-((neopentylamino)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiophene-2-carboxamide. LC-MS (ES, m/z): 625 [M+H].
Example 80
Synthesis of N-(l-((l-(2-cyano-4-(dimethylamino)-4-methylpent-2-enoyl)azetidin-3-yl)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide
Step 1
Into a 100-mL round-bottom flask, was placed a solution of tert-butyl 3-[(2-amino-lH- l,3-benzodiazol-l-yl)methyl]azetidine-l-carboxylate (Example 43, Step 3) (1 g, 3.31 mmol) in 50 mL of DMF. 5-(Difluoromethyl)thiophene-2-carboxylic acid (650 mg, 3.65 mmol), PyBop
(1.9 g, 3.66 mmol), and triethylamine (2.1 mL) were added to the reaction mixture. The resulting solution was stirred overnight at rt, and then it was diluted with H2O. The solids were collected by filtration, and dried in an oven under reduced pressure to give 1.6 g of tert-butyl 3-([2-[5- (difluoromethyl)-thiophene-2-amido]-lH-l,3-benzodiazol-l-yl]methyl)azetidine-l-carboxylate as a pink solid.
Step 2
Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 3-([2-[5-(difluoro- methyl)thiophene-2-amido]- 1H- 1 ,3-benzodiazol-l -yl]methyl)azetidine- 1-carboxylate (300 mg, 0.65 mmol) in DCM (10 mL) and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at rt, and then it was diluted with DCM. The resulting mixture was washed with saturated sodium bicarbonate (aq.), and concentrated under vacuum to give 200 mg of N-[l- (azetidin-3-ylmethyl)- 1H- 1 ,3-benzodiazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide as a yellow solid.
Step 3
Into a 100-mL round-bottom flask, was placed a solution of N-[l-(azetidin-3-ylmethyl)- lH-l,3-benzodiazol-2-yl]-5-(difluoromethyl)thiophene-2-carboxamide (270 mg, 0.75 mmol) in DMF (20 mL). 2-Cyanoacetic acid (70 mg, 0.82 mmol), triethylamine (380 mg, 3.76 mmol), and HATU (342 mg, 0.90 mmol) were added to the reaction mixture. The resulting solution was stirred overnight at rt, and then it was diluted with H2O. The solids were collected by filtration, and dried in an oven under reduced pressureto give 200 mg of N-(l-[[l-(2-cyano-acetyl)azetidin- 3-yl]methyl]-lH-l,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide as a brown solid.
Step 4
Into a 100-mL round-bottom flask, was placed a solution of N-(l-[[l-(2-cyanoacetyl)- azetidin-3-yl]methyl]- 1H- 1 ,3-benzodiazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide
(220 mg, 0.51 mmol), 2-(dimethylamino)-2-methylpropanal (300 mg, 2.60 mmol), and piperidine (130 mg, 1.53 mmol) in toluene (50 mL). The resulting solution was stirred overnight at 110° C in an oil bath, and then concentrated under vacuum. The crude product (150 mg) was purified by Prep-HPLC to afford 18 mg of N-(l-((l-(2-cyano-4-(dimethylamino)-4-methylpent-2- enoyl)azetidin-3 -yl)methyl)- 1 H-benzo[d] imidazol-2-yl)-5 -(difluoromethyl)thiophene-2- carboxamide as an off-white solid. LC-MS (m/z): 527 [M+H].
Example 81
Synthesis of N-(l-((l-(2-cyano-4-methyl-4-morpholinopent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide
Following the procedure in Step 4, Example 80, but substituting 2-methyl-2-morpholino- propanal in place of 2-(dimethylamino)-2-methylpropanal afforded N-(l-((l -(2-cyano-4-methyl- 4-morpholino-pent-2-enoyl)azetidin-3-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)-thiophene-2-carboxamide. LC-MS (m/z): 569 [M+H].
Example 82
Synthesis of N-( 1 -(( 1 -(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3 -yl)methyl)- 1 H- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide
Step 1
Following the procedure in Step 4, Example 80, but substituting tert-butyl N-(2-methyl- 1 - oxopropan-2-yl)carbamate in place of 2-(dimethylamino)-2-methylpropanal afforded tert-butyl (4-cyano-5-(3-((2-(5-(difluoromethyl)thiophene-2-carboxamido)-lH-benzo[d]imidazol-l- yl)methyl)-azetidin-l-yl)-2-methyl-5-oxopent-3-en-2-yl)carbamate.
Step 2
Into a 50-mL round-bottom flask, was placed a solution of tert-butyl (4-cyano-5-(3-((2- (5-(difluoromethyl)thiophene-2-carboxamido)- 1 H-benzo[d]imidazol- 1 -yl)methyl)azetidin- 1 -yl)- 2-methyl-5-oxopent-3-en-2-yl)carbamate (130 mg, 0.22 mmol) in DCM (10 mL) and
trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at rt, and then it was concentrated under vacuum. The crude product (90 mg) was purified by Prep-HPLC to afford 40 mg of N-(l-((l-(4-amino-2-cyano-4-methylpent-2-enoyl)azetidin-3-yl)methyl)-lH- benzo[d]imidazol-2-yl)-5-(difluoro-methyl)thiophene-2-carboxamide as the formic acid salt as a white solid. LC-MS (m/z): 499 [M+H].
Example 83
Synthesis of (R)-N-( 1 -((1 -(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)- 1 H- benzo[d]imidazol-2- -5-(difluoromethyl)thiophene-2-carboxamide
Into a 250-mL round-bottom flask, was placed a solution of 5-(difluoromethyl)-N-[l -
[(2R)-pyrrolidin-2-ylmethyl]-lH- l,3-benzodiazol-2-yl]thiophene-2-carboxamide (150 mg, from Step 3, Example 50) , 2-cyano-4,4-dimethylpent-2-enoic acid (70 mg, 0.46 mmol, 1. 15 equiv), HATU (177 mg, 0.47 mmol, 1.17 equiv), and triethylamine (0.2 mL) in DMF (30 mL). The resulting solution was stirred overnight at rt, and then it was diluted with water. The solids were collected by filtration. The crude product (100 mg) was purified by Prep-HPLC to afford 29.2 mg of (R)-N-(l-((l -(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)- lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide as an off-white solid. LC- MS (m/z): 512 [M+H]. Example 84
Synthesis of (R)-N-(l -((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)- lH- benzo [d] i lbenzamide
(R)-3-Methyl-N-( 1 -(pyrrolidin-2-ylmethyl)- 1 H-benzo[d]imidazol-2-yl)benzamide (prepared as in Example 50 but substituting 3-methylbenzoic acid for 5- (difluoromethyl)thiophene-2-carboxylic acid) was dissolved in N,N-dimethylformamide (10 mL). DIEA (231.9 mg, 1.79 mmol, 4.00 equiv), HATU (255.8 mg, 0.67 mmol, 1.50 equiv), and 2-cyano-4-methylpent-2-enoic acid (93.6 mg, 0.67 mmol, 1.50 equiv) were added to the reaction mixtureand the resulting solution was stirred overnight at rt. The reaction was quenched with
water and the resulting solution was extracted with dichloromethane, and the combined organic layers were concentrated under vacuum. The crude product (100 mg) was purified by Prep HPLC to afford 47.4 mg of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)-3-methylbenzamide as a white solid. LC-MS (m/z): 456.3 [M+l].
Example 85
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo [d] imi l)benzamide
(R)-3-(Difluoromethyl)-N-(l-(pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)- benzamide (prepared as in Example 50 but substituting 3-(difluoromethyl)benzoic acid for 5- (difluoromethyl)-thiophene-2-carboxylic acid) was reacted with 2-cyano-4-methylpent-2-enoic acid as in Example 84 to afford (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imidazol-2-yl)-3-(difluoromethyl)benzamide. LC-MS(m/z): 492.1
[M+H].
Example 86
Synthesis of (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imi 5-carboxamide
(R)-N-(l-(Pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide ( prepared as in Example 50 but substituting isoxazole-5-carboxylic acid for 5-(difluoromethyl)- thiophene-2-carboxylic acid), was reacted with 2-cyano-4-methylpent-2-enoic acid as in Example 84 to afford (R)-N-(l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-lH- benzo[d]imidazol-2-yl)isoxazole-5-carboxamide.LC-MS(m/z):433[M+H].
Example 87
Synthesis of N-(l-(2-(2-cyano-N,4,4-trimethylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2- yl)-5-(difluoromethyl)thiophene-2-carboxamide
5-(Difluoromethyl)-N-(l-(2-(methylamino)ethyl)-lH-benzo[d]imidazol-2-yl)thiophene-2- carboxamide, (prepared as in Example 50 but substituting tert-butyl (2-aminoethyl)(methyl)- carbamate for tert-butyl 2-(aminomethyl)pyrrolidine-l-carboxylate) was reacted as in Example 83 to afford N-(l-(2-(2-cyano-N,4,4-trimethylpent-2-enamido)ethyl)-lH-benzo[d]imidazol-2-yl)- 5-(difluoromethyl-)thiophene-2-carboxamide. LC-MS (m/z): 486 [M+H].
Example 88
Synthesis of (R)-N-( 1 -(( 1 -(2-cyano-5-hydroxy-4,4-dimethylpent-2-enoyl)pyrrolidin-2- yl)methyl)-lH-benzo[d]imi l)thiophene-2-carboxamide
Step 1
To a solution of 2,2-dimethylpropane-l,3-diol (10 g, 96.02 mmol, 1.00 equiv) and imidazole (9.8 g, 144.12 mmol, 1.50 equiv) in DCM (50 mL) was added a solution of TBSC1 (15.9 g, 106 mmol, 1.10 equiv) in DCM (50 mL) dropwise. The resulting solution was stirred for 3 h at rt, and then diluted with water. The resulting solution was extracted with DCM, and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum to give 18 g of 3-[(tert-butyldimethylsilyl)oxy]-2,2-dimethylpropan- 1 -ol as a light yellow oil.
Step 2
To a solution of 3-[(tert-butyldimethylsilyl)oxy]-2,2-dimethylpropan-l -ol (5 g, 22.89 mmol, 1.00 equiv) in dichloromethane (100 mL) was added Dess-Martin periodinane (10 g, 23.58 mmol, 1.03 equiv) and the resulting solution was stirred for 4 h at rt. The reaction mixture was diluted with 100 mL of DCM and the solids were filtered out. The filtrate was washed with saturated aqueous sodium bicarbonate solution and brine, dried over sodium sulfate and concentrated under vacuum to give 3.2 g of 3-[(tert-butyldimethylsilyl)oxy]-2,2- dimethylpropanal as a colorless oil.
Step 3
To a solution of 3-[(tert-butyldimethylsilyl)oxy]-2,2-dimethylpropanal (3.6 g, 16.64 mmol) in toluene, 2-cyanoacetic acid (1.5 g, 17.63 mmol) and ammonium acetate (200 mg, 2.59 mmol) were added. The resulting solution was stirred overnight at 140 °C in an oil bath. The resulting mixture was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under vacuum to give 2.4 g of 5-((tert-butyldimethylsilyl)oxy)-2-cyano-4,4- dimethylpent-2-enoic acid as a yellow oil.
Step 4
Into a 100-mL round-bottom flask, was placed a solution of 5-(difluoromethyl)-N-[l - [(2R)-pyrrolidin-2-ylmethyl]-lH-l ,3-benzodiazol-2-yl]thiophene-2-carboxamide (400 mg, 1.06 mmol) in 20 ml of DMF. 5-((tert-Butyldimethylsilyl)oxy)-2-cyano-4,4-dimethylpent-2-enoic acid (670 mg, 2.36 mmol), HATU (800 mg, 2.10 mmol), and triethylamine (0.5 mL) were added to the reaction mixture. The resulting solution was stirred overnight at rt, and then diluted with water. The resulting solution was extracted with dichloromethane, and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuumto give 300 mg of (R)-N-(l-((l -(5-((tert-butyldimethylsilyl)oxy)-2-cyano-4,4-dimethyl- pent-2-enoyl)pyirolidin-2-yl)methyl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide as a brown oil.
Step 5
To a solution of (R)-N-(l -((l-(5-((tert-butyldimethylsilyl)oxy)-2-cyano-4,4-dimethylpent- 2-enoyl)pyrrolidin-2-yl)methyl)- lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2- carboxamide (400 mg, 0.62 mmol) in 5 mL of methanol was added 4N HC1 in dioxane (5 mL). The resulting solution was stirred overnight at room temperature, and then it was concentrated under vacuum. The crude product (300 mg) was purified by Prep-HPLC to afford 166.0 mg (R)- N-(l -((l-(2-cyano-5-hydroxy-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)- lH- benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide as a light yellow solid. LC- MS (m/z): 528 [M+H].
Example 89
Synthesis of (R)-N-(l-(l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)-lH-benzo[d]imidazol- 2-yl)-5-(difluoromethyl)thiophene-2-carboxamide
(R)-5-(Difluoromethyl)-N-(l-(pyrrolidin-3-yl)-lH-benzo[d]imidazol-2-yl)thiophene-2- carboxamide (prepared as in Example 50 but substituting (R)-tert-butyl 3-aminopyrrolidine-l- carboxylate for (R)-tert-butyl 2-(aminomethyl)pyrrolidine-l -carboxylate) was dissolved in 20 mL of DMF. TEA (335.1 mg, 3.31 mmol), 2-cyano-4-methylpent-2-enoic acid (153.6 mg, 1.10 mmol, and HATU (629.5 mg, 1.66 mmol) were added to the reaction mixture. The resulting solution was stirred overnight at rt and then concentrated under vacuum. The crude product was purified by Prep-HPLC to afford 173 mg of (R)-N-(l-(l-(2-cyano-4-methylpent-2- enoyl)pyrrolidin-3-yl)-lH-benzo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-carboxamide LC-MS m/z: 484.2 [M+l].
Example 90
Synthesis of (R)-l-((l-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoro- methyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxamide
Step 1
To a solution of (R)-methyl l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-lH-benzo[d]imidazole-5-carboxylate (242 mg, 0.45 mmol) in THF (50mL) was added KOH (50.79 mg, 0.9 lmmol). The resulting mixture was heated at 45 °C for 3 days. The mixture was concentrated to an oil and purified by
chromatography to obtain 169 mg of (R)-l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2- (5-(difluoromethyl)-thiophene-2-carboxamido)-lH-benzo[d]imidazole-5-carboxylic acid.
Step 2
A mixture of (R)-l-((l-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoro- methyl)thiophene-2-carboxamido)-lH-benzo[d]imidazole-5-carboxylic acid (169 mg, 0.32 mmol), 2,2-dimethylpropan-l -amine (0.08 mL, 0.65 mmol), DIPEA (0.28 mL, 1.62 mmol) and DMF (6 mL) was stirred at rt for 5 minutes and then HATU (246.74mg, 0.65mmol) was added. After stirring 1 h, the crude was concentrated in vacuo and then purified by chromatography to obtain 160 mg of (R)-tert-butyl 2-((2-(5-(difluoromethyl)thiophene-2-carboxamido)-5- (neopentylcarbamoyl)- 1 H-benzo [d] imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate.
Step 3
To a mixture of (R)-tert-butyl 2-((2-(5-(difluoromethyl)thiophene-2-carboxamido)-5-
(neopentylcarbamoyl)- lH-benzo[d]imidazol- 1 -yl)methyl)pyrrolidine- 1 -carboxylate (160 mg, 0.27 mmol) and DCM (6 mL) was added 4N HC1 in dioxane (6.mL). The resulting mixture was stirred at room temp for lh, concentrated and dried in hi-vac to obtain 180 mg of (R)-2-(5- (difluoromethyl)-thiophene-2-carboxamido)-N-neopentyl-l-(pyrrolidin-2-ylmethyl)-lH- benzo[d]imidazole-5-carboxamide as the HC1 salt.
Step 4
To a solution of (R)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazole-5-carboxamide (132 mg, 0.27 mmol), DIPEA (0.37 mL, 2.16 mmol), 2-cyanoacetic acid (91.74 mg, 1.08 mmol) in DMF (6 mL) was stirred at rt for 10 minutes then HATU (153.68mg, 0.40mmol) was added. After 20 h, the mixture was evaporated and worked up with brine and DCM and the organic phase was concentrated.
Purification by chromatography afforded 140 mg of (R)-l-((l-(2-cyanoacetyl)pyrrolidin-2- yl)methyl)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole- 5-carboxamide as a white solid.
Step5
To a solution of (R)-l-((l-(2-cyanoacetyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)- thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxamide (70 mg, 0.13 mmol), pyrrolidine (0.03 mL, 0.38 mmol) and 2-methylpropanal (0.03 mL, 0.38 mmol) in DCM (8 mL) was added TMSC1 (0.06 mL, 0.50 mmol). After stirring for 7 hours, the crude mixture was worked up with water and DCM and the organic layers were dried (MgS04) and concentrated to afford oil which was purified by chroamtography to obtain l-((l-(2-cyano-4- methylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N- neopentyl-lH-benzo[d]imidazole-5-carboxamide (1 1 mg) as white solid. MS (pos. ion) m/z: 61 1 (M+H).
Example 91
Synthesis of (R)-l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxamide
Substituting 3-methyloxetane-3-carbaldehyde for 2-methylpropanal in Step 5, Example 90 above produced (R)-l-((l-(2-cyano-3-(3-methyloxetan-3-yl)acryloyl)pyrrolidin-2-yl)methyl)- 2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5- carboxamide. MS (pos. ion) m/z: 639 (M+l).
Example 92
Synthesis of (R)- 1 -(( 1 -acryloylpyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2- carboxamido)- -neopentyl-lH-benzo[d]imidazole-5-carboxamide
To a solution of (R)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-neopentyl-l- (pyrrolidin-2-ylmethyl)-lH-benzo[d]imidazole-5-carboxamide (82.35mg, 0.17mmol, Step 3 Example 89) in DCM (12 mL), was added TEA (0.09 mL, 0.67 mmol) followed by prop-2-enoyl chloride (0.02 mL, 0.25 mmol). After stirring 10 minutes, the reaction mixture was partitioned between water and DCM and the organic phase was dried (MgS04) and evaporated. The crude oil was purified by chromatography to provide (R)-l-((l-acryloylpyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)-thiophene-2-carboxamido)-N-neopentyl-lH-benzo[d]imidazole-5-carboxamide, 31mg (33.9%). MS (pos. ion) m/z: 544 (M+l).
Example 93
Synthesis of l-(((R)-l-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methyl)-2-(5- (difluoromethyl)thiophene-2-carboxamido)-N-((S)-3,3-dimethylbutan-2-yl)-lH-
Substituting (2S)-3,3-dimethylbutan-2-amine for 2,2-dimethylpropan-l -amine in Step 2, Example 89 above and continuing as in Steps 3 -5, Example 90 but substituting 2,2- dimethylpropanal for 2-methylpropanal in Step 5, afforded l-(((R)-l-(2-cyano-4,4-dimethylpent- 2-enoyl)pyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-((S)-3,3- dimethylbutan-2-yl)-lH-benzo[d]imidazole-5-carboxamide. MS (pos. ion) m/z: 639 (M+l).
Example 94
Synthesis of 1 -(((R)- 1 -acryloylpyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2- carboxamido)-N-((S)-3, -dimethylbutan-2-yl)-lH-benzo[d]imidazole-5-carboxamide
Substituting (2S)-3,3-dimethylbutan-2-amine for 2,2-dimethylpropan-l -amine in Step 2, Example 90 above and continuing as in Step 3, Example 89 produced 2-(5-(difluoromethyl)- thiophene-2-carboxamido)-N-((S)-3,3-dimethylbutan-2-yl)-l-((R)-pyrrolidin-2-ylmethyl)-lH- benzo[d]imidazole-5-carboxamide which was reacted as in Example 91 to obtain 1-(((R)-1- acryloylpyrrolidin-2-yl)methyl)-2-(5-(difluoromethyl)thiophene-2-carboxamido)-N-((S)-3,3- dimethylbutan-2-yl)-lH-benzo[d]imidazole-5-carboxamide, 31mg. MS (pos. ion) m/z: 558 (M+H).
Biological Examples
Example 1
Inhibition of Itk enzymatic activity ... in vitro assay
The ability of the compounds of the present disclosure to inhibit ITK was measured using the Caliper assay format, which is an electrophoretic separation of a phosphorylated peptide substrate from unphosphorylated peptide. The enzymatic reaction occured in a buffer of 100 mM HEPES pH 7.5, 5 mM MgCl2, 0.01% Triton-X 100, 0.1% Bovine Serum Albumin, and 1% DMSO. Three-fold dilutions of compounds were prepared in DMSO. Compounds were added to enzyme and pre-incubated for 15 minutes prior to reaction. The enzymatic reaction was initiated by addition of phospho-acceptor peptide FAM-GEEPLYWSFPAKKK-NH2 (also known as SRCtide) to 1 uM and ATP to its Km value (ITK: 10 uM). The reaction proceeded for 3 hours and was terminated by addition of EDTA. The assay employed an enzyme concentration of 1 nM. The top compound concentration was 5 uM. The amount of phosphorylated substrate was determined by the Caliper instrumentation, and dose-response curves were fit using standard methods to determine the IC50 values. The IC50 for a representative compound of the present disclosure is provided in Table 1 below.
Cpd # ITK Cpd # ITK Cpd # ITK
(see Cpd IC50 um (see Cpd Table 1 IC50 um (see Cpd IC50 um
Table 1 above) Table 1
above) above)
1 .929 32 0.142 102 0.0076
2 1.78 33 0.0070 108 0.026
3 0.53 36 0.040 114 0.179
4 >5 37 0.02 115 0.0145
5 0.67 40 0.0056 113 0.0023
7 >5 42 0.01 116 0.0103
10 1.72 44 0.0199 117 0.0093
12 0.12 49 0.005 118 0.0118
13 >4 50 0.037 119 0.92
14 0.32 51 0.013 121 0.035
17 0.13 53 0.12 122 0.052
18 0.028 54 1.89 124 0.17
19 0.01 58 0.0070 125 0.77
20 0.0006 59 0.0006 126 0.215
21 0.003 60 0.005 127 0.018
Cpd # ITK Cpd # ITK Cpd # ITK
(see Cpd IC50 um (see Cpd Table 1 IC50 um (see Cpd IC50 um
Table 1 above) Table 1
above) above)
22 0.0018 61 0.0024 128 0.0137
23 0.023 62 0.0035 129 0.68
24 0.019 68 0.127 132 0.028
25 0.137 69 0.571 134 0.0026
26 0.012 72 >5 135 0.019
30 0.312 73 >5 136 0.006
80 0.959 79 1.01 138 0.068
88 0.743 89 0.049 63 0.0013
86 0.044 87 0.0248 64 0.0054
85 0.0075 84 0.973
Example 2
Determination of Drug-Kinase Residence time
The following is a protocol to distinguish whether a compound displays a slow or nonexistent dissociation rate from Itk, such as typically would occur if a covalent bond is formed between the compound and the target. The read-out for slow dissociation was the extent that the compound of interest can block binding of an excess amount of a high affinity fluorescent tracer molecule to the kinase active site, as detected using time -resolved fluorescence resonance energy transfer (TR-FRET).
The experiment was conducted in a buffer consisting of 50 mM Hepes pH 7.5, 10 mM MgCl2, 0.01% Triton X-100, and 1 mM EGTA. 500 nM Itk (Invitrogen Cat. #PV3875) was incubated with 1.5 uM of test compound for 30 minutes in a volume of 10 uL. The mixture was then diluted 50-fold by addition of 4 uL sample to 196 uL of buffer. A 10 uL volume of the diluted kinase/test compound solution was then added to a well of a small volume 384 well plate (such as Greiner Cat. #784076). In order to probe for reversibility of the kinase-compound binding interaction, a competition solution containing both a high affinity fluorescent tracer and an antibody coupled to Europium was prepared. The competition solution contained 5 uM Tracer 236 (Invitrogen Cat. #PV5592), which is a proprietary high affinity ligand for Itk coupled to the fluorophore AlexaFluor 647. The competition solution also contained 12.5 nM of an Anti- His antibody coupled to Europium (Invitrogen Cat. #PV5594) which is designed to bind the His
purification tag in Itk. After addition of 10 uL of the competition solution to the Greiner plate, the mixture was incubated for various times to allow time for dissociation of non-covalent inhibitors and binding of the high affinity tracer. It was expected that slow dissociating inhibitors will block binding of the tracer while rapidly dissociating inhibitors will not. Binding of the tracer to Itk was detected using TR-FRET between the Europium moiety of the Anti-His antibody and the AlexaFluor 647 group of Tracer 236. Binding was evaluated using a Perkin Elmer Envision instrument (Model 2101) equipped with filters and mirrors compatible with LANCE-type TR-FRET experiments. The excitation wavelength was 337 nm and the emission wavelengths were 620 nm and 665 nm. Data was acquired as the ratio of emission at 665 nm to 620 nm and was plotted as the percentage of signal obtained in the absence of competitor compound. The background signal was obtained by omission of kinase from the reaction.
When the compound is an irreversible covalent inhibitor, tracer was completely blocked from binding to the target throughout the entire course of the experiment. When the compound was a reversible covalent inhibitor, the tracer bound to the target as the compound dissociated from the target. The data were evaluated as occupancy of the target at 1, 6 and 24 hours after initiation of dissociation. The results for representative compounds are shown in Table 2 below.
Example 3
Cellular potency measured T cell receptor (TCR)-induced activation of Jurkat cells Cellular potencies of ITK inhibitory compounds were measured by blockade of activation of the transcription factor Nuclear Factor in Activated T cells (NFAT) following stimulation of the T cell receptor. Activation was measured using the Cell Sensor cell line NFAT-bla Jurkat from Invitrogen (Madison, WI) that utilizes a reporter construct for NFAT activation. Tripling dilutions of ITK inhibitors were pre-incubated with Jurkat T cells for I hour followed by activation with predetermined ICso concentrations of anti-CD3 and anti-CD28 for 5 hours. The
NFAT reporter activity was then assessed by addition of the beta-lactamase substrate followed by incubation for an additional 2 hours. Substrate cleavage was then measufed by monitoring the change in fluorescence resonance energy transfer using appropriate excitation and emission wavelength filters. The percent inhibition was then plotted as a function of the log of the compound concentration to calculate an IC50 using standard curve-fitting software. Data for representative compounds are shown in Table 3 below.
Table 3
Example 4
IL-2 production in anti-CD3 and anti-CD28 stimulated human PBMCs Peripheral blood mononuclear cells (PBMCs) isolated from human whole blood were preincubated with or without inhibitors in RPMI 1640 + 10% fetal bovine serum at 37°C for 30 min. PBMCs were stimulated with 2.5 ug/ml plate bound anti-CD3 and 1 ug/ml soluble anti- CD28 overnight and supernatant was collected for AlphaLISA IL2 assay. The IL-2 production was measured as AlphaLISA signal counts using Envision plate reader. Human Blood was obtained from healthy volunteer through Stanford Blood Center. Blood was collected by venipuncture into sodium heparin tubes. Blood was layered over Ficoll-Histopaque in 50 ml conical tube and centrifuged at 2000 rpm for 20 minutes at room temperature. Mononuclear cells were collected into 50 ml conical tubes, pooled and diluted with IX PBS to make up final volume to 50 ml in each tube. Cells were pelleted at 1500 rpm for 5 minutes and cells are washed two times. The cells were counted in Vi-Cell using trypan blue to determine cell number and
viability. PBMCs were then resuspended in RPMI 1640 with 10% fetal bovine serum at a concentration 1 x 106 cells/ml.
A 96-well polystyrene plate was coated with 2.5 ug/ml anti-CD3 in PBS overnight at 4°C. The wells in column one were coated with PBS only for unstimulated controls. Compounds of the disclosure were dissolved at 10 mM in 100% DMSO and 1 :3 serial dilutions of compounds are prepared in DMSO. These compounds were further diluted in complete medium to make final DMSO 0.2%) in 96-well polypropylene plate. To treat PBMC with compounds, 100 ul of 1x105 cells were cultured in 96-well polypropylene plate. Then 8 ul of each diluted compound was added in the corresponding wells in duplicate and 8 ul of medium with 2.5% DMSO was added to control wells. The plates were incubated at 37°C incubator for 30 min. The anti-CD3 coated plates were washed with PBS twice. 92 ul of media containing 1 ug/ml anti-CD28 were added to all wells except unstimulated controls. In unstimulated wells, 92ul medium was added. Plates were incubated overnight at 37°C, 5% CO2 incubator.
The next day, 150 ul of supernatant was removed from each well for AlphaLISA IL2 assay. According to manufacturer's protocol, IX buffer, IL2 standards (10 cone), 2.5X acceptor plus biotinylated beads mixture, 2X streptavidin donor beads were prepared. To each well, 2.5 ul standards or samples are added and then 10 ul of 2.5X mixture beads were added to each well. The plate was sealed with aluminum plate sealer and incubated at room temp on shaker for 1 hr. 12.5 ul of streptavidin donor beads are added to each well in dark room. The plate was sealed with aluminum plate sealer and incubated at room temp on shaker for 30 min. The plate was read in an Envision plate reader.
The IC50 for each compound was determined from a ten-point dose response curve for all compounds, each dose being tested in duplicate wells. The IC50 represents the concentration of a compound that shows 50% inhibition of IL-2 production in response to anti-CD3+anti-CD28 stimulated PBMCs with compound to 50% of that in control wells without compounds, and was calculated using curve fitting software.
Data for representative compounds are shown in Table 4 below.
Table 4
Compound # CD3/CD28-induced IL-2
(see Cpd Table 1 (μΜ)
above)
20 .018
27 .049
40 1.07
34 .13
60 .15
61 .24
62 .42
63 .21
64 .24
Example 5
Delayed Type Hypersensitivity in mice
Delayed type hypersensitivity is a standard model for measuring T cell mediated skin inflammation in vivo. Previous studies suggest that an inhibitor of ITK should be efficacious in such a model (see von Bonin et al. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases, Exp Dermatol,2Q: \- l ', 2010). Starting on study day zero (0), mice were randomized by body weight (using MS Excel) in to treatment groups, sensitized with aliquots of 150 microliters of a 5% oxazolone (Sigma) solution (3 parts ethanol + 1 part acetone) epicutaneously on their shaved abdomens. The right ears of the same (Isoflurane anesthetized) mice were challenged with 3% oxazolone solution 7 days later (Day 7), (i.e., 10 microliters on the front and another 10 microliters on the back of the right ears; whereas the left ears were painted on both ears with the ethanol/acetone mixture. One hour prior to challenge, certain groups received an ITK inhibitor at a dose and route determined to be appropriate based on previous phmacodynamic studies. Twenty-four hours later, animals were terminated via cervical dislocation and then, a 7-mm disc of ear (by using a cork borer, from Fisher Scientific) was punched out and weighed since weight is proportional to edema.
Compound of the disclosure wereactive in this model.
Example 6
Mass spectral analysis
A protein kinase that is inhibited by compound of Formula (IA) or (I) may be subjected to mass spectral analysis to assess whether the compounds of Formula (IA) or (I) form permanent, irreversible covalent adducts or reversible covalent bond. Suitable analytical methods to examine intact full protein or peptide fragments generated upon tryptic cleavage of the protein kinase are generally known in the art. Such methods identify permanent, irreversible covalent protein adducts by observing a mass peak that corresponds to the mass of a control sample plus the mass of an irreversible adduct. One such method is described below.
Mass spectral analysis of intact full kinase
Method:
A protein kinase (5 uM) is incubated with a compound of Formula (IA) or I (25 uM, 5 equiv) for 1 h at room temperature in buffer (20 mM Hepes [pH 8.0], 100 mM NaCl, 10 mM MgC^). A control sample is also prepared which does not have a compound of Formula (IA) and I. The reaction is stopped by adding an equal volume of 0.4% formic acid, and the samples are analyzed by liquid chromatography (Microtrap CI 8 Protein column [Michrom Bioresources], 5% MeCN, 0.2% formic acid, 0.25 niL/min; eluted with 95% MeCN, 0.2% formic acid) and inline ESI mass spectrometry (LCT Premier, Waters). Molecular masses of the protein kinase and any adducts may be determined with MassLynx deconvolution software.
Results: High-resolution intact mass spectrometry analysis of a kinase that is inhibited by a compound of Formula (IA) or I where Rb is other than hydrogen will reveal a spectrum similar to the kinase in the absence of inhibitor (e.g. control sample). There will be no formation of a new peak in the mass spectrum corresponding to the molecular mass of the kinase plus the molecular mass of the compound of Formula (IA) or I. On the basis of this experiment no permanent, irreversible protein adduct will be apparent to one skilled in the art. Compounds of Formula (IA) or (I) where Rb is hydrogen willshow a new peak in the mass spectrum
corresponding to the molecular mass of the kinase plus the molecular mass of the compound of Formula (IA) or I respectively, indicating a permanent, irreversible covalent bond formation between the protein and the compound of Formula (IA) or (I) respectively.
Example 7
Recovery of kinase activity upon dialysis
Standard experimental methods to establish reversibility are known in the art. Protein dialysis is one such method. A solution containing a protein kinase that is inhibited by a compound of Formula (IA) or I may be subjected to extensive dialysis to establish if the kinase inhibitor is reversible. Partial or complete recovery of protein kinase activity over time during dialysis is indicative of reversibility.
Method:
A compound of Formula (IA) or I and/or pharmaceutically acceptable salt described herein (1 uM) is added to a solution of protein kinase (50 nM, pre-activated if necessary) in a buffer containing 20 mM Hepes [pH 8.0], 10 mM MgC^, 2.5 mM tris(2-carboxyethyl)phosphine (TCEP), 0.25 mg/mL BSA, and 100 uM ATP. After 60 min at rt, the reactions is transferred to a dialysis cassette (0.1-0.5 mL Slide-A-Lyzer, MWCO 10 kDa, Pierce) and dialyzed against 2 L of buffer (20 mM Hepes [pH 8.0], 10 mM MgCl2, 1 mM DTT) at 4°C. The dialysis buffer is exchanged after 2 h, and then is exchanged every 24 h until the end of the experiment. Aliquots are removed from the dialysis cassettes every 24 h, flash frozen in liquid nitrogen, and
subsequently analyzed for protein kinase activity in triplicate. Kinase activity for each sample is normalized to the DMSO control for that time point and expressed as the mean ± SD.
Results: Kinase activity recovers from inhibition by reversible kinase inhibitors upon dialysis. Upon extensive dialysis at 4°C or at room temperature, kinase activity partially or completely recovers in a time-dependent manner from inhibition by an excess (20 equiv, 1.0 uM) of reversible kinase inhibitor.
Example 8
Reversibility of Binding
The following approach can be used to differentiate compounds that form irreversible bonds with their targets, such as acrylamide compounds, from compound that bind reversibly such as a reversible covalent inhibitor. Reactions are prepared with the protein target at a higher concentration than the compounds of interest. Both irreversible and reversible compounds bind the target and became depleted from solution. The reactions are then treated with perturbations including both denaturation with 5 M guanidine hydrochloride and digestion with trypsin, disrupting proper folding of the target. It will be found that the perturbation returns reversible compounds to solution due to dissociation from the target while irreversible compounds remain bound to the target. The concentration of compound in solution is assessed both preceding and following perturbation using high performance liquid chromatography (HPLC) coupled to tandem mass spectrometry. Using this technique, it can be demonstrated that an acrylamide- containing compound i.e, compounds of Formula (IA) or (I) where Rb is hydrogen is depleted from solution in both the native and perturbed state, while reversible compounds compounds of Formula (IA) or (I) where Rb is other than hydrogen depletes in the folded state but returns to solution following perturbation of the target.
Pharmaceutical Compositions
Parenteral Composition
To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of Formula (IA) or I is dissolved in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.
Oral Composition
To prepare a pharmaceutical composition for oral delivery, 400 mg of a compound of Formula (IA) or I and the following ingredients are mixed intimately and pressed into single scored tablets.
Tablet Formulation
Ingredient Quantity per tablet
mg compound 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5
Capsule Formulation
The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Ingredient Quantity per capsule
mg
compound 200 lactose spray dried 148 magnesium stearate 2
Sublingual (Hard Lozenge) Composition
To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge, mix 100 mg of a compound of Formula (IA) or I with 420 mg of powdered sugar mixed, with 1.6 mL of light corn syrup, 2.4 mL distilled water, and 0.42 mL mint extract. The mixture is gently blended and poured into a mold to form a lozenge suitable for buccal administration.
Fast-Disintegrating Sublingual Tablet
A fast-disintegrating sublingual tablet is prepared by mixing 48.5% by weigh of a compound of Formula (IA) or I, 44.5% by weight of microcrystalline cellulose (KG-802), 5% by weight of low-substituted hydroxypropyl cellulose (50 μιη), and 2% by weight of magnesium stearate. Tablets are prepared by direct compression (AAPS PharmSciTech. 2006;7(2):E41). The
total weight of the compressed tablets is maintained at 150 mg. The formulation is prepared by mixing the amount of a compound of Formula (IA) or I with the total quantity of microcrystalline cellulose (MCC) and two-thirds of the quantity of low-substituted hydroxypropyl cellulose (L- HPC) by using a three dimensional manual mixer (lnversina ®, Bioengineering AG, Switzerland) for 4.5 minutes. All of the magnesium stearate (MS) and the remaining one-third of the quantity of L-HPC are added 30 seconds before the end of mixing.
Inhalation Composition
To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound of Formula (IA) or I is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
Topical Gel Composition
To prepare a pharmaceutical topical gel composition, 100 mg of a compound of Formula
(IA) or I is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration. Ophthalmic Solution Composition
To prepare a pharmaceutical opthalmic solution composition, 100 mg of a compound of Formula (IA) or I is mixed with 0.9 g of NaCl in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
Nasal spray solution
To prepare a pharmaceutical nasal spray solution, 10 g of a compound of Formula (IA) or I is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μΐ of spray for each application.
Claims
1. A compound of Formula (LA):
Formula (LA)
wherein:
(i) when Z is N, then ring B is:
(a)
wherein:
Z1, Z2, and Z3 are CH (or C if substituted with R1 or R2) or Z1, Z2, and Z3 are
independently N or CH (or C if substituted with R1 or R2) provided that only one of Z1, Z2, and Z3 is N; and
(ii) when Z is C , then ring B is:
wherein:
Z 2 and Z 3 are CH (or C if substituted with R 1 or R 2 ) or Z 2 and Z 3 are independently N or CH (or C if substituted with R1 or R2) provided that only one of Z2 and Z3 is N;
R1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NR3COR4, -CONR3R5, -(alkylene)-NR3R5 (where each R3 is hydrogen, or alkyl, R4 is alkyl, haloalkyl, cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, cycloalkylalkyl, or heterocyclylalkyl optionally substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxy, alkoxy, hydroxyalkyl, or alkoxyalkyl; or R3 and R5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloamino wherein the heterocycloamino ring is optionally
substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxyl, alkoxy, hydroxyalkyl, or alkoxyalkyl, -NR6R7 (where R6 is hydrogen or alkyl and R7 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or acyl, or R6 and R7 together with the nitrogen atom to which they are attached form heterocyclyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyl, hydroxyalkyl, or alkoxyalkyl), or -OR8 (where R8 is hydroxyalkyl, alkoxyalkyl, or heterocyclylalkyl optionally substituted with one, two, or three substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl);
R2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy;
Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
X is alkylene, cycloalkylene, (where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NRa-, or -(alkylene)-NR3- (where each Ra is hydrogen, alkyl or cycloalkyl);
Y is -CO- or -S02-;
Rb is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl;
R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNRdRe or cycloalkylene(alkylene)NRdRe (where Rd and Re are independently hydrogen, alkyl, or cycloalkyl), alkoxyalkyloxyalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
Rd is hydrogen or alkyl, or Rb and Rd together form a bond; provided that when Rb is other than hydrogen, then R° is not hydrogen and Rd is hydrogen;
and/or a pharmaceutically acceptable salt thereof.
2. The compound of Claim 1
wherein:
(a)
wherein:
Z1, Z2, and Z3 are CH (or C if substituted with R1 or R2) or Z1, Z2, and Z3 are
independently N or CH (or C if substituted with R1 or R2) provided that only one of Z1, Z2, and Z3 is N; and
(ii) when Z is C , then ring B is:
wherein:
Z and Z are CH (or C if substituted with R or R ) or Z and Z are independently N or CH (or C if substituted with R1 or R2) provided that only one of Z2 and Z3 is N;
R1 is hydrogen, hydroxyalkyl, alkoxyalkyl, -NR3COR4, - CONR3R5, -(alkylene)-NR3R5 (where each R3 is hydrogen, or alkyl, R4 is cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl, and each R5 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, acyl, or heterocyclylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl; or R3 and R5 together with the nitrogen atom to which they are attached form heterocycloamino or spiroheterocycloamino wherein the heterocyclyl ring is optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl, -NR6R7 (where R6 is hydrogen or alkyl and R7 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or acyl, or R6 and R7 together with the nitrogen atom to which they are attached form heterocyclyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyl, hydroxyalkyl, or
alkoxyalkyl), or -OR8 (where R8 is hydroxyalkyl, alkoxyalkyl, or heterocyclylalkyl optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxyalkyl);
R2 is hydrogen, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, halo, haloalkyl, or haloalkoxy;
Ar is aryl or heteroaryl, each ring optionally substituted with one, two, or three substituents independently selected from alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl;
X is alkylene, cycloalkylene, ' (where Z is bond or alkylene, and ring A is heterocycloamino optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or fluoro), -alkylene-O-, -cycloalkylene-NRa-, or -(alkylene)-NRa- (where each Ra is hydrogen, alkyl or cycloalkyl);
Y is -CO- or -S02-;
Rb is hydrogen, cyano, nitro, halo, haloalkyl, haloalkoxy, alkylthio, or alkylsulfonyl;
R° is hydrogen, alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNRdRe, cycloalkylene(alkylene)NRdRe (where Rd and Re are independently hydrogen, alkyl, or cycloalkyl), or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro; and
Rd is hydrogen, alkyl, or Rb and Rd together form a bond; provided that when Rb is other than hydrogen, then R° is not hydrogen and Rd is hydrogen;
or a pharmaceutically acceptable salt thereof.
3. The compound or a pharmaceutically acceptable salt thereof of Claim 1 or 2 wherein the compound of Formula (I) or a salt thereof has the structure (la):
(la)
4. The compound or a pharmaceutically acceptable salt thereof of Claim 3 wherein Z1, Z2, and Z3 are CH (or C if substituted with R2).
5. The compound or a pharmaceutically acceptable salt thereof of Claim 1 or 2 wherein the compound of Formula (I) has the structure (lb):
(lb)
6. The compound or a pharmaceutically acceptable salt thereof of Claim 5 wherein Z1 and Z3 are CH (or C if substituted with R2).
7. The compound or a pharmaceutically acceptable salt thereof of any of claims 1 -6 wherein Rb and R° are hydrogen.
8. The compound or a pharmaceutically acceptable salt thereof of any of claims 1 -6 wherein Rb is cyano and R° is alkyl, substituted alkyl, cycloalkyl, or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents independently selected from hydroxy, alkyl or fluoro.
9. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein R° is alkyl.
10. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein R° is cycloalkyl.
1 1. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein R° is substituted alkyl.
12. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein R° is alkyl substituted with hydroxy, alkoxy, -NRR' (where R is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl and R' is hydrogen or alkyl) or heterocyclyl which is optionally substituted with one or two groups independently selected from alkyl or hydroxyl.
13. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein R° is -C(CH3)2NH2, -C(CH3)2NHCH3, -C(CH3)2N(CH3)2, -C(CH3)2NHCH2CH3, -C(CH3)2NHCH(CH3)2,
-C(CH3)j-NH-(3-methyloxetaii-3-yl),
-C(CH3)3-N(CH3)(3-meftyloxetoii-3-yl),
-C(CH3)2niorpholin- -yl, -C(CI¾H3-meiiiyIoxfitan-3.yl), -C(CH3)2azetidin-3-yl, -CiCHj^l-methylazetidin-S-yl),
14. The compound or a pharmaceutically acceptable salt thereof of claim 8 wherein Rc is 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substitucnts independently selected from hydroxy, alkyl or fluoro-
16. The compound or a pharmaceutically acceptable salt thereof of any of claims 1-14
17. The compound or a harmaceuticall acceptable salt thereof of any of claims 1-14
19. The compound or a pharmaceutically acceptable salt thereof of any of claims 1-14
where
20. The compound or a phannaceutically acceptable salt thereof of any of claims 1-19 wherein R1 is hydrogen, -NR3COR4, or -(alkylene>NR3Rs where R3 is hydrogen or alkyL R4 is optionally substituted aryl or heteroaryl, and Rs is hydrogen, alkyl, haloalkyl, or acyl or RJ and R5 together with the nitrogen atom to which they arc attached form hetcrocycloamino optionally substituted with one or two substituents independently selected from alkyl, halo, hydroxyalkyl, or alkoxy alkyl.
21. The compound or a pharmaceutically acceptable salt thereof of Claim 20 wherein R1 is hydrogen.
22. The compound or a pharmaceutically acceptable salt thereof of Claim 20 wherein R1 is -NR3COR4.
23. The compound or a pharmaceutically acceptable salt thereof of Claim 20 wherein R1 is -(alkylene)-NR3R5 where R3 is hydrogen or alkyl and R5 is hydrogen, alkyl, haloalkyl, or acyl.
24. The compound or a pharmaceutically acceptable salt thereof of Claim 20 wherein R1 is (S)-CH2N(COCF3)CH(CH3)C(CH3)3, (S>CH2 HCH(C¾)C(CH3)3, or (S)- CH2 (CH3 3¾CH3)C(CH3)3. eferabry (S)-CH2NHCH(CH3)C(CII3)3.
25. The compound or a pharmaceutically acceptable salt thereof of any of claims 1-24 wherein R2 is hydrogen.
26. The compound or a pharmaceutically acceptable salt thereof of any of claims 1-24 wherein Ar is phenyl optionally substituted with one, two, or three substituents selected from, alkyl, alkoxy, hydroxy, cyano, alk hhio, halo, haloalkyl, haloalkoxy, cycloalkyl, optionally substituted phenyl, or optionally substituted heteroaryl.
27. The compound or a pharmaceutically acceptable salt thereof of Claim 26 wherein Ar is phenyl substituted with one, two, or three substituents independently selected from chloro, fluoro, methyl, trifluoromethyl, trifluoromethoxy, difluoromethoxy, or difluromethyl.
28. The compound or a phannaceutically acceptable salt thereof of any of claims 1-25 wherein Ar is heteroaryl optionally substituted with one, two, or three substituents selected from,
alkyl, alkoxy, hydroxy, cyano, alkylthio, halo, haioaHcyl, haloaHeoxy, cycloalkyL optionally substituted phenyl, or optionally substituted beteroaryl.
29. The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein Ai is thien-2-yl, 5-chlorothien-2-yl, 5-cyanotrrien-2-yL, 2-oxazol -ylthicn-5-yl, 5<:Fj-mirai--2-yl, 1-raetbyl- pyrazol-3-yl, oxazol-5-yl , 2-met yl-oxa2»l-5-yl, 2-methyl, 1,2 ,3-triazol-4-yl, oxazol-5-yl, 2-methyl- oxazo.-4-yt, 2-methyl-thiazol-5-yl, 5-CHF2thien-2-yI, or isox&20l-5-yl.
30. Λ compound or a pharmaceutically acceptable salt thereof chosen from:
N-(l^ cryloylpiperidin-4-yl)-lH-btt
chloiObenzamide;
N^l-(l-aciyloylpiperidh4-yl lH-beiizo[d]im^
N-(l-(l-acryloylpiperidin-3-yl)-lH-ben∞^
chlorobenzamide;
^chloro-N-(l-(l-(2 yano -methylpcnt^^
2(3H)-ylidene)benzamjde;
>Kl-(l-(2-cyano -methylpent-2-enoyl)pi^
ylidene)ntcotinamide
N-(l-(l-acryloylpiperid -3-yJ)-lH-benzo[d]i^
4 hloro-N-(l- (l-(2<yano -memylpent-2-enoyl)pyrrolidm-2-yl)methyl)-l H- benzo[dJimidazol-2(3II)-ylidene)benzamide;
N-( 1 -(( 1 -acr ioy lpyrrol id'm-2-yl)methy l)-lH-benzo[d]irn idazol-2(3H)-y lidene)-4- chlorobenzamide;
N-(1-(l-(2-cyano-4-memylpent-2-enoyl)piperidm-4-yl>-lH-benzo[d]ir^
ylidene)nicotinamide;
N-(l-((l-(2-cyano4-memylpent-2-enoyl)pyrrolidm-2-yl)methyl)-lH-ben∞
2(3I^ylidene)nicotinamide;
ylidene)tiicotiiiamide;
(S)-N-(l-(l-acryloylpiperidm-4-^^
berj_zo[d]imidazol-2(3H)-yHdene) →^
4-cMoro-N-(1 H2-cyano -memylpent-2<noyl)pipcridin-3-yl)-5^( -((S 3,3 dimethylbtrian-2-yl)-2,2,2-triflu^^
ylidene)benzamtde;
N-(l-(l-acryloylpiperidm-3-yl)-5^
trinuoroacrtaniido)methyl>lH-benzo[dJimida-»l-2(3H^
4<hlor< N^l-((l-(2-cyano^
3 ^imethylbutBJ>-2-yl)-2,2,2-trifluoroa(«tanii(lo)me^
ylidene)beii22injde;
N-(K(l-aciyloylpyiToUdin-2-yl)^^
trifluoroacetamido)methyl) H4)enzo^
4-cbloro-N-(l-((H2 cyano-4-me ^
dim^ylbutan-2-yl)(metiiyl)ammo)methyl lH-benzoLd)imjd
4-chloro-N-(l-(H2-cyano^-methy^^
dimethylbutan-2-ylXmethyl)amino)m^^
N^l-(l-(2-cyano^-methylpent-2-eiioyl)piperid -3-yl lH-benzofd]timda^ ylidene)-5-(1 H-pyiazol-4-yl)thiophene-2-caiboxamide
N<1-(l-aciyloylpiperidm-3-yl)-lH-bei-ZO[d]imidazol-2(3H ylide^
y l)thiophene-2-carboxamide
N^l-(l-(2^yancv4^dimrthylamino)^
benzo[dJimidazol-2(3H)-ylidene)-5^]H-^^
N-( l-( l-(4 dimethylamino)but-2-enoyl)piperidin-3-yl)- lH-b o[d]imidazol-2(3H ylidOTe)-5-(1H-pyrazoM-yl)thiophene-2-carboxamide;
4-cUoro-N-(HH2-cyanc-4-methylpent-2-enoyl)piperidi-i-3-yl)-5-((((SH dimethylbirtan-2-yl)amino)metfy
N-0-(l-(4-amino-2-cyano-^
dimcthylbirtan-2-yI)amino)methyl)-l^
4-cbloro-N-(l-(l-(2-cyan< 4-methyl^methy^
((((S)-3,3-dimethylbutan-2-yl)aii^
4-chIoro-N-(l-(l-(2-cyano^-(dimethylaii^
((((S)-3,3^methylbutan-2-yl)amino)m^
N-(l-(^acryloylpiperidm-3-yl)-5^(((S)-3,3-dim^^
benzo[d]imidazol-2-yl)-4-clilorobenzamide;
-cMoro- -(l-((H2^ no^-me lpent^^
dime1 ylbutan-2-yl)amino)metby
N-(l-((H4-amin<>-2^yano^methylpeti^
dmetoy ibutan-2-yl)ammo)methy 1>- 1 H-te
4^Won>-N-(l-((1-(2-cyano^-methyl^
l)m^ l>5-((((S)-3 -dim(^ lb-^
yl)benzamide;
4-chloro-N-(l -((1 -(2-cyano^(dimethyIamino)^me^^
yl)methyl)-5 (((S> ,3-diraethylbutan-2-y^
yl)benzamide;
4-chIoro-N-(H(l-(2^yano-4-etho^
((((S)-3,3-dime lbut-m-2-yl)am^
N-(l-((l-aciyloylpyriOlidin-2-yl)me l)-5K(((S)-3,3-<lim
1 H-benzo [d] ixn\ dazol-2-y l)- -chlorobenzamid ;
N l-(((R)-l-acryloylpyTTolidin-2^
yJ)amino)mcthyl)- lH-benzo[d]imcJa7^1-2-yl)^ hIorobenzaii-idc;
-cbJoro-N-(l-(l-(2-cyan<^4,4-dimethylpent-2-enoyl)p^eridin-3-yl
dimethylbutan-2-yl)amino)me l lH-benzo[d]imidazol-2-yl)
4-chloro- -(l -(0 -(2-cyan H4,4^3imethylpCTt-2^noyl)pyrrolidirw2-yl)i^
3,3-dimeAylbutan-2-yl)aii-ino)rnetbyI)-lH-bcnzo[d]iinidaM
^HO-aciyloylpyiTolidin^- met^
1 H-ben20[d] imidazol-2-y l)-4-(difluoromcthyl)ben2amide;
N^M(l-(2-cyano^methylpent-2-^
diinethylbutan-2-yl)amino)methyl)- 1 H-benzo[d]imidazol-2-yl -(difluoromctbyl)benzaiiiide;
N-(l-(0-aciyloylpyrroIidin-2-yl)me^
lH-ben∞[d]imidazol-2-yl>5-(difluoiome^
N-(l-((l-(2^yano^inethylpent-2-enoyl^^^
dimeihylbutan-2-yl)amino)roe<hyl)-l^^
carboxamide;
(R)-N-(l -((1 -(2-cyano-4-methy Ipent-2-emoyl)pyrrolidin-2-yI)methyl)- 1H- benz»[d]imidazol-2-yl)-5-(lH-pyrazol-^
N^MCH^-cyano^methyl CTt^^no O-iz^d^
yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide
(R)-N-(l-((H4-aroino-2-cyano^m
benzo[d]iTTiidazol-2-yl)-5^1H-pyrazol-4^^
(R N-( 1 -(( I -(2-cy 8ηο^ιηβ^1- ^θ Ηο1.πσρ6ηΙ-2-<Μον1)ρν rrolidin-2-y l)methy 1)- 1 H- benzo[d]imidazol-2-yl)-5-(lH-pyrazol-4-yl)tMophene-2 arboxatn
(S)-N-(l-((l-(2<yano^niethylpent-2^noyD
benzo[d]imidazol-2-yl)-5-(lH-^
(S)-N M(l-(4-wmo-2-c mo^me lpent-2^
benzo[d]imidazol-2-yJ>5-(lH-pyra^^
(S>N^l^(l-(2-c^ano -melhyl^morpholinopent-2 moyI)pyrroKdm^^ benzo[d]imi(ia-»l-2-yl)-5 lH-pyrazol^yl)thiopheD^2.car
N-(l-(2-(2-cyano-4-mefoylpert-2-ei^
pyrazol-4-yl)thiophene-2-carboxamide;
N^l^(l -cyi o^methyl^mor hoKno en^
benzo[d]imidazol-2-yl)-5-(1 H-pyrazol- -yl)t iophene-2-carboxamide;
N<l-(2-(4-amino-2-cyano^methy^
(1 H-pyrazol-4-yI)thiopliene-2-carbox2mide;
Ν^Η2-(2-^3ηο-4- β Μ^θφ ϊηορβ^^^
yl)-5-(lH-pyrazol-4-yl)thiophene-2-carboxamide;
(R)-N^1-((H2n;yano-4 ne ] ent-2-en^^
benzo[d]imida∞l-2-yI)-5 difluoromelbyl)ftiophene-2<arboxam
(S N-(1 -((H2-cyano-4-me hylpent-2^oyl)pyTrolidin-2-yl)methyl)-lH- beiizo[d]imidazol-2-yl)-5-(difluoromethyl)thiophene-2-caiboxd^
N^l-(2-(2^y-mo-N,4-dimethylpent-2-eiiamido)ethyl ^
pyrazol-4-y l)thiophene-2-carboxam ide;
N-(l-(2-(2<yano-N,4^imethyl-4-mo
benzo[d]imida»)l-2-yl)-5-(lH-pyr^
N^K((S)-l-acrylaylpynOUdfo-2-yI)m^^
yl)amho)methyl)-lH-b^o[d]imidazol-2-yl -4^hlotObenzam
N-(1-(((R)-1 -actyloyIpyiroUdin-2-yl)methyl)-5-((((S)-3 -dimethylbutan-2- yl)_ui-ino)methyl)-lH-bei-zo[d]im^
N-(H((R l-acryloyIpyiroUdin-2-yl^^
yl)am-no)methyl)-lH-benzo[d]imidazol-^^
:N H((R>M2-cyano^^
dimetbylbutan-2-yl)ammo)methyl)- lH-benzo[d]inu<JazoI-2-yl)-5-(di^
carboxaroide;
N-(l-(((R>l 2-cyano^Adimet ylpent-2-enoyl)pyn >Iidin-2-yl)ra^ dimethylbutan-2-yl)amino)methyl)-lH-b^
carboxamide;
N-<l-(((R)-l-(2-cyano-3-cyclopropy^
dimetbylbutan-2-yl)amino)me^
carboxamide;
N-(K((R)-H2-cyano-3-(3-metfayloxet^^
S^-diraeth lbut-m^- fflnino^etty^
2-carboxamide;
N-(l-(((R l-(2-cy-mo-4-ethoxy^meihylpent-2-enoyl)pym)lidii^
3 ^iraethylbutan-2-yl)£unmo)methyl^^
2-carboxamide;
(R)-N-(t -((1 ^2-cyano A4-dimethyIpent-2-enoy
benzo[d]imidazoI-2-yI)-5-(difluoromet^
(R)-N-(l-((l-(2-cyano^-(dimethyla^
1 H-benzo[d]imidazol-2-yl)-5-(difluo
(R)-N-(l -((1 -acryloylpy-Tolidin-2-yl)methy 1)- lH-benzo[d]imidazol-2-yl)-5- (difluoromethyl)thiopheiie-2-carboxamide;
N-(l^^-cyano-NA4-trimet ylpcnt-2-eiiaii-M
(difluoromethyl)tbiophene-2-carboxamidc;
(R)-N-(l-{(l-{2 yano-4-m^ylpent-2^noyl)p^
berizo[d]imidazol-2-yl)i∑M>xazole-5-c^boxainide;
(R)-N-(l-((l-(2-cyano-4-mdhyIpe^^
benzo[d]imida2ol-2-y])-3-(difluoromethyl)beiizamidc;
(R)-N-(l -(( 1 -^-cyano-^etoylpeiit^-eiioyl^^^
benzo[d]imidazol-2-yl)-3-(trifluon>^
(R)-N-(l-((l-(2-cyano-4-metoylp^ 1 H- benzo[d]imidazol-2-yl)-3-memylbenzan.ide;
(R N-(l^(l-(2^y.mo^me lpent-2-enoyl)pyro^
benzo[d]imidazol-2-yl)-3,4-difluorobenzamide;
(R)-N-(l-((H2^yano-5-hydroxy-4A4iro^
benro[d]iim(iazo)-2-yl)-5-(difluor^
ben2o[d]imidazol-2-yI)-5^difluoromethyl)thiophen
(S)-N-(l -(1 -(4-amino-2-cyano-^methylpent-2-enDyl)py-Tolidm-3-yl)-lII- benzo[d]imidazol-2-y -5-(difluorom
N-( 1 -(( 1 -(4-a.nino-2-cyano-4-inethy lpent-2-enoyl)azeti<iin-3-yl)methyl)-lH- ben.io[d]imidazol-2-yl>5-(difluoromelJiyl)tiiiopbene-2-carbox
(R)-N 1 -((l-(2-cyano-4-melhyl^^
beiizo[d]imidazol-2-yl)-5-(difluor^^
(S)-N-(l-((l-(2-(^ano -meftylprat-2^
benzo[d]imidazol-2-yl)-5-(difluorome^
N-(l-(2 2-cyano-N, ^imethyl-4-moiphoHnopent-2^fl-imido)^
beii2ofd]imidazoJ-2-yl)-5-(di)nuoromethyl)thiophene-2-(wbo
N-( 1 -(2-(2-cyano-4-(diinethy lamino)-N ,4-diinethy lpent-2-enamido)ethyl lH- ben∞[d]imidazol-2-yl>5-(difluoromelhy
N-(l-((H2-cyano^(dimemyIamino)^me^
benzo[d]irnidazol-2-yiy5-(difluorome ^
N-(l-((I-(2-cyano^-memyM-moipiiolmope^^^
b«aizo[d]imidazol-2~yl)-5-(difluorome^^
( N-(l (H2-cyano^mcthyIp^
lH-benzo[dJimidazol-2-yl)-5-(difluorom^
(R)-N-(l-((1^2-cyano- -methylpent-2-enoyl)pynO!idin-2-yl)methyI>5- ((neopentylamino)m^yl)-lH-benzoL^^
carboxamide;
(R>N-(l^(H2-cyano-4-methylpen^
(raoipholinome^yl lH-bei)Zo[d]im-daz»l-2-yl>5-(<ljfluorome&
N l-(((R l-(2^yano^methy]pent-2-enoy ^
di etb lmo holmo)meΛ l)-1H-benzo[d]i^
carboxamide;
W-N-(l-((l-(2 ymo^methylpemt-2-^
trifluoroemyl)amino)methyl)-lH-benzo[d]iititdazol-^^
carboxamide;
(R>N-(l-((l-(2-cyano^ nethylpent-2-e^
methylpiperazin-l-yl)mcthyl)-lH-beira
carboxamide;
(R>N=(l^( (2^cyano^memylp^
((neopentylamtoo)memyl)-lH-beiizo[d]irojd
carboxamide;
(R)-N-(l-((H2-cyano-4-meliiylpent-2-enoyl)pyrro]idin^
dimethy Ιωθφ1κ>1ϊηο)ιηβ 1)-1 H-benzof d] imidazol-2-y1>-5-(difluoromethyl)thiophene-2- carboxamide;
:N-(l-(((R)-l-(2-cyaiio -m^
dimelhylbutan-2-yl)ammo)methylH
carboxamide;
N-(H((R)-l-(2 yan<>^metbylpent-2-e^^^
dimethy lbutan-2-yI)am ino)methyl>lH-benzo[d] imidazol^ lVS- difluoTXOTemy^thiophene^- carboxamide;
(R)-N-(l-((l ^5-ammo-2^ano-4,4-dime1hylpeirt-2^
ben∞{d]imtda∞l-2-yl)-5-(difluoro
(R)-N^l-((l-(2-cyano-4,4^imemylpen^^
((neopeiitylaromo)methyl)-lH-beiizo[d]imidazol-2-yl)^
carboxamide;
(R)-N-(l-((l-(2-cyanc- ,4-o¾emylp^
(moφholinomethyl)- 1 H-beiizo[d] imidazol-2-y -5-(diiluoromethyl)tbiophene-2-carboxainide; 97
N-(l-(((R H2-cyano^J4^imethylpent-2-enoyl)pyrrolidm-2-yl)me^
dimethylmorpholino)metbyl)- ! n-benzo[d]imidazol-2-yl 5-(difliioromethyl)tiuophene-2^ carboxamide;
(R)-N-(l-((l-(2<yano-3-(3-me loxetan-3-yl)ac^^
((neopcntylaix±io)methyl)-lH-ben2»[d]imida2ol-2-y1 5-(difl^
carboxamide;
(R)-N-(l-((l-(2-cyano-3 3-memyloxetan-3-yl)∞^
(moTOholmomethylHH-benzo[d]iim\-aro^
carboxamide; 100
N 1-(((R)-1 -(2-cyano-3 3-mcthyto
drniethylmoipholino)memyl)-lH-benzo[d]imidazol-2-yi)-5^difl
carboxamide,
(R)-N l- (l-(2-c ano^-m^ lr^^
((isobutylamwo)methyl)-lH-benzo[d]i^
carboxamide;
(R)-N-(l-((l-(2-cy&nc^,4-dime&ylp^
((isoburylain o)memyl)-1H-benzo[d)iim^
carboxamide;
(R)-N-(l-((l-(2-cyano-3-(3-me ^
((isobutylamino)raethyl tH-be^
carboxamide;
(R)-N-(l-((H2-cyano^merayipent-2-eno^^
methyloxetan-3-yl)me1hyl)amino)methyl lH-benzo[d]irm
(difluoromethyl)diiophcne-2-carbox-u-iide;
(R)-N 1.((l-(2 yano-4,4-din)e1 ylpert-2^noyl)pynolidin^
me loxetan-3-yl)methyl)anui)o)rae ^
(difiiwromethy0thiophenc-2-carix)xamjde;
(R)- -(l-((l ^-cyano-3^3-H-ethyloxetan-3-yl)∞^
methyloxetan-3-yl)methyl)amino)inethyI)- 1 H-ben2»id]im idazol-2-yl)-5- (difluoron ethyl)thiophene-2-carboxamide;
(R)-N-(5 2-oxa-6-azaspiro[3 ]heptan-6-ylme l)-H(l-(2-cyan^
enoyl)pyrrolidin-2-yl)methyl)-lH-beii7X)[d]unidazoW
carboxamide;
yl)amino)methy 1)- 1 H-benzo[d] imidazol-2-yl)-5^difliioromeayl)tbiophene-2-wboxamide;
N-( 1 -(((R)- 1 -(but-2-y noyl)py-TOlidii.-2-yl)raethy l>-5-((((S)-3,3-diraetfiy lbutaa-2- y l)amino)methy 1)- 1 H-benzo[d] inuda7X)l-2-yl)-4^ oiObeiizamidc;
N^l 1-(but-2-ynoyl)piperidin-3-yl)-5-((((S)-3^^imelhylbutan^
benzo[d]jtnidazol-2-yl)-5-(difl-wrometfayl)thiopheDe-2-c^
N-(l-(l-(but-2-ynoyl)piperidin -yl)-5-((((S)-3^^imethylbutan-2-yl
ben2O[djimidazo!-2-yl)-4-chlorobenzamide;
(R)-N-(l-((l-(2-cyaao-3 3-me1hyloxetan-3-yl)aciyloyI)pyrrolidi
((neopentylamino)methyl)-l II-benzo[d]imidazol-2-yl 5-(difluorometliy l)thiopbcne-2- carboxamide.
(R N-( 1 -(( 1 -(5-ammo-2-cyano-4,4-dimethy lpent-2-enoy I)pyn*olidin^^ benzo[d]unidazol-2-yl)-5-(^
(R)-N-(l-((l-(2<yano-4-methylpe^
((neopentyl.unmo)-incthyl)-l H-benzo[d]imidazoI-2-yl)-S^drfluorome hyl)tl-iopheiie-2- carboxamide;
(R)-N-( 1 -(( 1 -(2-cyano-3-(3-methy loxetan-3-yl)aoryloyl)pynrolidin-2-yl)methy I)-6- ((neopentylainino)methyl lH-beii∞^
carboxamide;
(R)-N-(l-((H2-cyan(>-4-methylpent-2-ra^
methylpropy l)amino)metbyl)- 1 H-benzo[d]imidazol-2-yl>5-(difluoro^
carboxamide;
R)-N-(l-((l-(2-cyano^memylp(∞t-2^no^
(((cyc-opropylmethyI)arnino)me^
carboxamide;
(R)-l-((1^2 yano^merhylpent-2^noyl)py^
(difluoromethyl)thiophene-2^arto^
(R)-H(H2-cyano-3^3-methytoxetan-3-yl)ac^
(difluc*xjme l)thiopheiie-2-c^ 1 H-benzo[d]im idazole-5-carboxamide;
(R N^l-((H2-cyano-4-methylpcnr-2-ra^
hydiOxypropan-2-yl)azetidin -yl)methyl lH-benzo[d]iim
(difluoTomethyl^ophene^-carboxamide;
(R)- -(H(H2^anc- -mcthy1pe^
hydroxyazetidin-1 -yl)methyl)-l H4>eiizo[d]majclazol-2-yl)-5^d_fluorom
carboxamide;
( )-N-(l-((l-(2-cyano^metoy^
hydroxypropai -2-yl)piperidin-l-yl)methy_^^
(difluoromethyl)thiophene-2-carboxamide;
(R)-N-(l-(l-(2-cyano^ dimethylpent-^
y -S-Cdifluoromcthyl^iophene^-carboxamide;
(S N-(Hl-(2-cyano-4,4^imethylpent-2-»^
yI)-5-(ditTuoromethyl)thiophene-2-carboxamidc;
(R)*N W -(2-cyano-4,4-dfatethyl-5^^
5-(hydroxymetoyl)-lH-bCTzo[d]i-riida
(R l-(0-acryloylpynOlidfa-2-yl)methy^
carboxamido)-N-neopentyl-lH-beiizo[d]inu
N -(3-(((R)- 1 -(2-cyano^-(2-methoxyethoxy)^me lpeot-2
yl)methyl>-6^((((S)-3,3-dimethylbatan-2-yl)ammo)m^
(difluoromethyl)thiophenc-2-carboxamide;
1 -(((R 1 -acryloylpynDUdin-2-yl)methyl)-2^5-(difluoromethyl tbi
carboxamido)-N-((S)-3,3-dimetliy]bul^-2-y^^
(S>-N-(l -((l<2-cyano-4,4-dmethylpent-2^oyl)azetidin-3-yl ^
dimethylbrtan-2-yl)ammo)methyl lH-be-^
carboxamide;
1-{((R)-1.(2.cyano-4,4-dime^
(dLfluo-omethyl)th-ophene-2 iarbo^ 1 H- benzo[d]imidazole-5-carboxamide;
(R>N-(H(l-(2^yano^methylpert-2^oyl)pyrrolidin-2-yl)meftyl)-5-(3- hydroxypentan-3-yl)-lH-benzo[d]imidazo^^
N^l-((l-(2-cyano^,4-dimethylpent-2.enoyl)pyrroHdin-3-yI)m^
dimethylbutan-2-yl)£-mino)methyl>lH-ben2»[d]iimdazol-2-y
carboxamide;
(R)-N^l-((l-(2-cyano-4^oxy^methylp^
((neopentylamino)m«ithyJ 1 H-benzo dJimidazol-2-yl)-5-(difluoromethyI)tbjophene-2- carboxamide;
(R N<H(H2-cyano-4-methylpent-2-e^^
((ncopentylainmo)-methyl tH-berizo[d]imidazol-2-yl)i^
(R)-N-(l -((1 -(2- yano-4,4-dimediylpent-2-enoy l)pyrrolidjn-2-yl)]nethyl)-5- ((neopentylamino)rtiethyl)- lH-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide;
(R)-N-(H(H2-cyano-3-(3-methyloxeto-3-y0a^
((neopentylamino)melhyl)-lH-beiizofd]iinidazo]-2-yl)i^
(R)-N-0-((M2-cyano^mfithylpent-2^n^^
((neopenlylaii-mo^ethyO-lH-ben^
(R)-N-(l -((H2-cyano^me lpent-2-enoyl)pynoK
((Deopentylammo)mcthyl)-1H-betizo[d]imidazol-2-yl^
N-(1-(((R)-I-(2-cyano-4 Mimet^
dimethylbutan-2-yDan>ino)methyl)-lH^^
N-(l -(((R)-l ^2^ano-4^0xy^methylpent-2^noyl)pyrrolidin-2-yl)melhyl)-5^(((S> S^-dimetbylbutan^-yOaminoJmethy^
N-(l -(((R)- 1 -(2^yano 4-dme Ipent-2-enoyl)p^
dimet ylbutan-2-yl).unino)methy^
N H((R)-l-(2-cyan -4-e1hoxy^met]iylpent-2-enoyl)RynOUdin-3-y
3,3-dimethyIbutan-2-yl)Eanmo)me^l)-lH-beiizo[d]iiiiid
N-(l-(((S)-l-(2-cyano^4Hiime^^
dimethylbutan-2-y])aiTiino)methyl)-lH-benzo(d)inudazol-2-yl)isoxazole-5^
N l-(((S)-l-(2-cyano-4-rthoxy-4-methylpen^
3,3-dime hylbutan-2-yI)i-mino)methyl)-lH-beii2»(d)imid
M((S>l-(2-cymo^4-dimeto^
dime Ibutan-2-yi)amino)methy^^
carboxaroide;
N-(I-(((S)-H2-cyano- ^oxy- ^
3,3-dimethylbutao-2-yl)amino)m
2-carboxamide;
N-(l-(((R) ^2-cyano-4,4-dim^ylpent-2-enoyl)pyiTolidin-3-yl^
dim-^ylbutan-2-yl)amfflO)metoyl lH-^^
carboxaraide;
N-(M((R)-H2-<yano-4-etboxy^-methy^
3,3-dimethylbutan-2-yl)amino)me^
2-carbox-imideiN l ((R>l-(2-cyaiio-4,4-dimet ylpeDt-2-enoy
((((S)-3 dimethylbutan-2-yl)amino^
(diiluoromethyI)bcnzamide;
N^1-(((RH-(2-cyano^-methylpent-2^oy^
dimethyIbutan-2-yl)amino)mcthyl> 1 H-beii2o[d]imidarol-2-yl>-3^dif ioromethy l)benzamide;
N-(H((R)-l-(2-cyaoo-4-etooxy^methylpe^
3 -dimethylbutan-2-yl)ami o)m^yl lH-benzoLd]imid
(dtfluoromethyl)benzamide
(R)-N-(t-(l-(2-cyano^ dimethylpent-2-enoyl)piperidk -yl)-5-(hydro
benzo[d]itmdazol-2-yl>5-(difluorome^
N^l-((R>l-(2 :yano-4-_tooxy^-methylp^
dimethylbutan-2-y amino)methylHH-berc^
carboxamide;
N-(l-((R)-H2-c^ano^meU.ylpcirt-2^ro
2-yl)amino)methyl)-1H-beiizfl[d]i^
N 3^((RH-(2-cyano-4,4-dimethylr*ii^
dimethylbutan-2-y an»no)methyl)-3H m
(difluoromc-hyI)diiophene-2-carboxamide; or
N^3-(((R H2-cyimo- ^ox ^-mcft ]pert-^^
3 -dimethylbutan-2-yl)amino)met^
(diiluorometliyl)diiophcne-2-carboxamide;
(R N-(3-((l 2-cyan( 4,4-dimetijyJpent-2-enoyl)pyiroUdm
((neopentylamino)methyl)-3H-imidazo[4,5-blpyTidi^^
carboxamide; or
(R)-N-(3-((1
((neopent lamfoo)methyl 3H-™
carboxamide;or
an individual E or Z isomers thereof.
31. A pharmaceutical composition comprising a compound of any one of claims 1 -30, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipienL
32. A method of treating a disease treatable by inhibition of ΓΓ in a patient which method comprises administering to the patient in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-30, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipicnt
33- The method of claim 30, wherein the disease is chosen from inflammatory disorders, autoimmune disorders, and proliferative disorders.
34. The method of claim 33 wherein the disease is asthma, allergic dermatitis, atopic dermatitis, and psoriasis
35. The method of any one of claims 32-34, wherein the pharmaceutical composition is administered in combination with one or more anti-inflammatory, anti-autoimmune, or anti- l mphoproliferative agent
36. A compound or a salt of any of claims 1-30 for use as a medicament
37. A compound or a salt of any of claims 1-30 for use in (he treatment of inflammatory disorders, autoimmune disorders, and proliferative disorders.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13832770.5A EP2890691B1 (en) | 2012-08-31 | 2013-08-27 | Benzimidazole derivatives as itk inhibitors |
US14/424,480 US9573958B2 (en) | 2012-08-31 | 2013-08-27 | Benzimidazole derivatives as ITK inhibitors |
JP2015529958A JP2015526520A (en) | 2012-08-31 | 2013-08-27 | Benzimidazole derivatives as ITK inhibitors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695673P | 2012-08-31 | 2012-08-31 | |
US61/695,673 | 2012-08-31 | ||
US201261728670P | 2012-11-20 | 2012-11-20 | |
US61/728,670 | 2012-11-20 | ||
US201361782213P | 2013-03-14 | 2013-03-14 | |
US61/782,213 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014036016A1 true WO2014036016A1 (en) | 2014-03-06 |
Family
ID=50184254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/056877 WO2014036016A1 (en) | 2012-08-31 | 2013-08-27 | Benzimidazole derivatives as itk inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US9573958B2 (en) |
EP (1) | EP2890691B1 (en) |
JP (1) | JP2015526520A (en) |
WO (1) | WO2014036016A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015134210A1 (en) * | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS |
WO2015143148A1 (en) * | 2014-03-20 | 2015-09-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
WO2015143161A1 (en) * | 2014-03-20 | 2015-09-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
WO2016007185A1 (en) * | 2014-07-07 | 2016-01-14 | Eternity Bioscience Inc. | Aminopyridazinone compounds as protein kinase inhibitors |
US9440957B2 (en) | 2012-06-06 | 2016-09-13 | Novartis Ag | Compounds and compositions for modulating EGFR Activity |
WO2017053537A1 (en) * | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
WO2017049401A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmascience Inc. | New benzimidazoles derivatives as tec kinases family inhibitors |
EP3120852A4 (en) * | 2015-01-30 | 2017-05-24 | Taiho Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for immune diseases |
CN106939002A (en) * | 2016-01-05 | 2017-07-11 | 江苏恒瑞医药股份有限公司 | A kind of crystal form of BTK kinase inhibitors and preparation method thereof |
WO2017118277A1 (en) * | 2016-01-05 | 2017-07-13 | 江苏恒瑞医药股份有限公司 | Crystalline form of btk kinase inhibitor and preparation method thereof |
CN107660151A (en) * | 2015-05-26 | 2018-02-02 | 莫佛塞斯公司 | Combination of anti-CD 19 antibodies and bruton's tyrosine kinase inhibitor and application thereof |
WO2019013562A1 (en) | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same |
WO2019074275A1 (en) | 2017-10-11 | 2019-04-18 | 주식회사 대웅제약 | Novel phenylpyridine derivative and pharmaceutical composition containing same |
CN109983009A (en) * | 2016-08-17 | 2019-07-05 | Gb005股份有限公司 | Containing whorled compound and its medicinal usage |
WO2019162323A1 (en) | 2018-02-21 | 2019-08-29 | Boehringer Ingelheim International Gmbh | New benzimidazole compounds and derivatives as egfr inhibitors |
WO2020045941A1 (en) | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | Novel heterocyclic amine derivative and pharmaceutical composition comprising same |
WO2020260252A1 (en) | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
WO2021172922A1 (en) | 2020-02-26 | 2021-09-02 | 주식회사 대웅제약 | Method for preparation of heterocyclicamine derivatives |
RU2760184C1 (en) * | 2018-08-27 | 2021-11-22 | Даевунг Фармасьютикал Ко., Лтд. | New heterocyclic amine derivative and a pharmaceutical composition containing it |
US11180496B2 (en) | 2017-07-12 | 2021-11-23 | Daewoong Pharmaceutical Co., Ltd. | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same |
WO2022081478A1 (en) * | 2020-10-12 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
CN103524509B (en) | 2007-06-13 | 2016-03-02 | 因塞特控股公司 | The salt of Zhan Nasi kinase inhibitor (R)-3-(4-(7H-pyrrolo-[2,3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl propionitrile |
ES2761300T3 (en) | 2009-05-22 | 2020-05-19 | Incyte Holdings Corp | 3- [4- (7H-pyrrolo [2,3-d] pyrimidine-4-yl) -1H-pyrazol-1-yl] octane- or heptane-nitrile as JAK inhibitors |
KR102354472B1 (en) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
UA111588C2 (en) | 2010-05-21 | 2016-05-25 | Інсайт Холдінгс Корпорейшн | JAK INHIBITOR COMPOSITION FOR LOCAL APPLICATION |
AR083933A1 (en) | 2010-11-19 | 2013-04-10 | Incyte Corp | PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS |
EP2721028B1 (en) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
PL2919766T3 (en) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
PL3489239T3 (en) | 2013-03-06 | 2022-03-07 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
AU2014305989B2 (en) * | 2013-08-07 | 2019-11-28 | Incyte Holdings Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
CN109563081A (en) * | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | It can be used as the heterocycleamide class of protein modulators |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TW201924683A (en) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | Low dose combination therapy for treatment of myeloproliferative neoplasms |
UA127488C2 (en) | 2018-01-30 | 2023-09-06 | Інсайт Корпорейшн | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
FI3773593T3 (en) | 2018-03-30 | 2024-06-18 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
WO2003041708A1 (en) * | 2001-11-09 | 2003-05-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Benzimidazoles useful as protein kinase inhibitors |
WO2004014905A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
WO2005079791A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2264020A1 (en) | 1996-08-26 | 1998-03-05 | Jean Bemis | Inhibitors of phospholipase enzymes |
IL137540A0 (en) | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
JP2001199968A (en) | 2000-01-18 | 2001-07-24 | Teijin Ltd | Aminobenzimidazole derivative |
ATE375983T1 (en) | 2000-12-15 | 2007-11-15 | Vertex Pharma | BACTERIAL GYRASE INHIBITORS AND THEIR USE |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
GB2432834A (en) * | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
WO2005070420A1 (en) | 2004-01-14 | 2005-08-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
WO2006078891A2 (en) | 2005-01-21 | 2006-07-27 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
WO2007022305A2 (en) | 2005-08-16 | 2007-02-22 | Pharmacopeia, Inc. | 2-aminoimidazopyridines for treating neurodegenerative diseases |
LT2529621T (en) * | 2006-09-22 | 2017-01-10 | Pharmacyclics Llc | Inhibitors of bruton`s tyrosine kinase |
WO2008056396A1 (en) * | 2006-11-10 | 2008-05-15 | Maino International S.R.L. | Apparatus for the treatment of piece goods |
CA2874756C (en) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2010126745A1 (en) | 2009-04-27 | 2010-11-04 | High Point Pharmaceuticals, Llc | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS |
WO2011060440A2 (en) | 2009-11-16 | 2011-05-19 | The Regents Of The University Of California | Kinase inhibitors |
DE102010041240A1 (en) * | 2010-09-23 | 2012-03-29 | Robert Bosch Gmbh | Pump with electric motor |
WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CA2836449C (en) | 2011-05-17 | 2021-04-27 | The Regents Of The University Of California | Kinase inhibitors |
PL2710005T3 (en) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9629897B2 (en) * | 2012-04-25 | 2017-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing and using regulatory B-cells |
US9429565B2 (en) * | 2012-05-08 | 2016-08-30 | Cellecta, Inc. | Clonal analysis of functional genomic assays and compositions for practicing same |
EP2861578A1 (en) | 2012-06-06 | 2015-04-22 | Irm Llc | Compounds and compositions for modulating egfr activity |
JO3300B1 (en) * | 2012-06-06 | 2018-09-16 | Novartis Ag | Compounds and compositions for modulating egfr activity |
WO2013191965A1 (en) * | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
-
2013
- 2013-08-27 JP JP2015529958A patent/JP2015526520A/en active Pending
- 2013-08-27 WO PCT/US2013/056877 patent/WO2014036016A1/en active Application Filing
- 2013-08-27 EP EP13832770.5A patent/EP2890691B1/en active Active
- 2013-08-27 US US14/424,480 patent/US9573958B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
WO2003041708A1 (en) * | 2001-11-09 | 2003-05-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Benzimidazoles useful as protein kinase inhibitors |
WO2004014905A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
WO2005079791A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
Non-Patent Citations (8)
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9440957B2 (en) | 2012-06-06 | 2016-09-13 | Novartis Ag | Compounds and compositions for modulating EGFR Activity |
US9932329B2 (en) | 2014-03-03 | 2018-04-03 | Principia Biopharma, Inc. | Benzimidazole derivatives as RLK and ITK inhibitors |
WO2015134210A1 (en) * | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS |
KR20220100081A (en) * | 2014-03-20 | 2022-07-14 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
KR20170004969A (en) * | 2014-03-20 | 2017-01-11 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as tyrosine kinase inhibitors for the treatment of cancer |
EP3922630A1 (en) * | 2014-03-20 | 2021-12-15 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
US10005765B2 (en) | 2014-03-20 | 2018-06-26 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
CN106536506A (en) * | 2014-03-20 | 2017-03-22 | 卡佩拉医疗公司 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
US10683304B2 (en) | 2014-03-20 | 2020-06-16 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
US10647707B2 (en) | 2014-03-20 | 2020-05-12 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
CN106661027A (en) * | 2014-03-20 | 2017-05-10 | 卡佩拉医疗公司 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
US11242352B2 (en) | 2014-03-20 | 2022-02-08 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
JP2017512833A (en) * | 2014-03-20 | 2017-05-25 | カペラ セラピューティクス,インコーポレーテッド | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
KR102663309B1 (en) | 2014-03-20 | 2024-05-03 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
WO2015143161A1 (en) * | 2014-03-20 | 2015-09-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
JP7073316B2 (en) | 2014-03-20 | 2022-05-23 | カペラ セラピューティクス,インコーポレーテッド | Benzimidazole derivative as an ERBB tyrosine kinase inhibitor for the treatment of cancer |
US11787788B2 (en) | 2014-03-20 | 2023-10-17 | Capella Therapeutics, Inc. | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof |
JP2020007327A (en) * | 2014-03-20 | 2020-01-16 | カペラ セラピューティクス,インコーポレーテッド | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for treatment of cancer |
WO2015143148A1 (en) * | 2014-03-20 | 2015-09-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
KR20170004968A (en) * | 2014-03-20 | 2017-01-11 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as tyrosine kinase inhibitors for the treatment of cancer |
US11713322B2 (en) | 2014-03-20 | 2023-08-01 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
KR102409739B1 (en) * | 2014-03-20 | 2022-06-17 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
CN114989140A (en) * | 2014-03-20 | 2022-09-02 | 卡佩拉医疗公司 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
US10202398B2 (en) | 2014-03-20 | 2019-02-12 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
KR102416358B1 (en) * | 2014-03-20 | 2022-07-07 | 카펠라 테라퓨틱스, 인크. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
RU2741914C2 (en) * | 2014-03-20 | 2021-01-29 | Капелла Терапьютикс, Инк. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for treating cancer |
CN114940673A (en) * | 2014-03-20 | 2022-08-26 | 卡佩拉医疗公司 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
US10323037B2 (en) | 2014-07-07 | 2019-06-18 | Jiangsu Hengrui Medicine Co., Ltd. | Aminopyridazinone compounds as protein kinase inhibitors |
WO2016007185A1 (en) * | 2014-07-07 | 2016-01-14 | Eternity Bioscience Inc. | Aminopyridazinone compounds as protein kinase inhibitors |
US9951077B2 (en) | 2014-07-07 | 2018-04-24 | Jiangsu Hengrui Medicine Co., Ltd. | Aminopyridazinone compounds as protein kinase inhibitors |
US9782412B2 (en) | 2015-01-30 | 2017-10-10 | Taiho Pharmaceutical Co., Ltd. | Preventive and/or therapeutic agent of immune disease |
EP3120852A4 (en) * | 2015-01-30 | 2017-05-24 | Taiho Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for immune diseases |
CN113768935A (en) * | 2015-01-30 | 2021-12-10 | 大鹏药品工业株式会社 | Prophylactic and/or therapeutic agent for immune diseases |
CN107660151A (en) * | 2015-05-26 | 2018-02-02 | 莫佛塞斯公司 | Combination of anti-CD 19 antibodies and bruton's tyrosine kinase inhibitor and application thereof |
US11427565B2 (en) | 2015-09-23 | 2022-08-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
WO2017053537A1 (en) * | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
US10562893B2 (en) | 2015-09-25 | 2020-02-18 | Gb005, Inc. | Benzimidazoles derivatives as Tec kinases family inhibitors |
WO2017049401A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmascience Inc. | New benzimidazoles derivatives as tec kinases family inhibitors |
WO2017118277A1 (en) * | 2016-01-05 | 2017-07-13 | 江苏恒瑞医药股份有限公司 | Crystalline form of btk kinase inhibitor and preparation method thereof |
KR102688907B1 (en) | 2016-01-05 | 2024-07-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Crystalline forms of BTK kinase inhibitors and methods for their preparation |
CN106939002A (en) * | 2016-01-05 | 2017-07-11 | 江苏恒瑞医药股份有限公司 | A kind of crystal form of BTK kinase inhibitors and preparation method thereof |
CN107406453A (en) * | 2016-01-05 | 2017-11-28 | 江苏恒瑞医药股份有限公司 | A kind of crystal form of BTK kinase inhibitors and preparation method thereof |
KR20180099787A (en) * | 2016-01-05 | 2018-09-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Crystalline forms of BTK kinase inhibitors and methods for their preparation |
US10626116B2 (en) | 2016-01-05 | 2020-04-21 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of BTK kinase inhibitor and preparation method thereof |
EP3500566A4 (en) * | 2016-08-17 | 2020-01-01 | GB005, Inc. | Spirocyclic containing compounds and pharmaceutical uses thereof |
US10752615B2 (en) | 2016-08-17 | 2020-08-25 | Gb005, Inc. | Spirocyclic containing compounds and pharmaceutical uses thereof |
CN109983009A (en) * | 2016-08-17 | 2019-07-05 | Gb005股份有限公司 | Containing whorled compound and its medicinal usage |
JP2019527727A (en) * | 2016-08-17 | 2019-10-03 | ジービー005, インコーポレイテッド | Spiro ring-containing compound and pharmaceutical use thereof |
US11180496B2 (en) | 2017-07-12 | 2021-11-23 | Daewoong Pharmaceutical Co., Ltd. | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same |
WO2019013562A1 (en) | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same |
WO2019074275A1 (en) | 2017-10-11 | 2019-04-18 | 주식회사 대웅제약 | Novel phenylpyridine derivative and pharmaceutical composition containing same |
JP2020536093A (en) * | 2017-10-11 | 2020-12-10 | デウン ファーマシューティカル カンパニー リミテッド | A novel phenylpyridine derivative and a pharmaceutical composition containing the same. |
US11149019B2 (en) | 2017-10-11 | 2021-10-19 | Daewoong Pharmaceutical Co., Ltd. | Phenylpyridine derivative and pharmaceutical composition comprising the same |
WO2019162323A1 (en) | 2018-02-21 | 2019-08-29 | Boehringer Ingelheim International Gmbh | New benzimidazole compounds and derivatives as egfr inhibitors |
US11174245B2 (en) | 2018-02-21 | 2021-11-16 | Boehringer Ingelheim International Gmbh | Benzimidazole compounds and derivatives as EGFR inhibitors |
WO2020045941A1 (en) | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | Novel heterocyclic amine derivative and pharmaceutical composition comprising same |
RU2760184C1 (en) * | 2018-08-27 | 2021-11-22 | Даевунг Фармасьютикал Ко., Лтд. | New heterocyclic amine derivative and a pharmaceutical composition containing it |
WO2020260252A1 (en) | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
WO2021172922A1 (en) | 2020-02-26 | 2021-09-02 | 주식회사 대웅제약 | Method for preparation of heterocyclicamine derivatives |
WO2022081478A1 (en) * | 2020-10-12 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2890691A4 (en) | 2016-03-23 |
EP2890691A1 (en) | 2015-07-08 |
EP2890691B1 (en) | 2018-04-25 |
US9573958B2 (en) | 2017-02-21 |
US20150225412A1 (en) | 2015-08-13 |
JP2015526520A (en) | 2015-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2890691B1 (en) | Benzimidazole derivatives as itk inhibitors | |
US11078199B2 (en) | Quinolone derivatives as fibroblast growth factor receptor inhibitors | |
EP3181567B1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
US9932329B2 (en) | Benzimidazole derivatives as RLK and ITK inhibitors | |
US9676778B2 (en) | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors | |
CA2911706A1 (en) | Quinolone derivatives as fibroblast growth factor inhibitors | |
EP2710006A1 (en) | Azaindole derivatives as tyrosine kinase inhibitors | |
WO2017142947A1 (en) | Histone methyltransferase inhibitors | |
US20210371417A1 (en) | Azaindole compounds as histone methyltransferase inhibitors | |
US20240209005A1 (en) | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
US20240199661A1 (en) | Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
OA19439A (en) | Azaindole compounds as histone methyltranferase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13832770 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015529958 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14424480 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |